0000950170-24-023845.txt : 20240301 0000950170-24-023845.hdr.sgml : 20240301 20240301160933 ACCESSION NUMBER: 0000950170-24-023845 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 113 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STANDARD BIOTOOLS INC. CENTRAL INDEX KEY: 0001162194 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 770513190 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34180 FILM NUMBER: 24709733 BUSINESS ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502666000 MAIL ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: FLUIDIGM CORP DATE OF NAME CHANGE: 20011113 10-K 1 lab-20231231.htm 10-K 10-K
falseFY0001162194one years3 yearstwo yearsP1YP1YP1Y.34482760001162194us-gaap:CustomerConcentrationRiskMemberlab:OneGenomicsCustomerMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001162194us-gaap:CommonStockMember2021-12-310001162194lab:CorporateHeadquartersTwentyFirstFloorMember2023-01-012023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2034Member2022-12-310001162194us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001162194us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2018-08-020001162194us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001162194srt:MaximumMemberlab:ComputerEquipmentAndSoftwareMember2023-12-310001162194us-gaap:EmployeeSeveranceMember2023-12-310001162194us-gaap:ProductAndServiceOtherMember2022-01-012022-12-310001162194us-gaap:FacilityClosingMember2022-01-012022-12-310001162194us-gaap:OtherRestructuringMember2021-12-310001162194lab:CombinedCompanyMemberus-gaap:SubsequentEventMemberus-gaap:CommonStockMember2024-01-050001162194lab:InstruNorASMemberus-gaap:DevelopedTechnologyRightsMember2022-01-012022-12-310001162194srt:AmericasMember2023-01-012023-12-310001162194us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001162194us-gaap:DevelopedTechnologyRightsMember2023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024NonCurrentMember2023-12-310001162194us-gaap:SecuredDebtMember2021-08-020001162194us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310001162194srt:AsiaPacificMember2023-01-012023-12-310001162194us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001162194srt:MaximumMemberus-gaap:PerformanceSharesMember2023-01-012023-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2023-12-310001162194us-gaap:FurnitureAndFixturesMember2023-12-310001162194us-gaap:ServiceMembersrt:MinimumMember2023-01-012023-12-310001162194lab:TwoThousandAndElevenEquityIncentivePlanMember2023-12-3100011621942022-12-310001162194us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001162194us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310001162194lab:PatentsandLicenseAgreementsMember2023-12-310001162194srt:MaximumMemberus-gaap:ServiceMember2023-01-012023-12-310001162194us-gaap:StockCompensationPlanMember2023-01-012023-12-310001162194lab:LaboratoryAndManufacturingEquipmentMembersrt:MinimumMember2023-12-310001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001162194us-gaap:RetainedEarningsMember2023-12-310001162194us-gaap:SecuredDebtMember2023-12-310001162194us-gaap:CostOfSalesMember2023-01-012023-12-310001162194us-gaap:DomesticCountryMemberus-gaap:ResearchMember2023-12-3100011621942022-11-230001162194srt:AmericasMember2022-01-012022-12-310001162194us-gaap:OperatingSegmentsMemberlab:GenomicsMember2022-01-012022-12-310001162194country:SG2023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2034Member2022-01-012022-12-310001162194lab:ComputerEquipmentAndSoftwareMember2022-12-310001162194country:CA2022-12-310001162194lab:GenomicsMember2022-01-012022-12-310001162194us-gaap:OfficeEquipmentMember2022-12-310001162194lab:LaboratoryAndManufacturingEquipmentMember2022-12-310001162194us-gaap:RetainedEarningsMember2021-12-310001162194us-gaap:CustomerConcentrationRiskMemberlab:FiveLargestCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001162194lab:ServiceAndOtherRevenueMember2022-01-012022-12-310001162194us-gaap:ConvertiblePreferredStockMember2023-12-310001162194us-gaap:OtherRestructuringMember2022-01-012022-12-3100011621942023-12-310001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001162194us-gaap:ConvertiblePreferredStockMember2022-01-012022-12-310001162194srt:MinimumMember2023-01-012023-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194us-gaap:DomesticCountryMember2023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024Member2019-11-300001162194us-gaap:ShareBasedCompensationAwardTrancheOneMember2023-01-012023-12-310001162194us-gaap:ForeignCountryMember2023-12-310001162194us-gaap:EmployeeStockOptionMemberlab:TwoThousandSeventeenEmployeeStockPurchasePlanMember2023-12-310001162194us-gaap:SubsequentEventMemberus-gaap:CommonStockMemberlab:CombinedSubsidiariesMember2024-01-050001162194us-gaap:CustomerConcentrationRiskMemberlab:OneGenomicsCustomerMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310001162194us-gaap:CashAndCashEquivalentsMember2023-12-310001162194lab:EquityIncentivePlanMember2023-12-310001162194us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194us-gaap:ConvertiblePreferredStockMemberlab:CasdinMember2022-04-040001162194us-gaap:EmployeeSeveranceMember2021-12-310001162194us-gaap:CommonStockMember2022-01-012022-12-310001162194us-gaap:OfficeEquipmentMember2023-12-310001162194us-gaap:TreasuryStockCommonMember2023-12-310001162194lab:TwoThousandSeventeenEmployeeStockPurchasePlanMember2023-12-310001162194lab:OtherAsiaPacificMember2022-12-310001162194us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-01-012022-12-3100011621942023-06-300001162194us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310001162194us-gaap:SecuredDebtMember2022-12-310001162194us-gaap:CustomerConcentrationRiskMemberlab:CustomerOneMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001162194srt:AsiaPacificMember2022-01-012022-12-3100011621942024-01-012023-12-3100011621942022-01-012022-12-3100011621942020-09-012020-09-300001162194us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194lab:SomalogicIncMemberus-gaap:SubsequentEventMemberus-gaap:CommonStockMember2024-01-052024-01-050001162194lab:ConsumablesMember2022-01-012022-12-310001162194us-gaap:DevelopedTechnologyRightsMember2023-01-012023-12-310001162194us-gaap:StateAndLocalJurisdictionMember2023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2034Member2019-11-300001162194us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194us-gaap:OperatingSegmentsMemberlab:ProteomicsMember2022-01-012022-12-310001162194us-gaap:SecuredDebtMemberus-gaap:PrimeRateMember2023-01-012023-12-310001162194us-gaap:PerformanceSharesMember2023-12-310001162194us-gaap:ConvertiblePreferredStockMember2022-12-310001162194lab:LaboratoryAndManufacturingEquipmentMembersrt:MaximumMember2023-12-310001162194us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-310001162194us-gaap:CustomerConcentrationRiskMemberlab:FiveLargestCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2034Member2023-12-310001162194srt:MinimumMemberus-gaap:PerformanceSharesMember2023-01-012023-12-310001162194lab:VikingMemberus-gaap:ConvertiblePreferredStockMember2022-04-042022-04-040001162194us-gaap:EMEAMember2022-12-310001162194us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194lab:TwoThousandAndElevenEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2023-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194lab:SouthSanFranciscoMemberlab:CorporateHeadquartersEighteenthFloorMember2023-01-012023-12-310001162194lab:ComputerEquipmentAndSoftwareMember2023-12-310001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001162194us-gaap:AdditionalPaidInCapitalMember2023-12-310001162194us-gaap:EMEAMember2023-12-310001162194us-gaap:PerformanceSharesMember2022-12-310001162194lab:InstruNorASMemberus-gaap:DevelopedTechnologyRightsMember2022-04-012022-06-300001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024Member2023-01-012023-12-310001162194us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2018-08-022018-08-020001162194us-gaap:ConvertiblePreferredStockMember2022-04-042022-04-040001162194us-gaap:ProductMember2022-01-012022-12-310001162194us-gaap:AdditionalPaidInCapitalMember2022-12-310001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194lab:SeniorConvertibleNotesDue2024NonCurrentMemberus-gaap:ConvertibleDebtMember2022-12-310001162194us-gaap:ServiceMember2022-01-012022-12-310001162194country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310001162194us-gaap:OperatingSegmentsMemberlab:ProteomicsMember2023-01-012023-12-310001162194lab:TwoThousandAndSeventeenInducementAwardPlanMember2023-12-310001162194lab:ConsumablesMember2023-01-012023-12-310001162194us-gaap:RetainedEarningsMember2023-01-012023-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194us-gaap:ProductMembersrt:MinimumMember2023-01-012023-12-310001162194us-gaap:RestrictedStockUnitsRSUMember2022-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194lab:VikingMemberus-gaap:ConvertiblePreferredStockMember2022-04-040001162194us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310001162194us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001162194lab:LaboratoryAndManufacturingEquipmentMember2023-12-3100011621942025-01-012023-12-310001162194us-gaap:ConvertibleDebtMember2022-12-310001162194us-gaap:CostOfSalesMember2022-01-012022-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024Memberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2019-11-012019-11-300001162194lab:ComputerEquipmentAndSoftwareMembersrt:MinimumMember2023-12-310001162194lab:ProteomicsMember2023-01-012023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2023-12-310001162194us-gaap:EmployeeStockOptionMember2023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024CurrentMember2022-12-310001162194us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194us-gaap:ConvertiblePreferredStockMember2023-01-012023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024Member2022-01-012022-12-310001162194us-gaap:SecuredDebtMember2023-01-012023-12-310001162194us-gaap:CashAndCashEquivalentsMember2022-12-310001162194lab:PatentsandLicenseAgreementsMember2022-12-310001162194lab:TwoThousandAndSeventeenInducementAwardPlanMemberus-gaap:EmployeeStockOptionMember2023-12-310001162194us-gaap:FacilityClosingMember2022-12-310001162194lab:SouthSanFranciscoMember2022-08-012022-08-310001162194country:CNus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001162194us-gaap:TreasuryStockCommonMember2023-01-012023-12-310001162194us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194us-gaap:BridgeLoanMember2022-02-012022-03-310001162194us-gaap:ConvertiblePreferredStockMemberlab:CasdinMember2022-04-042022-04-040001162194lab:GenomicsMember2023-01-012023-12-310001162194lab:EquityIncentivePlanMember2023-01-012023-12-310001162194country:US2022-12-310001162194us-gaap:ConvertibleDebtMember2023-12-310001162194us-gaap:LeaseholdImprovementsMember2023-12-310001162194us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100011621942020-09-300001162194us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-12-310001162194lab:TwoThousandAndSeventeenInducementAwardPlanMemberus-gaap:RestrictedStockUnitsRSUMember2023-12-310001162194lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember2023-12-310001162194us-gaap:EMEAMember2022-01-012022-12-310001162194us-gaap:CorporateNonSegmentMember2023-01-012023-12-310001162194us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001162194us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194us-gaap:BridgeLoanMember2022-04-040001162194us-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-01-012023-12-310001162194us-gaap:AdditionalPaidInCapitalMember2021-12-310001162194srt:MaximumMember2023-01-012023-12-310001162194lab:InstrumentsMember2022-01-012022-12-310001162194lab:GenomicsMember2023-12-310001162194us-gaap:CommonStockMember2023-01-012023-12-310001162194us-gaap:DevelopedTechnologyRightsMember2022-12-310001162194us-gaap:CommonStockMember2022-12-3100011621942026-01-012023-12-310001162194us-gaap:RestrictedStockUnitsRSUMember2023-12-310001162194us-gaap:EmployeeSeveranceMember2022-12-310001162194lab:InstrumentsMember2023-01-012023-12-310001162194lab:SouthSanFranciscoMember2023-01-012023-12-310001162194us-gaap:ProductAndServiceOtherMember2023-01-012023-12-310001162194us-gaap:BridgeLoanMember2022-01-012022-12-310001162194us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100011621942023-01-012023-12-310001162194us-gaap:OperatingSegmentsMemberlab:GenomicsMember2023-01-012023-12-310001162194us-gaap:OtherRestructuringMember2022-12-310001162194us-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2034Member2014-02-012014-02-280001162194us-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001162194country:CNus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-3100011621942021-12-310001162194us-gaap:ShortTermInvestmentsMember2022-12-3100011621942023-12-312023-12-310001162194us-gaap:OtherRestructuringMember2023-01-012023-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194us-gaap:FacilityClosingMember2021-12-3100011621942027-01-012023-12-310001162194us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2022-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-12-310001162194lab:SouthSanFranciscoMember2022-08-310001162194us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194srt:MaximumMemberus-gaap:ProductMember2023-01-012023-12-310001162194us-gaap:CommonStockMember2023-12-310001162194country:CA2023-12-310001162194lab:SouthSanFranciscoMember2023-02-280001162194us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194us-gaap:LeaseholdImprovementsMember2022-12-310001162194us-gaap:TreasuryStockCommonMember2022-12-310001162194us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-12-310001162194lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2023-12-310001162194us-gaap:DevelopedTechnologyRightsMember2022-01-012022-12-310001162194us-gaap:CustomerConcentrationRiskMemberlab:CustomerOneMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001162194lab:ProteomicsMember2022-01-012022-12-3100011621942019-01-012019-12-310001162194country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-3100011621942024-02-210001162194lab:ServiceAndOtherRevenueMember2023-01-012023-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310001162194lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember2022-04-300001162194lab:TwoThousandAndElevenEquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2023-12-310001162194us-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194us-gaap:OtherRestructuringMember2023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024Member2019-11-012019-11-300001162194us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2023-12-310001162194country:US2023-12-310001162194us-gaap:BridgeLoanMember2022-01-230001162194us-gaap:PerformanceSharesMember2023-01-012023-12-310001162194us-gaap:CorporateNonSegmentMember2022-01-012022-12-310001162194lab:EquityIncentivePlanMember2022-01-012022-12-310001162194country:SG2022-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024Memberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001162194us-gaap:FacilityClosingMember2023-12-310001162194us-gaap:RestrictedStockUnitsRSUMemberlab:TwoThousandSeventeenEmployeeStockPurchasePlanMember2023-12-310001162194us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001162194lab:SouthSanFranciscoMember2023-02-282023-02-280001162194us-gaap:ProductMember2023-01-012023-12-310001162194us-gaap:EmployeeSeveranceMember2023-01-012023-12-310001162194lab:ProductAndServiceMember2023-01-012023-12-310001162194us-gaap:RetainedEarningsMember2022-01-012022-12-310001162194us-gaap:RetainedEarningsMember2022-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2034Member2023-01-012023-12-310001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001162194us-gaap:EMEAMember2023-01-012023-12-310001162194lab:ProteomicsMember2023-12-310001162194us-gaap:ServiceMember2023-01-012023-12-310001162194us-gaap:FacilityClosingMember2023-01-012023-12-310001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2024CurrentMember2023-12-310001162194us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194lab:ProductAndServiceMember2022-01-012022-12-310001162194us-gaap:ShortTermInvestmentsMember2023-12-310001162194us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194lab:OtherAsiaPacificMember2023-12-310001162194lab:GenomicsMember2022-12-310001162194us-gaap:EmployeeSeveranceMember2022-01-012022-12-310001162194lab:ProteomicsMember2022-12-31xbrli:purexbrli:sharesiso4217:USDxbrli:shareslab:MonthlyInstallmentlab:Segmentiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________

FORM 10-K

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

_____________________________________________

Commission file number: 001-34180

img186398206_0.jpg 

 

STANDARD BIOTOOLS INC.

(Exact name of registrant as specified in its charter)

Delaware

77-0513190

State or other jurisdiction of incorporation or organization

I.R.S. Employer Identification No.

 

 

 

2 Tower Place, Suite 2000

South San Francisco,

CA

 

94080

Address of principal executive offices

 

Zip Code

Registrant’s telephone number, including area code: (650) 266-6000

_____________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

LAB

The Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act:

None

_____________________________________________

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

☐

 

 

Accelerated filer

 

☐

Non-accelerated filer

 

☒

 

 

Smaller reporting company

 

☒

 

 

 

 

 

Emerging growth company

 

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☐ No ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of June 30, 2023, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $132.7 million based on the closing sale price on that date. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the Registrant have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.

As of February 21, 2024, there were 290,117,930 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s proxy statement in connection with the registrant’s annual meeting of stockholders, scheduled to be held in June 2024, are incorporated by reference in Part III of this report. Except as expressly incorporated by reference, such proxy statement shall not be deemed to be part of this report.

 

 

STANDARD BIOTOOLS INC.

FISCAL YEAR 2023

FORM 10-K

ANNUAL REPORT

 

TABLE OF CONTENTS

 

 

 

Page

PART I

 

 

 

 

ITEM 1.

 

Business

 

1

ITEM 1A.

 

Risk Factors

 

24

ITEM 1B.

 

Unresolved Staff Comments

 

58

ITEM 1C.

 

Cybersecurity

 

58

ITEM 2.

 

Properties

 

59

ITEM 3.

 

Legal Proceedings

 

60

ITEM 4.

 

Mine Safety Disclosures

 

60

 

 

 

 

 

PART II

 

 

 

 

 

 

 

 

 

ITEM 5.

 

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

61

ITEM 6.

 

[Reserved]

 

61

ITEM 7.

 

Management's Discussion and Analysis of Financial Condition and Results of Operations

 

62

ITEM 7A.

 

Quantitative and Qualitative Disclosures about Market Risk

 

71

ITEM 8.

 

Financial Statements and Supplementary Data

 

72

ITEM 9.

 

Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

 

105

ITEM 9A.

 

Controls and Procedures

 

105

ITEM 9B.

 

Other Information

 

105

ITEM 9C

 

Disclosures Regarding Foreign Jurisdictions that Prevent Inspections

 

105

 

 

 

 

 

PART III

 

 

 

 

 

 

 

 

 

ITEM 10.

 

Directors, Executive Officers and Corporate Governance

 

106

ITEM 11.

 

Executive Compensation

 

106

ITEM 12.

 

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

106

ITEM 13.

 

Certain Relationships and Related Transactions, and Director Independence

 

106

ITEM 14.

 

Principal Accounting Fees and Services

 

106

 

 

 

 

 

PART IV

 

 

 

 

 

 

 

 

 

ITEM 15.

 

Exhibits, Financial Statement Schedules

 

107

ITEM 16.

 

Form 10-K Summary

 

107

 

 

 

 

 

INDEX TO EXHIBITS

 

108

SIGNATURES

 

117

 

i

 

Special Note Regarding Forward-looking Statements and Industry Data

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management’s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally in the sections entitled “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include information concerning our possible or assumed future cash flow, revenue, sources of revenue and results of operations, cost of product revenue and product margin, operating and other expenses, unit sales and the selling prices of our products, business strategies, financing plans, expansion of our business, investments to expand our customer base, plans for our products, competitive position, industry environment, potential growth opportunities, market growth expectations, the effects of competition, our planned use of the proceeds from the Bridge Loans and Private Placement Issuance described herein, cost structure optimization, acceleration of growth, potential merger and acquisition (M&A) activity and restructuring plans (including expense reduction activities involving potential subleasing and talent relocation plans, modifications to the scope of the company’s proteomic and genomics businesses and discontinuing of certain product lines) and our expectations regarding the benefits and integration of acquired businesses and/or products (including in connection with our merger with SomaLogic, Inc. in January 2024). Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts, “projects,” “should,” “will,” “would,” or similar expressions and the negatives of those terms.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in the section entitled “Risk Factors” and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Annual Report on Form 10-K. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect.

This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain of our products, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events, or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.

Standard BioTools, the Standard BioTools logo, Fluidigm®, the Fluidigm logo, 48.Atlas™, Access Array™, Advanta™, Advanta EASE™, Atlas™, Biomark™, “Bringing new insights to life”™, C1™, Callisto™, Cell-ID™, CyTOF®, CyTOF XT™, the CyTOF XT logo, D3™, Delta Gene™, Direct™, Digital Array™, Dynamic Array™, EP1™, EQ™, FC1™, Flex Six™, Flow Conductor™, FluiDesign™, Helios™, High-Precision 96.96 Genotyping™, HTI™, Hyperion™, Hyperion+™, IMC™, Imaging Mass Cytometry™, Immune Profiling Assay™, Juno™, Maxpar®, MCD™, MSL®, Nanoflex™, Open App™, Pathsetter™, Polaris™, qdPCR 37K™, Script Builder™, Script Hub™, Singular™, SNP Trace™, SNP Type™, “Unleashing tools to accelerate breakthroughs in human health”™, X9™ Real Time PCR System, Xgrade™, SomaLogic®, SomaScan®, SOMAmer®, SomaSignal®, Power by SomaLogic™, DataDelve™, and CardioDM are trademarks or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. Other service marks, trademarks and trade names referred to in this Annual Report on Form 10-K are the property of their respective owners.

Unless the context requires otherwise, references in this Annual Report on Form 10-K to “Standard BioTools,” the “Company,” “we,” “us,” and “our” refer to Standard BioTools Inc. and its subsidiaries.

 

 

PART I

ITEM 1. BUSINESS

Overview

Standard BioTools Inc. is driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health. We develop, manufacture and sell technologies that help biomedical researchers in their search for developing medicines faster and better. Our tools provide insights in health and disease using our proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively.

Within proteomics our mass cytometry technology is embodied in two analytical platforms: flow cytometry and tissue imaging or spatial biology. Our flow cytometry systems (Helios™ and CyTOF XT) deeply profile cell phenotype and function. Referenced by more than 2,200 peer-reviewed publications around the world, our CyTOF technology has set a new standard in human immune profiling with our proprietary digital readout. Our spatial biology systems (Hyperion™ Imaging System and Hyperion+TM Imaging System) enable highly multiplexed protein biomarker detection at a single cellular level in tissues and tumors while still preserving tissue architecture and cellular morphology information and without any autofluorescence artifacts by using our Imaging Mass Cytometry™ (IMC™) technology.

Within genomics, our microfluidics technology with our proprietary Integrated Fluidic Circuits (IFCs) provides high throughput and automated workflows for quantitative polymerase chain reaction (PCR), gene expression, copy number variation analysis, and next-generation sequencing (NGS) library preparation. These automated systems are used to detect somatic and genomic variations from a range of different sample types which provide cost efficiencies, flexibility and proven analytical performance that customers need to meet the increasing demands of molecular biomarker analysis for diagnostics and research applications.

On January 5, 2024, we completed the merger (the Merger) with SomaLogic, Inc. (SomaLogic), creating a leading provider of differentiated multi-omics tools for research.

Strategic Investment Transaction and Business Restructuring

On April 1, 2022, our stockholders approved the closing of a private placement of preferred stock to Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (collectively, Casdin) and Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP (collectively, Viking and together with Casdin, the Purchasers). On the closing date, April 4, 2022, we sold an aggregate of $225.0 million worth, and converted $25.0 million of previously issued bridge loans (the Bridge Loans), into shares of Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock pursuant to separate Series B Convertible Preferred Stock Purchase Agreements, dated and effective as of January 23, 2022, with each of the Purchasers (the Private Placement Issuance). The $250.0 million proceeds from the Bridge Loans and Private Placement Issuance are being used for working capital and general corporate purposes. On the closing date, the stockholders also approved the name change of our company to “Standard BioTools Inc.”

In connection with the closing of the private placement, Dr. Michael Egholm was appointed President and Chief Executive Officer and Alex Kim as Chief Operating Officer of the Company. Between April 2022 and today, Mr. Egholm has rebuilt our entire executive leadership team, assembling a team of disciplined operators that we believe can execute our vision to become a diversified leader in life sciences tools. Collectively, the Standard BioTools executive leadership team has over 140 years of combined life sciences experience. We have also reconstituted our board of directors since early 2022, adding significant life sciences operating, technology and capital markets expertise. In only seven quarters since the initiation of our restructuring plans in April 2022, our new management has significantly improved our legacy business performance, as demonstrated by the results of the fiscal year ended December 31, 2023 during which revenues increased 9% year-to-year (including over 40% growth in instrument revenue), gross margins expanded by more than 25% year-to-year, operating expenses declined by approximately 17% year-to-year, and operating cash burn declined by 53% year-to-year.

Merger With SomaLogic, Inc.

On January 5, 2024, we completed the Merger with SomaLogic and Martis Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of the Company (Merger Sub), pursuant to which, at the effective time of the Merger (the Effective Time), among other matters, Merger Sub merged with and into SomaLogic, with SomaLogic surviving as a wholly owned subsidiary of the Company. Upon the terms and subject to the conditions set forth in that certain Agreement and Plan of Merger, dated as of October 4,

1

 

2023, by and between the Company, SomaLogic and Merger Sub (the Merger Agreement), at the Effective Time, each share of SomaLogic common stock, par value $0.0001 per share (SomaLogic Common Stock), converted into the right to receive 1.11 shares (the Exchange Ratio) of the Company’s common stock, par value $0.001 per share.

SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 11,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years SomaLogic has supported pharmaceutical companies, and academic and contract research organizations who rely on SomaLogic’s protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases.

The combination of Standard BioTools and SomaLogic represents an opportunity for the combined company to leverage this operational expertise and discipline to achieve cost synergies for the combined company and to create new revenue opportunities with the combined platform, which we believe will inure to the benefit of our customers and create long-term value for the combined company’s stockholders.

Including expected acquired cash and investments, the combined company had a balance of approximately $565.5 million of cash, cash equivalents, short-term investments and restricted cash at December 31, 2023, which amount includes SomaLogic’s unaudited cash, cash equivalents and short-term investments of $449.8 million as of December 31, 2023. For the year ended December 31, 2023, the combined company had pro forma revenue of $192.4 million, which amount includes SomaLogic’s unaudited 2023 revenue of $86.1 million. The preliminary combined company cash and revenue included in this Form 10-K has been prepared by, and is the responsibility of, Standard BioTools’ management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.

The disclosures in this Item 1 of this Annual Report on Form 10-K (the Annual Report) under the heading “Business” speak to the combined company subsequent to the Merger unless otherwise noted. However, the financial results described herein relate, except as otherwise expressly noted herein, to Standard BioTools on a standalone basis without to giving effect to Merger and, accordingly, do not include the results of SomaLogic. Future filings, beginning with our Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2024, will reflect the results of the combined company.

Strategy

Our new leadership team has identified three strategic priorities: revenue growth, improving operating discipline through the Standard BioTools Business Systems (SBS) and strategic capital allocation.

Revenue Growth

One of our top priorities is to grow our instrument, consumables and service revenue. We have established new growth strategies for our product lines, returning our business to growth in 2023. This growth has been driven by over 40% increase in instrument revenue, led by new placements of our Hyperion XTi Imaging System, which we launched in April 2023. Importantly, we believe growth in instrument placements is a leading indicator. And while we expect to see continued variability in quarter-to-quarter instrument placements, the growing installed base expands future consumables and service pull-through, which are significant drivers of both revenue and margin growth.

We continue to invest in research and development (R&D) to create and launch new products and have adopted best practice approaches to improve our lead generation and funnel management growth, among other things.

Improving Operating Discipline Through SBS

Our second priority is to improve our operating discipline through the implementation of SBS. We are leveraging SBS with a set of organizing principles, rigorous standard work processes, and a continuous improvement mindset to build more efficient operations and commercial execution and reduce costs.

Following the closing of our private placement described above, we implemented a phased restructuring plan designed to improve efficiencies, expand gross margins, reduce operating costs and better align our workforce with the current needs of our business.

Key highlights of our restructuring initiatives have included:

2

 

•
Expanding Gross Margins. Through implementation of lean SBS principles, we have reduced manufacturing costs, improved manufacturing efficiencies, reduced key raw materials costs, reduced obsolescence exposure and improved capacity utilization, all resulting in gross margin improvement of over 960 basis points in 2023, as compared to 2022.
•
Reducing General and Administrative Expenses. We have significantly lowered general and administrative spend through a reduction in headcount and a decrease in office space in order to better align our spending with more streamlined operations. Specifically, we reduced our real estate footprint, including our headquarters location in South San Francisco while fostering remote work for certain employees. As of December 31, 2023, we have entered into sublease agreements for approximately 50% of our corporate headquarters location and we expect to recognize future sublease rental income of $11.9 million over approximately 6 years.
•
Right Sizing Our Microfluidics Business. We have significantly reduced our expenses in microfluidics research and development and marketing while narrowing our commercial focus to high value niche markets for specialized applications. Gross margin for this business segment improved by over 1,950 basis points in 2023, as compared to 2022.
•
Rationalizing our Product Portfolio. We discontinued certain products including Laser Capture Microdissection (LCM), Flow Conductor, and COVID-19 diagnostic offerings, which are not essential to our core business focus.

Strategic Capital Allocation

Our third priority is strategic capital allocation. We are actively pursuing business development opportunities in the life sciences industry with consolidation and synergies expected to be a key growth driver to sustain the longer-term value proposition of the Company. The merger with SomaLogic is our latest step forward toward unlocking value in a highly fragmented market through scale, diversification and operational expertise.

Market Opportunity

We participate in growing and emerging market segments within the broader proteomics and genomics markets.

Proteomics

The market for proteomics is broadly defined as instruments, consumables and reagents, software, and services for all technologies used in the identification of proteins. Proteins perform a vast array of functions within living organisms, including catalyzing metabolic reactions, replicating DNA, signaling response to stimuli and transporting molecules from one location to another. The proteome varies and is dynamic. Every cell in an individual organism has the same set of genes, but the set of proteins produced in different tissues differ from one another and are dependent on gene expression. Protein analysis is required to profile and understand cellular function as well as the interaction in tissues and other complex microenvironments. Within the proteomics market, we focus on Flow Cytometry and Spatial Biology.

Flow Cytometry is a method to detect and measure physical and chemical characteristics of cells or particles. With our CyTOF technology, we focus in a smaller sub-segment of Flow Cytometry for high-parameter analysis defined as greater than 20 parameters.

•
Traditional flow cytometry utilizes a suspension of cells in a stream of fluid and passes them through an electronic detection apparatus to allow simultaneous multi-parameter analysis of the physical and chemical characteristics of up to thousands of cells per second. Although traditional flow cytometry technologies are high-throughput with single-cell analysis capabilities, a key limitation is the use of fluorescent dyes to label antibodies for detection. These fluorescent labels have emission spectra that typically overlap, making it challenging to optimize reagents to analyze many protein markers at once. In general, the number of protein targets for conventional flow cytometry is less than about 10 with significant reagent optimization often involved.
•
Our CyTOF technology is similar to traditional flow cytometry but is based primarily on antibodies using heavy metal isotope labels rather than fluorescent labels for detection of proteins, enabling the significant expansion of the number of parameters analyzed per individual cell versus conventional flow cytometry technologies, as well as providing superior data quality. With high-throughput, single-cell analysis capabilities and the ability to analyze more protein markers per individual cell, researchers have more granular information, which allows them to identify and characterize even finer subpopulations of cells.

Spatial Biology, which itself is a sub-segment of the broader Tissue Image Analysis market that includes immunohistochemistry and in-situ hybridization, is the study of single cells in its spatial context to understand the role of heterogeneity in cell function and assess complex phenotypes and tumor-immune interactions in the tissue and tumor microenvironment.

•
Immunohistochemistry is a method by which cells in a tissue section are stained with antibodies and then imaged with a

3

 

conventional or fluorescent microscope. Antibodies selected to bind to proteins of interest can be conjugated with either chromogenic or fluorescent labels, allowing cellular proteins to be visualized in spatial context. Immunohistochemistry is used broadly throughout the life sciences industry, and in clinical research to better understand the characteristics and relationship of cancerous versus normal cells in biopsy tissue. In general, the number of simultaneously imageable proteins is less than five, with researchers only able to achieve a higher-parameter resolution using serial sections (several adjacent sections of the same tissue) or other highly laborious, more serial staining methods.
•
Cyclic immunofluorescence is a method using an iterative process in which tissue slides are repeatedly stained and imaged with a fluorescent microscope, and then antibody stripping using denaturants. This method allows higher parameter analysis versus immunohistochemistry.
•
Imaging mass cytometry is similar to immunohistochemistry but is based primarily on antibodies using heavy metal isotope labels rather than fluorescent or chromogenic labels for detection of proteins. This method enables a significant expansion of the number of parameters simultaneously analyzed per tissue section rather than in adjacent sections or via serial staining protocols. This method also eliminates issues of using fluorescent technology to image highly auto-fluorescent tissues.

Genomics

The market for genomics is broadly defined as instruments, consumables and reagents, software, and services for all technologies used in the identification of genes (DNA, RNA) and their function. The hereditary material or nucleic acid of an organism is often referred to as its genome, the protein-encoding regions of which are commonly known as genes. Analysis of variations in genomes, genes and gene activity in and between organisms can provide insights into their health and functioning.

Within the genomics market, we focus on two sub-segments: qPCR analysis and NGS library preparation.

There are several forms of genetic analysis in use today, including genotyping, gene expression analysis and NGS:

•
Genotyping involves the analysis of DNA variations across individual genomes. There are multiple forms of variants, including single nucleotide polymorphism (SNPs), insertion-deletions and copy number variation. A common application of genotyping focuses on analyzing SNPs to determine whether a SNP or group of SNPs are associated with a particular genetic trait, such as propensity for a disease.
•
Gene expression analysis involves measuring the levels of particular ribonucleic acid sequences known as messenger RNAs (mRNAs), which have been transcribed from genes. Determining these levels is important because mRNAs are often translated by the cell into proteins and may affect the activity of the cell or the larger organism.
•
Gene expression and genotyping are studied through a combination of various technology platforms that characterize gene function and genetic variation. These platforms often rely on PCR amplification to generate exponential copies of a DNA sample to provide sufficient signal to facilitate detection. Real-time quantitative PCR (real-time qPCR) is a more advanced form of PCR that makes it possible to quantify the number of copies of DNA present in a sample.
•
NGS is a process by which researchers are able to determine the particular order of nucleotide bases that comprise all or a portion of a particular gene or genome (in the case of DNA sequencing) or gene transcript or sample transcriptome (in the case of RNA sequencing). NGS is routinely used for studies across the research continuum including basic research, biomarker discovery, translational research, and clinical research.

OEM Markets

We also utilize our proprietary microfluidics technology to collaborate with OEM providers to pursue market opportunities outside our core markets. These OEM markets are highly varied, and we believe represent significant expansion opportunities for our technology.

Products

We market life science tools, including preparatory and analytical instruments, consumables, and software for single cell proteomics analysis via mass cytometry and tissue imaging, and protein detection and analysis technologies and services for genomics analysis via real-time PCR and NGS library preparation.

4

 

Throughout 2022 and 2023, we have greatly enhanced our proteomics offerings through continuous quality improvements and targeting of our flagship flow cytometry instrument, the CyTOF XT™ System, and the commercial release of our third-generation imaging solution for spatial biology, the Hyperion XTi™ Imaging System.

We have begun to more clearly distinguish the technological and workflow advantages of our flow cytometry solution. The CyTOF XT is the only technology that can do a high number of both extra cellular markers and intra cellular markers. The ability to do both at the same time allows our customers to gain biological insights that would otherwise go unnoticed using competing technologies.

Since the commercial launch of the Hyperion XTi™ Imaging System in the second quarter of 2023, the system’s market-leading data quality and throughput continue to be very well-received, and we believe early customer feedback suggests that it is the strongest contender in the emerging field of spatial biology for translational research.

In addition, at the end of 2022, we completed the strategic repositioning of our microfluidics, or genomics, business, consolidating the portfolio to a single commercially available instrument, the Biomark X9, which combines the functionality of the Juno and the Biomark HD with improved workflow and performance. The Juno and Biomark HD are still available to legacy customers under certain circumstances. We continued to deliver the Signature Q100 microfluidics platform to our OEM collaborator, Olink Holding AB.

As discussed above, on January 5, 2024, we completed the Merger with SomaLogic, a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 11,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years, SomaLogic has supported pharmaceutical companies, and academic and contract research organizations who rely on SomaLogic’s protein detection and analysis technologies to fuel drug, disease and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases.

img186398206_1.jpg 

Standard BioTools offers a comprehensive suite of multi-omics technologies.

Our primary instrument offerings are summarized in the table below:

 

Product

 

Product Description

 

Applications

Single Cell Proteomics

 

 

 

 

 

 

 

 

 

Analytical Systems:

 

 

 

 

 

 

 

 

 

CyTOF XT™ System

 

The CyTOF XT mass cytometry system performs highly automated high-parameter (>50) single-cell analysis using antibodies conjugated to metal isotopes.

 

Flow Cytometry

 

 

 

 

 

Hyperion XTi™ Imaging System

 

Our third-generation spatial biology instrument, the Hyperion XTi™ Imaging System brings together

 

Tissue Imaging

5

 

Product

 

Product Description

 

Applications

 

 

imaging capability with proven high-parameter mass cytometry technology to enable the simultaneous detection of up to 40 protein markers in the spatial context of the tissue microenvironment.

 

 

 

 

 

 

 

Genomics

 

 

 

 

 

 

 

 

 

Analytical and Preparatory Instruments:

 

 

 

 

 

 

 

X9TM Real-Time PCR System

 

Real-time PCR analytical instrument, including pre-processing steps for microfluidics-based workflows using IFCs.

 

Real-time PCR analysis

 

 

 

 

 

BiomarkTM HD System

 

Real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs.

 

Real-time PCR analysis

 

 

 

 

 

IFC Controllers (HX, MX, and RX)

 

Each controller is designed to work with specific IFC formats: (i) IFC Controller MX- for priming and loading the 48.48 Dynamic ArrayTM IFC, the 12.765 Digital ArrayTM, IFC, the 48.770 Digital Array IFC, and qdPCR 37KTM , (ii) IFC Controller HX- for priming and loading the Flex SixTM Gene Expression IFC and Flex Six Genotyping IFC, 96.96 Dynamic Array IFC, (iii) IFC Controller RX- for loading the 192.24 Gene Expression IFC, 192.24 Genotyping IFC, and the 24.192 Dynamic Array IFC for gene expression.

 

Real-time PCR analysis

 

 

 

 

 

Integrated Fluidic Circuits

Our IFCs incorporate several different types of technology that together enable us to use multi-layer soft lithography (MSL) technology to rapidly design and deploy new microfluidic applications with state-of-the-art commercial manufacturing processes. The first level of our IFC technology is a library of components that perform basic microfluidic functions, such as pumps, mixers, single-cell capture chambers, separation columns, control logic, and reaction chambers. The second level of our IFC technology comprises the architectures we have designed to exploit our ability to conduct thousands of reactions on a single IFC. The third level of our IFC technology involves the interaction of our IFCs with the actual laboratory environment.

Instrumentation and Software

Our mass cytometry instrumentation technology includes a custom-designed inductively coupled plasma ion source, ion-optical and vacuum systems, and instrument control electronics. With our CyTOF systems, individual cells are atomized, ionized, and extracted. A time-of-flight mass analyzer separates atomic ions of different mass-to-charge ratios, providing information on temporal distribution of ions. Our Imaging Mass Cytometry systems combine mass cytometry technology with imaging capability to enable simultaneous interrogation of up to 50 protein markers in the spatial context of the tissue microenvironment. Our systems have the ability to utilize up to 135 channels to detect additional parameters to meet future market needs.

Our microfluidics-based X9 Real-Time PCR system includes our custom thermal cycler, a sophisticated fluorescence imaging system, and on-board scripting and protocol control software, and utilizes our IFC technology for a wide range automated genomics applications.

We also offer specialized software to manage and analyze the unusually large amounts of data produced by our systems. We offer Cytobank, our cloud-based platform of analytical tools, FCS Express7 Flow, and Maxpar Pathsetter data analysis packages for use with the CyTOF systems. For our Imaging Mass Cytometry platform, Hyperion, we offer various state of the art software packages to enable data analysis from basic to translational research: CyTOF Software 7.0, MCD Viewer, histoCAT, Visiopharm Phenomap and Indica Lab Halo. Our bioinformatic toolset, the Singular software, facilitates the analysis and visualization of single-cell gene expression data. More recently, we extended the scope of the toolset to include DNA analysis tools.

6

 

Assays and Reagents

We manufacture over 800 metal-conjugated antibodies for use with our mass cytometry and Imaging Mass Cytometry instruments to allow detection of up to 48 protein targets simultaneously in a single cell for a total of more than 50 detected cellular parameters. Our metal-conjugated antibodies are manufactured using metal-chelating polymers, which are produced using proprietary polymerization processes and subsequent post-polymerization modifications.

Our genotyping and single nucleotide polymorphism type (SNP Type) assay products consist of assay design and custom content delivery systems for gene expression and genotyping, respectively. These offerings provide low-cost alternatives to other available chemistries and allow customers to use IFCs in more flexible ways with validated assays for their targets of interest.

SomaLogic® Offerings and Applications

Effective with the closing of our Merger on January 5, 2024, our SomaLogic offering consists primarily of a service model whereby we receive samples (including from pharmaceutical, biotechnology or academic clients), perform the SomaScan® assay, and subsequently use bioinformatics and analytics to further refine the collected data and deliver the results back to the customer.

SomaScan® Assay

As of January 5, 2024, the SomaScan® assay measures approximately 11,000 protein targets in a single sample. The SomaScan® assay is designed to have breadth (or number of proteins measured), precision, specificity, dynamic range, depth (or lower limits of detection), and throughput. SomaScan® assay customers can also gain access to individual SOMAmer® reagents for a wide range of follow-up studies, which is a feature we consider to be a unique addition to our research services in comparison to the offerings of other proteomic platforms. The SomaScan 11K Platform is the largest proteomics offering available on the market.

SomaScan® Certified Sites

The SomaScan Certified Sites program allows global pharmaceutical and biotech companies, academic and core labs, and government research institutions to run our industry leading proteomics platform on site with the same precision, robustness, and reproducibility seen in our assay services facility. Certified Sites run the assay on the same equipment as in the SomaLogic Assay Service facility utilizing a reagent based kit. As of January 4, 2024, we had 17 Certified Sites, utilizing the SomaScan Assay kits.

SomaSignal™ Tests

As of January 5, 2024, we had 15 SomaSignal™ tests currently available for use as laboratory developed tests (LDTs) under our CLIA certification, with several more in various stages of development. As of January 5, 2024, we had 29 RUO tests primarily targeting clinical trial applications, such as characterizing and monitoring patients through the clinical trial cycle. We believe our SomaSignal™ tests will provide health systems and national health services with a leading-edge scientific tool set to allocate resources, risk stratify both populations and individual patients and personalize therapy.

SOMAmer® Reagents

Customers have been granted licenses to use a limited subset of our SOMAmer® reagents and to access to our Systematic Evolution of Ligands by Exponential enrichment (“SELEX”) technology in three ways: (i) through the transfer of individual reagents that have been developed by SomaLogic, (ii) through the transfer of custom reagents developed by SomaLogic on behalf of a customer, and (iii) through the development of custom reagents by a customer after receiving a license to perform the SELEX process and to use the subsequently developed reagents. An example of the commercial use of SOMAmer® reagents by a licensee of SomaLogic is the inclusion of SOMAmer® reagent-based inhibitors of thermophilic enzymes, such as polymerases used in a product category offered by certain biotechnology companies referred to as “hot-start” PCR amplification.

7

 

Customers

We sell our instruments and consumables for research use only (RUO) to leading academic research institutions, translational research and medicine centers, cancer centers, clinical research laboratories, and biopharmaceutical, biotechnology, and plant and animal research companies. One genomics customer accounted for 10% and 11% of our total revenue for the years ended December 31, 2023 and 2022, respectively.

Marketing, Sales, Service and Support

We distribute our systems through our direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in European, Latin American, Middle Eastern, and Asia-Pacific countries. Our sales and marketing efforts are targeted at laboratory directors and principal investigators at leading academic, translational research, healthcare consortiums, and biopharmaceutical companies who need reliable life science automation solutions to power their disease research with the goal of providing actionable insights.

Our sales process often involves numerous interactions and demonstrations with multiple people within an organization. Some potential customers conduct in-depth evaluations of the system, including running experiments on our system and competing systems. In addition, in most countries, sales to academic or governmental institutions require participation in a tender process involving preparation of extensive documentation and a lengthy review process. As a result of these factors and the budget cycles of our customers, our sales cycle, the time from initial contact with a customer to our receipt of a purchase order, can often be 12 months or longer.

Manufacturing

Our manufacturing operations are located in Singapore and Canada. Our facility in Singapore manufactures IFCs and assemblies of microfluidics instruments. In 2022, assembly of microfluidics instruments was insourced to our Singapore facility to reduce cost and improve product quality. All of our IFCs for commercial sale and some IFCs for our research and development purposes are also fabricated at our Singapore facility. Our mass cytometry instruments and reagents for commercial sale, as well as for internal research and development purposes, are manufactured at our facility in Canada. Our genomics reagent manufacturing was transferred from South San Francisco to Markham, Canada in late 2022.

Additionally, in connection with the Merger we acquired additional manufacturing operations in Boulder, Colorado. Our facility in Boulder manufactures reagents, SomaScan® assay kits, and other consumables used to run SomaScan® assays.

We rely on a limited number of suppliers for certain components and materials used in our products. Key components in Standard BioTools legacy products and SomaLogic products are supplied by sole or limited source suppliers. The loss of a single or sole source supplier would require significant time and effort to locate and qualify an alternative source of supply, if at all, and could adversely impact our business. For additional information, please refer to “Item 1A. Risk Factors.”

Laboratory Operations

We perform all of our SomaSignalTM tests in our laboratory facility located in Boulder, Colorado. Our laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare & Medicaid Services (CMS) in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and is licensed by certain other states requiring out-of-state licensure including California, Maryland, Pennsylvania and Rhode Island.

We believe that our existing laboratory facility is adequate to meet our business needs for at least the next 12 months and that additional laboratory space will be available on commercially reasonable terms, if required.

Quality Assurance

Our quality assurance function oversees the quality of our laboratory operations. We have established oversight for systems implementation and maintenance procedures, document control processes, supplier qualification, preventive or corrective actions and employee training processes that we believe achieves excellence in operations. We continuously monitor and improve our processes and procedures and believe this high-quality service leads to customer satisfaction and retention.

8

 

Research and Development

We have assembled experienced research and development teams at our South San Francisco, California, Markham, Ontario, Canada, and Singapore locations and have the scientific, engineering, software, bioinformatic, and process talent that we believe is required to grow our business.

The largest components of our current research and development efforts are in the areas of new products, new applications and new content. We launched our Hyperion Imaging System in October 2017. The Hyperion Imaging System provides spatial resolution of protein expression in complex tissue samples at the single-cell level, quantitative measurement using metal isotope tags, and analysis of up to 40 proteins, while having 135 channels available. We also developed metal-labeled antibodies compatible with formalin fixed paraffin embedded tissue samples, to be used with the Hyperion Imaging System. In 2022 we launched the Hyperion+ Imaging System, our second-generation imaging platform.

In 2019, we launched the Maxpar Direct Immune Profiling Assay, a sample-to-answer workflow for comprehensive human immune profiling for use with our CyTOF systems, which puts pre-titrated antibodies in dry format in a single tube, with automated software that provides data analysis in as few as five minutes. This assay is reproducible from site-to-site and lot-to-lot, which is important for translational and pharma/biotech research work. We have collaborated with industry partners to enable workflows and software for the Hyperion and CyTOF systems. Also in 2019, we added seven new metal antibody labels, becoming the first company to enable 50-plex cytometry panels, and launched three Imaging Mass Cytometry panel kits as well as CyTOF Software v7.0, an updated CyTOF software application.

In May 2021, we launched the new, fourth generation cell suspension mass cytometry system, CyTOF XT. Its main features include automation of sample introduction and acquisition, and lower cost of ownership and enhanced performance in resolution of cell populations. The system enables storage of pelleted samples in the cooled autosampler, automated resuspension of pellets, and addition of beads standards.

We also invest significantly in research and development efforts to expand our microfluidics applications. For example, we continue to develop and commercialize various panel sets for use with our systems. In 2017, we successfully launched the Advanta™ Immuno-Oncology Gene Expression Assay, which is a 170-gene expression qPCR assay that enables profiling of tumor immunobiology and new biomarker identification. In 2019, we launched the Advanta™ RNA-Seq NGS Library Prep Kit. Designed to drive significant improvement in the RNA-seq workflow, the Advanta RNA-Seq NGS Library Prep Kit together with the Juno™ system delivers an integrated solution for automated, cost-efficient NGS library prep. In 2020, we expanded our microfluidics franchise to develop products for the COVID-19 testing marketplace and we launched the AdvantaDx SARS-CoV-2 RT-PCR assay. These COVID-19 related products were discontinued in 2022.

In 2022, we launched the X9 Real Time PCR System: a next-generation system platform that integrates all the features of all our legacy platforms into one ultra-compact footprint with a simple-to-operate user interface. In addition, we secured significant development collaborations, including for development of OEM systems using our microfluidics technology.

The second component of our research and development effort is to continuously develop new manufacturing processes and test methods to drive down manufacturing costs, increase manufacturing throughput, widen fabrication process capability, and support new microfluidic devices and designs.

Additionally, in connection with the Merger we acquired research and development facilities in Boulder, Colorado and La Jolla, California. These facilities are focused on the discovery of protein biomarkers and the development of slow off-rate modified aptamers (SOMAmers®), which are modified nucleic acid-based protein binding reagents that are specific for their cognate proteins. The facility in La Jolla is specifically focused on creating small-mid plex solutions for SOMAmer® technology that will enable SomaLogic products to serve additional market segments.

We expect some synergies to be achieved in research and development activities as the combined company shares certain resources; however, the research and development efforts of SomaLogic and Standard BioTools will continue to operate independently for the foreseeable future, with primarily the same teams that were in place prior to the Merger.

Competition

The life science markets are highly competitive and expected to grow more competitive with the increasing knowledge gained from ongoing research and development. We believe that the principal competitive factors in our target markets include quality of product, cost of capital equipment and supplies; reputation among customers; innovation in product offerings; flexibility and ease of use; accuracy

9

 

and reproducibility of results; competition for human resources; and compatibility with existing laboratory processes, tools, and methods.

We compete with both established and development stage life science companies that design, manufacture, and market instruments for gene expression analysis, genotyping, other nucleic acid detection, protein expression analysis, imaging, and additional applications. In addition, a number of other companies and academic groups are in the process of developing novel technologies for life science markets. Many of our competitors enjoy several competitive advantages over us, including significantly greater name recognition; greater financial and human resources; broader product lines and product packages; larger sales forces and e-commerce channels; larger and more geographically dispersed customer support organizations; substantial intellectual property portfolios; larger and more established customer bases and relationships; greater resources dedicated to marketing efforts; better established and larger scale manufacturing capability; and greater resources and longer experience in research and development. For additional information, please refer to “Item 1A. Risk Factors.”

To successfully compete with existing products and future technologies, we need to demonstrate to potential customers that the performance of our technologies and products, the solutions we provide our customers, as well as our customer support capabilities, are superior to those of our competitors.

Intellectual Property

Patents

We have developed a portfolio of issued patents and patent applications directed towards commercial products and technologies in development. As of December 31, 2023, we owned or licensed approximately 400 patents and had over 175 pending patent applications worldwide. Our utility patents have expiration dates ranging up to year 2039, and our design patents have expiration dates ranging up to year 2047.

As of December 31, 2023, SomaLogic owned or licensed more than 660 patents and had approximately 435 pending patent applications worldwide. SomaLogic's utility patents have expiration dates ranging up to year 2043.

License Agreements

We have entered into licenses for technologies from various companies and academic institutions.

Genomics Technologies. Our core genomics technology originated at the California Institute of Technology (Caltech) in the laboratory of Professor Stephen Quake, who is a co-founder of Fluidigm (now Standard BioTools Inc.). We license genomics technology from Caltech, Harvard University, and Caliper Life Sciences, Inc. (Caliper), now a PerkinElmer company.

•
We exclusively license from Caltech relevant patent filings relating to developed technologies that enable the production of specialized valves and pumps capable of controlling fluid flow at nanoliter volumes. The license agreement will terminate as to each country and licensed product upon expiration of the last-to-expire patent covering licensed products in each country. The U.S. issued patents we have licensed from Caltech expire between now and year 2025.
•
We have entered into a co-exclusive license agreement with Harvard University for the license of relevant patent filings relating to genomics technology. The license agreement will terminate with the last-to-expire of the licensed patents. The U.S. issued patents we have licensed from Harvard University expire between now and year 2027.

Proteomics. Some of the intellectual property rights covering our mass cytometry products were subject to a license agreement (the Original License Agreement) between Fluidigm Canada Inc. (now Standard BioTools Canada Inc.), and PerkinElmer Health Sciences, Inc. (PerkinElmer). Under the Original License Agreement, Fluidigm Canada Inc, received an exclusive, royalty bearing, worldwide license to certain patents owned by PerkinElmer in the field of inductively coupled plasma (ICP)-based proteomics, including the analysis of elemental tagged materials in connection therewith (the Patents), and a non-exclusive license for reagents outside the field of ICP-based mass cytometry. In November 2015, we entered into a patent purchase agreement with PerkinElmer pursuant to which we purchased the Patents for a purchase price of $6.5 million and a patent assignment agreement pursuant to which PerkinElmer transferred and assigned to us all rights, title, privileges, and interest in and to the Patents and the Original License Agreement. Accordingly, we have no further financial obligations to PerkinElmer under the Original License Agreement. Contemporaneously with the purchase of the Patents, we entered into a license agreement with PerkinElmer pursuant to which we granted PerkinElmer a worldwide, non-exclusive, fully paid-up license to the Patents in fields other than (i) ICP-based mass analysis of atomic elements associated with a

10

 

biological material, including any elements that are unnaturally bound, directly or indirectly, to such biological material (Mass Analysis) and (ii) the development, design, manufacture, and use of equipment or associated reagents for such Mass Analysis. The license will terminate on the last expiration date of the Patents, currently expected to be in November 2026, unless earlier terminated pursuant to the terms of the license agreement.

InstruNor AS. In January 2020, we completed the acquisition of InstruNor AS (InstruNor) for $7.2 million, including $5.2 million in cash and $2.0 million in stock. InstruNor provided automated sample preparation solutions for proteomics and flow cytometry instrument markets and became part of Standard BioTools Inc.’s proteomics business. Included in this acquisition were certain intellectual property portfolio assets comprised of patents and/or patent applications directed to various aspects of automated cell pretreatment instruments. The expiration dates for the issued patents in this patent portfolio extended to March 2033. We recognized a $3.5 million impairment charge on InstruNor’s developed technology intangible asset in the second quarter of 2022 related to our discontinued Flow Conductor product line.

Any loss, termination, or adverse modification of our licensed intellectual property rights could have a material adverse effect on our business, operating results, and financial condition. For additional information, please refer to “Item 1A. Risk Factors.”

Other

In addition to pursuing patents and licenses on key technologies, we have taken steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, OEM counterparties and collaborators and, when needed, our advisers.

Government Regulation

We are subject to a variety of laws and regulations in the United States, the European Union and other countries. The level and scope of the regulation varies depending on the country or defined economic region, but may include, among other things, the research, development, testing, clinical trials, manufacture, storage, recordkeeping, marketing authorization, labeling, safety, efficacy, packaging, advertising, promotion and commercial sales and distribution, of many of our products.

Clinical Laboratory Improvement Amendments of 1988

We are required to hold certain federal, state and local licenses, certifications and permits to operate our clinical laboratory facility in Boulder, Colorado, including the performance of certain diagnostic assays. Under CLIA, we are required to hold a certificate applicable to the categories of laboratory tests we perform and to comply with standards applicable to our operations, including test processes, personnel, facilities administration, equipment maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA certification to be eligible to bill for diagnostic services provided to Medicare beneficiaries. Many commercial third-party payors also require CLIA certification as a condition of payment.

Our Boulder facility holds a current CLIA certificate. To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. We elect to participate in the accreditation program of CAP. CMS has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of inspection by CMS for CAP-accredited laboratories. Because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our business.

Penalties for non-compliance with CLIA or CAP requirements include suspension, limitation or revocation of the laboratory’s CLIA or CAP certificate, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties, as applicable.

State Laboratory Licensing

Our Boulder facility also holds a state license issued by the Colorado Department of Public Health and Environment (CDPHE). Colorado law and regulations establish standards for the day-to-day operation of a clinical laboratory, including the training and skills required of laboratory personnel and quality control.

Federal Oversight of Laboratory Developed Tests and Certain Devices

11

 

The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. We perform our diagnostic tests like the SomaSignal™ assays in our Boulder, Colorado CLIA-certified and CAP-accredited clinical laboratory, and we believe such tests are primarily regulated under CLIA, as administered by CMS, as well as by applicable state laws, as described above. The FDA regulates any diagnostic tests that meet the definition of a medical device, except under specific, narrow circumstances. The Federal Food, Drug and Cosmetic Act (FDCA) defines a medical device as "an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory, which is, among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes." By this definition, in vitro reagents and diagnostic tests are considered medical devices. Specifically, the FDA defines an in vitro diagnostic test (IVD), as "reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae." Therefore, the FDA generally considers diagnostic testing products like ours to be IVDs subject to the agency's regulatory requirements.

Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, pre-market clearance or approval, marketing and promotion and sales and distribution of medical devices, including IVDs, in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the export of medical devices manufactured in the United States to international markets. Many of the instruments, reagents, kits or other consumable products used within our laboratory facility are regulated as medical devices and therefore must comply with FDA quality system regulations and certain other device requirements. We have policies and procedures in place to ensure that we source such materials from suppliers that are in compliance with any applicable medical device regulatory requirements.

The FDCA classifies medical devices into one of three categories based on the risks associated with the device and the level of control necessary to provide reasonable assurance of safety and effectiveness. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices or devices deemed not substantially equivalent to a previously 510(k) cleared device, are categorized as class III. These devices typically require submission and approval of a premarket approval application (PMA). Devices deemed to pose lower risk are categorized as either class I or II. For most class II devices, a manufacturer must submit to the FDA a 510(k) premarket notification submission requesting clearance of the device for commercial distribution in the United States. However, some low-risk class II devices are exempted from this requirement. When a 510(k) premarket notification submission is required, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the device is "substantially equivalent" to a predicate device, which is: (i) a device that was legally marketed prior to May 28, 1976, for which PMA approval is not required, (ii) a legally marketed device that has been reclassified from class III to class II or class I, or (iii) another legally marketed, similar device that has been cleared through the 510(k) clearance process. Class II devices may also be subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling. Most class I devices are exempt from 510(k) premarket notification requirements, but like class II and III devices, are subject to general controls, such as registration and listing, quality system, labeling, and reporting requirements.

After the FDA permits a device to enter commercial distribution, numerous regulatory requirements apply. These include: the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; labeling regulations; the FDA’s general prohibition against promoting products for unapproved or "off-label" uses; and the medical device reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. The FDA has broad post-market and regulatory and enforcement powers. Failure to comply with the applicable U.S. medical device regulatory requirements could result in, among other things, warning letters, fines, injunctions, consent decrees, civil penalties, repairs, replacements, refunds, recalls or seizures of products, total or partial suspension of production, the FDA’s refusal to grant future premarket clearances or approvals, withdrawals or suspensions of current product applications, and criminal prosecution.

In February 2022, we were granted an Emergency Use Authorization (EUA) for our the Advanta Dx COVID-19 EASE Assay, which was authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab, oropharyngeal swab, mid-turbinate nasal swab, and anterior nasal swab specimens from individuals suspected of COVID-19 by their healthcare provider. Subsequently, in February 2023, the FDA granted our request to withdraw the EUA for our Advanta Dx SARS-CoV-2 RT-PCR Assay. We submitted our request to withdraw such EUA as we had discontinued commercial distribution of the product.

Although the FDA has statutory authority to assure that medical devices, including IVDs, are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable device regulations with respect to IVDs that are

12

 

designed, manufactured and used within a single high-complexity CLIA-certified laboratory. Such tests are referred to as LDTs. We believe that the SomaSignalTMassays we offer for clinical diagnostic use are LDTs, as are our near-term pipeline candidate tests intended for clinical diagnostic use. However, in October 2023, the FDA issued a proposed rule aimed at regulating LDTs under the current medical device framework and proposing to phase out its existing enforcement discretion policy for this category of diagnostic tests; the public comment period ended in early December 2023. The proposal envisions that the LDT enforcement policy phase-out process would occur in gradual stages over a total period of four years, with pre-market approval applications for high-risk tests to be submitted by the 3.5-year mark, although more details are expected to be provided with the upcoming final rule. The likelihood of the FDA finalizing the proposed rule in April 2024 (as is currently projected), as well as potential litigation challenging the agency’s authority to take such action, is uncertain at this time. Affected stakeholders continue to press for a comprehensive legislative solution to create a harmonized paradigm for oversight of LDTs by both the FDA and CMS, instead of implementation of the proposed FDA administrative action, which may be disruptive to the industry and to patient access to certain diagnostic tests.

Even though we presently commercialize some of our SomaSignalTM tests as LDTs, the FDA may disagree that such tests are within the scope of its current enforcement discretion criteria for LDTs, or our SomaSignalTM tests may in the future become subject to more onerous regulation by the FDA. For several years, members of Congress have been working with stakeholders on a possible bill to regulate in vitro clinical tests including LDTs. For example, as drafted and re-introduced for consideration in the 118th Congress, legislation called the Verifying Accurate, Leading-edge IVCT Development (VALID Act), has been garnering bipartisan and bicameral support. The VALID Act would codify into law the term "in vitro clinical test" (IVCT) to create a new medical product category separate from medical devices that includes products currently regulated as IVDs as well as LDTs. The VALID Act would also create a new system for labs and hospitals to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it takes for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients.

It is unclear whether the VALID Act would be passed by Congress in its current form or signed into law by the President. If the FDA finalizes its position on regulation of LDTs through the ongoing notice-and-comment rulemaking process or the VALID Act or other federal legislation is passed reforming the government’s regulation of LDTs, or alternatively, if the FDA disagrees with our assessment that our SomaSignalTMassays intended for clinical diagnostic use fall within the definition of an LDT, we could, for the first time, be subject to enforcement of regulatory requirements such as registration and listing requirements, medical device reporting requirements and quality control requirements. Any new legislation or FDA regulations affecting LDTs may result in increased regulatory burdens on our ability to continue marketing our tests and to develop and introduce new tests in the future. Additionally, if and when the FDA begins to actively enforce its premarket submission regulations with respect to LDTs generally or our SomaSignalTM tests in particular, whether as a result of new legislative authority or culmination of the current notice-and-comment rulemaking process, we may be required to obtain premarket clearance for our SomaSignalTM assays intended for clinical diagnostic use under Section 510(k) of the FDCA or approval of a PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to 12 months, but it can take significantly longer and clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA generally takes from one to three years or even longer and approval is not guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. If premarket review is required for some or all of our tests, the FDA could require that we stop selling our products pending clearance or approval and conduct clinical testing prior to making submissions to the FDA to obtain premarket clearance or approval. The FDA could also require that we label our SomaSignalTM tests as investigational or limit the labeling claims we are permitted to make.

Regulation of Clinical Trials

We may in the future conduct research studies for our SomaSignalTMtests intended for clinical diagnostic use and our other assays in development that involve clinical investigators and human subjects (or stored specimens from human subjects) at sites in the United States. We may need to conduct additional clinical trials for the SomaSignalTM tests for clinical use, as well as other tests we may offer in the future, to drive test adoption in the marketplace and reimbursement. Should we not be able to perform these studies, or should their results not provide clinically meaningful data and value for clinicians, adoption of our tests could be impaired and we may not be able to obtain reimbursement for them.

The conduct of clinical trials is also subject to extensive federal and institutional regulations intended to assure that the data and reported results are credible and accurate and that the rights, safety, and welfare of study participants are protected. Most studies involving human participants must be reviewed and approved by, and conducted under the auspices of, a duly-constituted institutional review board (IRB), which is a multi-disciplinary committee responsible for reviewing and evaluating the risks and benefits of a clinical trial for participating subjects and monitoring the trial on an ongoing basis. Companies sponsoring the clinical trials and investigators also must comply with, as applicable, regulations, guidelines and IRB requirements for obtaining informed consent from the study subjects, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. The sponsoring

13

 

company or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. In addition, trials involving human subjects often require significant time and cash resources to complete and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results.

Laboratory Technology for Research Use Only

Our proteomics, genomics, and analytical instruments, reagents, and other consumables are currently intended for, labeled and sold for research use only (RUO) applications, and we sell them to academic institutions, life sciences and clinical research laboratories that conduct research, and biopharmaceutical and biotechnology companies for non-clinical and non-diagnostic purposes. In addition, the SomaLogic offerings, other than the SomaSignalTM assays intended for clinical diagnostic use, are intended and offered for RUO applications. Such products are not intended or promoted for use in clinical practice in the diagnosis of disease or other conditions. Accordingly, they are not subject to pre- and post-market controls for medical devices by the FDA, with the exception that we must comply with the agency’s regulations relating to the labeling of IVDs intended for RUO applications. In accordance with such regulations, our RUO products are labeled, “For Research Use Only. Not for use in diagnostic procedures.”

The FDA’s final guidance document “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only” (the RUO/IUO Guidance), provides the FDA’s thinking on when IVDs are properly labeled for RUO or for IUO. The RUO/IUO Guidance explains that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA’s clearance, approval, or other regulatory requirements if the totality of circumstances surrounding the distribution of the product indicate that the manufacturer knows its product is being used by customers for clinical diagnostic uses or that the manufacturer intends such uses. These circumstances may include, among other things, written or verbal marketing claims regarding a product’s performance in clinical diagnostic applications, a manufacturer’s provision of technical support for clinical validation or clinical applications of the product, or solicitation of business from clinical laboratories, all of which FDA may consider evidence of intended uses that conflict with RUO/IUO labeling. In the future, certain of our products or related applications could become subject to regulation as medical devices by the FDA. If we are required to submit our products for pre-market review by the FDA, we may be required to delay marketing and commercialization while we obtain pre-market clearance or approval from the FDA. There would be no assurance that we could ever obtain such clearance or approval.

In some cases, our customers may, on their own initiative and without consulting us, use our RUO-labeled products in their own LDTs or in other FDA-regulated products for clinical diagnostic use.

Advertising of Laboratory Technologies and Services

Whether our proteomics or genomics technologies or our laboratory assays are not regulated by FDA, regulated as class I or class II devices, or subject to enforcement discretion with respect to FDA’s device requirements, advertising for such services and products is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (FTC), as well as comparable state consumer protection laws. Under the Federal Trade Commission Act (FTC Act), the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution.

Federal and State Anti-Kickback Laws

The Federal Anti-Kickback Statute makes it a felony for a person or entity, including a clinical laboratory, to knowingly and willfully offer, pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce or in return for the referral of an individual for the furnishing of, or the recommending or arranging for the furnishing of, purchasing, leasing, ordering or arranging for or recommending purchasing, leasing or ordering of any item or service that is reimbursable in whole or in part, under any federal healthcare program. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Courts have broadly interpreted the scope of the Anti-Kickback Statute and generally have held that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals.

14

 

In addition to statutory exceptions to the Anti-Kickback Statute, regulations provide for a number of safe harbors. If an arrangement meets the provisions of a safe harbor or exception, it is deemed not to violate the Anti-Kickback Statute, and the parties are immune from prosecution. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection.

Failure to meet the requirements of an exception or a safe harbor does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis, taking into account all facts and circumstances.

A violation of the Anti-Kickback Statute may result in imprisonment for up to ten years and significant fines for each violation and additional administrative civil money penalties, plus up to three times the amount of the remuneration paid. Convictions under the Anti-Kickback Statute result in mandatory exclusion from federal healthcare programs for a minimum of five years. In addition, a violation of the Anti-Kickback Statute can serve as the basis of liability under the federal False Claims Act, which is discussed in greater detail below.

Although the Anti-Kickback Statute applies only to items and services reimbursable under any federal healthcare program, a number of states, including California, have passed statutes substantially similar to the Anti-Kickback Statute that apply to all third-party payors, including commercial insurers, and, in some states, to patients without insurance. The California Attorney General and courts have interpreted the California anti-kickback and fee-splitting laws in substantially the same way as the courts have interpreted the Anti-Kickback Statute. Penalties under such state laws include imprisonment and significant monetary fines.

In addition, in October 2018, the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) was enacted as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. EKRA is an all-payor anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. However, unlike the Anti-Kickback Statute, EKRA is not limited to services covered by federal healthcare programs but applies more broadly to services covered by “healthcare benefit programs,” including commercial third-party payors. Although EKRA apparently was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. Further, certain of EKRA’s exceptions are inconsistent with the Anti-Kickback Statute and regulations. EKRA permits the U.S. Department of Justice to issue regulations clarifying EKRA’s exceptions or adding additional exceptions, but such regulations have not yet been issued.

Other Federal and State Healthcare Laws

In addition to the requirements discussed above, several other healthcare fraud and abuse laws could have an effect on our business. For example, federal law permits the Office of Inspector General for the Department of Health and Human Services (HHS-OIG) to exclude an individual or entity from Medicare or Medicaid for charging federal healthcare programs, including Medicare or Medicaid, substantially in excess of its usual charges for its items or services absent a finding of good cause. The terms “usual charge” and “substantially in excess” are subject to varying interpretations, and the HHS OIG has withdrawn multiple versions of a proposed rule intended to implement the statute.

The federal False Claims Act prohibits, among other things, a person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the alleged fraud pursuant to its qui tam provisions. Because the complaint in a qui tam action is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. Regardless of whether the government intervenes in the action, the relator, if successful, will receive a percentage of the recovery. In addition, providers and suppliers must report and return any overpayments received from the Medicare and Medicaid programs within 60 days of identification, and failure to identify and return such overpayments exposes the provider or supplier to federal False Claims Act liability. Violation of the federal False Claims Act may result payment of up to three times the actual damages sustained by the government, plus significant per-claim civil penalties, as well as mandatory exclusion from government healthcare programs. Several states, including California, have enacted comparable false claims laws that may apply regardless of payor.

The federal civil monetary penalties law (the CMP Law) prohibits, among other things, (1) the offering or transfer of remuneration (including a waiver of copayments and deductible amounts) to a Medicare or Medicaid beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or Medicaid, unless an exception applies; (2) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal healthcare program; (3) billing for services requested by an unlicensed physician or an excluded provider; (4) billing for medically unnecessary services; and (5) presenting or causing to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or

15

 

fraudulent. The penalties for violating the CMP Law may include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense.

Federal criminal statutes prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including those administered by commercial payors, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, this federal criminal statute requires a showing of intent, but a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

The Physician Payments Sunshine Act imposes annual reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare providers (such as nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians (as defined under the statute) and their immediate family members. It applies to manufacturers when their products become eligible for reimbursement under a federal healthcare program such as Medicare or Medicaid. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own IVD products solely for use by or within our Boulder laboratory facility, we believe that we are exempt from these reporting requirements. We may become subject to such reporting requirements under the terms of current CMS regulations, however, if enacted federal legislation renders our tests regulated by FDA, or if FDA finalizes its recently initiated notice-and-comment rulemaking to exercise authority over LDTs as medical devices or otherwise requires us to obtain premarket clearance or approval for one or more of our tests. A determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition.

We are also subject to applicable state restrictions on laboratory billing. These laws vary from state to state but generally are intended to prevent a provider who ordered but did not perform the service from billing for that service at a markup. For example, California has an anti-markup statute with which we must comply, which prohibits a provider from charging for any laboratory test that it did not perform unless the provider (a) notifies the patient, client or customer of the name, address and charges of the laboratory performing the test, and (b) charges no more than what the provider was charged by the clinical laboratory that performed the test except for any other service actually rendered to the patient by the provider (for example, specimen collection, processing and handling). This provision applies, with certain limited exceptions, to licensed persons such as physicians and clinical laboratories regulated under California’s Business and Professions Code. A violation of this provision can lead to imprisonment and/or a fine of up to $10,000. Other states have similar anti-markup and other client billing restrictions with which we must comply. Many states also have "direct-bill" laws, which require the party that performed the service to bill for the service, with certain exceptions.

If our operations are found to be in violation of any of the fraud and abuse laws described above or any other healthcare regulatory laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

U.S. Data Privacy and Security Laws

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) established comprehensive federal standards for the privacy and security of health information. In 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act (HITECH) provisions of the American Recovery and Reinvestment Act of 2009. HITECH amended HIPAA and, among other things, expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance and established new breach notification requirements. HIPAA applies to health plans, healthcare clearing houses and healthcare providers that conduct certain healthcare transactions electronically (collectively, Covered Entities), as well as individuals or entities that perform services for them involving the use, or disclosure of, individually identifiable health information or "protected health information" (PHI) under HIPAA (Business Associates). Under HIPAA, as amended by the HITECH Act, the U.S. Department of Health and Human Services (HHS) has issued regulations to protect the privacy and security of PHI used or disclosed by Covered Entities and Business Associates. HIPAA also regulates and standardizes the codes, formats and identifiers used in certain healthcare transactions and standardization of identifiers for health plans and providers, for example insurance billing. Any non-compliance with HIPAA and HITECH and related penalties, could adversely impact our business.

The HIPAA security standards require the adoption of administrative, physical and technical safeguards and the adoption of written security policies and procedures to maintain the security of protected health information.

16

 

The HIPAA privacy regulations address the privacy of PHI by limiting the use and release of such information. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a Covered Entity, including the right to access or amend certain records containing PHI, request an accounting of disclosures of PHI or to request restrictions on the use or disclosure of PHI. The HIPAA breach notification regulations impose certain reporting requirements on Covered Entities and their Business Associates in the event of a breach of PHI.

Covered Entities must report breaches of PHI that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of HHS (the Secretary). Breaches must be reported as soon as reasonably practicable, but no later than 60 days following discovery of the breach. Reports must be made to affected individuals, the HHS Secretary, and depending on the size of the breach, the local and national media. Covered Entities are also subject to the HHS HIPAA audit program and may be investigated in connection with a privacy or data security complaint.

Significant civil and criminal fines and other penalties may be imposed for violating HIPAA directly, and in connection with acts or omissions of any agents, including downstream business associates, as determined according to the federal common law of agency. Civil penalties are adjusted for inflation on an annual basis and can exceed $1.0 million per year for failure to comply with a HIPAA requirement. A single breach incident can violate multiple requirements. Additionally, a person who knowingly obtains or discloses PHI in violation of HIPAA may face criminal penalties (including fines and imprisonment), which increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use PHI for commercial advantage, personal gain or malicious harm. Covered Entities are also subject to enforcement by state Attorneys General who were given authority to enforce HIPAA.

Additionally, while HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.

Even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers’ personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTC Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC and state Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act and comparable state laws.

The HIPAA privacy and security regulations establish a uniform federal "floor" and do not preempt state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI. Certain state laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. The State of California, for example, has implemented comprehensive laws and regulations. The California Confidentiality of Medical Information Act (CMIA), imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. California has also recently adopted the California Consumer Privacy Act of 2018 (CCPA), which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. It also creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the law includes limited exceptions, including for PHI maintained by a Covered Entity or Business Associate under HIPAA and medical information maintained by healthcare providers under the CMIA, it may regulate or impact our processing of personal information depending on the context. Further, the California Privacy Rights Act (CPRA) went into effect January 1, 2023 amending and strengthening the CCPA. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data and expands the application of the CCPA to all human resources personal information of our California-based employees. It also created a new California data protection agency authorized to issue substantive regulations and is expected to result in increased privacy and information security enforcement. Various states such as Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, Texas, Utah and Virginia have enacted their own privacy laws similar to the CCPA, and other states are considering proposals for such laws, all of which increases the complexity of compliance and the risk of failures to comply.

17

 

Numerous other federal and state laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or medical information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, all 50 states have passed laws regulating the actions that a business must take if it experiences a data breach, as defined by state law, including prompt disclosure within a specified amount of time to affected individuals. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. Congress has also been considering similar federal legislation relating to data privacy and data protection.

Many states, such as Massachusetts, have also implemented genetic testing and privacy laws imposing specific patient consent requirements and requirements for protecting test results. The interplay of federal and state laws regulating genetic information may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on genetic privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify.

Information Blocking Rules

The Office of the National Coordinator for Health Information Technology (ONC), coordinates the ongoing development of standards to enable interoperable health information technology infrastructure nationwide in the healthcare sector. In May 2020, ONC released the final Information Blocking Rule to implement the interoperability and patient access provisions of the 21st Century Cures Act. We will need to continually review our practices for conduct that could be considered as likely to interfere with access, exchange or use of electronic health information, as those practices are prohibited by the Information Blocking Rule, unless one of the exceptions outlined in the Information Blocking Rule applies. Among other things, the Information Blocking Rule requires us to provide patients with on-demand access to laboratory test results. These requirements can be inconsistent with our obligations as a laboratory under state law and/or medical or ethical standards. It is currently unclear how the ONC will approach delays in providing patient access in these situations. Healthcare providers including laboratories will be subject to civil monetary penalties for violations of the Information Blocking Rule once the penalty regulations are finalized. The amount of such penalties is unknown, but the regulations for health industry networks (HINs), health information exchanges (HIEs), and certified developers of health information technology allow for up to $1.0 million in penalties per violation.

International Laws and Regulations

Many countries in which we may offer any of our testing products in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national healthcare program. In situations involving physicians employed by state-funded institutions or national healthcare agencies, violation of the local anti-kickback law may also constitute a violation of the U.S. Foreign Corrupt Practices Act (FCPA), and/or other applicable anti-corruption laws.

The FCPA prohibits any U.S. individual, business entity or employee of a U.S. business entity from offering or providing, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors’ activities that may fall within the purview of the FCPA, including its books and records provisions and its anti-bribery provisions.

The standard of intent and knowledge under the FCPA’s anti-bribery provisions is minimal intent and knowledge are usually inferred from the fact that bribery took place. The FCPA’s accounting provisions do not require intent. Violations of the FCPA’s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2.0 million and officers, directors, stockholders, employees and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other Organisation for Economic Co-Operation and Development Anti-Bribery Convention members, have similar anti-corruption regulations, such as the U.K. Bribery Act.

18

 

When marketing our testing products outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our testing products or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.

European Union IVD Laws and Regulations

Whether or not we are required to comply with requirements for marketing clinical diagnostic products in the United States, we may be required to obtain marketing authorizations from regulatory authorities in non-United States countries prior to the marketing of any product for clinical diagnostic use in such countries. The laws and regulations relating to laboratory equipment, reagents and assays in other jurisdictions vary from those in the United States and may be easier or more difficult to satisfy and are subject to change. For example, in the European Union (EU), IVDs had been regulated under EU-Directive 98/79/EC (IVD Directive) and corresponding national provisions prior to May 2022. The IVD Directive required that medical devices, including IVDs, meet the essential requirements, including those relating to device safety and efficacy, set out in an annex of the Directive. According to the IVD Directive, EU Member States have presumed compliance with these essential requirements for devices that are in conformity with the relevant national standards transposing the harmonized standards, such as ISO 13485:2016, the quality system standard for medical device manufacturers.

IVDs, other than devices for performance evaluation, must bear the CE marking of conformity when they are placed on the European market. The CE mark is a declaration by the manufacturer that the product meets all the appropriate provisions of the applicable legislation implementing the relevant European Directive. As a general rule, the manufacturer must follow the EU declaration of conformity procedure to obtain or apply a CE mark.

In May 2022, the Directive was replaced by the In Vitro Diagnostic Device Regulation (IVDR) (EU) 2017/746 that was published in May 2017 and given a 5-year transition period until its full implementation on May 26, 2022. Unlike the IVD Directive, the IVDR has binding legal force throughout every Member State. The major goal of the IVDR was to standardize diagnostic procedures within the EU, increase reliability of diagnostic analysis and enhance patient safety. Under the IVDR as enacted by the European Commission (EC), IVDs are subject to additional legal regulatory requirements. Among other things, the IVDR introduces a new risk-based classification system and requirements for conformity assessments. Under the IVDR and subsequent amendments, IVDs already certified by a Notified Body under the IVD Directive may remain on the market until May 26, 2025, and IVDs certified without the involvement of a Notified Body may be placed on, or remain in, the market for up to three additional years (until May 26, 2028) depending on the classification of the IVD. The manufacturers of such devices remaining on the market must comply with specific requirements in the IVDR, but ultimately, such products, as with all new IVDs, will have to undergo the IVDR’s conformity assessment procedures. In addition, the IVDR imposes additional requirements relating to post-market surveillance and submission of post-market performance follow-up reports.

The EC has designated 12 Notified Bodies to perform conformity assessments under the IVDR. MedTech Europe has issued guidance relating to the IVDR in several areas, e.g., clinical benefit, technical documentation, state of art, accessories, and EUDAMED. On December 5, 2023, the European Commission adopted Implementing Regulation (EU) 2023/2713 designating five EU Reference Laboratories covering the following types of high risk, class D IVDs: hepatitis and retroviruses; herpesviruses; bacterial agents; respiratory viruses that cause life-threatening diseases. The designated EU Reference Laboratories are responsible for verifying performance of IVDs in accordance with common specifications, batch testing of class D IVDs, collaborating with Notified Bodies to develop best practices for IVD conformity assessments, and providing scientific and technical assistance on the implementation of the IVDR.

International Data Privacy and Security Laws

The collection and use of personal health data in the EU is governed by the General Data Protection Regulation, or GDPR. The GDPR applies to any company established in the European Economic Area, or EEA, (which includes the EU Member States plus Iceland, Liechtenstein, and Norway) and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR establishes stringent requirements applicable to the processing of personal data, including strict requirements relating to the validity of consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct data protection impact assessments for “high risk” processing, limitations on retention of personal data, special provisions affording greater protection to and requiring additional compliance measures for “special categories of personal data” including health and genetic information of data subjects,

19

 

mandatory data breach notification (in certain circumstances), “privacy by design” requirements, and direct obligations on service providers acting as processors. The GDPR also prohibits the international transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place. Failure to comply with the GDPR requirements may subject an entity to litigation, regulatory investigations, enforcement notices and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.

Among other requirements, the GDPR also regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data. For example, in 2016, the EU and the United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Court of Justice of the EU invalidated the Privacy Shield when it decided the case Maximilian Schrems vs. Facebook (Case C-311-18), known as Schrems II. However, on July 10, 2023, the European Commission adopted an adequacy decision for a new mechanism for transferring data from the EU to the United States – the EU-US Data Privacy Framework, which provides EU individuals with several new rights, including the right to obtain access to their data, or obtain correction or deletion of incorrect or unlawfully handled data. The adequacy decision followed the signing of an executive order introducing new binding safeguards to address the points raised in the Schrems II decision. Notably, the new obligations were geared to ensure that data can be accessed by U.S. intelligence agencies only to the extent necessary and proportionate and to establish an independent and impartial redress mechanism to handle complaints from Europeans concerning the collection of their data for national security purposes. The European Commission will continually review developments in the United States along with its adequacy decision. Adequacy decisions can be adapted or even withdrawn in the event of developments affecting the level of protection in the applicable jurisdiction. Future actions of EU data protection authorities are difficult to predict. Some customers or other service providers may respond to these evolving laws and regulations by asking us to make certain privacy or data-related contractual commitments that we are unable or unwilling to make. This could lead to the loss of current or prospective customers or other business relationships.

Relatedly, following the United Kingdom’s withdrawal from the EU, the GDPR was implemented in the United Kingdom as the U.K. GDPR. which sits alongside the amended U.K. Data Protection Act 2018, which implements certain derogations in the EU GDPR into UK law. Under the U.K. GDPR, companies not established in the United Kingdom but who process personal data in relation to the offering of goods or services to individuals in the United Kingdom, or to monitor their behavior will be subject to the U.K. GDPR – the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to £17.5 million or 4% of global turnover. In June of 2021, the European Commission issued a decision, which will sunset on June 27, 2025 without further action, that the United Kingdom ensures an adequate level of protection for personal data transferred under the EU GDPR from the EU to the United Kingdom. The U.K. Parliament is currently considering the Data Protection and Digital Information Bill to harmonize the 2018 Data Protection Act, U.K. GDPR, and the Privacy and Electronic Communications Regulations under one legislative framework.

In China, rules relating to personal data protection and data security are part of a complex framework and are found across various laws and regulations. The three main pillars of the personal data protection framework in China are the Personal Information Protection Law (PIPL), the Cybersecurity Law (CSL) and the Data Security Law (DSL). The CSL, which became effective on June 1, 2017, and the Cybersecurity Review Measures promulgated by the Cyberspace Administration of China (CAC), provide that personal information and important data collected and generated by a critical information infrastructure operator in the course of its operations in mainland China must be stored in mainland China, and if a critical information infrastructure operator purchases internet products and services that affect or may affect national security, it should be subject to national security review by the CAC together with competent departments of the State Council. The DSL came into force on September 1, 2021, and requires that data (not limited to personal data) shall not be collected by theft or other illegal means, and it also provides for a data classification and hierarchical protection system, which protects data according to its importance in economic and social development and the potential damage to national security, public interests, or the legitimate rights and interests of individuals and organizations if the data is falsified, damaged, disclosed, illegally obtained or illegally used. Most significantly, the PIPL came into effect on November 1, 2021. The PIPL is the first comprehensive, national–level personal data protection law in China. The PIPL mirrors certain provisions found under the GDPR such as the purpose limitation principle, the concept of a data protection officer, data subject rights, the requirement to conduct data protection impact assessments, and restrictions on data exports. With respect to data exports, China has adopted its own standard contractual clauses which qualifying businesses can use to legitimize their data exports.

Other countries, such as Brazil and Japan, have enacted or amended omnibus laws, and others, such as Russia, have also passed laws that require personal data relating to their citizens to be maintained in the country under certain circumstances and impose additional data transfer restrictions. In addition, India enacted new privacy legislation, the Digital Personal Data Protection Act, 2023, which applies to the processing of personally identifiable digital data about an individual whether the data is processed in India or outside of the country in connection with the offering of goods or services to data subjects who are residents of India. Complying with these

20

 

numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of personal data (including sensitive or confidential patient or consumer information), whether by us or a third-party, could have a material adverse effect on our business, reputation, financial condition and results of operations, including but not limited to: material fines and penalties; damages; litigation; consent orders; extensive audits and inspections; bans on all or some processing of personal data carried out by noncompliant actors; and injunctive relief.

Environmental Matters

We are subject to many federal, state, local, and foreign environmental regulations. To comply with applicable regulations, we have and will continue to incur significant expenses and allocate internal resources to manage compliance-related issues. In addition, such regulations could restrict our ability to expand or equip our facilities or could require us to acquire costly equipment or to incur other significant expenses to comply with the regulations. For example, the Restriction on the Use of Certain Hazardous Substances in Electrical and Electronic Equipment Directive (RoHS), the Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) and the Waste Electrical and Electronic Equipment Directive (WEEE), enacted in the European Union, regulate the use of certain hazardous substances, notification of customers of the presence of any substances of very high concern in products, and require the collection, reuse, and recycling of waste from, products we manufacture. Certain products sold in these countries are subject to RoHS, REACH and WEEE requirements. If we fail to comply with any present and future regulations, we could be subject to future fines, penalties, and restrictions, such as the suspension of manufacturing of our products or a prohibition on the sale of products we manufacture. For additional information, please refer to “Item 1A. Risk Factors.”

Our research and development and manufacturing processes also involve the controlled use of hazardous materials, including flammables, toxics, corrosives, and biologics. Our research and manufacturing operations produce hazardous biological and chemical waste products. We seek to comply with applicable laws regarding the handling and disposal of such materials. The volume of such materials used or generated at our facilities is small. However, we cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We do not currently maintain separate environmental liability coverage and any such contamination or discharge could result in significant cost to us in penalties, damages, and suspension of our operations.

Geographic Area Information

During the last two years, a significant portion of our revenue was generated outside of the United States. Total revenue received from customers outside the United States was $62.2 million, or 59% of our total revenue, in 2023, compared to $56.9 million, or 58% of our total revenue, in 2022. The majority of our long-lived assets are located within the United States, Singapore and Canada. Refer to Note 3 to our consolidated financial statements for additional information regarding geographic areas.

Seasonality

Our fourth quarter revenues are often the highest, primarily due to seasonality since many of our customers tend to spend budgeted money before the end of their calendar fiscal year-end. Our revenue in the first quarter is generally sequentially lower than the prior year’s revenue in the fourth quarter.

Raw Materials

Certain raw materials used in our Delta Gene and SNP Type assays and Access Array target-specific primers are available from a limited number of sources. Additionally, certain metals used in our Maxpar reagents are available from a sole source. Currently, we do not have supply agreements with these suppliers. While we generally attempt to keep our inventory at minimal levels, we purchase incremental inventory as circumstances warrant to protect our supply chain.

Backlog

We manufacture products based on forecasts of our customers’ demand and advance non-binding commitments from customers as to future purchases. Our customers generally do not place purchase orders far in advance. A substantial portion of our products are sold on the basis of standard purchase orders that are cancellable prior to shipment without penalty. Accordingly, backlog at any given time is not a meaningful indicator of future sales.

21

 

Human Resource Capital

Our team members share our commitment to improving the human condition and, in turn, Standard BioTools strives to create an environment where our people can do their best work. We know that our employees, who supply the ideas, energy, and innovation that powers our business, are amongst some of Standard BioTools’ valued assets.

We are a values-driven organization. We believe strong shared values are essential for Standard BioTools to evolve and grow and to be successful for the long-term. Our values form our relationships with customers, suppliers, investors and each other. They help us to model respect and inclusiveness in our words and actions. Our core values conceived and developed by our employees are:

•
Customer commitment
•
Integrity
•
Respect
•
Continuous improvement

A Diverse Global Workforce

As of December 31, 2023, Standard BioTools had a total of 539 employees worldwide of which 534 were full-time employees and 130 were located in the United States. Additionally, 47% of our employees worldwide were female and 35% of our employees in the United States were female as of December 31, 2023. None of our employees are represented by a labor union nor are they subject to a collective bargaining agreement. Subsequent to the Merger with SomaLogic, which was completed on January 5, 2023, we had approximately 928 employees worldwide, with 510 employed in the United States and 418 employed at other non-U.S. locations.

Information About Our Executive Officers and Directors

The following persons were our executive officers and directors as of February 21, 2024:

Name

Position

Executive Officers

Michael Egholm, Ph.D.

President, Chief Executive Officer, and Director

Jeffrey Black

Chief Financial Officer

Hanjoon Alex Kim

Chief Operating Officer

Non-Employee Directors

Tom Carey

Chairperson of the Board of Directors

Fenel M. Eloi

Managing Partner of P&M Capital Partners, LLC

Eli Casdin

Founder and Chief Investment Officer of Casdin Capital, LLC and its affiliates

Troy Cox

Director and Chairperson of the Board of Directors of SOPHiA GENETICS SA, Director and Vice Chairperson of the Board of Directors of LetsGetChecked Inc., and Director at Zymeworks Inc.

Kathy Hibbs

Chief Administrative Officer of 23andMe

Frank Witney, Ph.D.

Operating Partner at Ampersand Capital Partners

Compensation and Benefits

The primary goal of our compensation program is to ensure that we attract, hire, and retain talented and highly skilled team members who are motivated to achieve or exceed our corporate goals.

22

 

We offer competitive total reward packages comprising various elements including market-driven base pay, short- and long-term incentives in the form of performance-based cash and equity, as well as comprehensive health and welfare benefits that include medical, dental, vision, group life, disability, and accidental death and dismemberment insurance, as well as our 401(k) or comparable non-U.S. retirement plans, subject to applicable law. We also provide vacation and other paid holidays to all employees at levels that we believe are comparable to those provided at peer companies.

Our intention is to align our compensation practices with the changing marketplace. By doing so, we strive to provide incentives to our team members to achieve short-term and long-term business goals, ensuring they feel rewarded for their performance and contributions.

Professional Development

In addition to providing attractive and competitive total rewards packages, Standard BioTools believes in fostering individual and organizational effectiveness by offering our team members a variety of professional development programs. These programs are designed to:

•
inform, educate, and inspire our people to reach their professional goals;
•
provide professional growth opportunities in different, easily accessible ways to accommodate diverse learning styles, including via classroom/live instructor-led trainings, online/e-learning modules, webinar/virtual trainings, blended learning, and professional coaching;
•
provide individuals and the organization with the knowledge and skills to respond effectively to customer needs as well as current and future business demands; and
•
provide ongoing support to the organization’s development efforts.

Diversity and Inclusion

At Standard BioTools, our commitment to diversity, inclusion and equity is reflective of our values. We believe that we are strongest when we embrace all forms of diversity, and that it is essential to seek out diverse, innovative ideas and foster an inclusive culture where all colleagues are respected and engaged. We endeavor to apply this commitment to diversity to every aspect of the employee experience, from recruitment to development, training and advancement.

Corporate and Available Information

We were incorporated in California in May 1999 as Mycometrix Corporation, changed our name to Fluidigm Corporation in April 2001, and reincorporated in Delaware in July 2007. On April 1, 2022, the Company changed its name from Fluidigm Corporation to Standard BioTools Inc. Our principal executive offices are located at Two Tower Place, South San Francisco, California 94080. Our telephone number is (650) 266-6000. Our website address is www.standardbio.com. We make available on our website, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC). Our SEC reports can be accessed through the investor relations page of our website located at http://investors.standardbio.com. The SEC also maintains an internet site at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

The contents of our website are not a part of, and are not incorporated by reference into, this Annual Report or any other report or document we file with the SEC. Any reference to our website is intended to be an inactive textual reference only.

We intend to use our website, www.standardbio.com as a means of disclosing material non-public information and for complying with our disclosure obligations under SEC Regulation FD. Such disclosures will be included on our website under “About> Investors.” Accordingly, investors should monitor the “Investors” section of our website, in addition to following our press releases, SEC filings, and public conference calls and webcasts.

23

 

Item 1A. Risk Factors

We operate in a rapidly changing environment that involves numerous uncertainties and risks. The following risks and uncertainties may have a material and adverse effect on our business, financial condition, or results of operations. You should consider these risks and uncertainties carefully, together with all of the other information included or incorporated by reference in this Annual Report. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, global sociopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price. If any of these risks occur, our business, results of operations, or financial condition could suffer, the trading price of our securities could decline, and you may lose all or part of your investment.

Summary of Risk Factors

Risks Related to our Business, Industry, and Strategy

 

•
Our financial results and revenue growth rates have varied significantly from quarter-to-quarter and year-to-year, and may not be consistent with expectations.
•
If we engage in future acquisitions or strategic collaborations, our capital requirements may increase, our stockholders may be diluted, we may incur debt or assume contingent liabilities, and we may be subject to other risks.
•
We have incurred losses since inception, and we may continue to incur substantial losses for the foreseeable future.
•
We are subject to risks associated with natural disasters and global events.
•
Market opportunities may not develop as we expect.
•
The life science markets are highly competitive and subject to rapid technological change.
•
If our research and product development efforts do not result in commercially viable products within anticipated timelines, if at all, our business and results of operations will be adversely affected.
•
Our future success is dependent upon our ability to expand our customer base and introduce new applications.
•
If our products fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected.
•
If we fail to achieve the expected financial and operational benefits of our recently announced restructuring plan and other strategic initiatives, our business and financial results may be harmed.
•
The planned implementation of a new company-wide enterprise resource planning (ERP) system could adversely affect our business.
•
Our business growth strategy involves the potential for significant acquisitions, and our operating results and prospects could be harmed if we are unable to integrate future acquisitions successfully.

Risks Related to Operations and Reliance on Third Parties

 

•
We may experience development or manufacturing problems or delays.
•
Our business depends on research and development spending levels of our customers.
•
Disruption of our manufacturing facilities or other operations, or in the operations of our customers or business partners, could result in cancellation of orders, delays in deliveries or other business activities, or loss of customers.
•
We rely on single and sole source suppliers for some of the components and materials used in our products.
•
We may not be able to convert our orders in backlog into revenue.
•
Any disruption or delay in the shipping or off-loading of our products may have an adverse effect on our financial condition and results of operations.
•
Our business operations depend upon the continuing efforts of our management team and other skilled and experienced personnel.
•
Our distribution capabilities and direct sales, field support, and marketing forces must be sufficient to meet our customers’ needs.
•
To use our analytical systems, customers typically need to purchase specialized reagents.
•
Security incidents, loss of data, cyberattacks, and other IT failures could adversely affect our business.

24

 

Risks Related to Quality and the Regulatory Environment

 

•
Our products could have defects or errors.
•
To the extent we elect to label and promote any of our products as medical devices, we would be required to obtain prior approval or clearance by the U.S. Food and Drug Administration (FDA) or comparable foreign regulatory authority.
•
Compliance or the failure to comply with current and future regulations affecting our products and business operations worldwide could cause us significant expense and adversely impact our business.

Risks Related to Economic Conditions and Operating a Global Business

 

•
We generate a substantial portion of our revenue internationally and our international business exposes us to additional business, regulatory, political, operational, financial, and economic risks.
•
Adverse conditions in the global economy may significantly harm our revenue, profitability, and results of operations.
•
We are subject to fluctuations in the exchange rate of the U.S. dollar and foreign currencies.

Financial, Tax, and Accounting Risks

 

•
Our future capital needs are uncertain and we may need to raise additional funds in the future.
•
Any failure to maintain effective internal control over financial reporting could adversely affect our business.
•
We may not realize the value of our goodwill or other intangible assets.
•
If we fail to comply with the covenants and other obligations under our debt facilities, the lenders may be able to accelerate amounts owed under the facilities and, in the case of our Credit Facility (as defined below), may foreclose upon the assets securing our obligations.
•
We are subject to risks related to taxation in multiple jurisdictions.
•
We have a significant amount of outstanding indebtedness.

Risks Related to Intellectual Property

 

•
Our ability to protect our intellectual property and proprietary technology is uncertain.
•
We may be involved in lawsuits to protect or enforce our patents and proprietary rights.
•
We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets.
•
We depend on certain technologies that are licensed to us.
•
We are subject to certain manufacturing restrictions related to licensed technologies that were developed with the financial assistance of U.S. governmental grants.
•
We are subject to certain obligations and restrictions relating to technologies developed in cooperation with Canadian government agencies.

Risks Related to the Recently Completed Merger

 

•
We have been exposed to litigation related to the Merger and may in the future be exposed to increased litigation, including stockholder litigation, which could have an adverse effect on our business and operations.
•
Combining the two companies may be more difficult, costly or time consuming than expected, and Standard BioTools may not realize all of the anticipated benefits of the Merger.

Risks Related to our Capital Structure

 

•
The holders of our Series B Preferred Stock (as defined below) own a significant portion of our total outstanding voting securities and may prevent other stockholders from influencing material corporate decisions.
•
The market value of our common stock could decline if the holders of our Series B Preferred Stock sell their shares.
•
The holders of our Series B Preferred Stock may exercise influence over us, including through their ability to designate members of our board of directors.

 

25

 

RISKS RELATED TO OUR BUSINESS, INDUSTRY, AND STRATEGY

Our financial results and revenue growth rates have varied significantly from quarter-to-quarter and year-to-year due to a number of factors, and a significant variance in our operating results or rates of growth from our financial guidance or market expectations, if any, could lead to substantial volatility in our stock price.

Our revenue, results of operations, and revenue growth rates have varied in the past and may continue to vary significantly from quarter-to-quarter or year-to-year. We may experience substantial variability in our product mix from period-to-period as revenue from sales of our instruments relative to sales of our consumables may fluctuate or deviate significantly from expectations. We may be unable to achieve revenue growth in future periods similar to some past years. Variability in our quarterly or annual results of operations, mix of product revenue, or rates of revenue growth, if any, may lead to volatility in our stock price as research analysts and investors respond to these fluctuations. These fluctuations are due to numerous factors that are difficult to forecast, including:

•
fluctuations in demand for our products;
•
changes in customer budget cycles, capital spending, and the availability of VAT and import tax exemptions;
•
seasonal variations in customer operations;
•
tendencies among some customers to defer purchase decisions to the end of the quarter;
•
the large unit value of our systems, particularly our proteomics systems;
•
changes in our pricing and sales policies or the pricing and sales policies of our competitors;
•
our ability to design, manufacture, market, sell, and deliver products to our customers in a timely and cost-effective manner;
•
our ability to timely obtain adequate quantities of the materials or components used in our products, which in certain cases are purchased through sole and single source suppliers;
•
staffing shortages, lack of skilled labor, increased turnover, and competitive job markets;
•
fluctuations or reductions in revenue from sales of legacy instruments that may have contributed significant revenue in prior periods;
•
quality control or yield problems in our manufacturing operations;
•
new product introductions and enhancements by us and our competitors;
•
unanticipated increases in costs or expenses;
•
our complex, variable and, at times, lengthy sales cycle;
•
trade restrictions and government protectionism;
•
global economic conditions; and
•
fluctuations in foreign currency exchange rates.

Additionally, we have certain customers who have historically placed large orders in multiple quarters during a calendar year. A significant reduction in orders from one or more of these customers could adversely affect our revenue and operating results, and if these customers defer or cancel purchases or otherwise alter their purchasing patterns, our financial results and actual results of operations could be significantly impacted. Similarly, the loss of one or more key customers, or the inability of any such customer to pay amounts owing to us, could materially and adversely affect our business, financial performance and results of operations. Other unknown or unpredictable factors also could harm our results.

In addition, inflationary pressure, including as a result of supply shortages, has adversely impacted and could continue to adversely impact our financial results. Our operating costs have increased, and may continue to increase, due to the recent growth in inflation. We may not fully offset these cost increases by raising prices for our products and services, which could result in downward pressure on our margins. Further, our customers may choose to reduce their business with us if we increase our pricing.

The foregoing factors, as well as other factors, could materially and adversely affect our quarterly and annual results of operations and rates of revenue growth, if any. We have experienced significant revenue growth in the past but we may not achieve similar growth rates in future periods. You should not rely on our operating results for any prior quarterly or annual period as an indication of our future operating performance. If we are unable to achieve adequate revenue growth, our operating results could suffer and our stock price could

26

 

decline. In addition, a significant amount of our operating expenses is relatively fixed due to our manufacturing, research and development, and sales and general administrative efforts. Any failure to adjust spending quickly enough to compensate for a shortfall relative to our anticipated revenue could magnify the adverse impact of such shortfalls on our results of operations. We expect that our sales will continue to fluctuate on an annual and quarterly basis and that our financial results for some periods may be below market expectations or projections of securities analysts, which could significantly decrease the price of our common stock.

If we engage in future acquisitions or strategic collaborations, our capital requirements may increase, our stockholders may be diluted, we may incur debt or assume contingent liabilities, and we may be subject to other risks.

We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic collaborations may entail numerous risks, including:

•
increased operating expenses and cash requirements;
•
the assumption of additional indebtedness or contingent liabilities;
•
the issuance of our equity securities;
•
the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;
•
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status, and their existing products or product candidates and marketing approvals; and
•
our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.

If we undertake acquisitions or pursue strategic mergers, such as the Merger with SomaLogic, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. In addition, the Merger was financed by the issuance of shares of our common stock to stockholders of SomaLogic. SomaLogic stockholders may decide not to hold the shares of our common stock they received in the Merger. Other SomaLogic stockholders, such as funds with limitations on the amount of stock they are permitted to hold in individual issuers, may be required to sell the shares of our common stock they received in the Merger. Such sales of our common stock could result in higher than average trading volume and may cause the market price for our common stock to decline. Any of the foregoing may materially harm our business, financial condition, results of operations, stock price and prospects.

We have incurred losses since inception, and we may continue to incur substantial losses for the foreseeable future.

We have incurred significant losses in each fiscal year since our inception, including net losses of $74.7 million and $190.1 million during the years 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $1.0 billion. These losses have resulted principally from costs incurred in our research and development programs, and from our manufacturing costs and selling, general, and administrative (SG&A) expenses. To date, we have funded our operations primarily through equity offerings, the issuance of debt instruments, and from sales of our products. Until we are able to generate additional revenue to support our level of operating expenses, we will continue to incur operating and net losses and negative cash flow from operations and may have to seek additional financing.

While we plan to reduce our operating expenses as part of ongoing restructuring initiatives, our cost restructuring efforts may not result in the anticipated savings or other economic benefits, or could result in total costs and expenses that are greater than expected, and there is no guarantee that our post-restructuring focus will be sufficient for us to achieve success. Consequently, we may incur operating losses for the foreseeable future and may never achieve profitability.

We are subject to risks associated with natural disasters and global events.

Our activities, including manufacturing, R&D and administration and information technology management, can be adversely affected by natural disasters such as major earthquakes, hurricanes, floods, tsunamis, tornadoes, fires and epidemics or pandemics, such as the COVID-19 pandemic. Climate change may cause certain of these events to become more severe and therefore more damaging. In the event of a major natural disaster affecting one or more of our facilities, our operations, including manufacturing and R&D, could be significantly disrupted. Such events could delay or prevent product manufacturing for an extended period of time. Any extended inability

27

 

to continue our operations at affected facilities following such an event could reduce our revenue. Further, geopolitical events like the war in Ukraine and conflict in the Middle East may also impact our operations by affecting our supply chain or impacting our operations located in the region of instability.

Market opportunities may not develop as we expect, limiting our ability to successfully sell our products, or our product development and strategic plans may change and our entry into certain markets may be delayed, if it occurs at all.

The application of our technologies to high-throughput genomics, single-cell genomics and, particularly, mass cytometry applications are in many cases emerging market opportunities. We believe these opportunities will take several years to develop or mature and we cannot be certain that these market opportunities will develop as we expect. The future growth of our markets and the success of our products depend on many factors beyond our control, including recognition and acceptance by the scientific community, and the growth, prevalence, and costs of competing methods of genetic and protein analysis. Additionally, our success depends on the ability of our sales organization to successfully sell our products into these new markets. If we are not able to successfully market and sell our products, or to achieve the revenue or margins we expect, our operating results may be harmed and we may not recover our product development and marketing expenditures. In addition, our product development and strategic plans may change, which could delay or impede our entry into these markets.

The life science markets are highly competitive and subject to rapid technological change, and we may not be able to successfully compete.

The markets for our products are characterized by rapidly changing technology, evolving industry standards, changes in customer needs, emerging competition, new product introductions, and strong price competition. We compete with both established and development stage life science research companies that design, manufacture, and market instruments and consumables for gene expression analysis, single-cell targeted gene expression and protein expression analysis, single nucleotide polymorphism (SNP) genotyping, quantitative polymerase chain reaction (qPCR), digital PCR, flow cytometry, tissue imaging, and additional applications using well established laboratory techniques, as well as newer technologies such as bead encoded arrays, microfluidics, next-generation DNA sequencing (NGS), microdroplets, spatial protein expression, and photolithographic arrays. Most of our current competitors have significantly greater name recognition, greater financial and human resources, broader product lines and product packages, larger sales forces, larger existing installed bases, larger intellectual property portfolios, and greater experience and scale in research and development, manufacturing, and marketing than we do.

We consider Agilent Technologies, Inc., Thermo Fisher Scientific Inc. (Thermo), Bio-Rad Laboratories, Inc., and Mesa Laboratories, Inc. (formerly Agena Bioscience, Inc.) to be our principal competitors in the genomics space. We believe that Cytek Biosciences, Inc. and Becton, Dickinson and Company are currently our principal competitors in Flow Cytometry, and that Akoya Biosciences, Inc., NanoString Technologies, Inc., and 10x Genomics, Inc. are our principal competitors in Spatial Biology. While the aforementioned principal competitors are the largest and most prevalent in their representative technology areas, the combined markets in which we compete have an additional 10 to 20 smaller competitors with competing approaches and technologies that we routinely face in selling situations.

Competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements. In light of these advantages, even if our technology is more effective than the product or service offerings of our competitors, current or potential customers might accept competitive products and services in lieu of purchasing our technology. We anticipate that we will continue to face increased competition in the future as existing companies and competitors develop new or improved products and as new companies enter the market with new technologies. Increased competition is likely to result in pricing pressures, which could reduce our profit margins and increase our sales and marketing expenses. In addition, mergers, consolidations, or other strategic transactions between two or more of our competitors, or between our competitor and one of our key customers, could change the competitive landscape and weaken our competitive position, adversely affecting our business.

If our research and product development efforts do not result in commercially viable products within anticipated timelines, if at all, our business and results of operations will be adversely affected.

Our business is dependent on the improvement of our existing products, our development of new products to serve existing markets, and our development of new products to create new markets and applications that were previously not practical with existing systems. We have developed design rules for the implementation of our technology that are frequently revised to reflect new insights we have gained about the technology. In addition, we have discovered that biological or chemical reactions sometimes behave differently when implemented on our systems rather than in a standard laboratory environment. Furthermore, many such reactions take place within the confines of single cells, which have also demonstrated unexpected behavior when grown and manipulated within microfluidic environments. As a result, research and development efforts may be required to transfer certain reactions and cell handling techniques

28

 

to our systems. In the past, product development projects have been significantly delayed when we encountered unanticipated difficulties in implementing a process on our systems. We may have similar delays in the future, and we may not obtain any benefits from our research and development activities. Any delay or failure by us to develop and release new products or product enhancements would have a substantial adverse effect on our business and results of operations.

Our future success is dependent upon our ability to expand our customer base and introduce new applications.

Our customer base is primarily composed of academic research institutions, translational research and medicine centers, cancer centers, clinical research laboratories, biopharmaceutical, biotechnology, and plant and animal research companies, and contract research organizations that perform analyses for research and commercial purposes. Our success will depend, in part, upon our ability to increase our market share among these customers, attract additional customers outside of these markets, and market new applications to existing and new customers as we develop such applications. Attracting new customers and introducing new applications require substantial time and expense. For example, it may be difficult to identify, engage, and market to customers who are unfamiliar with the current applications of our systems. Any failure to expand our existing customer base or launch new applications would adversely affect our ability to increase our revenue.

If our products fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected.

Our success depends on our ability to develop and market products that are recognized and accepted as reliable, enabling and cost-effective. Most of our potential customers already use expensive research systems in their laboratories and may be reluctant to replace those systems. Market acceptance of our systems will depend on many factors, including our ability to convince potential customers that our systems are an attractive alternative to existing technologies. Compared to some competing technologies, our technology is relatively new, and most potential customers have limited knowledge of, or experience with, our products. Prior to adopting our systems, some potential customers may need to devote time and effort to testing and validating our systems. Any failure of our systems to meet these customer benchmarks could result in customers choosing to retain their existing systems or to purchase systems other than ours, and revenue from the sale of legacy instruments that may have contributed significant revenue in prior periods may decrease.

In addition, it is important that our systems be perceived as accurate and reliable by the scientific and medical research community as a whole. Historically, a significant part of our sales and marketing efforts has been directed at convincing industry leaders of the advantages of our systems and encouraging such leaders to publish or present the results of their evaluation of our systems. If we are unable to continue to induce leading researchers to use our systems, or if such researchers are unable to achieve and publish or present significant experimental results using our systems, acceptance and adoption of our systems will be slowed and our ability to increase our revenue would be adversely affected.

We may not be able to develop new products or enhance the capabilities of our existing systems to keep pace with rapidly changing technology and customer requirements, which could have a material adverse effect on our business, revenue, financial condition, and operating results.

Our success depends on our ability to develop new products and applications for our technology in existing and new markets, while improving the performance and cost-effectiveness of our systems. New technologies, techniques, or products could emerge that might offer better combinations of price and performance than our current or future product lines and systems. Existing markets for our products, including high-throughput genomics, single-cell genomics and mass cytometry, as well as potential markets for our products such as high-throughput NGS and molecular applications, are characterized by rapid technological change and innovation. It is critical to our success for us to anticipate changes in technology and customer requirements and to successfully introduce new, enhanced, and competitive technology to meet our customers’ and prospective customers’ needs on a timely and cost-effective basis. Developing and implementing new technologies typically involve substantial development costs and we may not have adequate resources available to be able to successfully introduce new applications of, or enhancements to, our systems. We cannot guarantee that we will be able to maintain technological advantages over emerging technologies in the future. While we typically plan improvements to our systems, we may not be able to successfully implement these improvements. If we fail to keep pace with emerging technologies, demand for our systems will not grow and may decline, and our business, revenue, financial condition, and operating results could suffer materially. In addition, if we introduce enhanced systems but fail to manage product transitions effectively, customers may delay or forgo purchases of our systems and our operating results may be adversely affected by product obsolescence and excess inventory. Even if we successfully implement some or all of these planned improvements, we cannot guarantee that our current and potential customers will find our enhanced systems to be an attractive alternative to existing technologies, including our current products.

29

 

If we fail to achieve the expected financial and operational benefits of our previously announced or future restructuring plans and other strategic initiatives, our business and financial results may be harmed.

From time to time, we have implemented efficiency and cost-savings initiatives intended to stabilize our business operations. The purpose of the restructuring plans is to improve operational efficiency, reduce operating costs and better align our workforce with the current needs of our business. There is no guarantee that the restructuring plan will achieve its intended benefits and cost savings or that our post-restructuring focus will be sufficient for us to achieve success. For example, our cost restructuring efforts may not result in the anticipated savings or other economic benefits, or could result in total costs and expenses that are greater than expected, which could require us to seek potentially dilutive financing alternatives, disrupt or restrain the scope of our business activities, and would make it more difficult to attract and retain qualified personnel, each of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Similarly, changes in our commercial and strategic focus and allocation of resources contemplated by the restructuring plan, including reductions in our levels of investment in microfluidics research and development and marketing, as well as implementation of our other strategic initiatives, may be unsuccessful or result in unanticipated risks or other unintended consequences for our business, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

Risks associated with implementing a company-wide enterprise resource planning (ERP) system could adversely affect our business and results of operations or the effectiveness of internal control over financial reporting.

We are preparing to implement a new company-wide ERP system in 2024 to handle the business and financial processes within our operations and corporate functions. ERP implementations are complex and time-consuming projects that involve substantial expenditures on system software and implementation activities that can continue for several years. ERP implementations also require transformation of business and financial processes in order to reap the benefits of the ERP system. Our business and results of operations may be adversely affected if we experience operating problems and/or cost overruns during the ERP implementation process, or if the ERP system and the associated process changes do not give rise to the benefits that we expect. Additionally, if we do not effectively implement the ERP system as planned or if the system does not operate as intended, our business, results of operations, and internal controls over financial reporting could be adversely affected.

Our business growth strategy involves the potential for significant acquisitions, and our operating results and prospects could be harmed if we are unable to integrate future acquisitions successfully.

We may acquire other businesses to improve our product offerings or expand into new markets. Our future acquisition strategy will depend on our ability to identify, negotiate, complete, and integrate acquisitions and, if necessary, to obtain satisfactory debt or equity financing to fund those acquisitions. Mergers and acquisitions are inherently risky, and any transaction we complete may not be successful. Any merger or acquisition we may pursue would involve numerous risks, including but not limited to the following:

•
difficulties in integrating and managing the operations, technologies, and products of the companies we acquire;
•
diversion of our management’s attention from normal daily operation of our business;
•
our inability to maintain the key business relationships and the reputations of the businesses we acquire;
•
our inability to retain key personnel of the acquired company;
•
uncertainty of entry into markets in which we have limited or no prior experience and in which competitors have stronger market positions;
•
our dependence on unfamiliar affiliates and customers of the companies we acquire;
•
insufficient revenue to offset our increased expenses associated with acquisitions;
•
our responsibility for the liabilities of the businesses we acquire, including those which we may not anticipate;
•
our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs;
•
the possibility that we may not realize the value of acquired assets recorded as goodwill or intangible assets, and would be required to incur material charges relating to the impairment of those assets; and
•
our inability to maintain internal standards, controls, procedures, and policies.

We may be unable to secure the equity or debt funding necessary to finance future acquisitions on terms that are acceptable to us. If we finance acquisitions by issuing equity or convertible debt securities, our existing stockholders will likely experience dilution, and if we

30

 

finance future acquisitions with debt funding, we will incur interest expense and may have to comply with financial covenants and secure that debt obligation with our assets.

Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.

Our future growth may depend, in part, on our ability to develop and commercialize our testing products in foreign markets. We may not be permitted to market or promote any of our products before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our testing products. To obtain separate regulatory approval in many other countries, we and our collaborators and service providers must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our products. If we obtain regulatory approval of our products and ultimately commercialize them in foreign markets, we would be subject to additional risks and uncertainties, including any or all of the following:

•
different regulatory requirements for approval of laboratory instruments and IVDs in foreign countries;
•
reduced protection for intellectual property rights;
•
the existence of additional third-party patent rights of potential relevance to our business;
•
unexpected changes in tariffs, trade barriers and regulatory requirements;
•
economic weakness, including inflation, or political instability in particular foreign economies and markets;
•
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
•
foreign currency fluctuations, which could result in increased operating expenses and reduced revenue and other obligations incident to doing business in another country;
•
foreign reimbursement, pricing and insurance regimes;
•
workforce uncertainty in countries where labor unrest is common;
•
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
•
business interruptions resulting from geopolitical actions, including war and terrorism such as the current conflict in Ukraine and the Middle East, or natural disasters which may be exacerbated due to climate change, including earthquakes, typhoons, floods and fires.

 

RISKS RELATED TO THE RECENTLY COMPLETED MERGER AND THE COMBINED COMPANY’S BUSINESS FOLLOWING THE MERGER

The market price for our common stock following completion of the Merger may be affected by factors different from those that historically have affected shares of our common stock.

SomaLogic’s business differs in important respects from that of Standard BioTools and the combined company’s business now differs from that of Standard BioTools and SomaLogic prior to the completion of the Merger, including but not limited to, a primarily service-based revenue model and more concentrated customer base associated with the SomaLogic business. Accordingly, the results of operations of the combined company and the market price of Standard BioTools Common Stock after the completion of the Merger may be affected by factors different from those which affected the independent results of operations of each of Standard BioTools and SomaLogic prior to the completion of the Merger.

Combining the two companies may be more difficult, costly or time consuming than expected, and Standard BioTools may not realize all of the anticipated benefits of the Merger.

The success of the Merger will depend on, among other things, the combined company’s ability to integrate the businesses of SomaLogic and Standard BioTools in a timely fashion. Additionally, the combined company may not be able to successfully achieve the level of cost savings, revenue enhancements and synergies that it expects. If the combined company is not able to successfully achieve these objectives, the anticipated benefits of the Merger may not be realized fully or at all or may take longer to realize than expected. In

31

 

addition, failure to successfully integrate the businesses in the expected timeframe may adversely affect the combined company’s business, financial condition, results of operations or cash flows.

In addition, the combined operation of two businesses may be a complex, costly and time-consuming process. The difficulties of combining the operations of the companies include, among others:

•
the diversion of management attention to integration matters;

​

•
difficulties in integrating functions, personnel and systems;

​

•
difficulties in assimilating employees and in attracting and retaining key personnel;

​

•
difficulties in achieving anticipated cost savings, synergies, business opportunities and growth prospects from the combination;

​

•
challenges of managing a larger combined company following the Merger, including challenges of conforming standards, controls, procedures and accounting and other policies and compensation structures;

​

•
declines in Standard BioTools’ results of operations, financial condition or cash flows;

​

•
a decline in the market price of Standard BioTools Common Stock;

​

•
contingent liabilities that are larger than expected;

​

•
potential unknown liabilities, adverse consequences and unforeseen increased expenses associated with the Merger;

​

•
tax effects of the Merger, including the ability to realize the benefits of any deferred tax assets or liabilities;

​

•
disruption of existing relationships with business partners, and other constituencies; and

​

•
the disruption of, or the loss of momentum in, ongoing research and development activities.

​Many of these factors are outside the control of SomaLogic and Standard BioTools, and any one of them could result in increased costs, decreased expected revenues and diversion of management time and energy, which could materially impact the business, financial condition, results of operations and cash flows of the combined company. These factors could cause dilution to the earnings per share of the combined company, decrease or delay the expected accretive effect of the Merger and negatively impact the price of our common stock. As a result, it cannot be assured that the combined company will realize the full benefits anticipated from the Merger within the anticipated time frames, or at all.

In addition, following the Merger, Standard BioTools became responsible for SomaLogic’s liabilities and obligations, including with respect to legal, financial, regulatory, and compliance matters. These obligations will result in additional cost and investment by Standard BioTools and, if Standard BioTools has underestimated the amount of these costs and investments or if Standard BioTools fails to satisfy any such obligations, Standard BioTools may not realize the anticipated benefits of the Merger. Further, it is possible that there may be unknown, contingent or other liabilities or problems that may arise in the future, the existence and/or magnitude of which Standard BioTools was previously unaware. Any such liabilities or problems could have an adverse effect on the combined company’s business, financial condition, results of operations or cash flows.

Even if the businesses are successfully integrated, there can be no assurance that the Merger will result in the realization of the full benefit of the anticipated synergies and cost savings or that these benefits will be realized within the expected time frames or at all. Difficulties in integrating the businesses could harm the reputation of the combined company. In addition, by engaging in the Merger, Standard BioTools may forego or delay pursuit of other opportunities that may have proven to have greater commercial potential.

The future results of the combined company may be adversely impacted if the combined company does not effectively manage its complex operations following the completion of the merger.

Following the completion of the Merger, the size of the combined company’s business became significantly larger than the previous size of either Standard BioTools’ or SomaLogic’s business. The combined company’s ability to successfully manage this expanded business will depend, in part, upon management’s ability to design and implement strategic initiatives that address not only the integration of the Standard BioTools and SomaLogic businesses, but also the increased scale and scope of the combined business with its associated increased costs and complexity. There can be no assurances that the combined company will be successful in integrating

32

 

the businesses or that it will realize the expected operating efficiencies, cost savings and other benefits currently anticipated from the merger.

SomaLogic and Standard BioTools has and will continue to incur substantial direct and indirect costs as a result of the Merger and the combined company will continue to incur substantial direct and indirect costs in connection with combining the business of SomaLogic and Standard BioTools following the Merger.

SomaLogic and Standard BioTools has and will continue to incur substantial expenses in connection with and as a result of consummating the Merger. Standard BioTools also expects to incur substantial expenses as a combined company in connection with coordinating and, in certain cases, combining the businesses, operations, policies and procedures of SomaLogic and Standard BioTools. While SomaLogic and Standard BioTools have assumed that a certain level of transaction expenses will be incurred, factors beyond SomaLogic’s and Standard BioTools’ control could affect the total amount or the timing of these expenses. Although many of the expenses that will be incurred, by their nature, are difficult to estimate accurately, the current estimate of the aggregate transaction-related expenses that will be incurred by SomaLogic and Standard BioTools is approximately $34.8 million, which is subject to change. These expenses may exceed the costs historically borne by SomaLogic and Standard BioTools. These expenses could adversely affect the financial condition, results of operations and cash flows of the combined company going forward.

Uncertainties associated with the Merger may cause a loss of management personnel and other key employees, which could adversely affect the future business and operations of the combined company following completion of the Merger.

We are dependent on the experience and industry knowledge of our officers and other key employees to execute our business plans. The combined company’s success after the completion of the Merger will depend in part upon the ability of the combined company to retain certain key management personnel and employees of Standard BioTools and SomaLogic. As a result of the Merger, current and prospective employees may experience uncertainty about their roles following the completion of the transactions, which may have an adverse effect on our ability to attract or retain key management and other key personnel. In addition, no assurance can be given that the combined company will be able to attract or retain key management personnel and other key employees to the same extent that Standard BioTools and SomaLogic have previously been able to attract or retain their own employees.

We have been exposed to litigation related to the Merger and may in the future be exposed to increased litigation, including stockholder litigation, which could have an adverse effect on our business and operations.

We have been exposed to litigation related to the Merger and may in the future be exposed to increased litigation from stockholders, customers, suppliers and other third parties due to the combination of Standard BioTools’ business and SomaLogic’s business following the Merger. On November 28, 2023, a purported stockholder filed a complaint against us and the members of our Board in the United States District Court for the Northern District of California. The complaint has since been voluntarily dismissed. On December 12, 2023 two separate shareholder complaints were filed in the District of Delaware, The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. We are reviewing the complaints and have not yet formally responded to them. On December 13, 2023, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed transaction, which was denied by the Court on January 4, 2024. The non-injunctive claims, including breach of fiduciary duty, are still being litigated. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs’ claim is successful, this type of litigation may result in significant costs and divert management’s attention and resources, which could adversely affect the operation of our business.

Between October 24, 2023 and January 3, 2024, SomaLogic received 16 letters from purported shareholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement.

Additional lawsuits against us and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, we will not necessarily announce such additional filings.

Such litigation may have an adverse impact on our business and results of operations or may cause disruptions to our operations. In addition, in the past, stockholders have initiated class action lawsuits against biotechnology companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against us, could cause us to incur substantial costs and

33

 

divert management’s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.

SomaLogic previously identified material weaknesses over financial reporting and information systems for the year ended December 31, 2022 that had not been tested for remediation as of the closing of the Merger. If SomaLogic’s remediation measures are ineffective, or if we fail to successfully integrate the operations of SomaLogic into our internal controls over financial reporting, we may not be able to report our financial condition or results of operations accurately or on a timely basis, which could adversely affect our business and our stock price.

The requirement to evaluate and report on our internal control also applies to companies that we acquire. SomaLogic, our recently acquired wholly-owned subsidiary, previously identified material weaknesses surrounding its attestation of internal controls as of December 31, 2022. In 2023, SomaLogic commenced remediation actions which included the hiring of additional resources with significant accounting and financial reporting experience, devoting resources to improving its system of processes and internal controls and enhancing the design of its information technology general controls. If SomaLogic’s actions are not effective in correcting the material weaknesses and if we fail to successfully integrate the operations of SomaLogic into our internal controls over financial reporting, investors could lose confidence in the combined entity’s financial reporting, and our stock price could decline.

RISKS RELATED TO OPERATIONS AND RELIANCE ON THIRD PARTIES

We may experience development or manufacturing problems or delays that could limit the potential growth of our revenue or increase our losses.

We may encounter unforeseen situations in the manufacturing and assembly of our products that would result in delays or shortfalls in our production. For example, our production processes and assembly methods may have to change to accommodate any significant future expansion of our manufacturing capacity, which may increase our manufacturing costs, delay production of our products, reduce our product margin, and adversely impact our business. Conversely, if demand for our products shifts such that a manufacturing facility is operated below its capacity for an extended period, we may adjust our manufacturing operations to reduce fixed costs, which could lead to uncertainty and delays in manufacturing times and quality during any transition period.

Additionally, all of our IFCs for commercial sale are manufactured at our facility in Singapore. Production of the elastomeric block that is at the core of our IFCs is a complex process requiring advanced clean rooms, sophisticated equipment, and strict adherence to procedures. Any contamination of the clean room, equipment malfunction, or failure to strictly follow procedures can significantly reduce our yield in one or more batches. We have in the past experienced variations in yields due to such factors. A drop in yield can increase our cost to manufacture our IFCs or, in more severe cases, require us to halt the manufacture of our IFCs until the problem is resolved. Identifying and resolving the cause of a drop in yield can require substantial time and resources.

Furthermore, developing an IFC for a new application may require developing a specific production process for that type of IFC. While all of our IFCs are produced using the same basic processes, significant variations may be required to ensure adequate yield of any particular type of IFC. Developing such a process can be time consuming, and any unexpected difficulty in doing so can delay the introduction of a product.

If our manufacturing activities are adversely impacted, or if we are otherwise unable to keep up with demand for our products by successfully manufacturing, assembling, testing, and shipping our products in a timely manner, our revenue could be impaired, market acceptance for our products could be adversely affected and our customers might instead purchase our competitors’ products.

Our business depends on research and development spending levels of our customers, a reduction in which could limit our ability to sell our products and adversely affect our business.

We expect that our revenue in the foreseeable future will continue to be derived primarily from sales of our systems, IFCs, assays, and reagents to academic research institutions, translational research and medicine centers, cancer centers, clinical research laboratories, biopharmaceutical, biotechnology, and plant and animal research companies, and contract research organizations worldwide. Our success will depend upon their demand for and use of our products. Accordingly, the spending policies and practices of these customers—which have been impacted by the COVID-19 pandemic and may additionally be impacted by other factors, including a potential domestic and global recession—have had and will continue to have a significant effect on the demand for our technology. These policies may be based on a wide variety of factors, including concerns regarding any future federal government budget sequestrations, the availability of resources to make purchases, the spending priorities among various types of equipment, policies

34

 

regarding spending during recessionary periods, tariffs and trade restrictions, and changes in the political climate. In addition, academic, governmental, and other research institutions that fund research and development activities may be subject to stringent budgetary constraints that could result in spending reductions, reduced allocations, or budget cutbacks, which could jeopardize the ability of these customers to purchase our products. Our operating results have fluctuated and may continue to fluctuate substantially due to reductions and delays in research and development expenditures by our customers. For example, reductions in operating expenditures by global academic research facilities have resulted in lower than expected sales of our mass cytometry instruments. Additionally, the imposition of tariffs and delays in issuing VAT and import tax exemptions have adversely affected the sales of our products in China. Similar reductions and delays in customer spending have resulted and may continue to result from other factors that are not within our control, such as:

•
changes in economic conditions;
•
natural disasters or public health crises;
•
changes in government programs that provide funding to research institutions and companies;
•
macroeconomic conditions and the political climate;
•
governmental protectionism, the escalation of tariffs and other trade barriers;
•
availability of tax permits and incentives, including VAT and import tax exemptions;
•
changes in the regulatory environment affecting life science and plant and animal research companies engaged in research and commercial activities;
•
changes in our customers’ research priorities;
•
differences in budget cycles across various geographies and industries;
•
personnel shortages among our customers;
•
market-driven pressures on companies to consolidate operations and reduce costs;
•
mergers and acquisitions in the life science and plant and animal research industries; and
•
other factors affecting research and development spending.

Any decrease in our customers’ budgets or expenditures or in the size, scope, or frequency of capital or operating expenditures, as well as any increase in local tariffs could materially and adversely affect our operations or financial condition.

If one or more of our manufacturing facilities become unavailable or inoperable, we will be unable to continue manufacturing our instruments, IFCs, assays and/or reagents and, as a result, our business will be harmed until we are able to secure a new facility.

We manufacture our microfluidics analytical and preparatory instruments and IFCs for commercial sale at our facility in Singapore and our mass cytometry instruments, assays, and reagents for commercial sale at our facility in Canada. No other manufacturing facilities are currently available to us, particularly facilities of the size and scope of our Singapore and Canada operations. Our facilities and the equipment we use to manufacture our instruments, IFCs, assays, and reagents would be costly to replace and could require substantial lead times to repair or replace. Our facilities may be harmed or rendered inoperable by natural or man-made disasters, which may render it difficult or impossible for us to manufacture our products for some period of time. If any of our facilities become unavailable to us, we cannot provide assurances that we will be able to secure a new manufacturing facility on acceptable terms, if at all. The inability to manufacture our products, combined with our limited inventory of manufactured supplies, may result in the loss of customers or harm our reputation, and we may be unable to reestablish relationships with those customers in the future. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. If our manufacturing capabilities are impaired, we may not be able to manufacture and ship our products in a timely manner, which would adversely impact our business.

Disruption of our manufacturing facilities or other operations, or in the operations of our customers or business partners, due to earthquake, flood, other natural catastrophic events, public health crises, or terrorism could result in cancellation of orders, delays in deliveries or other business activities, or loss of customers and could seriously harm our business.

We have significant manufacturing operations in Singapore and Canada and operations in the United States. In addition, our business is international in nature, with our sales, service and administrative personnel and our customers located in numerous countries throughout the world. Operations at our manufacturing facilities and our subcontractors, as well as our other operations and those of our customers,

35

 

are subject to disruption for a variety of reasons, including work stoppages, acts of war, terrorism, public health crises, fire, earthquake, volcanic eruptions, energy shortages, flooding, or other natural disasters. Such disruption could cause delays in, among other things, shipments of products to our customers, our ability to perform services requested by our customers, or the installation of our products at customer sites.

We cannot provide any assurance that alternate means of conducting our operations (whether through alternate production capacity or service providers or otherwise) would be available if a major disruption were to occur or that, if such alternate means were available, they could be obtained on favorable terms.

We rely on a limited number of third-party suppliers for some of the components and materials used in our products, and the loss of any of these suppliers, or delays or problems in the supply of components and materials could harm our business.

We rely on a limited number of third-party suppliers for certain components and materials used in our products, including single and sole source suppliers. Additionally, certain of our instruments are assembled at the facilities of contract manufacturers in Singapore. We do not have long-term contracts with our suppliers of these components and materials or our assembly service providers. The loss of a single or sole source supplier of any of the following components and/or materials would require significant time and effort to locate and qualify an alternative source of supply, if at all:

•
The IFCs used in our microfluidic systems are fabricated using a specialized polymer, and other specialized materials, that are available from a limited number of sources. In the past, we have encountered quality issues that have reduced our manufacturing yield or required the use of additional manufacturing processes.
•
The electron multiplier detector included in the Hyperion/Hyperion+/CyTOF/CyTOF XT systems and certain metal isotopes used with the Hyperion/Hyperion+/CyTOF/CyTOF XT systems are purchased from sole source suppliers.
•
The raw materials for our Delta Gene and SNP Type assays and Access Array target-specific primers are available from a limited number of sources.
•
The microarray readout systems used to complete SomaScan assays, and which are included in assay kits sold to customers, are provided by a sole source supplier.
•
The supply of streptavidin beads used to complete the SomaScan assay is provided by a sole source supplier.
•
The Tecan Fluent 780, an automated liquid handling instrument required to perform the SomaScan assay, is sourced from a sole supplier. The Tecan Fluent 780 is purchased by SomaLogic and SomaLogic certified sites.

Our reliance on single and sole source suppliers and assembly service providers also subjects us to other risks that could harm our business, including the following:

•
we may be subject to increased component or assembly costs; and
•
we may not be able to obtain adequate supply or services in a timely manner or on commercially reasonable terms, if at all.

If, as a result of global economic or political instability, such as the ongoing escalation of the situation in Ukraine, or health pandemics, our suppliers experience shortages or delays for materials sourced or manufactured in the affected countries, their ability to supply us with instruments or product components may be affected. If any of these events occur, our business and operating results could be harmed. In connection with the global supply chain disruptions following the onset of the COVID-19 pandemic, we have experienced and are continuing to experience problems with some of our suppliers. In the third quarter of 2021, shortages of certain components caused a backlog and we were unable to fulfill all of the demand for our products during the quarter. We have in the past experienced supply issues, as well as quality control problems such as manufacturing errors, with some of our suppliers, and may again experience problems in the future. We may not be able to quickly establish additional or replacement suppliers, particularly for our single source components, or assembly service providers. Any continued or future interruption or delay in the supply of components or materials or assembly of our instruments, or our inability to obtain components, materials, or assembly services from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to cancel orders or switch to competitive products, which would harm our business. Additionally, in response to a surge in COVID-19 infections in the first half of 2022, the Chinese government imposed lockdowns in certain parts of the country that have negatively impacted and continue to negatively impact manufacturing and/or supply chains.

36

 

We may not be able to convert our orders in backlog into revenue.

Our backlog represents product orders from our customers that we have confirmed but have not been able to fulfill, and, accordingly, for which we have not yet recognized revenue. We may not receive revenue from these orders, and any order backlog we report may not be indicative of our future revenue.

Many events can cause an order to be delayed or not completed at all, some of which may be out of our control, including, for example, the impacts from the COVID-19 pandemic and our suppliers not being able to provide us with products or components. If we delay fulfilling customer orders or if customers reconsider their orders, those customers may seek to cancel or modify their orders with us. Customers may otherwise seek to cancel or delay their orders even if we are prepared to fulfill them. If our orders in backlog do not result in sales, our operating results may suffer.

Any disruption or delay in the shipping or off-loading of our products, whether domestically or internationally, may have an adverse effect on our financial condition and results of operations.

We rely on shipping providers to deliver products to our customers globally. Labor, tariff, or World Trade Organization-related disputes, piracy, physical damage to shipping facilities or equipment caused by severe weather or terrorist incidents, congestion at shipping facilities, complications related to public health crises (including the COVID-19 pandemic), inadequate equipment to load, dock, and offload our products, energy-related tie-ups, or other factors could disrupt or delay shipping or off-loading of our products domestically and internationally. Such disruptions or delays may have an adverse effect on our financial condition and results of operations.

Our business operations depend upon the continuing efforts of our management team and other skilled and experienced personnel, and if we are unable to retain them or to recruit and train new key executives, scientists, and technical support personnel, we may be unable to achieve our goals.

Our success depends largely on the skills, experience, and performance of our management team and scientific and technical support personnel. The loss of the services of certain members of our management team or our scientific or technical support staff might significantly delay or prevent the development of our products or achievement of other business objectives by diverting management’s attention to transition matters and identification of suitable replacements, and staffing shortages could also negatively impact our ability to expand and scale functions that are needed to support the development of our products and the growth of our business. Our research and product development efforts could also be delayed or curtailed if we are unable to attract, train, and retain highly skilled employees, particularly senior scientists and engineers. Competition for qualified senior management and key employees in our industry is intense. We have experienced increased turnover at all levels since the start of the COVID-19 pandemic and general labor shortages in various areas of our business, all of which could have a material adverse impact on our business. We may need to increase employee wages and benefits in order to attract and retain the personnel necessary to achieve our goals, and our business, operations, and financial results may suffer if we are unable to do so. Attrition and workforce reductions included in the August 2022 restructuring plan could adversely affect our reputation among job seekers. It may also cause our existing employees to experience distractions or a decrease in employee morale. It could result in a loss of institutional know-how, reduced productivity, slower customer service response, reduced effectiveness of internal compliance and risk-mitigation programs, and cancellations of or delays in completing new product developments and other strategic projects. We do not currently maintain key person life insurance covering any of our employees and all our employees, including our management team, may terminate employment without notice and without cause or good reason.

Additionally, in connection with our research and product development efforts, we need to retain and recruit scientists skilled in areas such as molecular and cellular biology, assay development, engineering physics, and manufacturing. We also need highly trained technical support personnel with the necessary scientific background and ability to understand our systems at a technical level to effectively support potential new customers and the expanding needs of current customers. Competition for these people is intense and we may face challenges in retaining and recruiting such individuals if, for example, our stock price declines, thereby reducing the retention value of equity awards, or our business or technology is no longer perceived as leading in our field. Because of the complex and technical nature of our systems and the dynamic market in which we compete, any failure to attract and retain a sufficient number of qualified employees could materially harm our ability to develop and commercialize our technology.

If our direct sales, field support, and marketing forces and distribution capabilities are not sufficient to adequately address our customers’ needs, our business will be adversely affected.

We may not be able to market, sell, and distribute our products effectively enough to support our planned growth. We sell our products primarily through our own sales force and through distributors in certain territories. Our future sales will depend on a number of factors including our ability to execute with our existing team, the scope of our marketing efforts and development of our direct sales force, field application specialists and service engineer teams. Our products are technically complex and used for highly specialized

37

 

applications. As a result, we believe it is necessary to continue to develop a direct sales force that includes people with specific scientific backgrounds and expertise, and a marketing group with technical sophistication.

In the past year, we have experienced significant changes and increased turnover in our sales and marketing organizations, and we face considerable challenges in recruiting and training qualified replacements. Our future success will depend largely on our ability to recruit, retain, and motivate the skilled sales and marketing force necessary to support our business activities, and any failure to maintain competitive levels of compensation will negatively impact our ability to so.

Because competition for such employees is intense, we can provide no assurance that we will be able to retain them on favorable or commercially reasonable terms, if at all. Failure to attract and retain our current personnel or to build an efficient and effective sales and marketing force would negatively impact sales of our products and reduce our revenue and profitability.

In addition, we may continue to enlist one or more sales representatives and distributors to assist with sales, distribution, and customer support globally or in certain regions of the world. If we do seek to enter into such arrangements, we may not be successful in attracting desirable sales representatives and distributors, or we may not be able to enter into such arrangements on favorable terms. If our sales and marketing efforts, or those of any third-party sales representatives and distributors, are not successful, our technologies and products may not gain market acceptance, which would materially and adversely impact our business operations.

To use our products—our X9, CyTOF, and Hyperion systems in particular—customers typically need to purchase specialized reagents. Any interruption in the availability of these reagents for use in our products could limit our ability to market them.

Our products, and our X9, CyTOF, and Hyperion systems in particular, must be used in conjunction with one or more reagents designed to produce or facilitate the particular biological or chemical reaction desired by the user. Many of these reagents are highly specialized and available to the user only from a single supplier or a limited number of suppliers. Although we sell reagents for use with certain of our products, our customers may purchase these reagents directly from third-party suppliers, and we have no control over the supply of those materials. In addition, our products are designed to work with these reagents as they are currently formulated. We have no control over the formulation of reagents sold by third-party suppliers, and the performance of our products might be adversely affected if the formulation of these reagents is changed. If one or more of these reagents were to become unavailable or were reformulated, our ability to market and sell our products could be materially and adversely affected.

In addition, the use of a reagent for a particular process may be covered by one or more patents relating to the reagent itself, the use of the reagent for the particular process, the performance of that process, or the equipment required to perform the process. Typically, reagent suppliers, who are either the patent holders or their authorized licensees, sell the reagents along with a license or covenant not to sue with respect to such patents. The license accompanying the sale of a reagent often purports to restrict the purposes for which the reagent may be used. If a patent holder or authorized licensee were to assert against us or our customers that the license or covenant relating to a reagent precluded its use with our systems, our ability to sell and market our products could be materially and adversely affected. For example, our X9 system involves real-time quantitative polymerase chain reaction (qPCR) technology. Leading suppliers of reagents for real-time qPCR reactions include Life Technologies Corporation (now part of Thermo) and Roche Diagnostics Corporation, who are our direct competitors, and their licensees. These real-time qPCR reagents are typically sold pursuant to limited licenses or covenants not to sue with respect to patents held by these companies. We do not have any contractual supply agreements for these real-time qPCR reagents, and we cannot assure you that these reagents will continue to be available to our customers for use with our systems, or that these patent holders will not seek to enforce their patents against us, our customers, or suppliers.

Security incidents, loss of data, cyberattacks, and other information technology failures could disrupt our operations, damage our reputation, and adversely affect our business, operations, and financial results.

We are dependent upon our data and information technology systems for the effective operation of our business and for the secure maintenance and storage of confidential data, personal data, and trade secret information relating to our business and third-party businesses. Our information technology systems may be damaged, disrupted or shut down due to cybersecurity attacks, which are often carried out by experienced programmers or hackers, which may be able to penetrate our security. Cyberattacks include deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyberattacks may also be due to employee error or malfeasance, power outages, hardware failures, telecommunication or utility failures, catastrophes or other unforeseen events, and our system redundancy and other disaster recovery planning may be ineffective or inadequate in preventing or responding to any of these circumstances. Techniques used in cybersecurity attacks to obtain unauthorized access, disable or sabotage information technology systems are evolving rapidly with data breaches and other cybersecurity events becoming commonplace. Furthermore, there may be a heightened risk of potential cyberattacks by state actors or others since the escalation of the war in Ukraine. Any such compromise of our information technology systems could result in the unauthorized access to, or acquisition or publication of our

38

 

confidential business or proprietary information, customer, supplier or employee data, or other personal data or trade secrets information, any of which could expose us to a risk of legal claims or proceedings, liability under privacy or other laws, disruption of our operations and damage to our reputation, which could divert our management’s attention from the operation of our business and materially and adversely affect our business, revenues, and competitive position. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security incidents, cyberattacks, and other related cybersecurity incidents. The cost and operational consequences of implementing further data protection measures, either as a response to specific cybersecurity incidents or as a result of evolving risks, could be material. In addition, our inability to use or access our information systems at critical points in time could adversely affect the timely and efficient operation of our business. Any delayed sales, significant costs or lost customers resulting from these technology failures could adversely affect our business, operations, and financial results.

We have implemented security controls to protect our information technology infrastructure but, due to the ever-evolving nature of cybersecurity threats, however, there can be no assurance that cybersecurity incidents that impact our systems will not occur, which could adversely affect our business and operations, and could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. For example, in early 2019, we experienced a ransomware attack that infiltrated and encrypted certain of our information technology systems, including systems containing critical business data. Immediately following the attack, actions were taken to recover the compromised systems and we were able to restore their operation without significant loss of business data within weeks. Based on the nature of the attack and its impact on our systems, we believe no confidential data was lost or disclosed. If, however, confidential or personal data were determined to have been accessed, acquired, or released in the course of any future event, it is possible that we could be the subject of actions by governmental authorities or claims from persons alleging they suffered damages from such access, acquisition, or release. We believe our mitigation measures and expanded information security program have reduced, but cannot eliminate, the risk of a similar attack, and we anticipate additional work and expense in the future as we continuously improve our security processes and initiatives in response to ever-changing information security challenges.

In addition to risks affecting our own systems, we could also be negatively impacted by a data breach or security incident impacting a third party’s network and affecting us, such as our third-party vendors and service providers. Third parties with which we conduct business have access to certain portions of our personal and sensitive data, including information pertaining to our customers and employees. In the event that these third parties do not adequately safeguard our data, cybersecurity incidents could result and negatively impact our business, operations, and financial results.

Since the beginning of the COVID-19 pandemic, a significant percentage of our employees has been working remotely. As a result, we may have increased cyber security and data security risks, due to increased use of home wi-fi networks and virtual private networks, as well as increased disbursement of physical machines. While we have implemented security controls, updated our policies, and augmented our information security training program to reduce the risk of cyberattacks and cybersecurity incidents, there is no guarantee that these measures will be adequate to safeguard all systems with the increased number of employees working remotely.

RISKS RELATED TO QUALITY AND THE REGULATORY ENVIRONMENT

Our products could have defects or errors, which may give rise to claims against us, adversely affect market adoption of our systems, and adversely affect our business, financial condition, and results of operations.

Our systems utilize novel and complex technology and such systems may develop or contain undetected defects or errors. We cannot assure you that material performance problems, defects, or errors will not arise, and as we increase the density and integration of our systems, these risks may increase. We generally provide warranties that our systems will meet performance expectations and will be free from defects. The costs incurred in correcting any defects or errors may be substantial and could adversely affect our operating margins. For example, we have experienced a performance issue with respect to certain IFCs used in our C1 systems due to the presence of more than one cell in an IFC chamber. Although we have redesigned such C1 IFCs, we may experience additional unexpected product defects or errors that could affect our ability to adequately address these performance issues.

In manufacturing our products, including our systems, IFCs, and assays, we depend upon third parties for the supply of various components, many of which require a significant degree of technical expertise to produce. In addition, we purchase certain products from third-party suppliers for resale. If our suppliers fail to produce components to specification or provide defective products to us for resale and our quality control tests and procedures fail to detect such errors or defects, or if we or our suppliers use defective materials or workmanship in the manufacturing process, the reliability and performance of our products will be compromised.

If our products contain defects, we may experience:

•
a failure to achieve market acceptance or expansion of our product sales;
•
loss of customer orders and delay in order fulfillment;
•
damage to our brand reputation;

39

 

•
increased cost of our warranty program due to product repair or replacement;
•
product recalls or replacements;
•
inability to attract new customers;
•
diversion of resources from our manufacturing and research and development departments into our service department; and
•
legal claims against us, including product liability claims, which could be costly and time consuming to defend and result in substantial damages.

In addition, certain of our products are marketed for use with products sold by third parties. For example, certain of our systems are marketed as compatible with major NGS instruments. If such third-party products are not produced to specification, are produced in accordance with modified specifications, or are defective, they may not be compatible with our products. In such case, the reliability and performance of our products may be compromised.

The occurrence of any one or more of the foregoing could negatively affect our business, financial condition, and results of operations.

The healthcare industry is highly regulated and if we fail to comply with applicable healthcare laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations.

We compete in markets in which we or our customers must comply with federal, state, local and foreign regulations, such as healthcare fraud and abuse, data privacy and medical product laws and regulations. The healthcare industry is subject to extensive and frequently changing international and United States federal, state and local laws and regulations. In addition, federal and state enforcement agencies have substantial powers and remedies to pursue suspected violations under broad laws and regulations relating to healthcare fraud and abuse, interactions and financial arrangements with healthcare professionals or entities, data privacy and misconduct involving government programs or contracts. If we, our employees, collaborators or contractors fail to comply with applicable laws and regulations, we could suffer civil and criminal damages, fines and penalties, exclusion from participation in governmental healthcare programs, and the loss of various licenses and authorizations necessary to operate our business, as well as incur liabilities from third-party claims, all of which could have a significant adverse effect on our business. The relevant laws and regulations include, among others:

•
CLIA’s and CAP’s regulation of our laboratory activities;
•
FDA laws and regulations, including but not limited to requirements for offering LDTs;
•
HIPAA and HITECH, which establish comprehensive federal standards with respect to the privacy and security of PHI, and requirements for the use of certain standardized electronic transactions with respect to transmission of such information, as well as similar laws protecting other types of personal information;
•
state laws governing the maintenance of personally identifiable information of state residents, including medical information, and which impose varying breach notification requirements, some of which allow private rights of action by individuals for violations and also impose penalties for such violations;
•
the federal Anti-Kickback Statute, which generally prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in return for or to induce a person to refer to an individual any good, facility, item or service that is reimbursable under a federal healthcare program;
•
the federal False Claims Act, which imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
•
the federal Civil Monetary Penalties Law, which generally prohibits, among other things, the offering or transfer of remuneration to a Medicare or Medicaid beneficiary if it is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or Medicaid;
•
EKRA, which imposes criminal penalties for knowing and willful payment or offer, or solicitation or receipt, of any remuneration, whether directly or indirectly, overtly or covertly, in cash or in kind, in exchange for the referral or inducement of laboratory testing (among other healthcare services) covered by healthcare benefit programs (including commercial insurers) unless a specific exception applies;

40

 

•
other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, insurance fraud laws, anti-markup laws, prohibitions on the provision of tests at no or discounted cost to induce physician or patient adoption and false claims acts, some of which may extend to services reimbursable by any third-party payor, including private payors;
•
state laws that prohibit other specified healthcare practices, such as billing physicians for tests that they order, waiving coinsurance, copayments, deductibles and other amounts owed by patients, business corporations practicing medicine or employing or engaging physicians to practice medicine and billing a state Medicaid program at a price that is higher than what is charged to one or more other payors;
•
the FCPA, and applicable foreign anti-bribery laws;
•
federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste and workplace safety for healthcare employees;
•
laws and regulations relating to health and safety, labor and employment, public reporting, taxation and other areas applicable to businesses generally, all of which are subject to change; and
•
similar foreign laws and regulations that apply to us in the countries in which we operate or may operate in the future.

Any future growth of our business, including, in particular, continued reliance on consultants, commercial partners and other third parties, may increase the potential for violating these laws. In some cases, our risk of violating these or other laws and regulations is further increased because of the lack of their complete interpretation by applicable regulatory authorities or courts, and their provisions are thus open to a variety of interpretations.

Given the complexity of these existing and changing rules and regulations, it is not always possible to identify and deter misconduct by employees, distributors, consultants and commercial partners and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with applicable laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business and harm our reputation. If our operations, including the conduct of our employees, consultants and commercial partners, are found to be in violation of any of these laws and regulations, we may be subject to applicable penalties associated with the violation, including administrative, civil and criminal penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs, refunding of payments received by us and curtailment or cessation of our operations. Any of these consequences could seriously harm our business and our financial results.

It is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws may prove costly. If we or our operations, or any of the rheumatologists or entities with whom we do business are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and/or criminal penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in U.S. federal or state healthcare programs, such as Medicare and Medicaid, and similar programs outside the United States, a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.

Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.

We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration and participation in proficiency testing, patient test management, quality control,

41

 

quality assurance and inspections. We have a current certificate of accreditation under CLIA because we are accredited to perform testing by CAP. To renew this certificate, we are subject to survey and inspection every two years. Moreover, inspectors from CMS or CAP may make random inspections of our clinical reference laboratory.

Although we are required to hold a certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we would be able to successfully maintain operations through either of these alternatives would depend upon the facts and circumstances surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the basis for termination and, if so, whether these were addressed to the satisfaction of the surveyors for the CLIA program (or another accrediting organization).

The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for tests provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.

Moreover, several states require that we hold licenses to test specimens from patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future.

If we were to lose our CLIA accreditation, whether as a result of a revocation, suspension or limitation, we would no longer be able to sell our testing products, which would limit our revenue and harm our business. If we were to lose our license in states where we are required to hold licenses, we would not be able to test specimens from those states, which would limit our revenue.

The FDA may disagree with our assessment that our SomaSignalTM test products and any other clinical diagnostic tests we may develop are LDTs and determine that such test products are medical devices subject to the FDCA and FDA regulations.

The FDA regulates any diagnostic test that meets the definition of a medical device, except under specific, narrow circumstances. The FDCA defines a medical device as “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is , among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.” By this definition, in vitro reagents and diagnostic tests are considered medical devices. Specifically, the FDA defines an IVD as “reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae.” Therefore, the FDA generally considers diagnostic testing products to be IVDs subject to the agency’s regulatory requirements for IVDs. However, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to LDTs, which are IVDs that are designed, manufactured, and used within a single high-complexity CLIA-certified laboratory. We believe that our SomaSignalTM test products intended for clinical diagnostic use are LDTs.

If the FDA were to disagree with our conclusion that our SomaSignalTM test products for clinical diagnostic use fall within the scope of the agency’s LDT definition and determines that such tests are thus subject to FDA’s medical device authorities and implementing regulations, we would become subject to extensive regulatory requirements and may be required to stop selling our existing tests or refrain from launching any other tests we may develop. In particular, the FDA may require us to obtain PMAs or another type of device marketing authorization in order for us to commercialize our SomaSignalTM tests for clinical diagnostic use. The premarket review process for diagnostic testing products can be lengthy, expensive, time-consuming, and unpredictable. As part of the process to prepare regulatory submissions for FDA review, we may be required to conduct formal clinical trials before applying for commercial marketing authorization. Performing additional, new nonclinical studies or clinical trials in order to obtain product approval from the FDA, if any

42

 

were to become necessary, would take a significant amount of time and would substantially delay our ability to commercialize our SomaSignalTM tests intended for clinical diagnostic use, all of which would adversely impact our business.

While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA with respect to LDTs, we cannot assure you that the FDA will agree with our determination. Any finding by the FDA or another regulatory authority that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations and financial condition.

The FDA may finalize its rulemaking to regulate LDTs or Congress may take action to reform the current legal requirements applicable to LDTs. In either case we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests intended for clinical diagnostic use or launching any other diagnostic tests we may develop, which may increase the cost of conducting, or otherwise harm, our business.

We currently market our SomaLogicTMtests intended for clinical diagnostic use as LDTs and may in the future market other diagnostic tests as LDTs. Although historically, the FDA has applied a policy of enforcement discretion with respect to LDTs whereby the FDA does not generally actively enforce its regulatory requirements for such tests, in October 2023, the FDA issued a proposed rule to regulate LDTs under the current medical device framework. The agency’s proposal also includes a plan to phase out its current enforcement discretion policy over several years. This FDA rulemaking was initiated after years of failed congressional attempts to harmonize the regulatory paradigms applicable to LDTs and other in vitro diagnostic tests, as discussed further below. The likelihood of the FDA finalizing the proposed rule following a public comment period, as well as potential litigation challenging its authority to take such action, is uncertain at this time as stakeholders continue to press for a comprehensive legislative solution instead of administrative agency action.

If there are changes in FDA regulations or legislative authorities such that the agency begins to exercise oversight over LDTs, or if the FDA disagrees that our marketed tests are within the scope of its criteria used for defining LDTs, we may become subject to extensive regulatory requirements and may be required to stop selling our existing diagnostic tests or launching any other similar tests we may develop and to conduct additional clinical trials or take other actions prior to continuing to market our tests. If the FDA allows our SomaSignalTM tests for clinical diagnostic use to remain on the market but there is uncertainty about our tests, if they are labeled investigational by the FDA or if labeling claims the FDA allows us to make do not include the claims necessary or desirable for successful commercialization, orders from healthcare providers or reimbursement for our diagnostic tests may decline.

In addition, as noted above, Congress had been working on legislation to create an LDT and IVD, regulatory framework that would be separate and distinct from the existing medical device regulatory framework. Reform legislation called the VALID Act garnered bipartisan and bicameral support in recent years but failed to move out of committee during the last congressional session. As drafted and re-introduced for consideration by the current Congress, the VALID Act would codify the term IVCT to create a new medical product category separate from medical devices to include products currently regulated as IVDs as well as LDTs, among other provisions. The VALID Act would also create a new system for laboratories to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it would take for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. The FDA’s October 2023 publication of an LDT proposed rule that would apply the existing medical device framework to laboratory-developed products has renewed stakeholder calls for a more targeted approach to modernizing the federal government’s oversight of clinical diagnostic tests. It remains possible that congressional action in this area could displace the need for the FDA to complete its recently proposed rulemaking.

If Congress were to pass the VALID Act or any other legislation applicable to the FDA’s regulation of LDTs, or if the FDA were to successfully promulgate new regulations for such products through the recently initiated notice-and-comment rulemaking or a future rulemaking proceeding, we will likely be subject to increased regulatory burdens such as registration and listing requirements, adverse event reporting requirements and quality control requirements. Any legislation or formal FDA regulatory framework affecting LDTs is also likely to have premarket application requirements prohibiting commercialization without FDA authorization and controls regarding modification to the tests that may require further FDA submissions. The premarket review process can be lengthy, expensive, time-consuming and unpredictable. Further, obtaining premarket clearance may involve, among other things, successfully completing clinical trials, which require significant time and cash resources and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results. If we are required to obtain premarket clearance or approval and/or conduct premarket clinical trials, our development costs could significantly increase, marketing of any new diagnostic tests we may develop may be delayed, and sales of our existing diagnostic tests could be interrupted or stopped. Any of these outcomes could

43

 

reduce our revenue or increase our costs and materially adversely affect our business, prospects, results of operations or financial condition.

The outcome and ultimate impact on our business of any changes to the federal government’s regulation of LDTs is difficult to predict. Failure to comply with any applicable FDA requirements could trigger a range of enforcement actions, including warning letters, fines, penalties, suspension of operations, product recalls or seizures, denial of applications for clearance or approval, injunctions and other civil or criminal sanctions, which could have a material and adverse effect upon our business, operating results and financial condition.

Furthermore, should it be required in the future, we cannot be sure that our SomaSignalTM tests intended for clinical diagnostic use, or any new diagnostic tests that we may develop, will be reviewed and authorized for marketing by the FDA in a timely or cost-effective manner, if authorized at all. Even if such tests are authorized for marketing by the FDA, the agency could limit the test’s indications for use, which may significantly limit the market for that product and may adversely affect our business and financial condition.

We are currently limited to RUO with respect to many of the materials and components used in our consumable products including our assays.

We sell our instruments and consumable products, and certain of our assays, with a restrictions that they be used for RUO applications. The sale of our RUO products for any clinical or diagnostic purposes may require that we obtain regulatory clearance or approval to market the products for such purposes and also that we acquire certain materials and components used in the products from suppliers without an RUO restriction. There can be no assurance that we will be able to acquire these materials and components for use in diagnostic products on acceptable terms, if at all. If we are unable to do so, we would not be able to expand our instrument, consumable and assay product offerings beyond RUO, and our business and prospects would suffer.

The RUO/IUO Labeling Guidance, emphasizes that the FDA will review the totality of the circumstances when evaluating whether equipment and testing components are properly labeled as RUO. It further states that merely including a labeling statement that a product is intended for RUO will not necessarily render the device exempt from the FDA’s 510(k) clearance, PMA, or other requirements, if the circumstances surrounding the distribution of the product indicate that the manufacturer intends for its product to be offered for clinical diagnostic use. These circumstances may include written or verbal marketing claims or links to articles regarding a product’s performance in clinical applications, a manufacturer’s provision of technical support for clinical validation or clinical applications, or solicitation of business from clinical laboratories, all of which could be considered evidence of intended uses that conflict with RUO labeling. If the FDA were to determine that our RUO products were intended for use in clinical investigation, diagnosis or treatment decisions, or that express or implied clinical or diagnostic claims were made for our RUO products, those products could be considered misbranded or adulterated under the FDCA. If the FDA determines that our RUO products are being marketed for clinical diagnostic use without the required PMA or 510(k) clearance, we may be required to cease marketing our products as planned, recall the products from customers, revise our marketing plans, and/or suspend or delay the commercialization of our products until we obtain the required authorization. We also may be subject to a range of enforcement actions by the FDA, including warning or untitled letters, injunctions, civil monetary penalties, criminal prosecution, and recall and/or seizure of products, as well as significant adverse publicity. For instance, some of our customers may, on their own initiative, use our RUO-labeled products in the development of their own LDTs or in other FDA-regulated products for clinical diagnostic use and may request our assistance in developing such uses or validating the instrument, consumable or assay for diagnostic use. If we provide such services or advice, FDA could determine that we intend such instruments, consumables, or assays for clinical or diagnostic uses in contradiction of the RUO labeling and require us to recall the products, prepare and submit applications for marketing authorization for the clinical or diagnostic uses or initiate enforcement actions against us. Any of these developments may adversely affect our business and financial condition.

If the FDA determines that our RUO products are medical devices or if we seek to market our RUO products for clinical diagnostic or health screening use, we will be required to obtain regulatory clearance(s) or approval(s), and may be required to cease or limit sales of our then marketed products, which could materially and adversely affect our business, financial condition and results of operations. Any such regulatory process would be expensive, time-consuming and uncertain both in timing and in outcome.

Our RUO products are focused on the life sciences research market. This includes laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies. Accordingly, our products are labeled as RUO, and are not intended for diagnostic use. While our marketing for our RUO products is focused on the life sciences research market, we may decide to expand our product line to encompass products that are intended to be used for the diagnosis of disease or other medical purposes. Laboratory instruments, consumables and assays intended for clinical or diagnostic purposes are subject to regulation by the FDA as medical devices, or comparable international agencies, including requirements for regulatory clearance or approval of such products before they can be marketed. If the FDA were to determine that our products are intended for

44

 

clinical use or if we decided to market our products for such use, we would be required to obtain 510(k) clearance or premarket approval from the agency in order to sell our products in a manner consistent with applicable U.S. laws and regulations. Such regulatory authorization processes are expensive, time-consuming and uncertain; our efforts may never result in any marketing authorization for our products; and failure by us to obtain or comply with such authorizations could have an adverse effect on our business, financial condition or operating results. Even if we obtain approval of a PMA or 510(k) clearance, where required, such authorization may not be for the use or uses we believe are commercially attractive and/or are critical to the commercial success of our products. As a result, being subject to the FDA’s premarket review and/or post-market control requirements for our products could materially and adversely affect our business, financial condition and results of operations.

If we are required to obtain approval of a PMA or 510(k) clearance for our instruments, consumables or assay products, we or they would be subject to a substantial number of additional requirements applicable to medical devices, including establishment registration; device listing; Quality Systems Regulations which cover the design, testing, production, control, quality assurance, labeling, packaging, servicing, sterilization (if required), and storage and shipping of medical devices (among other activities); device labeling; advertising and promotion; recordkeeping; post-market surveillance; post-market studies; adverse event reporting; and device corrections, removals and recalls. One or more of our current or future products may also require clinical trials in order to generate the data required for approval of a PMA. Complying with these requirements may be time-consuming and expensive. We may be required to expend significant resources to ensure ongoing compliance with applicable regulations and implement satisfactory corrective or preventive actions in response to quality issues or enforcement action, which may have a material adverse effect on the ability to design, develop and commercialize products using our technology as planned. Failure to comply with these requirements may subject us to a range of enforcement actions, such as warning letters, injunctions, civil monetary penalties, criminal prosecution, recall and/or seizure of products, and revocation of marketing authorizations, as well as significant adverse publicity. If we or our collaborators fail to obtain, or experience significant delays in obtaining, regulatory approvals for our products, we may not be able to launch or successfully commercialize such products in a timely manner, or at all.

Failure to comply with applicable FDA requirements could subject us to misbranding or adulteration allegations under the Federal Food, Drug, and Cosmetic Act. We could be subject to a range of enforcement actions, including warning letters.

The FTC and/or state enforcement or regulatory agencies may object to the methods and materials we use to promote our products and services and initiate enforcement against us, which could adversely affect our business and financial condition.

The FTC and/or state enforcement or regulatory agencies (including but not limited to the offices of state attorneys general) may object to the materials and methods we use to promote our services and our currently marketed instruments, reagents, or assays, including diagnostic LDTs, or other products we may develop in the future, including with respect to the product claims in our promotional materials or advertising, and may initiate enforcement actions against us. Enforcement actions by the FTC may include, among others, injunctions, civil penalties and equitable monetary relief.

Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations and financial condition.

Any failure or perceived failure by us to comply with federal or state laws or regulations, our internal policies and procedures or our contracts governing our use and disclosures of personal information could result in negative publicity, government investigations and enforcement actions including significant penalties, claims by third parties, and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.

Failure to comply with HIPAA, the HITECH Act, their implementing regulations and similar comparable state laws and regulations affecting the transmission, security and privacy of health information could result in significant penalties.

Numerous federal, state and foreign laws and regulations, including HIPAA and the HITECH Act, govern the collection, dissemination, disclosure, security, use and confidentiality of individually identifiable health information health-related and other personal information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of PHI within our company and with third-parties. The privacy, security and breach notification rules promulgated under HIPAA, as amended by the HITECH Act, Standards for Privacy of Individually Identifiable Health Information (Privacy Standards) and the Security Standards for the Protection of Electronic Protected Health Information (Security Standards) under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by Covered Entities and their Business Associates. HIPAA requires Covered Entities to develop and maintain policies and procedures with respect to individually identifiable health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect the privacy and security of such

45

 

information. HIPAA also requires us to provide individuals with certain rights with respect to their PHI. Business Associates must have a written Business Associate contracts or other arrangements with a Covered Entity that establishes specifically what the Business Associate has been engaged to do and requires the Business Associate to comply with the requirements of HIPAA. Further, in the event of a breach of unsecured PHI we must notify each individual whose PHI is breached as well as federal regulators and in some cases, must publicize the breach in local or national media.

HIPAA also includes standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered Entities, such as certain healthcare providers, are required to conform to such transaction set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. Submission of electronic healthcare claims and payment transactions that do not comply with the HIPAA electronic data transmission standards could result in delayed or denied payments.

In the conduct of our business, we process, maintain, and transmit sensitive data, including PHI. There can be no assurance that a breach of privacy or security will not occur. If there is a breach, we could be subject to various lawsuits, penalties and damages and may be required to incur costs to mitigate the impact of the breach on affected individuals.

Penalties for failure to comply with HIPAA requirements are substantial and could include corrective action plans and/or the imposition of civil or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.

Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may apply more broadly or be more stringent than HIPAA. For example, the CCPA, which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the CPRA went into effect in California amending the CCPA and may increase our compliance costs and potential liability, imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data and adds opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws (for example, the Colorado Privacy Act and other similar laws that recently went into effect in other states, such as Utah, Virginia, Connecticut, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, and Texas), any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.

In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to €20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the EU. In July 2023, however, the European Commission adopted an adequacy decision for a new mechanism for transferring data from the EU to the United States – the EU-US Data Privacy Framework, which provides EU individuals with several new rights, including the right to obtain access to their data, or obtain correction or deletion of incorrect or unlawfully handled data. The adequacy decision followed the signing of an executive order introducing new binding safeguards addressing the reasons behind the Court of Justice of the EU’s invalidation of the original Privacy Shield. The European Commission will continually review developments in the United States along with its adequacy decision. However, future actions of EU data protection authorities are difficult to predict.

Relatedly, following the United Kingdom’s withdrawal from the EU, the GDPR was implemented in the United Kingdom as the U.K. GDPR. which sits alongside the amended U.K. Data Protection Act 2018, which implements certain derogations in the EU GDPR into United Kingdom law. The U.K. GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. In June of 2021, the European Commission issued a decision, which will sunset on June 27, 2025 without further action, that the United Kingdom ensures an adequate level of protection for personal data transferred under the EU GDPR from the EU

46

 

to the United Kingdom. The U.K. Parliament is currently considering the Data Protection and Digital Information Bill to harmonize the 2018 Data Protection Act, U.K. GDPR, and the Privacy and Electronic Communications Regulations under one legislative framework.

The regulatory framework governing the collection, storage, use and sharing of certain information, particularly financial and other personal information, is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. Additionally, increasing concerns about health information privacy have recently prompted the federal government to issue guidance taking a newly expansive view of the scope of the laws and regulations that they enforce. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our existing practices. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our privacy policies, changing expectations, evolving laws, rules and regulations, industry standards or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations.

Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation and adversely affect our business and results of operations.

Our actual or perceived failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our business.

We are subject to domestic and international data protection laws and regulations that address privacy and data security and may affect our collection, use, storage, and transfer of personal information. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues with the potential to affect our business. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws and federal and state consumer protection laws govern the collection, use, disclosure and protection of health-related and other personal information. Failure to comply with data protection laws and regulations, where applicable, could result in government enforcement actions, which could include civil or criminal penalties, private litigation and/or adverse publicity and could negatively affect our operating results and business. For example, California has enacted the California Consumer Privacy Act (the “CCPA”), which went into effect in January of 2020. The CCPA established a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for California residents, requiring covered businesses to provide new disclosures to California residents, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. Additionally in 2020, California voters passed the CPRA which went into effect on January 1, 2023. The CPRA significantly amends the CCPA, potentially resulting in further uncertainty, additional costs and expenses in an effort to comply and additional potential for harm and liability for failure to comply. Among other things, the CPRA established a new regulatory authority, the California Privacy Protection Agency, which is tasked with enacting new regulations under the CPRA and will have expanded enforcement authority. In addition to California, more U.S. states are enacting similar legislation, increasing compliance complexity and increasing risks of failures to comply. In 2023, comprehensive privacy laws in Virginia, Colorado, Connecticut, and Utah all took effect, and laws in Montana, Oregon, and Texas will take effect in 2024. In addition, laws in other U.S. states are set to take effect beyond 2024, and additional U.S. states have proposals under consideration, all of which are likely to increase our regulatory compliance costs and risks, exposure to regulatory enforcement action and other liabilities.

Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. For example, the European Union’s General Data Protection Regulation (GDPR), became effective in 2018 and imposed a broad data protection framework that expanded the scope of EU data protection law, including to non-EU entities meeting the jurisdictional requirements that process, or control the processing of, personal data relating to individuals located in the EU, including clinical trial data. The GDPR sets out a number of requirements for controllers and/or processors, as applicable, that must be complied with when handling the personal data of EU based data subjects, including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be “forgotten” and rights to data portability, as well as enhanced current rights (e.g., access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; and a new mandatory data breach regime.

47

 

In particular, medical or health data, genetic data and biometric data are all classified as “special category” data under the GDPR and afford greater protection and require additional compliance obligations. Further, EU member states have a broad right to impose additional conditions—including restrictions—on these data categories. This is because the GDPR allows EU member states to derogate from the requirements of the GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical purposes).

The GDPR is applicable to part of our business and has increased our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional procedures to comply. The GDPR is complex and regulatory guidance continues to evolve. Furthermore, national GDPR variations, including the fields of clinical study and other health-related information may raise our costs of compliance and result in greater legal risks.

We are also subject to evolving GDPR requirements on data export, because we transfer data to third countries outside of the EU that are not deemed “adequate.” The GDPR only permits exports of personal data outside of the EU to “non-adequate” countries where there is a suitable data transfer mechanism in place to safeguard personal data (e.g., the EU Commission approved Standard Contractual Clauses or certification under the newly-adopted Data Privacy Framework). On July 16, 2020, the Court of Justice of the EU, or the CJEU, issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18) (Schrems II). This decision calls into question certain data transfer mechanisms as between the EU member states and the U.S. The CJEU is the highest court in Europe and the Schrems II decision heightened the burden to assess U.S. national security laws on their business, and future actions of EU data protection authorities are difficult to predict at this time. While the newly-adopted Data Privacy Framework was meant to address the concerns raised by the CJEU in Schrems II, it will likely be subject to future legal challenges. Consequently, there is some risk of any data transfers from the EU being halted. If we have to rely on third parties to carry out services for us, including processing personal data on our behalf, we are required under GDPR to enter into contractual arrangements to flow down or help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause customers to lose trust in us, which would have an adverse impact on our reputation and business. Any contractual arrangements requiring the processing of personal data from the EU to us in the U.S. will require greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data or increase costs of compliance. The GDPR provides an enforcement authority to impose large penalties for noncompliance, including the potential for fines of up to €20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater.

Applicable data privacy and data protection laws may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. That could require us to incur significant expenses, which could significantly affect our business. Failure to comply with data protection laws may expose us to risk of enforcement actions taken by data protection authorities or other regulatory agencies, private rights of action in some jurisdictions, and potential significant penalties if we are found to be non-compliant. Furthermore, the number of government investigations related to data security incidents and privacy violations continue to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and reputation.

RISKS RELATED TO ECONOMIC CONDITIONS AND OPERATING A GLOBAL BUSINESS

We generate a substantial portion of our revenue internationally and our international business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.

During the years ended December 31, 2023 and 2022 approximately 59% of our product and service revenue was generated from sales to customers located outside of the United States. We believe that a significant percentage of our future revenue will continue to come from international sources as we expand our international operations and develop opportunities in other countries. Engaging in international business inherently involves a number of difficulties and risks, including:

•
required compliance with existing and changing foreign regulatory requirements and laws that are or may be applicable to our business in the future, such as the European Union’s General Data Protection Regulation, comprehensive U.S. state privacy laws such as the California Consumer Privacy Act, and similar laws in Colorado, Connecticut, Utah, and Virginia, and other data privacy requirements, labor and employment regulations, anticompetition regulations, the U.K. Bribery Act of 2010 and other anticorruption laws, and the RoHS and WEEE directives and REACH regulation, which regulate the use and importation of certain hazardous substances in, and require the collection, reuse, and recycling of waste from, products we manufacture;

48

 

•
required compliance with U.S. laws such as the Foreign Corrupt Practices Act, and other U.S. federal laws and regulations established by the Office of Foreign Assets Control;
•
export requirements and import or trade restrictions;
•
laws and business practices favoring local companies;
•
longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;
•
changes in social, economic, and political conditions or in laws, regulations and policies governing foreign trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions in which we operate and into which we sell our products, including as a result of the separation of the United Kingdom from the European Union (Brexit) or the Russian invasion of Ukraine;
•
business interruptions and travel restrictions resulting from global sociopolitical events, including war and terrorism, public health crises (including the ongoing COVID-19 pandemic), and natural disasters including earthquakes, typhoons, floods and fires;
•
potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements, and other trade barriers;
•
difficulties and costs of staffing and managing foreign operations; and
•
difficulties protecting or procuring intellectual property rights.

During much of the COVID-19 pandemic, travel restrictions caused significant slowdowns in China, Japan, and other parts of the Asia-Pacific region. These slowdowns, in addition to shipment delays in China due to delays in obtaining VAT and import tax exemptions for our products, have caused our financial results to suffer. If these situations continue, or if other risks occur, we could be forced to dedicate significant resources to their resolution, and if we are unsuccessful in finding a solution, our financial condition and results will suffer.

In addition, political instability, civil unrest, the deterioration of the political situation in a country in which we have significant sales or operations, or the breakdown of trade relations between the United States and a foreign country in which we have significant operations, could adversely affect our business, financial condition, and results of operations. For example, a change in trade status between the United States and a foreign country could result in a substantial increase in the import duty applicable to products manufactured in that foreign country and imported into the United States. The United States has commenced certain trade actions, including imposing increased tariffs on certain goods imported into the United States from China, which has resulted in retaliatory tariffs by China. In addition, the United States has commenced certain trade actions as a result of the Russian invasion of Ukraine, which has resulted in retaliatory measures by Russia. Any increased trade barriers or restrictions on global trade imposed by the United States, or further retaliatory trade measures taken by China, Russia, or other countries in response, could adversely affect our business, financial condition, and results of operations.

Our business is subject to a variety of new U.S. and foreign export controls and economic sanctions regulations that were issued in response to Russia’s invasion of Ukraine; our failure to comply with these laws and regulations could harm our business.

Due to recent regulations, U.S. companies can no longer provide or receive services or conduct any business with, including selling, shipping, or otherwise transferring any U.S.-controlled products to, the Donetsk People’s Republic (DNR) and Luhansk People’s Republic (LNR) regions of Ukraine. Additionally, existing U.S. sanctions continue to extend these prohibitions to the Crimea region of Ukraine. Our business is also subject to the expansion of previously existing sanctions imposed by the Treasury Department’s Office of Foreign Assets Controls that now cover a significant number of individuals and entities located in Russia, Belarus, and surrounding regions as well as new U.S. export controls imposed by the U.S. Department of Commerce’s Export Administration Regulations on exports to Russia. These laws and regulations cover U.S. persons as well as U.S.-controlled products, software, and technologies wherever located. Failure to comply with U.S. and foreign export control and economic sanctions laws and regulations can result in criminal sanctions, civil fines, debarment from government contracting, the loss of export privileges, and, in some cases, imprisonment.

Any additional changes in export control laws, sanctions requirements, or our operations in the affected regions may require us to expend additional resources or to discontinue certain products or services, which would negatively affect our business, financial condition, and operating results. In addition, the increased attention focused upon liability issues as a result of lawsuits, regulatory proceedings, and legislative proposals could damage our brand or otherwise impact the growth of our business. Finally, our ability to receive payment from these regions has been significantly impacted. Any costs incurred or loss of business that occurs as a result of compliance or other liabilities under these laws or regulations could harm our business and operating results.

49

 

Adverse conditions in the domestic and global economy and disruption of financial markets may significantly harm our revenue, profitability, and results of operations.

Adverse economic conditions in the U.S. and international markets, including any worldwide economic disruption related to another or worsening global pandemic or a recession, could negatively impact our revenues and results of operations. The global credit and financial markets continue to experience volatility and disruptions, including diminished liquidity and credit availability, increased concerns about inflation, and uncertainty about economic stability. Geopolitical events including a potential recession, the Russian invasion of Ukraine, including any resulting adoption and expansion of trade restrictions by the United States, Russia, and/or China, and Brexit have caused significant economic, market, political and regulatory uncertainty in some of our markets. Volatility and disruption of financial markets could limit our customers’ ability to obtain adequate financing or credit to purchase and pay for our products in a timely manner or to maintain operations, which could result in a decrease in sales volume that could harm our results of operations. General concerns about the fundamental soundness of domestic and international economies may also cause our customers to reduce their purchases. Changes in governmental banking, monetary, and fiscal policies to address liquidity and increase credit availability may not be effective. Significant government investment and allocation of resources to assist the economic recovery of sectors that do not include our customers may reduce the resources available for government grants and related funding for life science, plant and animal research, and clinical research and development. Continuation or further deterioration of these financial and macroeconomic conditions could significantly harm our sales, profitability, and results of operations.

We are subject to fluctuations in the exchange rate of the U.S. dollar and foreign currencies.

Our revenue is generally denominated in the local currency of the contracting party. Historically, the majority of our revenue has been denominated in U.S. dollars and fluctuations in the value of the U.S. dollar relative to foreign currencies could decrease demand for our products and adversely impact our financial performance. For example, if the value of the U.S. dollar increases relative to foreign currencies, our products could become more costly to the international consumer and therefore less competitive in international markets, or if the value of the U.S. dollar decreases relative to the Singapore dollar or the Canadian dollar, it would become more costly in U.S. dollars for us to manufacture our products in Singapore and/or in Canada. Additionally, our expenses are generally denominated in the currencies where our operations are located, which is primarily in the United States, with a portion of expenses incurred in Singapore and Canada where our manufacturing facilities are located. Our results of operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates. The volatility of exchange rates depends on many factors that we cannot forecast with reliable accuracy. We have experienced and will continue to experience fluctuations in our net income or loss as a result of transaction gains or losses related to revaluing certain current asset and current liability balances that are denominated in currencies other than the functional currency of the entities in which they are recorded. Fluctuations in currency exchange rates could have an adverse impact on our financial results in the future.

FINANCIAL, TAX, AND ACCOUNTING RISKS

Our future capital needs are uncertain and we may need to raise additional funds in the future, which may cause dilution to stockholders or may be upon terms that are not favorable to us.

We continue to experience losses and, if that trend continues, we may need to seek additional sources of financing. In addition, we may need to raise substantial additional capital for various purposes, including:

•
funding our operations;
•
debt repayments;
•
acquiring other businesses or assets and licensing technologies;
•
expanding the commercialization of our products; and
•
furthering our research and development.

Our future funding requirements will depend on many factors, including:

•
market acceptance of our products;
•
the cost of our research and development activities;
•
the cost of filing and prosecuting patent applications;
•
the cost of defending any litigation including intellectual property, employment, contractual or other litigation;
•
the cost and timing of regulatory clearances or approvals, if any;

50

 

•
the cost and timing of establishing additional sales, marketing, and distribution capabilities;
•
the cost and timing of establishing additional technical support capabilities;
•
fluctuations in cash demands (e.g., due to interest or principal payments or payouts under existing cash compensation plans);
•
variability in sales and timing of related cash collections;
•
the effectiveness of our efficiency, cost-savings and other strategic initiatives (including those contemplated by the restructuring plan that we announced in August 2022);
•
the impact of any natural disasters or public health crises (including the COVID-19 pandemic);
•
the effect of competing technological and market developments; and
•
the extent to which we acquire, license or otherwise invest in businesses, products, and technologies.

To the extent we draw on our Revolving Credit Facility or otherwise incur additional indebtedness, the risks described above could increase. Further, if we increase our indebtedness, our actual cash requirements in the future may be greater than expected. Our cash flow from operations may not be sufficient to repay all of the outstanding debt as it becomes due, and we cannot assure you that we will be able to obtain additional funds on acceptable terms, or at all. In recent years, there has been significant volatility in the global capital markets, increasing the cost of—and adversely impacting access to—capital. If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing in addition to the Credit Facility (as defined below), if available, may involve covenants restricting our operations or our ability to incur additional debt. Any additional debt or equity financing that we raise may contain terms that are not favorable to us or our stockholders, and our ability to raise additional capital may be adversely impacted by the impact of the COVID-19 pandemic on the economy.

If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us. If we do not have or are unable to raise adequate funds, we may have to liquidate some or all of our assets, delay development or commercialization of our products, or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to reduce marketing, customer support, research and development, or other resources devoted to our products, or cease operations. Any of these factors could harm our operating results.

If we fail to maintain effective internal control over financial reporting in the future, the accuracy and timing of our financial reporting may be impaired, which could adversely affect our business and our stock price.

The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our testing may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses.

Our compliance with Section 404 requires that we incur substantial accounting expense and expend significant management time on compliance-related issues. We currently do not have an internal audit group, and we continue to evaluate our need for additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. We also monitor our ability to retain and motivate our key existing workers with highly trained accounting and finance skills in a competitive market. Our restructuring activities could diminish our resource capacity and impact our control processes with changes implemented. Our planned enterprise resource planning (ERP) upgrade in 2023 will also result in changes to our processes and control procedures. If we do not comply with the requirements of Section 404, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, the Securities and Exchange Commission (SEC), or other regulatory authorities, which would require additional financial and management resources.

We may not realize the value of our goodwill or other intangible assets, which would be reflected in an impairment charge.

Our business acquisitions typically result in goodwill and other intangible assets, which affect the amount of future period amortization expense and possible impairment expense. We make estimates and assumptions in valuing such intangible assets that affect our consolidated financial statements. As of December 31, 2023, we had approximately $107.7 million of goodwill and net intangible assets, including approximately $106.3 million of goodwill and $1.4 million of net intangible assets. These assets represent a significant portion

51

 

of the assets recorded on our consolidated balance sheet. In addition, if in the future we acquire additional businesses, technologies, or other intangible assets, a substantial portion of the value of such assets may be recorded as goodwill or intangible assets.

We assess the realizability of goodwill and indefinite-lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We also assess the realizability of definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances may include a significant deterioration in overall economic conditions, a decline in our market capitalization, reorganizations of our business, the disposal of all or a portion of a reporting unit, operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of these businesses, including our ability to realize revenue growth, cost savings, and other macro factors which impact the enterprise value. These cash flows in turn depend in part on how well we have integrated these businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.

In determining the fair value of our two operating segments, significant assumptions including forecasted cash flows (revenue growth rates), discount rates, earnings multiples and an implied control premium are utilized. As these assumptions are inherently judgmental and subject to uncertainty, future impairments that cannot be reasonably estimated, but could be material, may occur. We performed our annual goodwill assessment as of December 31, 2023 and concluded that we did not have a goodwill impairment as of December 31, 2023.

If we fail to comply with the covenants and other obligations under our Term Loan Facility, the lending bank may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations.

The stated maturity of the Term Loan Facility is July 1, 2025. However, if the principal amount of our convertible debt exceeds $0.6 million as of June 1, 2024 or if the maturity of our 2019 Notes has not been extended beyond January 1, 2026 by June 1, 2024, then the maturity date of the Term Loan Facility will be June 1, 2024. The interest rate on the Term Loan Facility is the greater of 4.0% or a floating per annum rate equal to three quarters of one percentage point (0.75%) above the prime rate. Interest on any outstanding term loan advances is due and payable monthly. In addition to the monthly interest payments, a final payment equal to 6.5% of the original principal amount of each advance is due on the earlier of the maturity date or the date the advance is repaid. Principal balances are required to be repaid in twenty-four equal installments beginning on August 1, 2023. The Term Loan Facility is secured by substantially all of our assets, other than intellectual property. The Term Loan Facility contains customary affirmative and negative covenants which, unless waived by the bank, limit our ability to, among other things, incur additional indebtedness, grant liens, make investments, repurchase stock, pay dividends, transfer assets, enter into affiliate transactions, undergo a change of control, or engage in merger and acquisition activity, including merging or consolidating with a third party. Additionally, we are required to maintain a minimum Adjusted Quick Ratio (as defined in the Term Loan Facility) of at least 1.25 to 1.00. If we fail to comply with the covenants and our other obligations under the Term Loan Facility, the lending bank would be able to accelerate the required repayment of amounts due under the Term Loan Facility and, if they are not repaid, could foreclose upon the assets securing our obligations under the Term Loan Facility.

Our ability to use net operating loss carryforwards to offset future taxable income for U.S. federal income tax purposes and other tax benefits may be limited.

Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by net operating loss carryforwards (NOLs) if a corporation experiences an “ownership change.” As provided in Section 382 of the Code, an “ownership change” occurs when a company’s “five-percent shareholders” collectively increase their ownership in the company by more than 50 percentage points (by value) over a rolling three-year period. Various states also have limitations on the use of state NOLs following an ownership change.

Future changes in our stock ownership, some of which are outside our control, could result in an ownership change under Section 382 of the Code. In 2022, we experienced an ownership change, which substantially limited our ability to use our NOLs. There is no assurance that we will be able to fully utilize our future NOLs or other tax benefits, which could adversely impact our results of operations.

We believe that these tax benefits are a valuable asset for us and we monitor our stock ownership to determine whether our NOLs are at material risk of limitation based on an ownership change pursuant to Section 382. If our board of directors determines a potential risk exists that our NOLs could be limited, it could elect to adopt a tax benefit preservation plan in an effort to protect our tax benefits. Adoption of a tax benefit preservation plan could make it more difficult for a third party to acquire, or could discourage a third party from acquiring, us or a large block of our common stock.

52

 

We are subject to risks related to taxation in multiple jurisdictions and our effective income tax rate could be adversely affected and we could have additional tax liability if existing tax laws or regulations change or if taxing authorities disagree with our interpretations of tax laws or regulations.

We are subject to income taxes in both the United States and certain foreign jurisdictions. Significant judgments based on interpretations of existing tax laws or regulations are required in determining the provision for income taxes. For example, we have made certain interpretations of existing tax laws or regulations based upon the operations of our business internationally and we have implemented intercompany agreements based upon these interpretations and related transfer pricing analyses. If the U.S. Internal Revenue Service or other taxing authorities disagree with the positions, our effective income tax rate could be adversely affected and we could have additional tax liability, including interest and penalties. From time to time, we may review our corporate structure and tax positions in the various international jurisdictions in which we operate and such review may result in changes to how we structure our international business operations, which may adversely impact our effective income tax rate. Our effective income tax rate could also be adversely affected by changes in the mix of earnings in tax jurisdictions with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in existing tax laws or tax rates, changes in the level of non-deductible expenses (including share-based compensation), changes in our future levels of research and development spending, mergers and acquisitions, or the result of examinations by various tax authorities. Payment of additional amounts as a result of changes in applicable tax law or upon final adjudication of any disputes could have a material impact on our results of operations and financial position.

Changes in accounting principles, or interpretations thereof, could have a significant impact on our financial position and results of operations.

We prepare our consolidated financial statements in accordance with U.S. GAAP. These principles are subject to interpretation by the SEC and various bodies formed to interpret and create appropriate accounting principles. A change in these principles can have a significant effect on our reported results and may even retroactively affect previously reported transactions. Additionally, the adoption of new or revised accounting principles may require that we make significant changes to our systems, processes and controls.

It is not clear if or when potential changes in accounting principles may become effective, whether we have the proper systems and controls in place to accommodate such changes and the impact that any such changes may have on our financial position and results of operations.

We have a significant amount of outstanding indebtedness, and our financial condition and results of operations could be adversely affected if we do not efficiently manage our liabilities.

We have significant outstanding convertible debt. As of December 31, 2023, we had outstanding $0.6 million aggregate principal amount of our 2.75% Convertible Senior Notes due 2034 that were issued in February 2014 (2014 Notes) and $55.0 million aggregate principal amount of our 5.25% Convertible Senior Notes due 2024 that were issued in November 2019 (2019 Notes and, together with the 2014 Notes, the Convertible Notes). The 2014 Notes will mature on February 1, 2034, unless earlier converted, redeemed, or repurchased in accordance with the terms of the 2014 Notes. Pursuant to the terms of the indenture governing the 2014 Notes, holders of the 2014 Notes may require us to repurchase all or a portion of their 2014 Notes at a repurchase price in cash equal to 100% of the principal amount of such 2014 Notes plus accrued and unpaid interest thereon, on each of February 6, 2024 and February 6, 2029. On February 6, 2024, one holder of the 2014 Notes exercised their repurchase right, and we repurchased an immaterial amount of principal and accrued interest. The 2019 Notes will mature on December 1, 2024, unless earlier converted or repurchased in accordance with the terms of the 2019 Notes.

If we undergo a fundamental change (as defined in the indenture governing the 2014 Notes or the 2019 Notes, as applicable), holders of the applicable series of Convertible Notes may require us to repurchase such Convertible Notes in whole or in part for cash at a repurchase price equal to 100% of the principal amount of the applicable series of Convertible Notes plus accrued and unpaid interest. If we refinance all or any portion of the Convertible Notes, we may issue additional convertible notes or other debt, which could include additional company obligations and represent more dilution to existing stockholders and noteholders.

This significant amount of debt has important risks to us and our investors, including:

•
requiring a portion of our cash flow from operations to make interest payments on this debt;
•
increasing our vulnerability to general adverse economic and industry conditions;
•
reducing the cash flow available to fund capital expenditures and other corporate purposes and to grow our business;
•
limiting our flexibility in planning for, or reacting to, changes in our business and the industry; and

53

 

•
limiting our ability to borrow additional funds as needed or take advantage of business opportunities as they arise.

In addition, to the extent we draw on our Revolving Credit Facility or otherwise incur additional indebtedness, the risks described above could increase. Further, if we increase our indebtedness, our actual cash requirements in the future may be greater than expected. Our cash flow from operations may not be sufficient to repay all of the outstanding debt as it becomes due, and we may not be able to borrow money, sell assets or otherwise raise funds on acceptable terms, or at all, to refinance our debt.

RISKS RELATED TO INTELLECTUAL PROPERTY

Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain.

Our commercial success depends in part on our ability to protect our intellectual property and proprietary technologies. We rely on patent protection, where appropriate and available, as well as a combination of copyright, trade secret, and trademark laws, and nondisclosure, confidentiality, and other contractual restrictions to protect our proprietary technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We apply for patents covering our products and technologies and uses thereof, as we deem appropriate. However, we may fail to apply for patents on important products and technologies in a timely fashion or at all. Our pending U.S. and foreign patent applications may not issue as patents or may not issue in a form that will be sufficient to protect our proprietary technology and gain or keep our competitive advantage. Any patents we have obtained or do obtain may be subject to re-examination, reissue, opposition, or other administrative proceeding, or may be challenged in litigation, and such challenges could result in a determination that the patent is invalid or unenforceable. In addition, competitors may be able to design alternative methods or devices that avoid infringement of our patents. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.

Furthermore, the laws of some foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Changes in either the patent laws or in interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example:

•
we might not have been the first to make the inventions covered by each of our pending patent applications;
•
we might not have been the first to file patent applications for these inventions;
•
the patents of others may have an adverse effect on our business; and
•
others may independently develop similar or alternative products and technologies or duplicate any of our products and technologies.

To the extent our intellectual property, including licensed intellectual property, offers inadequate protection, or is found to be invalid or unenforceable, our competitive position and our business could be adversely affected.

We may be involved in lawsuits to protect or enforce our patents and proprietary rights, to determine the scope, coverage and validity of others’ proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business or stock price.

Litigation may be necessary for us to enforce our patent and proprietary rights, determine the scope, coverage, and validity of others’ proprietary rights, and/or defend against third-party claims of intellectual property infringement against us as well as against our suppliers, distributors, customers, and other entities with which we do business. Litigation could result in substantial legal fees and could adversely affect the scope of our patent protection. The outcome of any litigation or other proceeding is inherently uncertain and might not be favorable to us, and we might not be able to obtain licenses to technology that we require. Even if such licenses are obtainable, they may not be available at a reasonable cost. We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our product margins or financial position. Further, we could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products.

As we move into new markets and applications for our products, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of impeding our entry into such markets or as a means to extract substantial license and royalty payments from us. Our commercial success may depend in part on our non-infringement of the patents or proprietary rights of third parties. Numerous significant intellectual property issues have been litigated, and will likely continue to be litigated, between existing and new participants in our existing and targeted markets. For example, some of our products provide for the testing and analysis of genetic material, and patent rights relating to genetic materials remain a developing area of patent law. A recent U.S. Supreme Court decision held, among other things, that claims to isolated genomic DNA occurring in nature are not patent eligible, while claims relating

54

 

to synthetic DNA may be patent eligible. We expect the ruling will result in additional litigation in our industry. In addition, third parties may assert that we are employing their proprietary technology without authorization, and if they are successful in making such claims, we may be forced to enter into license agreements, pay additional royalties or license fees, or enter into settlements that include monetary obligations or restrictions on our business.

Our customers have been sued for various claims of intellectual property infringement in the past, and we expect that our customers will be involved in additional litigation in the future. In particular, our customers may become subject to lawsuits claiming that their use of our products infringes third-party patent rights, and we could become subject to claims that we contributed to or induced our customer’s infringement. In addition, our agreements with some of our suppliers, distributors, customers, and other entities with which we do business may require us to defend or indemnify these parties to the extent they become involved in infringement claims against us, including the claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify any of these third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.

We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees’ former employers or other institutions or third parties with which such employees may have been previously affiliated.

Many of our employees were previously employed at universities or other life science or plant and animal research companies, including our competitors or potential competitors. In the future, we may become subject to claims that our employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or other third parties or institutions with which our employees may have been previously affiliated. Litigation may be necessary to defend against these claims. A resulting loss of key research personnel work product could hamper or prevent our ability to commercialize certain potential products or a loss of or inability to hire key marketing, sales or research and development personnel could adversely affect our future product development, sales and revenues, any of which could severely harm our business. Even if we are successful in defending against any such claims, litigation could result in substantial costs and be a distraction to management.

We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling our products, which would have an adverse effect on our business.

We rely on licenses in order to be able to use various proprietary technologies that are material to our business, including our core IFC, multi-layer soft lithography, and mass cytometry technologies. In some cases, we do not control the prosecution, maintenance, or filing of the patents to which we hold licenses, or the enforcement of these patents against third parties. Additionally, our business and product development plans anticipate and may substantially depend on future in-license agreements with additional third parties, some of which are currently in the early discussion phase. For example, our Canadian subsidiary (SB Canada) was party to an interim license agreement, now expired, under which the licensor granted SB Canada a worldwide, non-exclusive, RUO, royalty bearing license to certain cytometric reagents, instruments, and other products. While we were able to secure a license under a new license agreement with the licensor, we cannot provide assurances that we will always be able to obtain suitable license rights to technologies or intellectual property of other third parties on acceptable terms, if at all.

In December 2021, SomaLogic entered into the Collaboration Agreement with Illumina, Inc. (Illumina) to develop co-branded, distributable NGS-based proteomic products. As part of the Collaboration Agreement, Illumina will develop and deploy NGS-based protein identification and measurement tools into laboratories worldwide, and facilitate the development and use of high-plex protein pattern recognition tests.

There can be no assurance that any current contractual arrangements between us and third parties, such as Illumina, for example, or between our strategic partners and other third parties will be continued on materially similar terms and will not be breached or terminated early. Any failure to obtain or retain the rights to necessary technologies on acceptable commercial terms could require us to re-configure our products and services, which could negatively impact their commercial sale or increase the associated costs, either of which could materially harm our business and adversely affect our future revenues and ability to achieve sustained profitability.

In-licensed intellectual property rights that are fundamental to our business being operated present numerous risks and limitations. For example, all or a portion of the license rights granted may be limited for RUO, and in the event we attempt to expand into diagnostic applications, we would be required to negotiate additional rights, which may not be available to us on commercially reasonable terms, if at all.

55

 

Our rights to use the technology we license are also subject to the negotiation and continuation of those licenses. Certain of our licenses contain provisions that allow the licensor to terminate the license upon specific conditions. Our rights under the licenses are subject to our continued compliance with the terms of the license, including the payment of royalties due under the license. Because of the complexity of our products and the patents we have licensed, determining the scope of the license and related royalty obligation can be difficult and can lead to disputes between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful and the license is terminated, we might be barred from marketing, producing, and selling some or all of our products, which would have an adverse effect on our business. Potential disputes between us and one of our existing licensors concerning the terms or conditions of the applicable license agreement could result, among other risks, in substantial management distraction; increased expenses associated with litigation or efforts to resolve disputes; substantial customer uncertainty concerning the direction of our product lines; potential infringement claims against us and/or our customers, which could include efforts by a licensor to enjoin sales of our products; customer requests for indemnification by us; and, in the event of an adverse determination, our inability to operate our business as currently operated. Termination of material license agreements could prevent us from manufacturing and selling our products unless we can negotiate new license terms or develop or acquire alternative intellectual property rights that cover or enable similar functionality. Any of these factors would be expected to have a material adverse effect on our business, operating results, and financial condition and could result in a substantial decline in our stock price.

We are subject to certain manufacturing restrictions related to licensed technologies that were developed with the financial assistance of U.S. governmental grants.

We are subject to certain U.S. government regulations because we have licensed technologies that were developed with U.S. government grants. In accordance with these regulations, these licenses provide that products embodying the technologies are subject to domestic manufacturing requirements. If this domestic manufacturing requirement is not met, the government agency that funded the relevant grant is entitled to exercise specified rights, referred to as “march-in rights,” which if exercised would allow the government agency to require the licensors or us to grant a non-exclusive, partially exclusive, or exclusive license in any field of use to a third party designated by such agency. All of our microfluidic systems revenue is dependent upon the availability of our IFCs, which incorporate technology developed with U.S. government grants. Our genomics instruments, including microfluidic systems and IFCs, are manufactured at our facility in Singapore. The federal regulations allow the funding government agency to grant, at the request of the licensors of such technology, a waiver of the domestic manufacturing requirement. Waivers may be requested prior to any government notification. We are not currently manufacturing instruments and IFCs in the United States that incorporate the relevant licensed technology. If our lack of compliance with any such provisions constituted a material breach of the license agreement, the license of the relevant patents could be terminated or we could be compelled to relocate our manufacturing of microfluidic systems and IFCs to the United States to avoid or cure a material breach of the license agreement. Any of the exercise of march-in rights, the termination of our license of the relevant patents or the relocation of our manufacturing of microfluidic systems and IFCs to the United States could materially adversely affect our business, operations and financial condition.

We are subject to certain obligations and restrictions relating to technologies developed in cooperation with Canadian government agencies.

Some of our Canadian research and development is funded in part through government grants and by government agencies. The intellectual property developed through these projects is subject to rights and restrictions in favor of government agencies and Canadians generally. In most cases the government agency retains the right to use intellectual property developed through the project for non-commercial purposes and to publish the results of research conducted in connection with the project. This may increase the risk of public disclosure of information relating to our intellectual property, including confidential information, and may reduce its competitive advantage in commercializing intellectual property developed through these projects. In certain projects, we have also agreed to use commercially reasonable efforts to commercialize intellectual property in Canada, or more specifically in the province of Ontario, for the economic benefit of Canada and the province of Ontario. These restrictions will limit our choice of business and manufacturing locations, business partners and corporate structure and may, in certain circumstances, restrict our ability to achieve maximum profitability and cost efficiency from the intellectual property generated by these projects. In one instance, a dispute with the applicable government funded entity may require mediation, which could lead to unanticipated delays in our commercialization efforts to that project. One of our Canadian government funded projects is also subject to certain limited “march-in” rights in favor of the government of the Province of Ontario, under which we may be required to grant a license to our intellectual property, including background intellectual property developed outside the scope of the project, to a responsible applicant on reasonable terms in circumstances where the government determines that such a license is necessary in order to alleviate emergency or extraordinary health or safety needs or for public use. In addition, we must provide reasonable assistance to the government in obtaining similar licenses from third parties required in connection with the use of its intellectual property. Instances in which the government of the Province of Ontario has exercised similar

56

 

“march-in” rights are rare; however, the exercise of such rights could materially adversely affect our business, operations and financial condition.

RISKS RELATED TO OUR CAPITAL STRUCTURE

The market value of our common stock could decline if the Purchasers sell their Series B Preferred Stock or common stock.

Pursuant to the Registration Rights Agreement that we entered into on January 23, 2022 with the Purchasers, we registered the resale of the shares of common stock issuable upon conversion of the Series B Preferred Stock with the SEC, which means that such shares would become eligible for resale in the public markets, subject to any applicable transfer restrictions. Any sale of such shares, or the anticipation of the possibility of such sales, could create downward pressure on the market price of our common stock.

Our Series B Preferred Stock has rights, preferences and privileges that are not held by, and are preferential to, the rights of our common stockholders, which could adversely affect our liquidity and financial condition, result in the interests of holders of our Series B Preferred Stock differing from those of our common stockholders and make an acquisition of us more difficult.

Holders of our Series B Preferred Stock have (i) a liquidation preference, (ii) rights to dividends, which are senior to all of our other equity securities, (iii) the right to require us to repurchase any or all of their Series B Preferred Stock in connection with certain change of control events, and (iv) conversion price adjustments upon the occurrence of certain events, each subject to the terms, conditions and exceptions contained in the applicable Certificate of Designations. These dividend and other rights and obligations could impact our liquidity and reduce the amount of cash flows available for working capital, capital expenditures, growth opportunities, acquisitions, and other general corporate purposes.

The terms of our Series B Preferred Stock could also limit our ability to obtain additional financing or increase our borrowing costs, which could have an adverse effect on our financial condition. The preferential rights could also result in divergent interests between the Purchasers and holders of our common stock. Furthermore, a sale of our Company, as a change of control event, may require us to repurchase the Series B Preferred Stock, which could have the effect of making an acquisition of our Company more expensive and potentially deterring proposed transactions that may otherwise be beneficial to our stockholders.

The holders of our Series B Preferred Stock are entitled to vote with the holders of our common stock with voting power measured in a manner related to the conversion ratio of the shares of Series B Preferred Stock, and the holders of our Series B Preferred Stock have rights to approve certain actions. The holders of our Series B Preferred Stock may exercise influence over us, including through the ability of the holders of the Series B-1 Preferred Stock and the holders of the Series B-2 Preferred Stock to each designate a member of our board of directors.

The holders of our Series B Preferred Stock are generally entitled to vote with the holders of our common stock on all matters submitted for a vote of holders of our common stock (voting together with the holders of common stock as one class) with voting power measured in a manner related to the conversion ratio of the shares of Series B Preferred Stock, subject to certain voting limitations as described in the applicable Certificate of Designations. Additionally, the consent of the holders of at least 60% of the shares of Series B Preferred Stock is required for, among other things, (i) amendments to our certificate of incorporation or bylaws that have an adverse effect on the rights, preferences, privileges or voting powers of the Series B Preferred Stock and (ii) issuances by us of securities that are senior to, or equal in priority with, the Series B Preferred Stock.

Additionally, pursuant to the Certificates of Designations for the Series B Preferred Stock, the holders of a majority of the outstanding Series B-1 Preferred Stock and the holders of a majority of the outstanding Series B-2 Preferred Stock each have the right to nominate and elect one member to our board of directors at each annual meeting of the stockholders of the Company or at any special meeting called for the purpose of electing directors, for so long as the Casdin Preferred Percentage or Viking Preferred Percentage (each as defined in the applicable Certificate of Designations), as applicable, is equal to or greater than 7.5%. Such directors are not subject to the classified board of directors provisions of our certificate of incorporation, and are entitled to serve on committees of our board of directors, subject to applicable law and Nasdaq rules. Notwithstanding the fact that all directors will be subject to fiduciary duties to us and to applicable law, the interests of the directors designated by the holders of Series B Preferred Stock may differ from the interests of our security holders as a whole or of our other directors.

These significant stockholders may be able to determine or significantly influence matters requiring stockholder approval. The interests of significant stockholders may not always coincide with our interests or the interests of other stockholders. The Certificates of Designations for the Series B Preferred Stock also provide that for so long as the Casdin Preferred Percentage or Viking Preferred Percentage, as applicable, is equal to or greater than 7.5%, the director designated by the holders of the Series B-1 Preferred Stock or the Series B-2 Preferred Stock, as applicable, will have certain consent rights over, among other things: (i) any increase in the number

57

 

of directors on our board of directors beyond seven; (ii) the hiring, promotion, demotion, or termination of the Company’s Chief Executive Officer; (iii) entering into or modifying (including by waiver) any transaction, agreement or arrangement with any Related Person (as defined in the Certificates of Designations for the Series B Preferred Stock), subject to certain exceptions; (iv) any voluntary petition under any applicable federal or state bankruptcy or insolvency law effected by the Company; (v) any change in the principal business of the Company or entry by the Company into any material new line of business; and (vi) for a period of three years after the closing date of the Private Placement Issuance, (A) any acquisition (including by merger, consolidation or acquisition of stock or assets) of any assets, securities or property of any other person or (B) any sale, lease, license, transfer or other disposition of any assets of the Company or any of its subsidiaries, in each case, other than acquisitions or dispositions of inventory or equipment in the ordinary course of business consistent with past practice, for consideration in excess of $50.0 million in the aggregate in any six month period.

As a result, the holders of our Series B Preferred Stock have the ability to influence the outcome of certain matters affecting our governance and capitalization. Our obligations to the holders of our Series B Preferred Stock could also limit our ability to obtain additional financing or increase our borrowing costs, which could have an adverse effect on our financial condition.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY

Risk Management and Strategy

Standard BioTools regularly assesses risks from cybersecurity threats; monitors our information systems for potential vulnerabilities; and tests those systems pursuant to our cybersecurity policies, processes, and practices, which are integrated into our overall risk management program. To protect our information systems from cybersecurity threats, we use various security tools that are designed to protect against cyber security incidents, as well as to identify, escalate, investigate, resolve, and recover from security incidents in a timely manner. As part of this program, we conduct periodic assessments of our assets to evaluate the effectiveness of applicable security controls. These assessments are informed by industry standard frameworks (NIST, ISO) and include a review of our information security controls, policies and procedures to assess cybersecurity maturity against industry standards. In accordance with our IT Risk Management Program, we actively identify and assess risks based on the probability and potential impact to key business systems and processes. All risks identified will be assessed to identify the range of possible outcomes and risks will be prioritized by their level of importance. Each risk will be assigned to a risk owner who will track, monitor, and report on the status with a risk response aligned to the probability and impact of occurrence. Risks that are considered high are incorporated into our corporate risk management program overseen by the Audit Committee and our Board of Directors.

All employees receive cybersecurity training upon hire with at least annual training thereafter with job-specific topic considerations. Our Information Security team, consisting of the VP of Information Technology, Sr. Manager of Network Security and IT Security Manger, among others, engage third-party vendors to assist with providing timely cybersecurity threat alerts in addition to monitoring for cybersecurity threats and our defenses against cyberattacks. This monitoring includes the proactive identification of vulnerabilities in our systems through testing and threat intelligence awareness. The employees within our Information Security team and broader IT team who specialize in cybersecurity operations are responsible for coordinating and overseeing the activities of these third-party vendors.

Additionally, we require each third-party service provider with access to our internal systems, applications or data to certify that it has the ability to implement and maintain appropriate security measures, consistent with all applicable laws, to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of its security measures that may affect our company. Our practice is to perform due diligence, including the completion of security questionnaires and risk assessments, as appropriate, on these third parties.

We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition in our risk factor titled “Security incidents, loss of data, cyberattacks, and other information technology failures could disrupt our operations, damage our reputation, and adversely affect our business, operations, and financial results,” in Part I, Item 1A. "Risk Factors." Refer to this risk factor for additional description of cybersecurity risks and potential related impacts on our Company.

58

 

As previously disclosed, in early 2019, we became aware of a ransomware attack that infiltrated and encrypted certain information technology systems, including systems containing critical business data. The financial impact of this incident was not material, and there were no changes to the previously released financial results or financial statements. As previously disclosed, immediately following the discovery, we commenced an investigation and were able to recover access to the compromised systems and restore their operation without significant loss of business data within weeks of the incident. Following the incident, we implemented additional protective measures and internal control policies and procedures. We also retained a professional cybersecurity investigation firm to conduct a full forensic analysis of the incident, and concluded that there was no evidence of malware, persistence mechanisms or other compromised exchange on-premises accounts within the Company’s environment.

In early 2024, Standard BioTools completed a merger with SomaLogic Operating Co, Inc. Critical to integration activities has been a wholesale review of policies, procedures and tools relevant to the combined cybersecurity environment with the objective of deploying and maintaining those which serve to reinforce our security presence to the greatest extent. While these activities persist, it has been noted that the SomaLogic organization takes a comparable, if not more stringent, approach to their cyber and information security posture inclusive of their ongoing ISO27001 compliance certification.

Governance

While our management team is responsible for the day-to-day management of the risks Standard BioTools faces, our Board has the responsibility to oversee management’s processes for identifying, monitoring, and addressing enterprise risks, evaluate and discuss with management its assessments of matters relating to enterprise risks, and oversee and monitor management’s plans to address such risks. The Board takes an enterprise-wide approach to risk management designed to support the achievement of organizational objectives, including strategic objectives, to improve long-term organizational performance, and to enhance stockholder value. In order to understand the most significant risks faced by the Company and the steps being taken to manage those risks, Standard BioTools conducts quarterly enterprise risk management assessments, facilitated by the Company’s executive leadership team in collaboration with the internal audit function, which are presented by management at each quarterly Board meeting. The Board’s review of our business is an integral aspect of its assessment of management’s tolerance for risk and its determination as to the appropriate level of risk for our Company.

Although the Board has determined that enterprise risk management should be the responsibility of the Board as a whole, it has delegated responsibility to oversee specific areas of risk management to its committees. Our Audit Committee oversees and reviews the Company’s cybersecurity, data privacy, and other information technology risks, controls and procedures, including the Company’s plans to mitigate cybersecurity risks and respond to data breaches. At periodic meetings of the Board and its committees and in other meetings and discussions, management reports to the Board and its committees with respect to the most significant risks that could affect our business, including cybersecurity-related risks. Our Audit Committee also receives prompt and timely information regarding any cybersecurity incident to meet reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed.

Our cybersecurity risk management and strategy processes are led by our Chief Financial Officer and our Vice President of Information Technology. Our Vice President of Information Technology has over 18 years of work experience in various roles involving managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs and has carried relevant degrees and certifications, including Certified Information Systems Auditor. These management team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, these management team members report to the Audit Committee of our Board of Directors about cybersecurity threat risks, among other cybersecurity related matters, on an at least annual basis. Should a material breach be identified, as defined by the Board and the executive team, these management team members will notify the executive team and the Board and draft the required disclosure.

ITEM 2. PROPERTIES

We lease approximately 78,000 square feet of office and laboratory space at our headquarters in South San Francisco, California under a 10-year operating lease that commenced in March 2020. In Singapore, we lease approximately 40,000 square feet of office, laboratory and manufacturing space that expires in June 2027 and 5,000 square feet of similar mixed-use space that expires at the end of April 2024. In Ontario, Canada, we lease a 9,000 square foot property that expires in February 2025, a 44,500 square feet property that that expires in March 2026 and a 19,000 square feet property that expires in March 2027. As of December 31, 2023, we also lease office space in Japan, China, and France under short-term arrangements that expire through November 2026.

59

 

In August 2022, we entered into an operating agreement to sublease approximately 25% of our corporate headquarters facility in South San Francisco, California for $4.8 million over a 39-month term. On February 28, 2023, we entered into a separate agreement with an unrelated party to sublease an additional 25% of the headquarters facility. We expect to recognize $9.1 million in sublease income over the 77-month term of the agreement, which commenced in December 2023 and expires concurrent with the expiration of the head-lease in April 2030.

In connection with the Merger, on January 5, 2023, we assumed leases for office and laboratory space in Boulder, Colorado and La Jolla, California. We lease approximately 60,000 square feet of space under two leases in Boulder, Colorado, and approximately 10,000 square feet under one lease in La Jolla, California. All leases serve as both office and laboratory space.

We believe that all of our leased properties are in good condition and are adequate and suitable to use for their intended purpose, and that suitable additional space would be available on commercially reasonable terms if required. Refer to Note 7 of our consolidated financial statements for additional information about leased properties in this Annual Report.

Shareholder Litigation

On November 28, 2023, a purported stockholder filed a complaint against us and the members of our Board in the United States District Court for the Northern District of California. The complaint has since been voluntarily dismissed. On December 12, 2023 two separate shareholder complaints were filed in the District of Delaware, The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. We are reviewing the complaints and have not yet formally responded to them. On December 13, 2023, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed transaction, which was denied by the Court on January 4, 2024. The non-injunctive claims, including breach of fiduciary duty, are still being litigated. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs’ claim is successful, this type of litigation may result in significant costs and divert management’s attention and resources, which could adversely affect the operation of our business.

Between October 24, 2023 and January 3, 2024, SomaLogic received 16 letters from purported shareholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement.

Additional lawsuits against us and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, we will not necessarily announce such additional filings.

In the normal course of business, we are from time to time involved in legal proceedings or potential legal proceedings, including matters involving employment, intellectual property, or others. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of any currently pending matters would not have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

60

 

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market for Our Common Stock; Dividends

Our common stock began trading on the Nasdaq Global Select Market under the symbol “FLDM” on February 10, 2011. As of April 2022, in connection with the closing of the Private Placement Issuance and the approval of our Eighth Amended and Restated Certificate of Incorporation, our common stock is listed on the Nasdaq Global Select Market under the symbol “LAB”.

We had 267 stockholders of record as of February 21, 2024; however, because many of our outstanding shares are held by brokers or other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial owners represented by the holders of record.

We have never declared or paid cash dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our earnings in the foreseeable future will be used for the operation and growth of our business.

Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

On November 23, 2022, our board of directors authorized a share repurchase program (the 2022 Share Repurchase Program) pursuant to which we may repurchase up to $20.0 million of our common stock through open market or privately negotiated transactions until December 31, 2023. The repurchases are contingent upon favorable market and business conditions and are funded by cash on hand. The program does not obligate us to acquire any specific number of shares. On October 4, 2023, we terminated the share repurchase program.

The following table provides information with respect to the shares of common stock repurchased by us during the year ended December 31, 2023:

 

Period

 

Total Number of Shares Purchased

 

 

Average Price Paid Per Share (1)

 

 

Total Number of Shares Purchased as Part of Publicly Announced Program

 

 

Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program

 

January 1, 2023 - March 31, 2023

 

 

1,250,484

 

 

$

1.97

 

 

 

1,250,484

 

 

$17.0 million

 

April 1, 2023 - June 30, 2023

 

 

1,208,200

 

 

$

1.96

 

 

 

1,208,200

 

 

$14.6 million

 

July 1, 2023 - September 30, 2023

 

 

175,910

 

 

$

2.27

 

 

 

175,910

 

 

$14.2 million

 

October 1, 2023 - December 31, 2023

 

 

75,109

 

 

$

2.32

 

 

 

75,109

 

 

 

—

 

 

1 Average price paid per share includes related expenses.

On February 6, 2024, our board of directors authorized a new share repurchase program (the 2024 Share Repurchase Program) pursuant to which we may repurchase up to $50.0 million of shares of our common stock in the open market, in one or more Rule 10b5-1 trading plans, or in negotiated transactions through March 1, 2026. The repurchases are contingent upon favorable market and business conditions and are funded by cash on hand. The program does not obligate us to acquire any specific number of shares. As of the date of this Annual Report on Form 10-K, we have not repurchased any shares of our common stock under the 2024 Share Repurchase Program.

ITEM 6. RESERVED

61

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to help the reader understand the results of operations and financial condition of Standard BioTools. This MD&A is provided as a supplement to, and should be read together with, our consolidated financial statements and the notes to those statements included elsewhere in this Annual Report. This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include information concerning our possible or assumed future cash flow, revenue, sources of revenue and results of operations, cost of product revenue and product margin, operating and other income and expenses, unit sales and the selling prices of our products, business strategies and strategic priorities, changes in commercial and strategic focus, restructuring plan, reduction-in-force and real estate footprint reduction plans, microfluidics research and development and marketing investment reduction plans, other cost reduction initiatives, portfolio rationalization initiatives, operating discipline improvement plans, implementation of Standard BioTools Business Systems, expected costs and cost savings associated with such plans and initiatives, future product offerings, financing plans, capital allocation plans, expansion of our business, merger and acquisition opportunities, competitive position, industry environment, potential growth opportunities and drivers, market growth expectations, the effects of competition and public health crises on our business, the global supply chain, and our customers, suppliers and other business partners, and our expectations with respect to the Merger with SomaLogic , the anticipated financial impact and potential benefits to us related to the Merger, and integration of the businesses and other matters related to the Merger;. Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part I, Item 1A, “Risk Factors” in this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Annual Report.

Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Unless otherwise stated, our forward-looking statements do not reflect the potential impact of the Merger or any other future acquisitions, mergers, dispositions, joint ventures or investments we may make. You should read this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect.

 

Overview

Standard BioTools Inc. is driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health. We have an established portfolio of essential, standardized next-generation high resolution technologies that assist biomedical researchers develop medicines faster and better. Our tools are designed to provide reliable and repeatable insights in health and disease using our proprietary mass cytometry and microfluidics technologies, which are useful in proteomics and genomics that help transform scientific discoveries into better patient outcomes. We work with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

 

We distribute our systems through our direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in several European, Latin American, Middle Eastern, and Asia-Pacific countries. Our manufacturing operations are located in Singapore and Canada.

On January 5, 2024, we completed the Merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research.

62

 

Recent Developments

Reductions in Headcount and Sub-Leases

We took additional actions in the year ended December 31, 2023 under our strategic initiative to improve operating discipline, including reductions to our headcount in Europe and additional reductions to our real estate footprint in the U.S. On February 28, 2023, we signed an agreement to sublease an additional 25% of our corporate headquarters for a period of 77 months. As a result, 50% of the space at our headquarters was subleased as of December 31, 2023. We expect to recognize $9.1 million of sublease income over the term of this new agreement, and payments commenced on December 1, 2023.

Merger

On January 5, 2024, we completed the Merger pursuant to the Merger Agreement by and among us, SomaLogic and Merger Sub, pursuant to which Merger Sub merged with and into SomaLogic, with SomaLogic surviving as a wholly owned subsidiary of Standard BioTools. Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each share of SomaLogic common stock converted into the right to receive 1.11 shares of our common stock.

In addition, as of the Effective Time, we assumed each SomaLogic stock incentive plan, outstanding option to purchase shares of SomaLogic Stock and outstanding restricted stock units convertible into shares of SomaLogic common stock, whether vested or unvested. In addition, as of the Effective Time, each SomaLogic warrant was treated in accordance with its terms.

Financial Operations Overview

Revenue

We generate revenue primarily from sales of our products and services. Other revenue consists of revenue from product development and license agreements.

Our product revenue consists of sales of instruments and consumables. Consumables revenue is largely driven by the size of our active installed base of instruments and the level of usage per instrument. Service revenue is linked to the sales and active installed base of our instruments as our service revenue primarily consists of post-warranty service contracts, preventive maintenance plans, instrument parts, installation and training for our instruments. We expect the average selling prices of our products and services to fluctuate over time based on market conditions, product mix and currency fluctuations.

Cost of Revenue

Cost of product revenue includes manufacturing costs incurred in the production process, including component materials, labor and overhead, installation, packaging and delivery costs. In addition, cost of product revenue includes amortization of developed technology and intangibles, royalty costs for licensed technologies included in our products, warranty costs, provisions for slow-moving excess and obsolete inventory and stock-based compensation expense. Our cost of product revenue and related product margin may fluctuate depending on the capacity utilization of our manufacturing facilities in response to market conditions and the demand for our products.

Cost of service revenue includes direct labor hours, overhead and instrument parts. Our cost of service revenue and related service margin may fluctuate depending on the variability in material and labor costs of servicing.

Research and Development (R&D)

R&D expense consists primarily of compensation-related costs, product development and material expenses and other allocated facilities and information technology expenses. Our R&D efforts have focused primarily on enhancing our technologies and supporting development and commercialization of new and existing products and services. R&D expense also includes costs incurred in conjunction with research grants and product development arrangements.

Selling, General, and Administrative

SG&A expense consists primarily of personnel costs for our sales and marketing, business development, finance, legal, human resources, information technology and general management teams, as well as professional services, including legal and accounting services.

63

 

Restructuring and Related Charges

Restructuring and related charges primarily consist of severance costs and facilities costs for floors we have subleased or have the intent to sublease (net of sublease income) under our facility lease in South San Francisco. These costs, including a reduction in force, are incurred to improve operational efficiency, achieve cost savings and align our workforce to the future needs of the business. In addition to the reduction in force, we are reducing leased office space, optimizing our manufacturing footprint and streamlining support functions.

Transaction-related expenses

Transaction-related expenses consist of costs incurred during the year ended December 31, 2023 in connection with the Merger Agreement, including legal, advisory, accounting and other transaction-related costs. We expect to continue incurring these costs through the first quarter of 2024. The costs incurred during the year ended December 31, 2022 relate to the private placement whereby the Company issued and sold an aggregate of $225.0 million of convertible preferred stock in connection with the conversion of the bridge loans, which closed on April 4, 2022.

Results of Operations

The following table presents our consolidated statements of operations and as a percentage of total revenue for the years ended December 31, 2023 and 2022 ($ in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Revenue

 

$

106,340

 

 

 

100

%

 

$

97,948

 

 

 

100

%

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

 

44,942

 

 

 

42

%

 

 

52,555

 

 

 

54

%

Cost of service and other revenue

 

 

10,948

 

 

 

11

%

 

 

8,342

 

 

 

9

%

Total cost of revenue

 

 

55,890

 

 

 

53

%

 

 

60,897

 

 

 

63

%

Gross profit

 

 

50,450

 

 

 

47

%

 

 

37,051

 

 

 

37

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

25,948

 

 

 

24

%

 

 

37,382

 

 

 

38

%

Selling, general and
   administrative

 

 

87,541

 

 

 

82

%

 

 

102,285

 

 

 

104

%

Restructuring and related charges

 

 

7,076

 

 

 

7

%

 

 

9,732

 

 

 

10

%

Transaction-related expenses

 

 

6,485

 

 

 

6

%

 

 

3,857

 

 

 

4

%

Total operating expenses

 

 

127,050

 

 

 

119

%

 

 

153,256

 

 

 

156

%

Loss from operations

 

 

(76,600

)

 

 

(72

)%

 

 

(116,205

)

 

 

(119

)%

Interest expense

 

 

(4,567

)

 

 

(4

)%

 

 

(4,331

)

 

 

(4

)%

Loss on forward sale of Series B
   Preferred Stock

 

 

—

 

 

 

—

%

 

 

(60,081

)

 

 

(61

)%

Loss on Bridge Loans

 

 

—

 

 

 

—

%

 

 

(13,719

)

 

 

(14

)%

Other income (expense), net

 

 

6,963

 

 

 

6

%

 

 

1,408

 

 

 

1

%

Loss before income taxes

 

 

(74,204

)

 

 

(70

)%

 

 

(192,928

)

 

 

(197

)%

Income tax benefit (expense)

 

 

(452

)

 

 

—

%

 

 

2,830

 

 

 

3

%

Net loss

 

$

(74,656

)

 

 

(70

)%

 

$

(190,098

)

 

 

(194

)%

 

Revenue

Revenue by product type and as a percentage of total revenue were as follows ($ in thousands):

 

 

 

Year Ended December 31,

 

 

Year-over-

 

 

 

2023

 

 

2022

 

 

Year Change

 

Product revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Instruments

 

$

37,459

 

 

 

36

%

 

$

25,664

 

 

 

26

%

 

 

46

%

Consumables

 

 

41,739

 

 

 

39

%

 

 

46,790

 

 

 

48

%

 

 

(11

)%

Total product revenue

 

 

79,198

 

 

 

75

%

 

 

72,454

 

 

 

74

%

 

 

9

%

Service revenue

 

 

25,980

 

 

 

24

%

 

 

23,712

 

 

 

24

%

 

 

10

%

Other revenue

 

 

1,162

 

 

 

1

%

 

 

1,782

 

 

 

2

%

 

 

(35

)%

Total revenue

 

$

106,340

 

 

 

100

%

 

$

97,948

 

 

 

100

%

 

 

9

%

 

64

 

Total revenue grew 9% to $106.3 million for the year ended December 31, 2023, compared to 2022. The growth was primarily attributable to increased instrument placements, primarily in our proteomics end user markets, offset by declines in our genomics end user markets as the result of our decision to reorganize, simplify and reposition our business over the past year. Revenue reported for the year ended December 31, 2022 includes a $1.6 million instrument revenue reduction for a one-time reserve recorded for our discontinued LCM product line in the genomics segment.

Instrument revenue grew 46% to $37.5 million for the year ended December 31, 2023, compared to 2022. Combined consumables and services revenue has experienced a flat to moderate decrease in 2023; however, the increase in instrument revenue is expected to drive increased consumables and services pull-through based on an expanded installed base, particularly in our proteomics end user markets.

 

Revenue by segment and as a percentage of total revenue were as follows ($ in thousands):

 

 

 

Year Ended December 31,

 

 

Year-over-

 

 

 

2023

 

 

2022

 

 

Year Change

 

Proteomics revenue

 

$

63,883

 

 

 

60

%

 

$

52,502

 

 

 

54

%

 

 

22

%

Genomics revenue

 

 

42,457

 

 

 

40

%

 

 

45,446

 

 

 

46

%

 

 

(7

)%

Total revenue

 

$

106,340

 

 

 

100

%

 

$

97,948

 

 

 

100

%

 

 

9

%

 

Total proteomics revenue grew 22% for the year ended December 31, 2023, compared to 2022, primarily due to the timing of customer orders. Our growth in proteomics was driven by expanded adoption of our flow symmetry solution, the CYTOF XT and early traction from the April 2023 release of Hyperion XTi, our next-generation imaging solution.

 

Total genomics revenue decreased 7% for the year ended December 31, 2023, compared to 2022, with instrument growth offsetting declines in consumables, service, and development revenues during the year. Consumables revenue in genomics was down over 2022, driven by the impact of initial consumables purchases by our OEM partner in 2022. The anticipated decline in the genomics segment was a primary driver of our decision to reorganize, simplify and reposition this business over the past year. We have implemented our strategy to focus on growing the OEM business and manage this segment to sustainable positive contribution margin in the near-term.

 

Cost of Revenue

Product and service cost, gross profit, and gross margin were as follows ($ in thousands):

 

 

 

Year Ended December 31,

 

 

Year-over-

 

 

 

2023

 

 

2022

 

 

Year Change

 

Cost of product revenue

 

$

44,942

 

 

$

52,555

 

 

 

(14

)%

Cost of service and other revenue

 

 

10,948

 

 

 

8,342

 

 

 

31

%

Total cost of revenue

 

$

55,890

 

 

$

60,897

 

 

 

(8

)%

Gross profit

 

$

50,450

 

 

$

37,051

 

 

 

36

%

Gross margin

 

 

47.4

%

 

 

37.8

%

 

 

9.6

%

 

Gross profit increased by $13.4 million, or 36%, for the year ended December 31, 2023, compared to 2022. The increases in gross profit were primarily attributable to certain one-time reductions to gross profit recognized during 2022, including a $7.9 million provision for excess and obsolete inventory, a $1.6 million revenue reserve related to the discontinuation of our laser capture microdissection products during the second quarter of 2022, and cost reductions driven by the relocation of operations to lower cost regions completed at the end of 2022.

 

Gross profit by segment was as follows ($ in thousands):

 

 

 

Year Ended December 31,

Year-over-

 

 

 

2023

 

 

2022

Year Change

 

Proteomics gross profit

 

$

26,239

 

 

$

20,041

 

 

 

31

%

Genomics gross profit

 

 

24,211

 

 

 

17,010

 

 

 

42

%

Total gross profit

 

$

50,450

 

 

$

37,051

 

 

 

36

%

 

65

 

During 2023, the proteomics business returned to growth with a gross profit improvement of 31% for the year ended December 31, 2023, compared to 2022. The increase was primarily attributable to increased proteomics revenue of $11.4 million as well as improved manufacturing efficiencies driven by higher unit sales of instruments. Genomics gross profit improved by 42% for the year ended December 31, 2023, compared to 2022. The year over year increase was primarily attributable to one certain one-time reductions to gross profit recognized during 2022, including $7.2 million of inventory write-offs involving discontinued products and other slow-moving inventory. We expect profitable growth in the genomics business in future years. These impacts resulted in an overall increase of 36% to gross profit for the year ended December 31, 2023.

Operating Expenses

Operating expenses were as follows ($ in thousands):

 

 

 

Year Ended December 31,

 

 

Year-over-

 

 

 

2023

 

 

2022

 

 

Year Change

 

Research and development

 

$

25,948

 

 

$

37,382

 

 

 

(31

)%

Selling, general and administrative

 

 

87,541

 

 

 

102,285

 

 

 

(14

)%

Restructuring and related charges

 

 

7,076

 

 

 

9,732

 

 

 

(27

)%

Transaction-related expenses

 

 

6,485

 

 

 

3,857

 

 

 

68

%

Total operating expenses

 

$

127,050

 

 

$

153,256

 

 

 

(17

)%

 

Research and Development

R&D expense decreased by $11.4 million, or 31%, for the year ended December 31, 2023, compared to 2022. The decreases were primarily due to a $3.5 million impairment charge related to our acquisition of InstruNor AS (InstruNor) recognized during the year December 31, 2022, as well as lower compensation and consulting costs and reduced spending on laboratory supplies. These reductions were related to our strategic initiatives to reduce headcount and improve operating efficiencies by engaging in lower-cost and more focused R&D projects and activities.

 

Selling, General and Administrative

SG&A expense decreased by $14.7 million, or 14%, for the year ended December 31, 2023 compared to 2022. The decreases were primarily attributable to decreased salaries and benefits expense and stock-based compensation expense as a result of the restructuring plan that downsized our global workforce.

 

Restructuring and Related Charges

Restructuring and related charges consisted of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

Year-over-

 

 

 

2023

 

 

2022

 

 

Year Change

 

Severance and other termination benefits

 

$

2,379

 

 

$

5,849

 

 

 

(59

)%

Facilities and other

 

 

4,697

 

 

 

3,883

 

 

 

21

%

Total restructuring and related charges

 

$

7,076

 

 

$

9,732

 

 

 

(27

)%

 

Restructuring and related charges decreased by $2.7 million for the year ended December 31, 2023 compared to 2022, due to decreased severance costs and decreased facilities expenses (net of sublease income) as a result of the subleases that commenced in October 2022 and December 2023 as part of our restructuring plan. During the year ended December 31, 2023, we recognized $2.7 million in sublease income which offset operating lease expense within restructuring and related charges on our consolidated statements of operations. As of December 31, 2023, we expect to recognize an additional $11.9 million in sublease income over the remaining lease terms to further offset operating lease expense.

 

Transaction-related expenses

Transaction-related expenses increased by $2.6 million for the year ended December 31, 2023 compared to 2022. The increase was due to legal, advisory, and accounting costs incurred in connection with the Merger Agreement offset by $3.9 million in costs related to our Private Placement which closed in April 2022. The Company expects to incur additional amounts in future periods for the Merger Agreement.

66

 

 

Other Non-Operating Income (Expense)

The increase in other income (expense), net of $5.6 million for the year ended December 31, 2023 compared to 2022, was primarily due to the interest earned on money market funds and short-term investments. We previously had no such investments until the second half of 2022.

 

The improvement in non-operating income (expense) in the year ended December 31, 2023, compared to 2022, primarily reflects losses related to the Private Placement. The Series B Convertible Preferred Stock Purchase Agreements entered into with various investors were accounted for as forward sales contracts and recorded at fair value. The loan agreements (collectively, the Bridge Loans) that we entered into on January 23, 2022 with various investors for a $25.0 million term loan were also recorded at fair value. In the year ended December 31, 2022 the $60.1 million loss on the forward sales of Series B Preferred Stock and the loss on the Bridge Loans of $13.7 million reflected the increase in the price of our common stock from January 23, 2022 (the date of the Purchase Agreements and the Bridge Loan agreements) to the Private Placement Closing Date.

 

Income Tax Benefit (Expense)

We recorded income tax expense of $0.5 million for the year ended December 31, 2023 and an income tax benefit of $2.8 million for the year ended December 31, 2022. The increase in our tax provision reflects the effect of our foreign operations, which reported pre-tax income in the year ended December 31, 2023 and pre-tax loss in the year ended December 31, 2022.

 

Our effective tax rates for both periods differ from the 21% U.S. Federal statutory tax rate primarily due to valuation allowances recorded against deferred tax assets on domestic losses and the tax rate differences between the U.S. and foreign countries.

Liquidity and Capital Resources

 

We have experienced operating losses since inception and have an accumulated deficit of $1.0 billion as of December 31, 2023. To date, we have funded our operating losses primarily through equity offerings, term loans, convertible notes and redeemable preferred stock. Our ability to fund future operations and meet debt covenant requirements will depend upon our level of future revenue and operating cash flow and our ability to access additional funding through either equity offerings, issuances of debt instruments or both.

 

Our liquidity and capital requirements depend upon many factors, including market acceptance of our products and services; effectiveness of our business improvement initiatives and restructuring programs; costs of supporting sales growth, product quality, R&D and capital expenditures, including our ERP upgrade; and costs and timing of acquiring other businesses, assets or technologies.

 

We continually evaluate our liquidity requirements considering our operating needs, growth initiatives and capital resources. We expect that our existing liquidity and sources of capital will be sufficient to support our operations for at least the next 12 months from the filing date of this Annual Report.

 

Sources of Liquidity

Our principal sources of liquidity are cash, cash equivalents and short-term investments. Our collective balances of cash, cash equivalents and short-term investments were $114.9 million at December 31, 2023 and $165.8 million at December 31, 2022. Our working capital was $48.9 million at December 31, 2023.

Giving effect to our Merger with SomaLogic on January 5, 2024, our balance of cash, cash equivalents, short-term investments and restricted cash on a pro forma basis was $565.5 million at December 31, 2023.

 

Capital Resources and Commitments

We enter into arrangements that serve as sources of capital and the associated contractual agreements may result in firm or contingent obligations of us. In addition to our common stockholders’ equity, our sources of capital primarily include debt, mezzanine equity and operating leases. Our Series B Preferred Stock, which is classified as mezzanine equity, contains rights that may result in their conversion to our common stock or their redemption in cash. Our term loan and operating lease arrangements require cash repayment and our convertible debt that matures on December 1, 2024 contains rights that may result in their conversion to our common stock prior to maturity. We also enter into contractual and legally binding commitments to purchase goods.

A summary of our significant future capital requirements include:

67

 

Purchase Obligations and Commitments

Purchase obligations consist of contractual and legally binding commitments to purchase goods and services. Our purchase obligations with suppliers specify all significant terms, including fixed, minimum or variable price provisions, and the approximate timing of the transaction The majority of our contracts are cancellable with little or no notice or penalty. However, once a vendor has incurred costs to fulfill a contract with us, and which costs cannot be otherwise deployed, we are liable for those costs upon cancellation. As of December 31, 2023, these purchase commitments totaled $9.7 million. Capital expenditure commitments as of December 31, 2023 were immaterial. In addition, we have certain non-cancellable commitments with service providers that are not material in the aggregate.

In connection with the Merger, on January 5, 2024, we assumed a purchase commitment of $6.9 million to a contract manufacturer. Under the contract manufacturing agreement, we are required to spend $2.3 million per year for three years.

We have additional obligations beyond the purchase of goods and services, including the following:

•
Series B. Contingent obligations to our Series B Redeemable Preferred Stockholders. Refer to Note 9 to the consolidated financial statements for additional information.
•
Convertible Notes. The 2019 Notes mature on December 1, 2024. If the price of our common stock has equaled or exceeded 130% of the conversion price then in effect for a specified number of days as defined in the indenture, (currently $2.90 per share, subject to adjustment), we may, at our option, elect to convert the 2019 Notes in whole but not in part into our shares. If our common stock does not meet this price, we will settle the 2019 Notes in cash. The aggregate net carrying value of the 2014 and 2019 Notes was $55.1 million at December 31, 2023, of which $54.5 million is due and payable in 2024. In addition, holders may require the Company to repurchase all or a portion of their 2014 Notes on each of February 6, 2024 and February 6, 2029, at a repurchase price in cash equal to 100% of the principal amount of the 2014 Notes plus accrued and unpaid interest. On February 6, 2024, one holder of the 2014 Notes exercised their repurchase right, and we repurchased an immaterial amount of principal and accrued interest. Refer to Note 6 of the consolidated financial statements for additional information.
•
Term Loan. The principal amount of the term loan advances was repayable beginning on August 1, 2023, in twenty-four equal monthly installments. Principal amounts due under the Term Loan, including end-of-term fees, totaled $8.4 million at December 31, 2023, of which $5.0 million is due and payable in 2024. However, if the principal amount of the Company’s convertible debt exceeds $0.6 million as of June 1, 2024 or if the maturity date of the 2019 Notes has not been extended beyond January 1, 2026 by June 1, 2024, then the Term Loan will be due in full on June 1, 2024. Refer to Note 6 of the consolidated financial statements for additional information.
•
Leases. Future payments for operating lease obligations (net of sublease income) at December 31, 2023 totaled $36.8 million, of which $5.2 million is expected to be paid in 2024. Refer to Note 7 of the consolidated financial statements for additional information.
•
Additional information on our obligations under license and patent agreements, and indemnification agreements entered into in the ordinary course of business is provided in Note 7 to the consolidated financial statements .

The expected timing of payments of our obligations is estimated based on current information. Timing of payments and actual amounts paid may be different, depending on the timing of receipt of goods or services, or changes to agreed-upon amounts for some obligations. In addition, some of our future purchasing needs are not current contractual obligations and are therefore not included in the commitment amounts above as they are not handled through binding contracts or are not fulfilled by vendors on a purchase order basis within short time horizons.

 

Cash Flow Activity

 

Our cash flow summary was as follows ($ in thousands):

 

68

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Cash flow summary:

 

 

 

 

 

 

Net cash used in operating activities

 

$

(43,287

)

 

$

(89,370

)

Net cash provided by (used in) investing activities

 

 

20,237

 

 

 

(88,127

)

Net cash provided by (used in) financing activities

 

 

(6,809

)

 

 

230,758

 

Effect of foreign exchange rate fluctuations on cash
   and cash equivalents

 

 

34

 

 

 

(404

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

$

(29,825

)

 

$

52,857

 

 

We derive cash flows from operations primarily by collecting amounts due from sales of our products and services, and fees earned under our product development and license agreements. Our cash flows from operating activities are also significantly influenced by our use of cash for operating expenses and working capital to support the business. We have historically experienced negative cash flows from operating activities as we have expanded our business and built our infrastructure, domestically and internationally.

 

In the year ended December 31, 2023, we used $23.1 million of net proceeds from the sales and maturities of short-term investments to help fund $43.3 million of net cash used in operating activities, $5.4 million of common stock repurchases and $2.1 million of term loan repayments.

 

In the year ended December 31, 2022, we used $230.7 million of net debt and Series B Preferred Stock proceeds in part to fund $89.4 million used in operating activities, the purchase of short-term investments of $137.3 million and a $52.9 million increase in cash, cash equivalents and restricted cash.

 

Operating Activities

Net cash used in operating activities for the year ended December 31, 2023 decreased by $46.1 million compared to the same period in 2022. The decrease reflects a lower net loss and adjustments for non-cash items, which collectively used $45.1 million in the year ended December 31, 2023 compared to $73.9 million used in the same period of 2022, and changes in net operating assets and liabilities which provided $1.8 million and used $15.5 million in the years ended December 31, 2023 and 2022, respectively.

Investing Activities

Net cash provided by investing activities for the year ended December 31, 2023 was $20.2 million compared to $88.1 million used in the year ended December 31, 2022. The year ended December 31, 2023 primarily reflects $23.1 million of proceeds from sales and maturities of short-term investments, net of purchases. Net proceeds from the Private Placement issuance and the Bridge Loans were used to purchase short-term investments of $137.3 million during the year ended December 31, 2022.

 

Financing Activities

Financing activities used cash of $6.8 million for the year ended December 31, 2023 and provided cash of $230.8 million in the same period of 2022. These changes in cash from financing activities primarily reflect $5.4 million of common stock share repurchases and $2.1 million of term loan repayments in the year ended December 31, 2023, and $25.0 million of borrowings under the Bridge Loans and the repayment of $6.8 million borrowed under our Revolving Credit Facility as well as $225.0 million proceeds received from the issuance of Series B Preferred Sock less payments of $12.5 million in equity issuance costs in the year ended December 31, 2022.

Critical Accounting Estimates

The consolidated financial statements and related notes included in this Annual Report are prepared in accordance with U.S. GAAP. Preparing U.S. GAAP financial statements requires the use of estimates and assumptions to determine the value of the assets, liabilities, revenues and expenses reported on the consolidated balance sheets and statements of operations. We develop these estimates after considering historical transactions, the current economic environment and various other assumptions considered reasonable under the circumstances. Actual results may differ materially from these estimates and judgments. Accounts that rely heavily on estimated information to determine their values include revenue, trade receivables, inventories, right-of-use assets, goodwill, long-lived intangible assets, lease liabilities, and preferred equity. Refer to Note 2 to our consolidated financial statements for further information on our most significant accounting policies.

Revenue

We recognize revenue based on the amount of consideration we expect to receive in exchange for the goods and services we transfer to the customer. Our commercial arrangements typically include multiple, distinct products and services, and we allocate purchase

69

 

consideration to the products and services based on each item’s relative standalone selling price. Standalone selling prices (SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, we estimate a product’s SSP using a cost plus margin approach or by applying a discount to the product’s list price.

We have entered and may continue to enter into development agreements with customers that require us to recognize revenue using an input method that determines the extent of our progress toward completion by comparing the actual costs incurred to the total expected cost. As part of the accounting for these arrangements, we develop estimates and assumptions that require judgment to determine the transaction price and progress towards completion. We review these estimates at the end of each reporting period using the best available information, revise the estimates as necessary, and recognize revenue commensurate with our progress toward completion.

Inventories

Inventories are stated at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. We regularly review inventory for excess and obsolete products and components. Significant judgment is required in determining provisions for slow-moving, excess, and obsolete inventories which are recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, product expiration, and quality issues.

Goodwill and Long-Lived Assets

Assessing goodwill and long-lived assets for impairment requires significant judgment as it involves selecting an appropriate valuation method, identifying reporting units, assigning assets and liabilities to the reporting units, and estimating future cash flows, remaining service lives, revenue growth rates, terminal values and discount rates. Refer to Note 4 to the consolidated financial statements for additional information.

Series B Redeemable Preferred Stock

The Purchase Agreements (as defined in Note 9 to the consolidated financial statements) for the issuance of shares of Series B Preferred Stock were accounted for as forward sales contracts at fair value in accordance with ASC 480, Distinguishing Liabilities from Equities. The Series B Preferred Stock was treated as mezzanine equity and recorded at its fair value upon issuance, net of issuance costs due to its redemption features, such as change of control and liquidation preference, which are outside of the Company’s control. Subsequent remeasurement of the Series B Redeemable Preferred Stock amount presented within mezzanine equity to its redemption amount is not required since it is not probable that the instrument will become redeemable. Mezzanine equity which has characteristics of both liabilities and shareholders’ equity (deficit) is presented separately on the consolidated balance sheets between these two items because it has some characteristics of both. Refer to Note 9 to the consolidated financial statements for additional information.

Stock-Based Compensation

The Company recognizes compensation costs for all stock-based awards, including stock options, Restricted Share Units (RSUs), Performance Share Units (PSUs) and stock purchased under the Company's Employee Share Purchase Plan (ESPP), based on the grant date fair value of the award. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service periods for non-performance-based awards. For RSUs, fair value is measured based on the closing fair market value of the Company's common stock on the date of grant. For PSUs with a market condition, the Company uses a Monte Carlo simulation pricing model to incorporate the market condition effects at the grant date. The Monte Carlo pricing model requires inputs which are subjective and generally requires judgment. For PSUs with performance conditions, stock-based compensation expense is recognized over the requisite service period when the achievement of each individual performance goal becomes probable.

The fair value of options and stock purchases under ESPP on the grant date is estimated using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions, including expected term, volatility, risk-free interest rate and the fair value of the Company's common stock. These assumptions generally require judgment. Refer to Note 11 to the consolidated financial statements for additional information.

70

 

Recent Accounting Changes and Accounting Pronouncements

Adoption of New Accounting Guidance

None.

Recent Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our consolidated financial statements included in this Annual Report.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

71

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Index to Consolidated Financial Statements

 

Page

 

 

Report of Independent Registered Public Accounting Firm (PCAOB ID 238)

73

 

 

Consolidated Balance Sheets as of December 31, 2023 and 2022

75

 

 

Consolidated Statements of Operations for the years ended December 31, 2023 and 2022

76

 

 

Consolidated Statements of Comprehensive Loss for the years ended December 31, 2023 and 2022

77

 

 

Consolidated Statements of Stockholders' Equity (Deficit) for the years ended December 31, 2023 and 2022

78

 

 

Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022

79

 

 

Notes to Consolidated Financial Statements

80

 

 

72

 

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Standard BioTools Inc.

Opinion on the Financial Statements

We have audited the consolidated financial statements, including the related notes, of Standard BioTools Inc. and its subsidiaries (the “Company”) as listed in the accompanying index (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Revenue recognition – product revenues

As described in Notes 2 and 3 to the consolidated financial statements, the Company’s product revenue was $79.2 million for the year ended December 31, 2023. The Company generates revenue primarily from the sale of products and services. Product revenue is derived from the sale of instruments and consumables and is recognized once control of goods passes to the customer and the Company has an enforceable right to payment. The Company recognizes revenue based on the amount of consideration the Company expects to receive in exchange for the goods transferred to the customer.

The principal consideration for our determination that performing procedures relating to revenue recognition for product revenues is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company’s revenue recognition.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) testing the completeness, accuracy and occurrence of revenue recognized for a sample of revenue transactions by obtaining and inspecting source documents, such as sales contracts,

73

 

purchase orders, customer invoices, and proof of delivery and (ii) confirming a sample of outstanding customer invoice balances as of December 31, 2023 and, for confirmations not returned, obtaining and inspecting source documents, such as invoices, proof of delivery, and subsequent cash receipts.

/s/ PricewaterhouseCoopers LLP

San Jose, California

March 1, 2024

We have served as the Company’s auditor since 2015.

74

 

STANDARD BIOTOOLS INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

 

 

 

December 31,

 

 

 

2023

 

 

2022

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

51,704

 

 

$

81,309

 

Short-term investments

 

 

63,191

 

 

 

84,475

 

Accounts receivable (net of allowances of $312 and $592 at December 31, 2023 and 2022, respectively)

 

 

19,660

 

 

 

17,280

 

Inventories, net

 

 

20,533

 

 

 

21,473

 

Prepaid expenses and other current assets

 

 

3,127

 

 

 

4,278

 

Total current assets

 

 

158,215

 

 

 

208,815

 

Property and equipment, net

 

 

24,187

 

 

 

25,652

 

Operating lease right-of-use asset, net

 

 

30,663

 

 

 

33,883

 

Other non-current assets

 

 

2,285

 

 

 

3,109

 

Developed technology, net

 

 

1,400

 

 

 

12,600

 

Goodwill

 

 

106,317

 

 

 

106,251

 

Total assets

 

$

323,067

 

 

$

390,310

 

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

9,236

 

 

$

7,914

 

Accrued compensation and related benefits

 

 

11,867

 

 

 

9,153

 

Operating lease liabilities, current

 

 

4,323

 

 

 

3,682

 

Deferred revenue, current

 

 

11,607

 

 

 

10,792

 

Deferred grant income, current

 

 

3,612

 

 

 

3,644

 

Other accrued liabilities

 

 

9,152

 

 

 

6,175

 

Term loan, current

 

 

5,000

 

 

 

2,083

 

Convertible notes, current

 

 

54,530

 

 

 

—

 

Total current liabilities

 

 

109,327

 

 

 

43,443

 

Convertible notes, non-current

 

 

569

 

 

 

54,615

 

Term loan, non-current

 

 

3,414

 

 

 

8,194

 

Deferred tax liability

 

 

841

 

 

 

1,055

 

Operating lease liabilities, non-current

 

 

30,374

 

 

 

34,081

 

Deferred revenue, non-current

 

 

3,520

 

 

 

3,816

 

Deferred grant income, non-current

 

 

10,755

 

 

 

14,359

 

Other non-current liabilities

 

 

1,065

 

 

 

961

 

Total liabilities

 

 

159,865

 

 

 

160,524

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

Mezzanine equity:

 

 

 

 

 

 

Redeemable preferred stock: $0.001 par value; 256 shares authorized, issued and outstanding at December 31, 2023 and 2022; aggregate liquidation preference of $255,559 at December 31, 2023 and 2022

 

 

311,253

 

 

 

311,253

 

Stockholders’ deficit:

 

 

 

 

 

 

Preferred stock: $0.001 par value, 9,744 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022

 

 

—

 

 

 

—

 

Common stock: $0.001 par value, 400,000 shares authorized at December 31, 2023 and 2022; 83,364 and 79,904 shares issued at December 31, 2023 and 2022, respectively; 80,232 and 79,482 shares outstanding at December 31, 2023 and 2022, respectively

 

 

83

 

 

 

80

 

Additional paid-in capital

 

 

860,816

 

 

 

847,008

 

Accumulated other comprehensive loss

 

 

(2,221

)

 

 

(1,896

)

Accumulated deficit

 

 

(1,000,752

)

 

 

(926,096

)

Treasury stock at cost: 3,132 and 422 shares at December 31, 2023 and 2022, respectively

 

 

(5,977

)

 

 

(563

)

Total stockholders’ deficit

 

 

(148,051

)

 

 

(81,467

)

Total liabilities, mezzanine equity and stockholders’ deficit

 

$

323,067

 

 

$

390,310

 

 

See accompanying notes

75

 

STANDARD BIOTOOLS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Revenue:

 

 

 

 

 

 

Product revenue

 

$

79,198

 

 

$

72,454

 

Service and other revenue

 

 

27,142

 

 

 

25,494

 

Total revenue

 

 

106,340

 

 

 

97,948

 

Cost of revenue:

 

 

 

 

 

 

Cost of product revenue

 

 

44,942

 

 

 

52,555

 

Cost of service and other revenue

 

 

10,948

 

 

 

8,342

 

Total cost of revenue

 

 

55,890

 

 

 

60,897

 

Gross profit

 

 

50,450

 

 

 

37,051

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

25,948

 

 

 

37,382

 

Selling, general and administrative

 

 

87,541

 

 

 

102,285

 

Restructuring and related charges

 

 

7,076

 

 

 

9,732

 

Transaction-related expenses

 

 

6,485

 

 

 

3,857

 

Total operating expenses

 

 

127,050

 

 

 

153,256

 

Loss from operations

 

 

(76,600

)

 

 

(116,205

)

Interest expense

 

 

(4,567

)

 

 

(4,331

)

Loss on forward sale of Series B Preferred Stock

 

 

—

 

 

 

(60,081

)

Loss on Bridge Loans

 

 

—

 

 

 

(13,719

)

Other income (expense), net

 

 

6,963

 

 

 

1,408

 

Loss before income taxes

 

 

(74,204

)

 

 

(192,928

)

Income tax benefit (expense)

 

 

(452

)

 

 

2,830

 

Net loss

 

$

(74,656

)

 

$

(190,098

)

Net loss per share, basic and diluted

 

$

(0.94

)

 

$

(2.43

)

Shares used in computing net loss per share, basic and diluted

 

 

79,160

 

 

 

78,305

 

 

See accompanying notes

76

 

STANDARD BIOTOOLS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Net loss

 

$

(74,656

)

 

$

(190,098

)

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

(849

)

 

 

(487

)

Net change in unrealized gain (loss) on investments

 

 

524

 

 

 

(502

)

Other comprehensive income (loss), net of tax

 

 

(325

)

 

 

(989

)

Comprehensive loss

 

$

(74,981

)

 

$

(191,087

)

 

See accompanying notes

77

 

STANDARD BIOTOOLS INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands)

 

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accum.
Other

 

 

Accum.

 

 

Treasury Stock

 

 

Total Stockholders’
Equity

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Comp. Loss

 

 

Deficit

 

 

Shares

 

 

Amount

 

 

(Deficit)

 

Balance as of December 31, 2021

 

 

76,919

 

 

 

77

 

 

 

831,424

 

 

 

(907

)

 

 

(735,998

)

 

 

—

 

 

 

—

 

 

 

94,596

 

Issuance of restricted stock, net of shares withheld
   for taxes

 

 

2,373

 

 

 

2

 

 

 

(213

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(211

)

Issuance of common stock under ESPP

 

 

583

 

 

 

1

 

 

 

819

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

820

 

Issuance of common stock from option exercises

 

 

29

 

 

 

—

 

 

 

98

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

98

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

14,880

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

14,880

 

Repurchase of common stock

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(422

)

 

 

(563

)

 

 

(563

)

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(190,098

)

 

 

—

 

 

 

—

 

 

 

(190,098

)

Other comprehensive loss, net of tax

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(989

)

 

 

0

 

 

 

—

 

 

 

—

 

 

 

(989

)

Balance as of December 31, 2022

 

 

79,904

 

 

 

80

 

 

 

847,008

 

 

 

(1,896

)

 

 

(926,096

)

 

 

(422

)

 

 

(563

)

 

 

(81,467

)

Issuance of restricted stock, net of shares withheld
   for taxes, and other

 

 

2,946

 

 

 

3

 

 

 

(119

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(116

)

Issuance of common stock from option exercises

 

 

44

 

 

 

—

 

 

 

81

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

81

 

Issuance of common stock under ESPP

 

 

470

 

 

 

—

 

 

 

723

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

723

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

13,123

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

13,123

 

Repurchase of common stock

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,710

)

 

 

(5,414

)

 

 

(5,414

)

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(74,656

)

 

 

—

 

 

 

—

 

 

 

(74,656

)

Other comprehensive loss net of tax

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(325

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(325

)

Balance as of December 31, 2023

 

 

83,364

 

 

 

83

 

 

 

860,816

 

 

 

(2,221

)

 

 

(1,000,752

)

 

 

(3,132

)

 

 

(5,977

)

 

 

(148,051

)

 

See accompanying notes

78

 

STANDARD BIOTOOLS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Operating activities

 

 

 

 

 

 

Net loss

 

$

(74,656

)

 

$

(190,098

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Loss on forward sale of Series B Preferred Stock

 

 

—

 

 

 

60,081

 

Loss on bridge loans

 

 

—

 

 

 

13,719

 

Stock-based compensation expense

 

 

13,123

 

 

 

14,880

 

Amortization of developed technology

 

 

11,200

 

 

 

11,528

 

Depreciation and amortization

 

 

3,980

 

 

 

3,499

 

Provision for excess and obsolete inventory

 

 

1,496

 

 

 

7,874

 

Impairment of InstruNor developed technology intangible

 

 

—

 

 

 

3,526

 

Amortization of debt discounts, premiums and issuance costs

 

 

770

 

 

 

830

 

Other non-cash items

 

 

(987

)

 

 

273

 

Changes in assets and liabilities:

 

 

 

 

 

 

Accounts receivable, net

 

 

(2,991

)

 

 

1,063

 

Inventories, net

 

 

(4,914

)

 

 

(8,470

)

Prepaid expenses and other assets

 

 

960

 

 

 

33

 

Accounts payable

 

 

1,618

 

 

 

(2,776

)

Accrued compensation and related benefits

 

 

3,018

 

 

 

4,113

 

Deferred revenue

 

 

884

 

 

 

(3,467

)

Other liabilities

 

 

3,212

 

 

 

(5,978

)

Net cash used in operating activities

 

 

(43,287

)

 

 

(89,370

)

Investing activities

 

 

 

 

 

 

Purchases of short-term investments

 

 

(94,896

)

 

 

(137,302

)

Proceeds from sales and maturities of investments

 

 

117,964

 

 

 

53,000

 

Purchases of property and equipment

 

 

(2,831

)

 

 

(3,825

)

Net cash provided by (used in) investing activities

 

 

20,237

 

 

 

(88,127

)

Financing activities

 

 

 

 

 

 

Proceeds from bridge loans

 

 

—

 

 

 

25,000

 

Proceeds from issuance of Series B Preferred Stock

 

 

—

 

 

 

225,000

 

Repayment of term loan and advances under revolving credit facility

 

 

(2,083

)

 

 

(6,838

)

Payment of debt and equity issuance costs

 

 

—

 

 

 

(12,547

)

Repurchase of common stock

 

 

(5,414

)

 

 

(563

)

Proceeds from ESPP stock issuance and exercise of stock options

 

 

827

 

 

 

917

 

Payments for taxes related to net share settlement of equity awards and other

 

 

(139

)

 

 

(211

)

Net cash provided by (used in) financing activities

 

 

(6,809

)

 

 

230,758

 

Effect of foreign exchange rate fluctuations on cash and cash equivalents

 

 

34

 

 

 

(404

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

(29,825

)

 

 

52,857

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

82,324

 

 

 

29,467

 

Cash, cash equivalents and restricted cash at end of period

 

$

52,499

 

 

$

82,324

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information

 

 

 

 

 

 

Cash paid for interest

 

$

3,819

 

 

$

3,493

 

Cash paid for income taxes, net of refunds

 

$

801

 

 

$

309

 

Non-cash right-of-use assets and lease liabilities

 

$

629

 

 

$

651

 

Asset retirement obligations

 

$

758

 

 

$

718

 

 

See accompanying notes

79

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023

1. Description of Business

Standard BioTools Inc. (Standard BioTools or the Company), formerly known as Fluidigm Corporation, is a Delaware corporation headquartered in South San Francisco, California.

The Company has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company endeavors to provide reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy.

On January 5, 2024, the Company completed its previously announced merger (the Merger) with SomaLogic, Inc. (SomaLogic) a protein biomarker discovery company enabling researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. See Note 16 – Subsequent Events, for more information.

2. Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of the Company's wholly owned subsidiaries. As of December 31, 2023, the Company had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, Italy, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves, the carrying value of goodwill and other long-lived assets, and the potential outcome of uncertain tax positions that have been recognized in the Company's financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company's consolidated financial statements.

Foreign Currency

Assets and liabilities of non-U.S. subsidiaries that use their local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. Income and expense accounts are translated at monthly average exchange rates during the year. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity (deficit).

Revenue Recognition

The Company generates revenue primarily from the sale of its products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. The Company also generates revenue from product development agreements, license and royalty agreements, and grants. Revenue is reported net of any sales, use and value-added taxes the Company collects from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue.

The Company recognizes revenue based on the amount of consideration it expects to receive in exchange for the goods and services it transfers to the customer. The Company's commercial arrangements typically include multiple distinct products and services, and the Company allocates revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices

80

 

(SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price.

Product Revenue

The Company recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in 30 to 60 days.

The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.

Service and Other Revenue

The Company recognizes revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed.

Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally one to three years. The Company believes this time-elapsed approach is appropriate for service contracts because the Company provides services on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments made in advance of service are reported on the Company's consolidated balance sheet as deferred revenue.

Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.

The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC Topic 606, Revenue from Contracts with Customers, as the grant agreement is not with a customer. As there is no authoritative U.S. GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC Topic 958, Not-for-Profit Entities by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.

Significant Judgments

Applying the revenue recognition practices discussed above often requires significant judgment. Significant judgment is required when interpreting commercial terms in sales agreements and determining when control of goods and services passes to the customer. Judgment is also required when identifying performance obligations, estimating SSP and allocating purchase consideration in agreements that include multiple performance obligations. Any material changes created by errors in judgment could have a material effect on the Company's operating results and overall financial condition.

Cash and Cash Equivalents

The Company considers all highly liquid financial instruments with maturities at the time of purchase of three months or less to be cash equivalents. Cash and cash equivalents balance at December 31, 2023, and 2022 represent cash on deposit with banks and money market funds.

Short-term Investments

Short-term investments are comprised of U.S treasury securities that mature within one year. The Company classifies its short-term investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets. Any unrealized gains and losses from short-term investments are reported as a component of other comprehensive income (loss) within the consolidated statements of comprehensive loss and as a separate component of stockholders’ equity (deficit). The Company evaluates its short-term investments to assess whether investments with unrealized loss positions are other-than-temporarily impaired. An investment is

81

 

considered to be other-than-temporarily impaired if the impairment is related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of their cost basis. No investment has been assessed as other than temporarily impaired. Realized gains and losses are calculated on the specific identification method and are recorded as interest income (loss). There were no realized gains and losses from sales of short-term investments during any of the periods presented.

The Company excludes accrued interest from the fair value and amortized cost basis of its short-term investments.

Accounts Receivable, net

Trade accounts receivable are recorded at net invoice value. The Company reviews its exposure to accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The Company evaluates such allowances on a regular basis and adjust them as needed.

Concentrations of Business and Credit Risk

Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, short-term investments, and accounts receivable. The Company's cash, cash equivalents, and short-term investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of risk. Under the Company's investment policy, the Company invests exclusively in securities issued by the U.S. government or U.S. government agencies, or in government money-market funds. The goals of the Company's investment policy, in order of priority, are to: preserve capital, meet liquidity needs, and optimize returns. For these reasons, management believes that the Company is not exposed to significant credit risk.

The Company generally does not require collateral to support credit sales. To reduce credit risk, the Company performs credit evaluations of its customers.

The Company's products include components that are currently procured from a single source or a limited number of sources. The Company believes that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, the Company attempts to maintain an adequate supply of critical limited-source components.

Inventories, net

Inventories are stated at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company regularly reviews inventory for excess and obsolete products and components. Significant judgment is required in determining provisions for slow-moving, excess, and obsolete inventories which are recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, product expiration, discontinuance of product lines, and quality issues.

Property and Equipment, net

Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Accumulated depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The estimated useful lives of the Company's property and equipment are generally as follows: computer equipment and software, three to four years; laboratory and manufacturing equipment, two to seven years; and office furniture and fixtures, five years.

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. Lease terms are determined at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For its long-term operating leases, the Company recognizes a lease liability and a right-of-use asset (ROU) on its consolidated balance sheets. ROU assets represent the Company's right-to-use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The lease liability is determined at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a term similar to the lease arrangement. Significant judgment is required in determining the incremental

82

 

collateralized borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. Lease expense is recognized on a straight-line basis over the lease term. Sublease income from an operating lease is recognized on a straight-line basis over the sublease term. The Company does not have any finance leases.

The Company elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify, the Company will not recognize ROU assets or lease liabilities for leases with an initial lease term of one year or less. The Company also elected not to separate lease and nonlease components for the Company's building leases. The nonlease components are generally variable in nature and are expected to represent most of the Company's variable lease costs. Variable costs are expensed as incurred. The Company has taken a portfolio approach for its vehicle leases by country.

Business Combinations, Goodwill, Intangible Assets and Other Long-Lived Assets

The Company has completed acquisitions of businesses in the past and may acquire additional businesses or technologies in the future. The results of businesses acquired in a business combination are included in the Company's consolidated financial statements from the date of acquisition. The Company allocates the purchase price, which is the sum of the consideration provided in a business combination, to the identifiable assets and liabilities of the acquired business at their acquisition date fair values. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and estimates of future revenue.

Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The Company's intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Judgment is needed to assess the factors that could indicate an impairment of intangible assets.

Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that the Company will be required to recognize an impairment charge include, but are not limited to, declines in the Company's stock price or market capitalization, economic downturns and other macroeconomic events, declines in the Company's market share or revenues, or significant litigation. Any impairment charges could have a material adverse effect on the Company's operating results and net asset value in the period in which the Company recognizes the impairment charge.

In evaluating goodwill and intangible assets with indefinite lives for indications of impairment, the Company first conducts an assessment of qualitative factors to determine whether it is more likely than not that the fair value of each of the Company's reporting units is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of each of its reporting units is less than its carrying amount, the Company compares the fair value of each of its reporting units to its carrying value. If the fair value of each of the Company's reporting units exceeds its carrying value, goodwill is not considered impaired, and no further analysis is required. If the carrying value of each of the Company's reporting units exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill.

The Company evaluates its long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, the Company estimates the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly.

Series B Redeemable Preferred Stock

The Purchase Agreements (as described in Note 9) for the issuance of shares of Series B Redeemable Preferred Stock were accounted for as forward sales contracts at fair value in accordance with ASC Topic 480, Distinguishing Liabilities from Equities. The Series B Redeemable Preferred Stock was classified as mezzanine equity and recorded at fair value upon issuance, net of issuance costs, due to its redemption features that are outside of the Company’s control. Mezzanine equity is presented separately on the consolidated balance sheets between liabilities and shareholders’ equity because it shares characteristics of both. In the year ended December 31, 2022, the Company recognized a $60.1 million loss on the forward sales of Series B Preferred Stock and a $13.7 million loss on the Bridge Loans due to the increase in the price of the Company's common stock from January 23, 2022 (the date of the Purchase Agreements and the Bridge Loan agreements) to the Private Placement Closing Date. See Note 9 for additional information.

83

 

Restructuring and Related Charges

The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Costs for involuntary separation programs are recorded when management has approved the plan for separation, the employees are identified and made aware of the benefits they are entitled to, it is unlikely that the plan will change significantly, and if applicable, any required governmental notification is made. Costs associated with benefits that are contingent on the employee continuing to provide service are recognized over the required service period. Costs associated with leased facilities (net of sublease income, if applicable) that the Company has vacated as part of a restructuring plan are also included.

Transaction-related Expenses

The Company expensed certain costs incurred related to the merger agreement with SomaLogic, described further in Note 16, including legal, advisory, accounting and other transaction-related costs. The expenses in the prior period relate to the private placement whereby the Company issued and sold an aggregate of $225.0 million of convertible preferred stock in connection with the conversion of the bridge loans, which closed on April 4, 2022.

Deferred Grant Income

Proceeds from the NIH Contract have been principally recorded as capital expenditures and to offset applicable operating costs. The non-operating income recognized from the grant proceeds received in excess of the amounts spent for capital expenditures and operating expenses is reflected on the consolidated statement of operations as surplus funding from the NIH contract.

The NIH Contract met the definition of grants related to assets as the primary purpose for the payments was to fund the purchase and construction of capital assets to scale up production capacity. The Company elected to record the grants received as deferred income in accordance with International Accounting Standards (IAS) 20.

Deferred grant income related to production capacity expansion is being amortized for the related assets as a reduction of depreciation expense.

Term Loan, net

The term loan is recorded at its carrying value, which includes the outstanding principal amount and the cumulative accreted final payment, less unamortized debt issuance costs. Amortization of the debt issuance costs and accretion of the final payment are reflected in interest expense. The final payment is being accreted to the carrying value of the term loan through the expected maturity of July 1, 2025 using the effective interest method. Debt issuance costs were recorded as an offset to the carrying value of the loan and are amortized over the expected term also using the effective interest method.

Convertible Notes, net

The Company records the 2014 Notes and 2019 Notes (as described in Note 6) at their carrying values, which includes their principal amounts plus accrued and unpaid interest. Offering-related costs, including underwriting costs, on the 2014 Notes and 2019 Notes were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method.

Treasury Stock

The Company uses the cost method to account for the repurchases of its common stock in accordance with ASC 505-30, Equity-Treasury Stock. The direct costs associated with settled share repurchases, including trading commissions, are reported as treasury stock in the shareholders’ equity (deficit) section of the Company's consolidated balance sheets.

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of cash and cash equivalents, restricted cash, short-term investments, accounts receivable, accounts payable, term loan and convertible notes. The Company's cash equivalents, restricted cash, accounts receivable and accounts payable generally have short maturity or payment periods. Accordingly, their carrying values approximated their fair values at December 31, 2023 and 2022. The Company's short-term investments consist of U.S. treasury securities that are classified as available-for-sale and reported at fair value on the Company's consolidated balance sheets. The convertible notes and term loan are presented at their net carrying values.

84

 

As a basis for computing fair value, the Company follows a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level I: observable inputs such as quoted prices in active markets;

Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and

Level III: unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's cash equivalents, which include money market funds are classified as Level I because they are valued using quoted market prices. The Company's short-term investments, which include U.S. treasuries, are classified as Level II because they are valued using non-binding market consensus prices that were corroborated with observable market data, quoted market prices for similar instruments, or pricing models.

The Company's convertible notes are not regularly traded, and it is difficult to estimate a reliable and accurate market price for these securities. The estimated fair values of these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the Company's term loan also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's term loan was estimated using a discounted cash flows approach and current market interest rate data for similar loans. The carrying value of the Company's lines of term loan approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions.

Research and Development

The Company recognizes research and development expenses in the period incurred. Research and development (R&D) expenses generally consist of personnel costs, independent contractor costs, prototype and materials expenses, allocated facilities and information technology expenses, and related overhead expenses.

Advertising Costs

The Company expenses advertising costs as incurred. The Company incurred advertising costs of $2.0 million and $3.9 million during the years ended December 31, 2023 and 2022, respectively.

Stock-Based Compensation

The Company recognizes compensation costs for all stock-based awards, including stock options, Restricted Share Units (RSUs), Performance Share Units (PSUs) and stock purchased under the Company's Employee Share Purchase Plan (ESPP), based on the grant date fair value of the award. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service periods for non-performance-based awards. For RSUs, fair value is measured based on the closing fair market value of the Company's common stock on the date of grant. For PSUs with a market condition, the Company uses a Monte Carlo simulation pricing model to incorporate the market condition effects at the grant date. The Monte Carlo pricing model requires inputs which are subjective and generally requires judgment. For PSUs with performance conditions, stock-based compensation expense is recognized over the requisite service period when the achievement of each individual performance goal becomes probable.

The fair value of options and stock purchases under ESPP on the grant date is estimated using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions, including expected term, volatility, risk-free interest rate and the fair value of the Company's common stock. These assumptions generally require judgment. The Company determines the expected volatility based on the Company's historical stock price volatility generally commensurate with the estimated expected term of the stock awards. The expected term of an award is based on historical forfeiture experience, exercise activity, and the terms and conditions of the stock awards. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each grant’s expected term. The Company accounts for forfeitures as they occur.

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and

85

 

liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans and estimates. Should the actual amounts differ from the Company's estimates, the amount of the valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to the Company's tax provision in a period in which such estimates are changed, which in turn would affect net income or loss.

The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. Any interest and penalties related to uncertain tax positions are reflected in the income tax provision.

Segment Reporting

The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.

The Company's CEO, who is its Chief Operating Decision Maker (CODM), measures segment performance using gross profit which is determined by subtracting cost of product and service revenues from segment revenues. Depreciation and amortization expense is included in each segment’s gross profit.

Comprehensive Loss

Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on the Company's short-term investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of comprehensive loss.

Net Loss per Share

The Company's basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. RSUs, PSUs, stock options to purchase the Company's common stock, ESPP shares pending issuance, Series B Preferred Stock and convertible notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.

The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

RSUs, PSUs, stock options and ESPP shares

 

 

16,740

 

 

 

15,752

 

Series B Preferred Stock

 

 

75,164

 

 

 

75,164

 

2019 Notes(1)

 

 

18,966

 

 

 

18,966

 

2014 Notes

 

 

10

 

 

 

10

 

Total

 

 

110,880

 

 

 

109,892

 

 

(1)
The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to Note 6 for additional information on the 2019 Notes.

 

The 2,709,703 common shares that were repurchased during the year ended December 31, 2023 have also been excluded from the Company's earnings per share and diluted earnings per share calculations.

86

 

Recent Accounting Changes and Accounting Pronouncements

Adoption of New Accounting Guidance

From time to time, new accounting standards are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures, which requires disclosure of more detailed information about a reportable segment’s expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.

Reclassification

Certain amounts in the consolidated financial statements have been reclassified from their original presentation to conform to current year presentation.

3. Revenue and Geographic Area

Disaggregation of Revenue by Product Type and Geographic Area

The following tables present the Company's revenue for the years ended December 31, 2023 and 2022, respectively, based on product type and the geographic location of customers’ facilities (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Instruments

 

$

37,459

 

 

$

25,664

 

Consumables

 

 

41,739

 

 

 

46,790

 

Total product revenue

 

 

79,198

 

 

 

72,454

 

Service revenue

 

 

25,980

 

 

 

23,712

 

Product and service revenue

 

 

105,178

 

 

 

96,166

 

Other revenue

 

 

1,162

 

 

 

1,782

 

Total revenue

 

$

106,340

 

 

$

97,948

 

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Americas

 

$

46,196

 

 

$

43,982

 

Europe, Middle East and Africa (EMEA)

 

 

36,201

 

 

 

33,136

 

Asia-Pacific

 

 

23,943

 

 

 

20,830

 

Total revenue

 

$

106,340

 

 

$

97,948

 

 

Most of the Company's principal operations, other than manufacturing, are located at its corporate headquarters in the United States. Revenue from customers in the United States represented $44.1 million, or 42%, of total revenues for the year ended December 31,

87

 

2023, and $41.0 million, or 42%, of total revenues for the year ended December 31, 2022. Refer to Note 13 for additional information on revenue by reporting segment.

Revenue from customers in China represented $15.8 million, or 15%, of total revenues for the year ended December 31, 2023, and 11% of total revenues for the year ended December 31, 2022. With the exception of China in 2023 and 2022, no foreign country or jurisdiction had revenue in excess of 10% of the Company's total revenue during the years ended December 31, 2023 and 2022.

One genomics customer accounted for 10% and 11% of the Company's total revenue for the years ended December 31, 2023 and 2022, respectively, and 14% and 16% of outstanding net trade receivables at December 31, 2023 and 2022, respectively. No other customer represented more than 10% of the Company's total revenue for the fiscal years ended December 31, 2023 and 2022. Revenue from the Company's five largest customers represented 24% of total revenue for the year ended December 31, 2023 and 19% of total revenue the year ended December 31, 2022.

Long-lived Assets by Geographical Area

The Company had long-lived assets consisting of property and equipment, net of accumulated depreciation, and operating lease ROU assets, net of accumulated amortization, in the following geographic areas for each year presented (in thousands):

 

 

December 31,

 

 

2023

 

 

2022

 

United States

 

$

29,646

 

 

$

31,785

 

Singapore

 

 

17,097

 

 

 

21,178

 

Canada

 

 

6,231

 

 

 

5,394

 

Other Asia-Pacific

 

 

889

 

 

 

875

 

EMEA

 

 

987

 

 

 

303

 

Total

 

$

54,850

 

 

$

59,535

 

Unfulfilled Performance Obligations

The consolidated balance sheets as of December 31, 2023 and 2022 included total deferred revenue of $15.1 million and $14.6 million, respectively. During the year ended December 31, 2023, $10.6 million of the opening deferred revenue balance was recognized as revenue and $11.1 million of net additional advance payments, primarily for instrument service contracts, were received from customers.

 

The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of December 31, 2023 in the following periods (in thousands):

 

Fiscal Year

 

Expected Revenue (1)

 

2024

 

 

13,253

 

2025

 

 

6,634

 

2026

 

 

3,061

 

Thereafter

 

 

1,112

 

Total

 

$

24,060

 
(1)
Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins.

The Company also has unsatisfied performance obligations for service contracts with an expected term of one year or less not included in the amounts above.

4. Goodwill and Intangible Assets, net

During the second quarter of 2022, the Company discontinued the sale of products that utilized the developed technology acquired from InstruNor and recorded a $3.5 million impairment charge to write-off the unamortized portion of the related intangible asset.

The Company assessed goodwill for impairment when it performed its annual testing at the end of the fourth quarter of 2023. A qualitative approach was employed which included assessing significant events and circumstances such as the Company's current results,

88

 

assumptions regarding future performance, strategic initiatives and overall macroeconomic factors to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of each of the Company's reporting units is less than their carrying value. The Company determined there was no impairment as of December 31, 2023.

The changes in the carrying value of goodwill by segment are as follows (in thousands):

 

 

Proteomics

 

 

Genomics

 

 

Total

 

Balance as of December 31, 2022

 

$

85,752

 

 

$

20,499

 

 

$

106,251

 

Foreign currency translation

 

 

46

 

 

 

20

 

 

 

66

 

Balance as of December 31, 2023

 

$

85,798

 

 

$

20,519

 

 

$

106,317

 

 

Intangible assets with finite lives include developed technology, patents and licenses. In the consolidated balance sheets, developed technology is reported separately while patents and licenses are reported in other non-current assets. Intangible assets, net, were as follows (in thousands):

 

 

 

December 31, 2023

 

 

Gross Amount

 

 

Accumulated
Amortization
and
Impairment

 

 

Net

 

 

Weighted-
Average
Amortization
Period

Developed technology

 

$

117,354

 

 

$

(115,954

)

 

$

1,400

 

 

10.0 years

Patents and licenses

 

$

11,250

 

 

$

(11,243

)

 

$

7

 

 

7.0 years

 

 

 

December 31, 2022

 

 

Gross Amount

 

 

Accumulated
Amortization

 

 

Net

 

 

Weighted-
Average
Amortization
Period

Developed technology

 

$

117,194

 

 

$

(104,594

)

 

$

12,600

 

 

10.0 years

Patents and licenses

 

$

11,247

 

 

$

(10,669

)

 

$

578

 

 

7.0 years

 

Total amortization expense of the Company's intangible assets was $11.8 million and $12.2 million for the years ended December 31, 2023 and 2022, respectively. The $3.5 million impairment charge for the InstruNor developed technology intangible asset was recorded in research and development expense in 2022 and it is reflected in accumulated amortization in the above table.

Based on the net carrying value of intangible assets at December 31, 2023, the Company expects annual amortization expense to be as follows (in thousands):

 

Fiscal Year

 

Developed
Technology
Amortization
Expense

 

 

Patents and
Licenses
Amortization
Expense

 

 

Total

 

2024

 

 

1,400

 

 

 

7

 

 

 

1,407

 

Total

 

$

1,400

 

 

$

7

 

 

$

1,407

 

 

5. Balance Sheet Details

Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Cash and cash equivalents

 

$

51,704

 

 

$

81,309

 

Restricted cash

 

 

795

 

 

 

1,015

 

Total cash, cash equivalents and restricted cash

 

$

52,499

 

 

$

82,324

 

 

89

 

 

Restricted cash of $0.8 and $1.0 million is included in other non-current assets on the consolidated balance sheets as of December 31, 2023 and 2022, respectively.

Inventories, net

Inventories, net consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Raw materials

 

$

15,539

 

 

$

16,866

 

Work-in-process

 

 

282

 

 

 

945

 

Finished goods

 

 

11,753

 

 

 

15,245

 

Total inventory, gross

 

 

27,574

 

 

 

33,056

 

Allowance for excess and obsolete inventory

 

 

(7,041

)

 

 

(11,583

)

Total inventories, net

 

$

20,533

 

 

$

21,473

 

 

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Laboratory and manufacturing equipment

 

$

35,563

 

 

$

33,329

 

Leasehold improvements

 

 

13,785

 

 

 

12,234

 

Computer equipment and software

 

 

6,232

 

 

 

5,793

 

Office furniture and fixtures

 

 

1,762

 

 

 

1,713

 

Property and equipment, gross

 

 

57,342

 

 

 

53,069

 

Less accumulated depreciation and amortization

 

 

(35,489

)

 

 

(29,029

)

Construction-in-progress

 

 

2,334

 

 

 

1,612

 

Property and equipment, net

 

$

24,187

 

 

$

25,652

 

 

Depreciation expense was $3.4 million and $2.8 million for the years ended December 31, 2023 and 2022, respectively.

Accrued Compensation and Related Benefits

Accrued compensation and related benefits, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Accrued incentive compensation

 

$

7,337

 

 

$

1,170

 

Accrued vacation

 

 

2,711

 

 

 

2,795

 

Accrued payroll taxes and other

 

 

994

 

 

 

1,174

 

Accrued restructuring

 

 

825

 

 

 

4,014

 

Accrued compensation and related benefits

 

$

11,867

 

 

$

9,153

 

 

Refer to Note 14 for additional information on restructuring.

90

 

Other Accrued Liabilities

Other accrued liabilities, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Accrued commissions

 

$

1,010

 

 

$

800

 

Accrued interest

 

 

295

 

 

 

318

 

Accrued legal expenses

 

 

964

 

 

 

349

 

Accrued taxes

 

 

1,230

 

 

 

1,443

 

Uninvoiced receipts

 

 

1,516

 

 

 

1,078

 

Accrued warranties

 

 

2,593

 

 

 

678

 

Customer advances

 

 

447

 

 

 

577

 

Accrued restructuring

 

 

—

 

 

 

19

 

Accrued other

 

 

1,097

 

 

 

913

 

Other accrued liabilities

 

$

9,152

 

 

$

6,175

 

Deferred Grant Income

In September 2020, the Company executed a contract with the National Institutes of Health (NIH) under NIH’s Rapid Acceleration of Diagnostics program to support the expansion of the Company’s production capacity for its COVID-19 test products. Under the now-completed contract, the Company received $34.0 million of funding from the NIH and used $22.2 million on capital expenditures for their Singapore manufacturing facility. The amortization of the deferred income, which is offset against depreciation, was $3.6 million and $3.5 million for the years ended December 31, 2023 and 2022, respectively. Cumulative amounts amortized and offsetting against depreciation expense for these assets placed in service were $7.8 million and $4.2 million as of December 31, 2023 and 2022, respectively, and the carrying values of these assets were $14.4 million and $18.0 million, respectively, as of these same dates.

The current portion of deferred grant income on the Company’s consolidated balance sheets represents amounts expected to be offset against depreciation expense over the next twelve months. The non-current portion of deferred grant income includes amounts expected to be offset against depreciation expense in later periods.

6. Debt

The carrying value of debt consists of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Convertible notes:

 

 

 

 

 

 

2014 Notes

 

$

569

 

 

$

568

 

2019 Notes, non-current

 

 

—

 

 

 

54,047

 

2019 Notes, current

 

 

54,530

 

 

 

—

 

Total convertible notes, net

 

 

55,099

 

 

 

54,615

 

Term loan, non-current

 

 

3,414

 

 

 

8,194

 

Term loan, current

 

 

5,000

 

 

 

2,083

 

Total debt

 

$

63,513

 

 

$

64,892

 

 

Convertible Notes

In February 2014, the Company closed an underwritten public offering of 2014 Senior Convertible Notes (2014 Notes), which will mature on February 1, 2034, unless earlier converted, redeemed or repurchased in accordance with the terms of the 2014 Notes. Holders may require the Company to repurchase all or a portion of their 2014 Notes on each of February 6, 2024 and February 6, 2029, at a repurchase price in cash equal to 100% of the principal amount of the 2014 Notes plus accrued and unpaid interest. On February 6, 2024, one holder of the 2014 Notes exercised their repurchase right, and the Company repurchased an immaterial amount of principal and accrued interest.

 

In November 2019, the Company issued $55.0 million aggregate principal amount of 2019 Senior Convertible Notes (2019 Notes). Net proceeds from the 2019 Notes issuance of $52.7 million, after deductions for commissions and other debt issuance costs, were used to retire all but $1.1 million of the aggregate principal value of the 2014 Notes then outstanding. The 2019 Notes bear interest at 5.25% per annum, payable semiannually on June 1 and December 1 of each year. The 2019 Notes will mature on December 1, 2024, unless

91

 

earlier repurchased or converted pursuant to their terms. The 2019 Notes will be convertible at the option of the holder at any point prior to the close of business on the second scheduled trading day preceding the maturity date. The initial conversion rate of the 2019 Notes is 344.8276 shares of the Company’s common stock per $1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately $2.90 per share). The conversion rate is subject to adjustment upon the occurrence of certain specified events. Those certain specified events include voluntary conversion of the 2019 Notes prior to the Company’s exercise of the Issuer’s Conversion Option (as defined therein) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2019 Notes. The conversion rate will not be adjusted for any accrued and unpaid interest. The 2019 Notes are convertible at the Company’s option in whole but not in part into shares of the Company’s common stock upon certain conditions if the volume-weighted average price of the Company’s common stock has equaled or exceeded 130% of the conversion price then in effect for a specified number of days.

Offering-related costs related to both notes were capitalized as debt issuance costs and are recorded as an offset to the carrying value of the 2019 Notes.

Revolving Credit Facility

On August 2, 2018, the Company entered into a revolving credit facility with Silicon Valley Bank (as amended, the Revolving Credit Facility) in an aggregate principal amount of up to the lesser of (i) $15.0 million or (ii) the sum of (a) 85% of eligible receivables and (b) 50% of eligible inventory, in each case, subject to certain limitations (Borrowing Base), provided that the amount of eligible inventory that may be counted towards the Borrowing Base shall be subject to a cap as set forth in the Revolving Credit Facility. The Revolving Credit Facility was collateralized by substantially all the Company’s property, other than intellectual property and contained certain financial covenants. There were no borrowings under the Revolving Credit Facility and it expired on August 2, 2023.

Term Loan Facility, net

On August 2, 2021, the Company amended its Revolving Credit Facility to, amongst other things, provide for a new $10.0 million term loan facility (the Term Loan Facility). As of December 31, 2023, the Term Loan Facility was fully drawn with an outstanding principal balance of $7.9 million and a carrying value of $8.4 million. The interest rate on the Term Loan Facility is the greater of 4.0% per annum or a floating per annum rate equal to the prime rate plus 0.75%. Interest on any outstanding term loan advances is due and payable monthly. In addition to the monthly interest payments, a final payment equal to 6.5% of the original principal amount of each advance is due the earlier of the maturity date or the date the advance is repaid. Principal balances are required to be repaid in 24 equal installments which began on August 1, 2023. The stated maturity of the Term Loan Facility is July 1, 2025. However, if the principal amount of the Company’s convertible debt exceeds $0.6 million as of June 1, 2024 or if the maturity date of the 2019 Notes has not been extended beyond January 1, 2026 by June 1, 2024, then the maturity date of the Term Loan Facility will be June 1, 2024. As there were no contractual requirement to repay the loan as of the balance sheet date, $3.4 million of the Term Loan Facility's carrying value is classified as non-current, consistent with its terms, on the Company’s balance sheet as of December 31, 2023.

On October 26, 2023, the Company entered into an amendment to the Term Loan Facility agreement which removed certain collateral covenants related to the Revolving Credit Facility due to its expiration on August 2, 2023.

Future minimum payments under the Term Loan Facility including the end of term fee payment as of December 31, 2023, are as follows (in thousands):

 

2024

 

$

5,000

 

2025

 

 

2,917

 

 

 

7,917

 

End of term fee and debt issuance costs

 

 

497

 

Total Term Loan Facility

 

$

8,414

 

Bridge Loans

On January 23, 2022, the Company entered into separate loan agreements (collectively, the Bridge Loan Agreements) with various investors for a $25.0 million term loan (collectively, the Bridge Loans). The Bridge Loans were fully drawn on January 24, 2022, and automatically converted into Series B Preferred Stock upon the subsequent closing of the Private Placement (as defined below) on April 4, 2022 (the Private Placement Closing Date).

Applying the guidance in ASC 825 Financial Instruments, the Company elected to record the Bridge Loans at their fair value using a probability‐weighted expected return method for the valuation analysis of the Bridge Loans. This resulted in a $13.7 million change

92

 

in fair value of the Bridge Loans from $25.0 million at inception to $38.7 million as of the Private Placement Closing Date, including the portion attributable to accrued interest, which is reflected as a non-operating unrealized loss on the Bridge Loans in the accompanying consolidated statements of operations for the year ended December 31, 2022. See Note 9 for further detail.

7. Commitments and Contingencies

Leases

The Company has operating leases for buildings, equipment and vehicles. Existing leases have remaining terms ranging from less than one year to approximately 6 years. Some leases contain options to extend the lease, usually for up to five years, along with termination options. The Company’s facility lease has an expiration date of April 30, 2030 and contains an option to extend the lease, for up to five years, along with termination options. The Company is utilizing one floor (19th floor) for its corporate operations with all expense for this floor included within selling, general and administrative expense on the Company’s consolidated statement of operations for the years ended December 31, 2023 and 2022.

As part of the Company’s restructuring plan discussed further in Note 14, in August 2022, the Company entered into an agreement to sublease approximately 25% of its corporate headquarters space (18th floor) in South San Francisco, California for a period of 39 months. As of December 31, 2023, 24 months were remaining on the sublease. The Company expects to recognize $4.8 million of sublease income over the lease term that commenced in October 2022. At December 31, 2023, $2.9 million sublease income is expected to be recognized over the remaining lease term. In addition, on February 28, 2023, the Company signed a second agreement to sublease an additional 25% of its corporate headquarters (21st floor) for a period of 77 months, which commenced on December 1, 2023. The Company expects to recognize additional sublease income of $9.1 million over the lease term. At December 31, 2023, $9.0 million sublease income is expected to be recognized over the remaining lease term.

Rent expense, net of sublease income, is reported within restructuring and related charges for the year ended December 31, 2023, in the consolidated statements of operations. The Company is currently in the process of fully vacating and potentially subleasing an additional floor (20th floor).

Information about the Company's operating leases is as follows:

 

 

December 31, 2023

 

 

December 31, 2022

 

Weighted average remaining lease term (in years)

 

5.9 years

 

 

6.8 years

 

Weighted average discount rate per annum

 

 

11.8

%

 

 

11.8

%

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Operating lease cost (including variable costs)

 

$

11,159

 

 

$

10,917

 

Variable costs (including non-lease components)

 

$

3,164

 

 

$

2,930

 

Sublease income

 

$

2,679

 

 

$

189

 

Cash paid for amounts included in the measurement of
   operating lease liabilities

 

$

7,931

 

 

$

7,540

 

 

Future minimum lease payments and sublease income as of December 31, 2023 under commenced non-cancelable operating leases are as follows (in thousands):

 

93

 

Fiscal Year

 

Minimum Lease
Payments for
Operating Leases

 

 

Sublease Income

 

 

Net Minimum Lease Payments for Operating Leases

 

2024

 

$

8,086

 

 

$

(2,877

)

 

$

5,209

 

2025

 

 

8,135

 

 

 

(2,952

)

 

 

5,183

 

2026

 

 

7,821

 

 

 

(1,381

)

 

 

6,440

 

2027

 

 

7,395

 

 

 

(1,430

)

 

 

5,965

 

2028

 

 

7,355

 

 

 

(1,480

)

 

 

5,875

 

Thereafter

 

 

10,225

 

 

 

(2,058

)

 

 

8,167

 

Total future minimum payments (receipts)

 

 

49,017

 

 

$

(12,178

)

 

$

36,839

 

Imputed interest

 

 

(14,320

)

 

 

 

 

 

 

Total operating lease liabilities

 

 

34,697

 

 

 

 

 

 

 

Less: current portion of operating lease liabilities

 

 

4,323

 

 

 

 

 

 

 

Operating lease liabilities, net of current portion

 

$

30,374

 

 

 

 

 

 

 

Other Commitments

In the normal course of business, the Company enters into various contractual and legally binding purchase commitments. As of December 31, 2023, the Company's open commitments totaled $9.7 million. Capital expenditure commitments as of December 31, 2023 were immaterial.

The Company has entered into several license and patent agreements. Under these agreements, the Company pays annual license maintenance fees, non-refundable license issuance fees, and royalties as a percentage of net sales for the sale or sublicense of products using the licensed technology. Future payments related to these license agreements have not been included in the open commitments above, as the period of time over which the future license payments will be required to be made, and the amount of such payments, are indeterminable. The Company does not expect the license payments to be material in any particular year.

Indemnification

From time to time, the Company has entered into indemnification provisions under certain of its agreements in the ordinary course of business, typically with business partners, customers and suppliers. Pursuant to these agreements, the Company may indemnify, hold harmless and agree to reimburse the indemnified parties on a case-by-case basis for losses suffered or incurred by the indemnified parties in connection with any patent or other intellectual property infringement claim by any third party with respect to the Company’s products. The term of these indemnification provisions is generally perpetual from the time of the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is typically not limited to a specific amount. In addition, the Company has entered into indemnification agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding.

Litigation

On November 28, 2023, a purported stockholder filed a complaint against the Company and the members of the Company’s Board in the United States District Court for the Northern District of California. The complaint has since been voluntarily dismissed. On December 12, 2023 two separate shareholder complaints were filed in the District of Delaware, The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. The Company is reviewing the complaints and has not yet formally responded to them. On December 13, 2023, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed transaction, which was denied by the Court on January 4, 2024. The non-injunctive claims, including breach of fiduciary duty, are still being litigated. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs’ claim is successful, this type of litigation may result in significant costs and divert management’s attention and resources, which could adversely affect the operation of the Company.

94

 

Between October 24, 2023 and January 3, 2024, SomaLogic received 16 letters from purported shareholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement.

Additional lawsuits against the Company and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, the Company will not necessarily announce such additional filings.

In the normal course of business, the Company is from time to time involved in legal proceedings or potential legal proceedings, including matters involving employment, intellectual property, or others. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of any currently pending matters would not have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

8. Fair Value of Financial Instruments

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy (in thousands):

 

 

 

 

 

 

Fair Value Measurements At Reporting Date Using

 

 

 

Total

 

 

Quoted Prices in Active Markets For Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

As of December 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

35,385

 

 

$

35,385

 

 

$

—

 

 

$

—

 

Total cash and cash equivalents

 

$

35,385

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

63,191

 

 

$

—

 

 

$

63,191

 

 

$

—

 

Total short-term investments

 

$

63,191

 

 

$

—

 

 

$

63,191

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets measured at fair value

 

$

98,576

 

 

$

35,385

 

 

$

63,191

 

 

$

—

 

 

 

 

 

 

 

Fair Value Measurements At Reporting Date Using

 

 

 

Total

 

 

Quoted Prices in Active Markets For Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

As of December 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

53,894

 

 

$

53,894

 

 

$

—

 

 

$

—

 

Total cash and cash equivalents

 

$

53,894

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

84,475

 

 

$

84,475

 

 

$

—

 

 

$

—

 

Total short-term investments

 

$

84,475

 

 

$

84,475

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets measured at fair value

 

$

138,369

 

 

$

138,369

 

 

$

—

 

 

$

—

 

 

There were no transfers within the hierarchy and no changes in the valuation techniques used during the year ended December 31, 2023.

The following table summarizes available-for-sale-securities (in thousands):

95

 

 

 

 

 

 

 

 

 

As of December 31, 2023

 

 

 

Maturity (in years)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

$

35,385

 

Total cash and cash equivalents

 

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

$

35,385

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

1 or less

 

$

63,169

 

 

$

22

 

 

$

—

 

 

$

63,191

 

Total short-term investments

 

 

 

$

63,169

 

 

$

22

 

 

$

—

 

 

$

63,191

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total available-for-sale securities

 

 

 

$

98,554

 

 

$

22

 

 

$

—

 

 

$

98,576

 

 

 

 

 

 

 

 

 

As of December 31, 2022

 

 

 

Maturity (in years)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

$

53,894

 

Total cash and cash equivalents

 

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

$

53,894

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

1 or less

 

$

84,977

 

 

$

—

 

 

$

(502

)

 

$

84,475

 

Total short-term investments

 

 

 

$

84,977

 

 

$

—

 

 

$

(502

)

 

$

84,475

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total available-for-sale securities

 

 

 

$

138,871

 

 

$

—

 

 

$

(502

)

 

$

138,369

 

As of December 31, 2023, none of the available-for-sale securities held have been in an unrealized loss position for greater than 12 months. The Company does not intend to sell these investments and it is not likely that the Company will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recorded.

Debt

The 2014 Notes and 2019 Notes (collectively, the Convertible Notes) are not regularly traded. The estimated fair values for these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the 2019 Notes was $58.2 million and $48.4 million as of December 31, 2023 and 2022, respectively. The carrying value of the 2014 Notes approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions.

The estimated fair value of the Term Loan Facility also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's Term Loan Facility was estimated using a discounted cash flow model and current market interest rate data for similar loans. The carrying value of the Company's lines of Term Loan Facility approximates fair value as interest rates applied to the underlying debt are adjusted quarterly to market interest rates.

 

9. Mezzanine Equity

Series B Redeemable Preferred Stock

On January 23, 2022, the Company entered into separate Series B Convertible Preferred Stock Purchase Agreements (collectively, the Purchase Agreements) with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, Casdin), and Viking Global Opportunities Illiquid Investments Sub Master LP and Viking Global Opportunities Drawdown LP (together, Viking, and together with Casdin, the Lenders), whereby the Company issued and sold an aggregate of $225.0 million of convertible preferred stock, consisting of: (i) 112,500 shares of the Company’s Series B-1 Convertible Preferred Stock, par value $0.001 per share (the Series B-1 Preferred Stock), at a purchase price of $1,000 per share; and (ii) 112,500 shares of the Company’s Series B-2 Convertible Preferred Stock, par value $0.001 per share (the Series B-2 Preferred Stock, and together with the Series B-1 Preferred Stock, the Series B Preferred Stock or the Series B Redeemable Preferred Stock) at a purchase price of $1,000 per share (together with the issuance of shares of Series B Preferred Stock in connection with the conversion of the Bridge Loans, the Private Placement). On the Private Placement Closing Date, 225,000 shares of Series B Preferred Stock were issued in accordance with the Purchase Agreements and the Bridge Loans

96

 

converted into 30,559 shares of Series B Preferred Stock, for a total of 255,559 shares of Series B Preferred Stock. The Company recorded the Series B Preferred Stock as mezzanine equity at its fair value upon issuance, net of any issuance costs, on the consolidated balance sheets as it has features, such as change of control and liquidation preference, which are outside of the Company’s control.

The Purchase Agreements were accounted for as forward sales contracts at fair value in accordance with the authoritative accounting guidance as the Series B Preferred Stock included certain contingent redemption features that created an obligation for the Company to repurchase its shares. The fair value of the payable portion of the forward sales contracts was determined using a Monte Carlo Simulation, which relies on significant assumptions regarding the estimated yield and term of the Series B Preferred Stock.

The components of the carrying value of the Series B Preferred Stock as of December 31, 2023 and 2022 were as follows (in thousands):

 

Proceeds from Purchase Agreements

 

$

225,000

 

Proceeds from Bridge Loans

 

 

25,000

 

Change in fair value of Forward Purchase Agreements

 

 

60,081

 

Change in the fair value of Bridge Loans

 

 

13,719

 

Less equity issuance costs

 

 

(12,547

)

Total Series B Redeemable Preferred Stock

 

$

311,253

 

 

The Series B Preferred Stock ranks senior to the Company's common stock with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The holders of Series B Preferred Stock are entitled to participate in all dividends declared on the Company's common stock on an as-converted basis.

10. Shareholders' Deficit

Stock Repurchase Program

On November 23, 2022, the Company’s board of directors authorized the repurchase of up to $20.0 million in shares of the Company’s common stock in the open market or in negotiated transactions through December 31, 2023. The Company repurchased a total of 2,709,703 shares of common stock under the program at a cost of $5.4 million, excluding commission fees, for an average of $1.98 per share for the year ended December 31, 2023. Repurchases under the program were able to be suspended or discontinued at any time at the Company’s discretion, and on October 4, 2023, the Company terminated the program in connection with the announcement of the merger agreement with SomaLogic.

Common Shares Reserved

As of December 31, 2023, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

 

 

 

Securities To Be Issued Upon Exercise Of Options

 

 

Securities To Be Issued Upon Release Of Restricted Stock

 

 

Number Of Remaining Securities Available For Future Issuance

 

2022 Inducement Equity Incentive Plan

 

 

7,595

 

 

 

1,277

 

 

 

208

 

2011 Equity Incentive Plan

 

 

1,640

 

 

 

5,964

 

 

 

4,656

 

2017 Inducement Award Plan

 

 

59

 

 

 

2

 

 

 

—

 

2017 Employee Stock Purchase Plan

 

 

—

 

 

 

—

 

 

 

1,581

 

Total common stock reserved for future issuance

 

 

9,294

 

 

 

7,243

 

 

 

6,445

 

 

11. Stock-based Compensation

Equity Compensation Plans

2011 Equity Incentive Plan

In January 2011, the Company's board of directors adopted the 2011 Equity Incentive Plan (2011 Plan) under which incentive stock options, non-statutory stock options, RSUs, stock appreciation rights, PSUs, and performance shares may be granted to its employees, directors, and consultants.

97

 

2022 Inducement Equity Incentive Plan

In April 2022, the Company's board of directors adopted the 2022 Inducement Plan and reserved 9.5 million shares of common stock for the issuance of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares and PSUs. In accordance with Nasdaq listing rules, equity awards issued under the 2022 Inducement Plan are restricted to individuals who are not already employees or directors of the Company. The terms and conditions of the 2022 Inducement Plan are substantially similar to those of the 2011 Plan.

The Company's board of directors sets the terms, conditions, and restrictions related to the grant of stock options, RSUs and performance-based awards under its stock-based plans, as well as employee participation in the 2017 Employee Stock Purchase Plan (ESPP). The Company's board of directors determines the number of awards to grant and also sets vesting criteria. In general, RSUs vest on a quarterly basis over a period of four years from the date of grant at a rate of 25% on the first anniversary of the grant date and ratably each quarter over the remaining 12 quarters, or ratably over 16 quarters, subject to the employees’ continued employment. The Company may grant RSUs with different vesting terms from time to time. Stock options granted under the Company's 2022 Inducement Plan and 2011 Plan have a term of no more than ten years from the date of grant and an exercise price of at least 100% of the fair market value of the underlying common stock on the date of grant. Generally, options vest at a rate of either 25% on the first anniversary of the option grant date and ratably each month over the remaining period of 36 months, or ratably each month over 48 months. The Company may grant options with different vesting terms from time to time. For performance-based share awards, the Company's board of directors sets the performance objectives and other vesting provisions in determining the number of shares or value of performance units and performance shares that will be paid out. Such payout will be a function of the extent to which performance objectives or other vesting provisions have been achieved.

Restricted Stock Units

 

 

 

Number of Units
 (in thousands)

 

 

Weighted-Average
Grant Date Fair Value per Unit

 

Balance at December 31, 2022

 

 

7,120

 

 

$

2.58

 

RSU granted

 

 

3,728

 

 

$

2.32

 

RSU released

 

 

(2,970

)

 

$

2.68

 

RSU forfeited

 

 

(945

)

 

$

2.17

 

Balance at December 31, 2023

 

 

6,933

 

 

$

2.46

 

 

As of December 31, 2023, the unrecognized compensation costs related to outstanding unvested RSUs under the Company’s equity incentive plans were $13.9 million. The Company expects to recognize those costs over a weighted-average period of 2.5 years.

Stock Options

 

 

 

Number of
Options (in thousands)

 

 

Weighted-Average
Exercise Price
per Option

 

 

Weighted-
Average Remaining Contractual Life (in years)

 

 

Aggregate
Intrinsic
Value (1) (in thousands)

 

Balance at December 31, 2022

 

 

7,882

 

 

$

4.43

 

 

 

7.9

 

 

$

—

 

Options granted

 

 

2,609

 

 

$

2.57

 

 

 

 

 

 

 

Options exercised

 

 

(44

)

 

$

1.84

 

 

 

 

 

 

 

Options cancelled

 

 

(1,153

)

 

$

6.84

 

 

 

 

 

 

 

Balance at December 31, 2023

 

 

9,294

 

 

$

3.62

 

 

 

8.5

 

 

$

439

 

Vested at December 31, 2023

 

 

3,497

 

 

$

3.98

 

 

 

8.2

 

 

$

78

 

Unvested awards at December 31, 2023

 

 

5,797

 

 

$

3.40

 

 

 

8.7

 

 

$

361

 

 

 

Aggregate intrinsic value as of December 31, 2023 was calculated as the difference between the closing price per share of the Company’s common stock on the last trading day of December, which was $2.21, and the exercise price of the options, multiplied by the number of in-the-money options.

The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022 was immaterial. The total intrinsic value of options vested during the years ended December 31, 2023 and 2022 was $0.1 million and zero, respectively. As of December 31,

98

 

2023, the unrecognized compensation costs related to outstanding unvested options under the Company’s equity incentive plans were $12.4 million. The Company expects to recognize those costs over a weighted-average period of 2.3 years.

The weighted average assumptions used to estimate the fair value of options granted were as follows:

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Stock options

 

 

 

 

 

 

Weighted average expected volatility

 

 

97.1

%

 

 

91.8

%

Weighted average expected term

 

4.7 years

 

 

4.3 years

 

Weighted average risk-free interest rate

 

 

3.9

%

 

 

2.6

%

Dividend yield

 

 

—

 

 

 

—

 

Weighted-average fair value per share

 

$

1.49

 

 

$

2.21

 

Expected Term—The expected term of options granted represents the period of time that the options are expected to be outstanding and is derived by analyzing historical exercise behavior.

Expected Volatility—The estimated volatility was based on the historical volatility of the common stock of the Company.

Risk-Free Interest Rate—The risk-free interest rate is the implied yield in effect at the time of the option grant based on U.S. Treasury securities with contract maturities similar to the expected term of the Company’s stock options.

Dividend Rate—The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used.

Performance-based Awards

The Company previously granted PSUs to certain executive officers and senior-level employees with the number of PSUs ultimately earned under these awards being calculated by comparing the Total Shareholder Return (TSR) of the Company’s common stock over the applicable three-year period against the TSR of a defined group of peer companies. The Company’s relative performance against its peer group determined the payout, which could range from 0% to 200% of the base awards. As these awards required continuous service in order to vest and these officers and senior level employees are no longer with the Company, they were canceled as of June 30, 2023.

In July 2023, the Company granted performance-based restricted stock units to certain executive officers that will vest in the first quarter of 2024 based upon the achievement of specified revenue and EBITDA targets for the twelve months ended December 31, 2023, and the executive’s continued employment with the Company. Stock-based compensation expense is being recognized over the requisite service period, as it is deemed probable the Company will satisfy the performance measures.

Activity under the performance-based awards was as follows:

 

 

 

Number of Units
(in thousands)

 

 

Weighted-Average
Grant Date Fair Value per Unit

 

Balance at December 31, 2022

 

 

453

 

 

$

4.81

 

PSU granted

 

 

309

 

 

$

2.42

 

PSU released

 

 

(52

)

 

$

9.60

 

Performance adjustment for 2020 awards

 

 

(401

)

 

$

4.19

 

Balance at December 31, 2023

 

 

309

 

 

$

2.42

 

Stock-based Compensation Expense

Stock-based compensation expense is reported in the Company's consolidated statement of operations as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Cost of product revenue

 

$

811

 

 

$

592

 

Research and development expense

 

 

1,671

 

 

 

2,481

 

Selling, general and administrative expense

 

 

10,641

 

 

 

11,807

 

Total stock-based compensation expense

 

$

13,123

 

 

$

14,880

 

 

99

 

12. Income Taxes

The Company' loss before income taxes consists of the following (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Domestic

 

$

(40,587

)

 

$

(174,041

)

International

 

 

(33,617

)

 

 

(18,887

)

Loss before income taxes

 

$

(74,204

)

 

$

(192,928

)

 

Significant components of the Company's benefit (expense) from income taxes are as follows (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Current:

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

State

 

 

(197

)

 

 

(87

)

Foreign

 

 

(373

)

 

 

(405

)

Total current tax expense

 

 

(570

)

 

 

(492

)

Deferred:

 

 

 

 

 

 

Federal

 

 

—

 

 

 

—

 

State

 

 

—

 

 

 

—

 

Foreign

 

 

118

 

 

 

3,322

 

Total deferred benefit

 

 

118

 

 

 

3,322

 

Total benefit (expense) from income taxes

 

$

(452

)

 

$

2,830

 

 

Reconciliation of income taxes at the statutory rate to the benefit (expense) from income taxes recorded in the statements of operations is as follows:

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Tax benefit at federal statutory rate

 

 

21.0

%

 

 

21.0

%

State tax expense, net of federal benefit

 

 

1.3

 

 

 

0.8

 

Foreign tax expense

 

 

8.1

 

 

 

0.8

 

NOL carryforwards expiring unutilized

 

 

(5.5

)

 

 

(22.8

)

Change in valuation allowance

 

 

(21.9

)

 

 

17.1

 

Federal R&D credit

 

 

0.2

 

 

 

0.2

 

Unrecognized tax benefit

 

 

—

 

 

 

0.9

 

Non-deductible interest/premium

 

 

—

 

 

 

(0.3

)

Non-deductible loss on Forward Sale of Preferred Stock and
   Bridge Loans

 

 

—

 

 

 

(8.0

)

R&D tax credits expiring unutilized

 

 

—

 

 

 

(5.2

)

Transaction costs

 

 

(1.5

)

 

 

—

 

Executive stock-based compensation

 

 

(2.6

)

 

 

(0.8

)

Return to provision

 

 

2.5

 

 

 

—

 

Other, net

 

 

(2.0

)

 

 

(2.2

)

Effective tax rate

 

 

(0.4

)%

 

 

1.5

%

 

100

 

 

Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforward

 

$

96,242

 

 

$

85,182

 

Reserves and accruals

 

 

3,152

 

 

 

3,943

 

Depreciation and amortization

 

 

564

 

 

 

563

 

Capitalized R&D costs

 

 

5,962

 

 

 

3,840

 

Tax credit carryforwards

 

 

15,463

 

 

 

14,456

 

Stock-based compensation

 

 

1,143

 

 

 

2,064

 

Right-of-use lease liabilities

 

 

7,782

 

 

 

8,663

 

Total gross deferred tax assets

 

 

130,308

 

 

 

118,711

 

Valuation allowance on deferred tax assets

 

 

(124,124

)

 

 

(107,893

)

Total deferred tax assets, net of valuation allowance

 

 

6,184

 

 

 

10,818

 

Deferred tax liabilities:

 

 

 

 

 

 

Fixed assets and intangibles

 

 

(54

)

 

 

(3,913

)

Right-of-use assets

 

 

(6,836

)

 

 

(7,729

)

Total deferred tax liabilities

 

 

(6,890

)

 

 

(11,642

)

Net deferred tax liability

 

$

(706

)

 

$

(824

)

 

 

 

 

 

 

 

Deferred tax liability per balance sheet

 

$

(841

)

 

$

(1,055

)

Less deferred tax assets included in other long-term assets

 

 

135

 

 

 

231

 

Net deferred tax liability

 

$

(706

)

 

$

(824

)

 

Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company completed its Section 382 Study through December 31, 2022 and determined that an ownership change occurred on April 4, 2022 due to the issuance of preferred equity. As a result of this ownership change, a portion of net operating loss (NOL) carryforwards and all R&D credits will expire unutilized. Further limitations are also expected as a result of the merger with SomaLogic that occurred on January 5, 2024.

The Company establishes a valuation allowance for deferred tax assets if the Company determines it is more likely than not the related tax benefit will not be realized. The Company relies on several factors when assessing the realizability of deferred tax assets, including historical financial results, the Company's ability to recover net operating loss carry-forwards, the projected future operating results, and the Company's ability to use tax planning strategies.

The valuation allowances of $124.1 million and $107.9 million as of December 31, 2023 and 2022, respectively, primarily relate to temporary tax differences, net operating losses and research and development credits generated in the current and prior years. The Company believes it is more likely than not that U.S. federal and state, Canada and Netherlands deferred tax assets relating to temporary differences, net operating losses and research and development credits are not realizable. As such, full valuation allowances have been applied against the deferred tax assets relating to jurisdictions of the U.S. federal and state, Canada and Netherlands.

A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended December 31, 2023 and 2022 is as follows (in thousands):

 

 

Valuation Allowance

 

December 31, 2021

 

$

141,087

 

Charges to earnings

 

 

—

 

Charges to other accounts

 

 

(33,194

)

December 31, 2022

 

 

107,893

 

Charges to earnings

 

 

—

 

Charges to other accounts

 

 

16,231

 

December 31, 2023

 

$

124,124

 

 

As of December 31, 2023, the Company had net operating loss carryforwards for U.S. federal income tax purposes of $363.5 million, and U.S. federal research and development tax credits of $0.5 million, which begin expiring in 2042. As of December 31, 2023, the

101

 

Company had net operating loss carryforwards for state income tax purposes of $220.4 million, which will expire through 2043, and California research and development tax credits of $14.0 million, which do not expire. As of December 31, 2023, we had foreign net loss carryforwards of $36.6 million, which will begin to expire in 2041, and foreign tax credit carryforwards of $6.9 million, which begin to expire in 2037.

The aggregate changes in the balance of the Company's gross unrecognized tax benefits during 2023, and 2022 were as follows (in thousands):

 

December 31, 2021

 

$

8,515

 

Increases in balances related to tax positions during a prior
   period

 

 

154

 

Increases in balances related to tax positions taken during
   current period

 

 

—

 

Decreases in balances related to tax positions taken during prior
   period

 

 

(1,697

)

December 31, 2022

 

 

6,972

 

Increases in balances related to tax positions during a prior
   period

 

 

105

 

Decreases in balances related to tax positions taken during
   current period

 

 

(138

)

December 31, 2023

 

$

6,939

 

 

As of December 31, 2023, there were no unrecognized tax benefits that, if recognized, would reduce the Company's effective tax rate. The Company does not anticipate that existing unrecognized tax benefits will significantly increase or decrease within the next 12 months.

Accrued interest and penalties related to unrecognized tax benefits was included in the income tax provision. The amount was immaterial as of December 31, 2023 and 2022.

The Company files income tax returns in the United States, its various states, and in certain foreign jurisdictions. As a consequence of having operating loss carryforwards, all tax years are open to federal and state examination in the United States. Tax years from 2012 are open to examination in various foreign countries.

13. Segment Reporting

The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.

During 2023, the CODM began using gross profit to measure the operating performance of the segments. The Company determines each segment’s gross profit by subtracting cost of product and service revenues from segment revenues.

The Company does not prepare or report segmented balance sheet information as the CODM does not use the information to assess segment operating performance. The segments adhere to the same accounting policies as the Company as a whole.

102

 

The Company's business segment information was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Revenue:

 

 

 

 

 

 

Proteomics

 

$

63,883

 

 

$

52,502

 

Genomics

 

 

42,457

 

 

 

45,446

 

Total revenue

 

$

106,340

 

 

$

97,948

 

 

 

 

 

 

 

 

Gross profit:

 

 

 

 

 

 

Proteomics

 

$

26,239

 

 

$

20,041

 

Genomics

 

 

24,211

 

 

 

17,010

 

Total gross profit

 

$

50,450

 

 

$

37,051

 

 

 

 

 

 

 

 

Depreciation & amortization:

 

 

 

 

 

 

Proteomics

 

$

12,072

 

 

$

12,223

 

Genomics

 

 

601

 

 

 

230

 

Total depreciation & amortization

 

$

12,673

 

 

$

12,453

 

 

14. Restructuring and Related Charges

Beginning with the appointment of the Company’s new management team in April 2022 and as further announced in August 2022, the Company has implemented a restructuring plan, including a reduction in force, to improve operational efficiency, achieve cost savings and align the Company’s workforce to the future needs of the business. In addition to the reduction in force, the Company is reducing leased office space, optimizing its manufacturing footprint and streamlining support functions. The Company is developing a more disciplined cost management culture throughout its organization by investing in training and advanced information systems.

The Company records restructuring and related charges as incurred. These items are classified within restructuring and related charges in the consolidated statements of operations for the year ended December 31, 2023, and primarily include severance costs as well as facility costs (net of sublease income) for leased space in South San Francisco that the Company has vacated as part of the restructuring plan. The Company recognized restructuring and related charges of $7.1 million and $9.7 million for the years ended December 31, 2023 and 2022, respectively.

The Company expects to relieve the majority of the existing liability for restructuring charges primarily related to employee severance in 2024. Ongoing restructuring charges will continue to be incurred for facility related costs through the termination of the facility leases. These estimates are subject to a number of assumptions, and actual results may differ.

The following table summarizes the change in the Company’s restructuring and other related liabilities for the years ended December 31, 2023 and 2022 (in thousands):

 

 

 

Severance
and other
employee-
related
benefits(1)

 

 

Facility
Costs

 

 

Other(2)

 

 

Total

 

Balance at December 31, 2021

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Restructuring and related charges

 

 

5,849

 

 

 

2,885

 

 

 

998

 

 

 

9,732

 

Cash payments

 

 

(1,835

)

 

 

(2,885

)

 

 

(979

)

 

 

(5,699

)

Balance at December 31, 2022

 

$

4,014

 

 

$

—

 

 

$

19

 

 

$

4,033

 

Restructuring and related charges

 

 

2,379

 

 

 

4,160

 

 

 

537

 

 

 

7,076

 

Cash payments

 

 

(5,568

)

 

 

(4,160

)

 

 

(556

)

 

 

(10,284

)

Balance at December 31, 2023

 

$

825

 

 

$

—

 

 

$

—

 

 

$

825

 

 

(1)
Restructuring liabilities are recorded in accrued compensation and related benefits on the consolidated balance sheets.
(2)
Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the consolidated balance sheets.

103

 

The Company’s restructuring and related charges by segment and corporate were as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Restructuring:

 

 

 

 

 

 

Proteomics

 

$

1,010

 

 

$

1,363

 

Genomics

 

 

714

 

 

 

1,273

 

Corporate expenses

 

 

5,352

 

 

 

7,096

 

Total restructuring and related charges

 

$

7,076

 

 

$

9,732

 

 

15. 401(k) Plan

The Company sponsors a 401(k) savings plan for its employees in the United States that stipulates that eligible employees may elect to contribute to the plan, subject to certain limitations, up to the lesser of 90% of eligible compensation or the maximum amount allowed by the U.S. Internal Revenue Service. In 2019 and onward, the employee match formula was 100% up to $3,000 annually. Employer matching contributions to the 401(k) plan were $0.5 million and $0.6 million for the years ended December 31, 2023 and 2022.

16. Subsequent Event

SomaLogic Merger

On January 5, 2024, the Company completed the previously announced Merger pursuant to the Agreement and Plan of Merger, dated as of October 4, 2023 (the “Merger Agreement”), by and among the Company, SomaLogic, and Martis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub). Pursuant to the Merger Agreement, Merger Sub merged with and into SomaLogic, with SomaLogic surviving as a wholly owned subsidiary of Standard BioTools. At the consummation of the Merger, each issued and outstanding share of common stock of SomaLogic, was converted into the right to receive 1.11 shares of common stock of Standard BioTools, and cash in lieu of fractional shares. At the effective time of the Merger, SomaLogic’s common stockholders owned approximately 57%, and the Company’s common stockholders owned approximately 43%, of the outstanding shares of common stock of the combined company on a fully diluted basis.

In addition, as of the effective time of the Merger, the Company assumed each SomaLogic stock incentive plan, outstanding option to purchase shares of SomaLogic common stock and outstanding restricted stock units convertible into shares of SomaLogic common stock, whether vested or unvested. In addition, as of the Effective Time, each SomaLogic warrant was treated in accordance with its terms.

Due to the limited time between the Merger date and the filing of this Annual Report, it is not practicable for the Company to disclose the preliminary allocation of the purchase price to assets acquired and liabilities assumed.

104

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f)) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Management assessed our internal control over financial reporting as of December 31, 2023. Management based its assessment on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal controls over financial reporting due to the Company's status as a non-accelerated filer and smaller reporting company.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on the Effectiveness of Controls

Control systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.

ITEM 9B. OTHER INFORMATION

None.

ITEM 9C. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

None.

105

 

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information called for by this item will be set forth in our proxy statement for the 2024 annual meeting of stockholders (the Proxy Statement) to be filed with the SEC within 120 days of the fiscal year ended December 31, 2023 and is incorporated herein by reference.

Our board of directors has adopted a Code of Ethics and Conduct that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer and other executive and senior financial officers. The full text of our code of business conduct and ethics is posted on the investor relations page on our website, which is located at www.standardbio.com. We will post any amendments to our code of business conduct and ethics, or waivers of its requirements, on our website.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this item will be set forth in our Proxy Statement and is incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information, if any, required by this item will be set forth in our Proxy Statement and is incorporated herein by reference.

The information, if any, required by this item will be set forth in our Proxy Statement and is incorporated herein by reference.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this item will be set forth in our Proxy Statement and is incorporated herein by reference.

106

 

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

1.
Financial Statements. See “Index to Consolidated Financial Statements” in Part II, Item 8 of this Annual Report.
2.
Financial Statement schedule. N/A.
3.
Exhibits. The exhibits listed in the accompanying Index to Exhibits are filed herewith or are incorporated by reference to exhibits previously filed with the U.S. Securities and Exchange Commission.

ITEM 16. FORM 10-K SUMMARY

None.

107

 

INDEX TO EXHIBITS

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

2.1††

 

Agreement and Plan of Merger, dated January 28, 2014, by and among DVS Sciences, Inc., Standard BioTools Inc. (formerly Fluidigm Corporation), Dawid Merger Sub, Inc. and Shareholder Representative Services LLC.

 

8-K

 

001-34180

 

2.1

 

1/29/2014

 

 

 

 

 

 

 

 

 

 

 

2.2††

 

Merger Agreement, dated as of March 28, 2021, as amended by the First Amendment thereto dated as of May 12, 2021 and the Second Amendment thereto dated as of July 15, 2021, by and among SomaLogic, Inc. (CM Life Sciences II, Inc.), S-Craft Merger Sub, Inc., and SomaLogic Operating Co., Inc. (formerly SomaLogic, Inc.).

 

S-4/A

 

333-256127

 

2.1

 

8/5/2021

 

 

 

 

 

 

 

 

 

 

 

2.3†

 

Agreement and Plan of Merger, dated as of July 25, 2022, by and among SomaLogic, Inc., Panther Merger Subsidiary I, LLC, Panther Merger Subsidiary I, LLC, Palamedrix, Inc., and Securityholder Representative Services LLC.

 

8-K

 

001-40090

 

2.1

 

7/27/2022

 

 

 

 

 

 

 

 

 

 

 

2.4††

 

Agreement and Plan of Merger, dated as of October 4, 2023, by and among Standard BioTools Inc., SomaLogic, Inc., and Martis Merger Sub, Inc.

 

8-K

 

001-34180

 

2.1

 

10/4/2023

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Eighth Amended and Restated Certificate of Incorporation of Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-K

 

001-34180

 

3.1

 

3/28/2011

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Amended and Restated Bylaws of Standard BioTools Inc. (formerly Fluidigm Corporation).

 

S-8

 

333-264086

 

4.8

 

4/1/2022

 

 

 

 

 

 

 

 

 

 

 

3.3

 

Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation of Standard BioTools Inc. (formerly Fluidigm Corporation).

 

S-8

 

333-264086

 

4.3

 

4/1/2022

 

 

 

 

 

 

 

 

 

 

 

3.4

 

Second Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation of Standard BioTools Inc.

 

8-K

 

001-34180

 

3.1

 

1/5/2024

 

 

 

 

 

 

 

 

 

 

 

3.5

 

Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock.

 

8-K

 

001-34180

 

3.1

 

11/22/2016

 

 

 

 

 

 

 

 

 

 

 

3.6

 

Certificate of Elimination of Series A Participating Preferred Stock of Fluidigm Corporation.

 

8-K

 

001-34180

 

3.1

 

8/2/2017

 

 

 

 

 

 

 

 

 

 

 

3.7

 

Certificate of Designations of Rights, Preferences and Privileges of Series B-1 Convertible Preferred Stock.

 

8-K

 

001-34180

 

3.6

 

4/5/2022

 

 

 

 

 

 

 

 

 

 

 

3.8

 

Certificate of Designations of Rights, Preferences and Privileges of Series B-2 Convertible Preferred Stock.

 

8-K

 

001-34180

 

3.7

 

4/5/2022

 

 

 

 

 

 

 

 

 

 

 

4.1

 

Specimen Stock Certificate of Standard BioTools Inc.

 

S-8

 

333-264086

 

4.1

 

4/1/2022

 

 

 

 

 

 

 

 

 

 

 

4.2

 

Description of Securities.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.3

 

Indenture, dated February 4, 2014, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and U.S. Bank National Association.

 

8-K

 

001-34180

 

4.1

 

2/4/2014

 

 

 

 

 

 

 

 

 

 

 

108

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

4.4

 

First Supplemental Indenture, dated February 4, 2014, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and U.S. Bank National Association.

 

8-K

 

001-34180

 

4.2

 

2/4/2014

 

 

 

 

 

 

 

 

 

 

 

4.5

 

Form of Global Note (included in Exhibit 4.4).

 

8-K

 

001-34180

 

4.3

 

2/4/2014

 

 

 

 

 

 

 

 

 

 

 

4.6

 

Indenture, dated November 22, 2019, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and U.S. Bank National Association.

 

8-K

 

001-34180

 

4.1

 

11/22/2019

 

 

 

 

 

 

 

 

 

 

 

4.7

 

Form of 5.25% Convertible Senior Note due 2024 (included in Exhibit 4.6).

 

8-K

 

001-34180

 

4.2

 

11/22/2019

 

 

 

 

 

 

 

 

 

 

 

4.8

 

Warrant Agreement, dated as of February 22, 2021, by and between SomaLogic, Inc. (formerly CM Life Sciences II Inc.) and Continental Stock Transfer & Trust Company.

 

8-K

 

001-40090

 

10.1

 

2/26/2021

 

 

 

 

 

 

 

 

 

 

 

4.9

 

Form of SomaLogic, Inc. Subscription Agreement.

 

8-K

 

001-40090

 

10.1

 

3/29/2021

 

 

 

 

 

 

 

 

 

 

 

10.1#

 

Form of Indemnification Agreement entered into by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and certain of its officers and directors.

 

S-1/A

 

333-170965

 

10.1

 

1/28/2011

 

 

 

 

 

 

 

 

 

 

 

10.2#

 

Form of Indemnification Agreement entered into by and between Standard BioTools Inc. and certain of its officers and directors.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.3

 

Lease, dated as of March 20, 2019, by and between AP3-SF3 CT North, LLC and Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-Q

 

001-34180

 

10.1

 

5/7/2019

 

 

 

 

 

 

 

 

 

 

 

10.4

 

First Amendment to Lease, dated as of April 26, 2019, by and between AP3-SF3 CT North, LLC and Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-Q

 

001-34180

 

10.2

 

5/7/2019

 

 

 

 

 

 

 

 

 

 

 

10.5

 

Second Amendment to Lease, dated as of February 25, 2020, by and between AP3-SF3 CT North, LLC and Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-K

 

001-34180

 

10.2B

 

2/25/2021

 

 

 

 

 

 

 

 

 

 

 

10.6†

 

Office Lease, dated as of August 17, 2015, by and among Rodick Equities Inc., Standard BioTools Canada Inc. (formerly Fluidigm Canada Inc.), and Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-Q

 

001-34180

 

10.1

 

11/9/2015

 

 

 

 

 

 

 

 

 

 

 

10.7

 

Tenancy for Flatted Factory Space, dated as of July 27, 2005, by and between JTC Corporation and Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.).

 

S-1

 

333-170965

 

10.20

 

12/3/2010

 

 

 

 

 

 

 

 

 

 

 

10.8

 

Offer of Tenancy for Facility Lease, dated as of October 14, 2013, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and SBC Institutional Trust Services (Singapore) Limited, as Trustee of Ascendas Real Estate Investment Trust.

 

10-K

 

001-34180

 

10.21

 

3/12/2014

 

 

 

 

 

 

 

 

 

 

 

10.9

 

Offer of Tenancy for Lease of Additional Space, dated as of April 2, 2015, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and HSBC Institutional Trust Services (Singapore) Limited, as Trustee of Ascendas Real Estate Investment Trust.

 

10-Q

 

001-34180

 

10.1

 

8/10/2015

 

 

 

 

 

 

 

 

 

 

 

109

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

10.10

 

Lease Agreement, dated as of November 19, 2020, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust.

 

10-Q

 

001-34180

 

10.2

 

8/6/2021

 

 

 

 

 

 

 

 

 

 

 

10.11

 

Lease Agreement, dated as of June 8, 2021, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust.

 

10-Q

 

001-34180

 

10.3

 

8/6/2021

 

 

 

 

 

 

 

 

 

 

 

10.12

 

Lease Agreement, dated as of December 13, 2021, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust.

 

10-K

 

001-34180

 

10.5D

 

3/8/2022

 

 

 

 

 

 

 

 

 

 

 

10.13

 

Sublease, dated as of August 30, 2022, by and between Standard BioTools Inc. and CIRC Bio, Inc.

 

10-Q

 

001-34180

 

10.1

 

11/9/2022

 

 

 

 

 

 

 

 

 

 

 

10.14

 

Sublease, dated as of February 28, 2023, by and between Standard BioTools Inc. and First Databank, Inc.

 

10-Q

 

001-34180

 

10.1

 

5/9/2023

 

 

 

 

 

 

 

 

 

 

 

10.15††

 

Lease Agreement, dated February 10, 2022, by and between SomaLogic Operating Co., Inc. and Louisville 1 Industrial Owner, LLC.

 

8-K

 

001-40090

 

10.1

 

2/16/2022

 

 

 

 

 

 

 

 

 

 

 

10.16††

 

Lease Agreement, dated February 10, 2022, by and between SomaLogic Operative Co., Inc. and Louisville 2 Industrial Owner, LLC.

 

8-K

 

001-40090

 

10.2

 

2/16/2022

 

 

 

 

 

 

 

 

 

 

 

10.17†

 

Second Amended and Restated License Agreement, dated as of May 1, 2004, by and between California Institute of Technology and Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-Q

 

001-34180

 

10.2

 

11/9/2020

 

 

 

 

 

 

 

 

 

 

 

10.18†

 

First Addendum to Second Amended and Restated License Agreement, dated as of March 29, 2007, by and between California Institute of Technology and Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-Q

 

001-34180

 

10.2A

 

11/9/2020

 

 

 

 

 

 

 

 

 

 

 

10.19†

 

Co-Exclusive License Agreement, dated as of October 15, 2000, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Mycometrix Corporation).

 

10-Q

 

001-34180

 

10.3

 

11/9/2020

 

 

 

 

 

 

 

 

 

 

 

10.20†

 

First Amendment to Co-Exclusive License Agreement, dated as of October 15, 2000, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Mycometrix Corporation).

 

10-Q

 

001-34180

 

10.3A

 

11/9/2020

 

 

 

 

 

 

 

 

 

 

 

10.21†

 

Co-Exclusive License Agreement, dated as of October 15, 2000, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Mycometrix Corporation).

 

10-Q

 

001-34180

 

10.4

 

11/9/2020

 

 

 

 

 

 

 

 

 

 

 

110

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

10.22†

 

Co-Exclusive License Agreement, dated as of October 15, 2000, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Mycometrix Corporation).

 

10-Q

 

001-34180

 

10.5

 

11/9/2020

 

 

 

 

 

 

 

 

 

 

 

10.23†

 

Letter Agreement, dated as of December 22, 2004, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-Q

 

001-34180

 

10.6

 

11/9/2020

 

 

 

 

 

 

 

 

 

 

 

10.24†

 

License Agreement, dated as of July 17, 2008, by and between MDS Analytical Technologies, a business unit of MDS INC., and Standard BioTools Inc. (formerly DVS Sciences Inc.).

 

10-Q/A

 

001-34180

 

10.3

 

9/15/2014

 

 

 

 

 

 

 

 

 

 

 

10.25†

 

Sublicense Agreement, dated as of January 28, 2014, by and between Standard BioTools Inc. (formerly DVS Sciences Inc.) and Standard BioTools Inc. (formerly Fluidigm Corporation).

 

10-Q/A

 

001-34180

 

10.4

 

9/15/2014

 

 

 

 

 

 

 

 

 

 

 

10.26†

 

Loan and Security Agreement, dated as of August 2, 2018, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Silicon Valley Bank.

 

8-K

 

001-34180

 

10.1

 

8/2/2018

 

 

 

 

 

 

 

 

 

 

 

10.27

 

Default Waiver and First Amendment to Loan and Security Agreement, dated as of September 1, 2018, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Silicon Valley Bank.

 

10-K

 

001-34180

 

10.13A

 

2/27/2020

 

 

 

 

 

 

 

 

 

 

 

10.28

 

Second Amendment to Loan and Security Agreement, dated as of November 20, 2019, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Silicon Valley Bank.

 

8-K

 

001-34180

 

10.2

 

11/22/2019

 

 

 

 

 

 

 

 

 

 

 

10.29

 

Third Amendment to Loan and Security Agreement, dated as of April 21, 2020, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Silicon Valley Bank.

 

8-K

 

001-34180

 

10.1

 

4/22/2020

 

 

 

 

 

 

 

 

 

 

 

10.30

 

Fourth Amendment to Loan and Security Agreement, dated as of August 2, 2021, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Silicon Valley Bank.

 

8-K

 

001-34180

 

10.1

 

8/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.31

 

Fifth Amendment to Loan and Security Agreement, dated as of December 27, 2021, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Silicon Valley Bank.

 

10-K

 

001-34180

 

10.19E

 

3/8/2022

 

 

 

 

 

 

 

 

 

 

 

10.32

 

Default Waiver and Consent to Loan and Security Agreement, dated as of March 4, 2022, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Silicon Valley Bank.

 

10-K

 

001-34180

 

10.19F

 

3/8/2022

 

 

 

 

 

 

 

 

 

 

 

10.33

 

Purchase Agreement, dated as of November 20, 2019, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Barclays Capital Inc., as representative of the several initial purchasers named in Schedule I thereto.

 

8-K

 

001-34180

 

10.1

 

11/22/2019

 

 

 

 

 

 

 

 

 

 

 

10.34†

 

Solicitation/Contract/Order for Commercial Items, dated as of July 30, 2020, by and between Standard BioTools Inc.

 

10-Q

 

001-34180

 

10.1

 

11/9/2020

111

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

 

 

(formerly Fluidigm Corporation) and National Institutes of Health, as amended on September 28, 2020.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.35†

 

Amendment of Solicitation/Modification of Contract, dated as of May 10, 2021, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and the National Institutes of Health.

 

10-Q

 

001-34180

 

10.1

 

8/6/2021

 

 

 

 

 

 

 

 

 

 

 

10.36†

 

Amendment of Solicitation/Modification of Contract, dated as of September 29, 2021, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and the National Institutes of Health.

 

10-Q

 

001-34180

 

10.1

 

11/9/2021

 

 

 

 

 

 

 

 

 

 

 

10.37

 

Series B-1 Loan Agreement, dated as of January 23, 2022, by and among Standard BioTools Inc. (formerly Fluidigm Corporation), Casdin Partners Master Fund, L.P., and Casdin Private Growth Equity Fund II, L.P.

 

8-K/A

 

001-34180

 

10.1

 

2/11/2022

 

 

 

 

 

 

 

 

 

 

 

10.38

 

Series B-2 Loan Agreement, dated as of January 23, 2022, by and among Standard BioTools Inc. (formerly Fluidigm Corporation), Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.

 

8-K

 

001-34180

 

10.2

 

1/24/2022

 

 

 

 

 

 

 

 

 

 

 

10.39

 

Series B-1 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, by and among Standard BioTools Inc. (formerly Fluidigm Corporation), Casdin Private Growth Equity Fund II, L.P., and Casdin Partners Master Fund, L.P.

 

DEF 14A

 

001-34180

 

Anx. B

 

2/24/2022

 

 

 

 

 

 

 

 

 

 

 

10.40

 

Series B-2 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, by and among Standard BioTools Inc. (formerly Fluidigm Corporation), Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.

 

DEF 14A

 

001-34180

 

Anx. C

 

2/24/2022

 

 

 

 

 

 

 

 

 

 

 

10.41

 

Private Placement Warrants Purchase Agreement, dated February 22, 2021, by and among SomaLogic, Inc. (formerly CM Life Sciences II Inc.), CMLS Holdings LLC and certain directors (and/or entities controlled by them) named in Exhibit A thereto.

 

8-K

 

001-40090

 

10.4

 

2/26/2021

 

 

 

 

 

 

 

 

 

 

 

10.42

 

Registration Rights Agreement, dated as of January 23, 2022, by and between Standard BioTools Inc. (formerly Fluidigm Corporation), Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.

 

8-K

 

001-34180

 

10.5

 

1/24/2022

 

 

 

 

 

 

 

 

 

 

 

10.43

 

SomaLogic, Inc. (formerly CM Life Sciences II Inc.) Form of Amended and Restated Registration Rights Agreement.

 

8-K

 

001-40090

 

10.6

 

3/29/2021

 

 

 

 

 

 

 

 

 

 

 

10.44

 

Letter Agreement, dated as of March 25, 2022, by and among Standard BioTools Inc. (formerly Fluidigm Corporation), Casdin Capital, LLC, and Viking Global Investors LP.

 

8-K

 

001-34180

 

10.1

 

3/28/2022

 

 

 

 

 

 

 

 

 

 

 

10.45

 

Letter Agreement, dated as of May 10, 2023, by and between Standard BioTools Inc. and Vikram Jog.

 

8-K

 

001-34180

 

10.3

 

5/15/2023

112

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

 

 

 

 

 

 

 

 

 

 

 

10.46

 

Support Agreement, dated as of March 29, 2022, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Caligan Partners LP and certain of its affiliates.

 

8-K

 

001-34180

 

10.1

 

3/29/2022

 

 

 

 

 

 

 

 

 

 

 

10.47#

 

Endorsement Split-Dollar Life Insurance Agreement, dated as of September 9, 2017, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Stephen Christopher Linthwaite.

 

10-Q

 

001-34180

 

10.5

 

11/7/2017

 

 

 

 

 

 

 

 

 

 

 

10.48#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) Executive Bonus Plan.

 

10-Q

 

001-34180

 

10.25

 

3/28/2011

 

 

 

 

 

 

 

 

 

 

 

10.49#

 

Form of Amended and Restated Employment and Severance Agreement entered into by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and each of its executive officers.

 

8-K

 

001-34180

 

10.14

 

12/11/2012

 

 

 

 

 

 

 

 

 

 

 

10.50#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) Form of Retention Letter.

 

8-K

 

001-34180

 

10.10

 

1/24/2022

 

 

 

 

 

 

 

 

 

 

 

10.51#

 

Michael Egholm Offer Letter.

 

8-K

 

001-34180

 

10.7

 

1/24/2022

 

 

 

 

 

 

 

 

 

 

 

10.52#

 

Hanjoon Alex Kim Offer Letter.

 

8-K

 

001-34180

 

10.9

 

1/24/2022

 

 

 

 

 

 

 

 

 

 

 

10.53#

 

Jeffery G. Black Offer Letter.

 

8-K

 

001-34180

 

10.1

 

5/15/2023

 

 

 

 

 

 

 

 

 

 

 

10.54#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) 2020 Change of Control and Severance Plan.

 

10-Q

 

001-34180

 

10.5

 

8/7/2020

 

 

 

 

 

 

 

 

 

 

 

10.55#

 

Standard BioTools Inc. 2020 Change of Control and Severance Plan Participation Agreement, dated as of May 10, 2023, by and between Standard BioTools Inc. and Jeffery G. Black.

 

8-K

 

001-34180

 

10.2

 

5/15/2023

 

 

 

 

 

 

 

 

 

 

 

10.56#

 

Standard BioTools Inc. 2023 Change of Control and Severance Plan.

 

8-K

 

001-34180

 

10.1

 

7/28/2023

 

 

 

 

 

 

 

 

 

 

 

10.57#

 

Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement, dated as of July 27, 2023, by and between Standard BioTools Inc. and Michael Egholm, Ph.D.

 

8-K

 

001-34180

 

10.2

 

7/28/2023

 

 

 

 

 

 

 

 

 

 

 

10.58#

 

Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement, dated as of July 24, 2023, by and between Standard BioTools Inc. and Hanjoon Alex Kim.

 

10-Q

 

001-34180

 

10.9

 

8/8/2023

 

 

 

 

 

 

 

 

 

 

 

10.59#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) 2009 Equity Incentive Plan, as amended.

 

S-1

 

333-170965

 

10.3

 

12/3/2010

 

 

 

 

 

 

 

 

 

 

 

10.60#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) 2009 Equity Incentive Plan Forms of Agreements.

 

S-1

 

333-170965

 

10.3A

 

12/3/2010

 

 

 

 

 

 

 

 

 

 

 

10.61#

 

Amendments to the Standard BioTools Inc. 2011 Equity Incentive Plan, the Standard BioTools Inc. (formerly Fluidigm Corporation) 2009 Equity Incentive Plan and the Standard BioTools Inc. (formerly DVS Sciences, Inc.) 2010 Equity Incentive Plan.

 

8-K

 

001-34180

 

10.2

 

8/2/2017

 

 

 

 

 

 

 

 

 

 

 

113

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

10.62#

 

Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan.

 

8-K

 

001-34180

 

10.1

 

1/5/2024

 

 

 

 

 

 

 

 

 

 

 

10.63#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan Forms of Agreements for U.S. Participants.

 

SC TO-I

 

005-86635

 

(d)(2)

 

8/23/2017

 

 

 

 

 

 

 

 

 

 

 

10.64#

 

Rules of the Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan for Restricted Stock Unit Awards Granted to French Participants.

 

SC TO-I

 

005-86635

 

(d)(3)

 

8/23/2017

 

 

 

 

 

 

 

 

 

 

 

10.65#

 

Rules of the Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan for Options Granted to French Participants.

 

SC TO-I

 

005-86635

 

(d)(4)

 

8/23/2017

 

 

 

 

 

 

 

 

 

 

 

10.66#

 

UK Sub-Plan to the Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan.

 

SC TO-I

 

005-86635

 

(d)(5)

 

8/23/20217

 

 

 

 

 

 

 

 

 

 

 

10.67#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan Form of Restricted Stock Unit Agreement for Non-U.S. Participants.

 

SC TO-I

 

005-86635

 

(d)(6)

 

8/23/2017

 

 

 

 

 

 

 

 

 

 

 

10.68#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan Form of Stock Option Agreement for Non-U.S. Participants.

 

SC TO-I

 

005-86635

 

(d)(7)

 

8/23/2017

 

 

 

 

 

 

 

 

 

 

 

10.69#

 

Standard BioTools Inc. 2011 Equity Incentive Plan Form of PSU Award Agreement.

 

8-K

 

001-34180

 

10.3

 

7/28/2023

 

 

 

 

 

 

 

 

 

 

 

10.70#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) 2017 Inducement Award Plan and Form of Agreements.

 

8-K

 

001-34180

 

10.1

 

1/11/2017

 

 

 

 

 

 

 

 

 

 

 

10.71#

 

Standard BioTools Inc. (formerly Fluidigm Corporation) Amended and Restated 2017 Employee Stock Purchase Plan.

 

8-K

 

001-34180

 

10.1

 

6/24/2020

 

 

 

 

 

 

 

 

 

 

 

10.72#

 

Standard BioTools Inc. 2022 Inducement Equity Incentive Plan.

 

S-8

 

333-264086

 

4.9

 

4/1/2022

 

 

 

 

 

 

 

 

 

 

 

10.73#

 

Standard BioTools Inc. 2022 Inducement Equity Incentive Plan Form of Notice of Stock Option Grant and Stock Option Agreement.

 

S-8

 

333-264086

 

99.1

 

4/1/2022

 

 

 

 

 

 

 

 

 

 

 

10.74#

 

Standard BioTools Inc. 2022 Inducement Equity Incentive Plan Form of Notice of Restricted Stock Unit Grant and Restricted Stock Unit Agreement.

 

S-8

 

333-264086

 

99.2

 

4/1/2022

 

 

 

 

 

 

 

 

 

 

 

10.75#

 

SomaLogic, Inc. 2009 Equity Incentive Plan.

 

S-4

 

333-256127

 

10.7

 

5/14/2021

 

 

 

 

 

 

 

 

 

 

 

10.76#

 

Form of Non-Statutory Stock Option Agreement under the SomaLogic, Inc. 2009 Equity Incentive Plan.

 

S-4

 

333-256127

 

10.8

 

5/14/2021

 

 

 

 

 

 

 

 

 

 

 

10.77#

 

Form of Incentive Stock Option Agreement under the SomaLogic, Inc. 2009 Equity Incentive Plan.

 

S-4

 

333-256127

 

10.9

 

5/14/2021

 

 

 

 

 

 

 

 

 

 

 

10.78#

 

SomaLogic, Inc. 2017 Equity Incentive Plan.

 

S-4

 

333-256127

 

10.10

 

5/14/2021

 

 

 

 

 

 

 

 

 

 

 

10.79#

 

Form of Option Agreement (Incentive Stock Option or Non-statutory Stock Option) under the SomaLogic, Inc. 2017 Equity Incentive Plan.

 

S-4

 

333-256127

 

10.11

 

5/14/2021

 

 

 

 

 

 

 

 

 

 

 

10.80#

 

SomaLogic, Inc. 2021 Omnibus Incentive Plan.

 

S-4/A

 

333-256127

 

10.1

 

8/5/2021

 

 

 

 

 

 

 

 

 

 

 

114

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

10.81#

 

SomaLogic, Inc. Employee Stock Purchase Plan.

 

S-4/A

 

333-256127

 

10.2

 

8/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.82#

 

Form of Stock Appreciation Rights Agreement pursuant to the SomaLogic, Inc. 2021 Omnibus Incentive Plan.

 

S-4/A

 

333-256127

 

10.3

 

6/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.83#

 

Form of Incentive Stock Option Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan.

 

S-4/A

 

333-256127

 

10.4

 

6/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.84#

 

Form of Restricted Stock Unit Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan.

 

S-4/A

 

333-256127

 

10.5

 

6/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.85#

 

Form of Restricted Stock Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan.

 

S-4/A

 

333-256127

 

10.6

 

6/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.86#

 

Form of Non-Qualified Stock Option Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan.

 

S-4/A

 

333-256127

 

10.7

 

6/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.87

 

Third Amendment to Collaboration Agreement, dated September 21, 2023, by and among SomaLogic, Inc., Illumina Cambridge, Ltd., and Illumina, Inc.

 

10-Q

 

001-40090

 

10.1

 

11/8/2023

 

 

 

 

 

 

 

 

 

 

 

10.88

 

Second Amendment to Collaboration Agreement, dated June 15, 2023, by and among SomaLogic, Inc., Illumina Cambridge, Ltd., and Illumina Inc.

 

10-Q

 

001-40090

 

10.4

 

8/14/2023

 

 

 

 

 

 

 

 

 

 

 

10.89

 

First Amendment to Collaboration Agreement, dated November 14, 2022, by and among SomaLogic, Inc., Illumina Cambridge, Ltd. and Illumina, Inc.

 

10-K

 

001-39796

 

10.38

 

3/28/2023

 

 

 

 

 

 

 

 

 

 

 

10.90† ††

 

Collaboration Agreement, dated December 31, 2021, by and among SomaLogic, Inc., Illumina Cambridge, Ltd. and Illumina, Inc.

 

10-K

 

001-40090

 

10.36

 

3/29/2022

 

 

 

 

 

 

 

 

 

 

 

10.91†

 

Amendment No. 2 to Master Collaboration Agreement, dated as of January 4, 2023, by and between SomaLogic Operating Co., Inc. and Novartis Pharma AG.

 

8-K

 

001-40090

 

10.1

 

1/10/2023

 

 

 

 

 

 

 

 

 

 

 

10.92†

 

Master Collaboration Agreement, dated September 20, 2019, by and between SomaLogic, Inc. and Novartis Pharma AG.

 

S-4/A

 

001-39796

 

10.33

 

6/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.93†

 

Amended and Restated Master SomaScan Discovery Services Agreement, dated October 13, 2020, by and between SomaLogic, Inc. and Amgen Inc.

 

S-4/A

 

001-39796

 

10.34

 

6/5/2021

 

 

 

 

 

 

 

 

 

 

 

10.94

 

Second Amendment to Supply Agreement, dated April 11, 2023, by and between SomaLogic, Inc. and Agilent Technologies, Inc.

 

10-Q

 

001-40090

 

10.1

 

8/14/2023

 

 

 

 

 

 

 

 

 

 

 

10.95†

 

Supply Agreement, dated April 8, 2019, by and between SomaLogic, Inc. and Agilent Technologies, Inc., as amended by that certain First Amendment to Supply Agreement, dated October 1, 2021, by and between SomaLogic, Inc. and Agilent Technologies, Inc.

 

10-K

 

001-40090

 

10.34

 

3/29/2022

 

 

 

 

 

 

 

 

 

 

 

10.96#

 

Standard BioTools Inc. Amended and Restated Outside Director Equity Compensation Policy.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

115

 

Exhibit

Number

 

Description

 

Incorporated

by Reference

From Form

 

File Number

 

Incorporated

by Reference

From Exhibit

Number

 

Date Filed

21.1

 

Subsidiaries of Standard BioTools Inc.

 

Filed herewith

 

 

 

 

 

 

23.1

 

Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24.1

 

Power of Attorney (contained in the signature page to this Form 10-K).

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of Chief Executive Officer.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of Chief Financial Officer.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

32.1~

 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Chief Executive Officer.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

32.2~

 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Chief Financial Officer.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

97.1#

 

Standard BioTools Inc. Clawback Policy.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

Filed herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

# Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.

† Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv) or pursuant to an order granted by the Securities and Exchange Commission for confidential treatment.

†† The schedules and exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K.

~ In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that Standard BioTools Inc. specifically incorporates it by reference.


 

116

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

STANDARD BIOTOOLS INC.

 

 

 

Dated: March 1, 2024

By:

 

/s/ Michael Egholm, Ph.D.

 

 

 

Michael Egholm, Ph.D.

 

 

 

President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Egholm and Jeffrey Black, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/Michael Egholm, Ph.D.

 

President and Chief Executive Officer (Principal Executive Officer); Director

 

March 1, 2024

Michael Egholm, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Jeffrey Black

 

Chief Financial Officer (Principal Financial and Accounting Officer)

 

March 1, 2024

Jeffrey Black

 

 

 

 

 

 

 

 

 

/s/ Tom Carey

 

Chairman of the Board of Directors

 

March 1, 2024

Tom Carey

 

 

 

 

 

 

 

 

 

/s/ Fenel M. Eloi

 

Director

 

March 1, 2024

Fenel M. Eloi

 

 

 

 

 

 

 

 

 

/s/ Eli Casdin

 

Director

 

March 1, 2024

Eli Casdin

 

 

 

 

 

 

 

 

 

/s/ Kathy Hibbs

 

Director

 

March 1, 2024

Kathy Hibbs

 

 

 

 

 

 

 

 

 

/s/ Troy Cox

 

Director

 

March 1, 2024

Troy Cox

 

 

 

 

 

 

 

 

 

/s/ Frank Witney, Ph.D.

 

Director

 

March 1, 2024

Frank Witney, Ph.D.

 

 

 

 

 

 

 EX-4.2 2 lab-ex4_2.htm EX-4.2 EX-4.2

Exhibit 4.2

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

As of December 31, 2023, Standard BioTools, Inc. (“Standard BioTools,” “we,” “us,” “our,” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common stock, par value $0.001 per share (the “Standard BioTools Common Stock”).

Description of Common Stock

The following description of the Standard BioTools Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended (the “Standard BioTools Charter”), and the Company’s Amended and Restated Bylaws (the “Standard BioTools Bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.2 is a part. The Company encourages you to read the Standard BioTools Charter, Standard BioTools Bylaws, and the applicable provisions of the Delaware General Corporation Law, for additional information.

Authorized Capital Stock

The Standard BioTools authorized capital stock consists of 600,000,000 shares of Standard BioTools Common Stock and 10,000,000 shares of Standard BioTools’ Series B-1 preferred stock, par value $0.001 per share (the “Series B-1 Preferred Stock”), and Standard BioTools’ Series B-2 preferred stock, par value $0.001 per share (the “Series B-2 Preferred Stock,” and together with the Series B-1 Preferred Stock, the “Series B Preferred Stock”). Out of the Series B Preferred Stock, as of February 21, 2024, 128,267 shares have been designated Series B-1 Preferred Stock and 128,267 shares have been designated Series B-2 Preferred Stock. As of February 21, 2024, there were 290,117,930 shares of Standard BioTools Common Stock outstanding, 127,780 shares of Series B-1 Preferred Stock outstanding and 127,779 shares of Series B-2 Preferred Stock outstanding.

Common Stock

The holders of Standard BioTools Common Stock are entitled to one vote per share on all matters to be voted on by the Standard BioTools stockholders. Subject to preferences that may be applicable to any outstanding shares of Series B Preferred Stock, holders of Standard BioTools Common Stock are entitled to receive ratably such dividends as may be declared by the Board of Directors of the Company (the “Standard BioTools Board”) out of funds legally available for that purpose. In the event of the liquidation, dissolution or winding up of Standard BioTools, the holders of Standard BioTools Common Stock are entitled to share ratably in all assets remaining after the payment of liabilities, subject to the prior distribution rights of Series B Preferred Stock then outstanding. Except as otherwise described below in the section entitled “Preemptive Rights; Standstill; Transfer Restrictions,” holders of Standard BioTools Common Stock have no preemptive, conversion or subscription rights. There are no redemption or sinking fund provisions applicable to the Standard BioTools Common Stock.

Voting Rights

Holders of Standard BioTools Common Stock are entitled to one vote for each share held by such holder on any matter submitted to a vote at a meeting of stockholders. In addition, the Standard BioTools Charter provides that certain corporate actions require the approval of the Standard BioTools stockholders. These actions, and the vote required, are as follows:

•
the removal of a director requires the vote of a majority of the voting power of the issued and outstanding capital stock entitled to vote in the election of directors; and
•
the amendment of provisions of the Standard BioTools Charter relating to blank check preferred stock, the classification of the Standard BioTools Board, the removal of directors, the filling of vacancies on the Standard BioTools Board, cumulative voting, procedures for annual and special meetings of the stockholders, action by written consent of stockholders and procedures for the amendment of the Standard BioTools Charter require the vote of 66 2/3% of the Standard BioTools then outstanding voting securities.

 

 

Preferred Stock

The Standard BioTools Board has the authority, without further action by the Standard BioTools stockholders, to designate and issue the preferred stock in one or more series. The Standard BioTools Board may also fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions, of each such series of the Series B Preferred Stock, any or all of which may be greater than or senior to those of the Standard BioTools Common Stock. Though the actual effect of any such issuance on the rights of the holders of Standard BioTools Common Stock will not be known until the Standard BioTools Board determines the specific rights of the holders of Preferred Stock, the potential effects of such an issuance include:

•
diluting the voting power of the holders of Standard BioTools Common Stock;
•
reducing the likelihood that holders of Standard BioTools Common Stock will receive dividend payments;
•
reducing the likelihood that holders of Standard BioTools Common Stock will receive payments in the event of a liquidation, dissolution, or winding up; and
•
delaying, deterring or preventing a change-in-control or other corporate takeover.

Series B-1 Preferred Stock

The following is a summary of the principal terms of the Series B-1 Preferred Stock.

The powers, preferences and rights, and the qualifications, limitations or restrictions of the Series B-1 Preferred Stock are set forth in the Certificate of Designations of Rights, Preferences and Privileges of Series B-1 Convertible Preferred Stock, Par Value $0.001, of Standard BioTools Inc., dated April 1, 2022 (the “Series B-1 Certificate of Designations”).

The Series B-1 Preferred Stock ranks senior to the Standard BioTools Common Stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of Standard BioTools.

Dividend Rights

The holders of Series B-1 Preferred Stock are entitled to participate in all dividends declared on the Standard BioTools Common Stock on an as-converted basis, on the terms and subject to the conditions set forth in the Series B-1 Certificate of Designations.

Liquidation Rights

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of Standard BioTools, the Series B-1 Preferred Stock has a liquidation preference equal to the greater of (i) the Liquidation Preference (as defined in the Series B-1 Certificate of Designations) and (ii) the amount per share of Series B-1 Preferred Stock that such holder would have received had all holders of Series B Preferred Stock, immediately prior to such voluntary or involuntary liquidation, dissolution or winding up of the affairs of Standard BioTools, converted all shares of Series B Preferred Stock into Standard BioTools Common Stock pursuant to the terms of the Certificate of Designations, as applicable (without regard to any limitations on conversion contained therein).

Conversion and Redemption Rights

Subject to certain limitations contained in the Series B-1 Certificate of Designations, the Series B-1 Preferred Stock is convertible at the option of the holders thereof at any time into a number of shares of Standard BioTools Common Stock equal to the Conversion Rate (as defined in the Series B-1 Certificate of Designations).

At any time after the fifth anniversary of the Original Issuance Date, if the Last Reported Sale Price of the Standard BioTools Common Stock is greater than the Mandatory Conversion Price for at least twenty consecutive Trading Days immediately preceding the date of the Notice of Mandatory Conversion (as such terms are defined in the Series B-1 Certificate of Designations), Standard BioTools may elect to convert all of the outstanding shares of Series B Preferred Stock into shares of Standard BioTools Common Stock at the Conversion Rate.

If Standard BioTools undergoes certain change of control transactions, each holder of outstanding Series B-1 Preferred Stock will have the option, subject to the holder’s right to convert all or a portion of the shares of Series B-1 Preferred Stock held by such holder into Standard BioTools Common Stock prior to such redemption, to require

2

 

Standard BioTools to purchase all or a portion of such holder’s outstanding shares of Series B-1 Preferred Stock that have not been converted into Standard BioTools Common Stock at a purchase price per share of Series B-1 Preferred Stock, payable in cash, equal to the greater of (A) the Liquidation Preference of such share of Series B-1 Preferred Stock, and (B) the amount of cash and/or other assets that such holder would have been entitled to receive if such holder had converted such share of Series B-1 Preferred Stock into Standard BioTools Common Stock immediately prior to the change of control transaction (“B-1 Change of Control Put”). In the event of a change of control in which Standard BioTools is anticipated to merge with another person and will not be the surviving corporation or if the Standard BioTools Common Stock will no longer be listed on a U.S. national securities exchange, Standard BioTools will have a right to redeem, subject to the holder’s right to convert into Standard BioTools Common Stock prior to such redemption, all of such holder’s shares of Series B-1 Preferred Stock, or if a holder exercises the B-1 Change of Control Put in part, the remainder of such holder’s shares of Series B-1 Preferred Stock, at a redemption price per share payable in cash, equal to the greater of (A) the Liquidation Preference of such share of Series B-1 Preferred Stock, and (B) the amount of cash and/or other assets that the holder would have received if such holder had converted such share of Series B-1 Preferred Stock into Standard BioTools Common Stock immediately prior to the change of control transaction.

After the seventh anniversary of the Original Issuance Date (as defined in the Series B-1 Certificate of Designations), subject to certain conditions, Standard BioTools may, at its option, redeem all of the outstanding shares of Series B-1 Preferred Stock at a redemption price per share of Series B Preferred Stock, payable in cash, equal to the Liquidation Preference.

Voting Rights; Consent Rights

The holders of shares of Series B-1 Preferred Stock have voting power measured in a manner related to the conversion ratio of the shares of Series B-1 Preferred Stock and are entitled to vote as a single class with the holders of the Standard BioTools Common Stock and the holders of any other class or series of equity interest of Standard BioTools then entitled to vote with the Standard BioTools Common Stock on all matters submitted to a vote of the holders of Standard BioTools Common Stock; provided, among other things, that to the extent the Series B-1 Preferred Stock held by the Casdin Parties (as defined in the Series B-1 Certificate of Designations) would, in the aggregate, represent voting rights with respect to more than 19.9% of the Standard BioTools Common Stock (including the Series B-1 Preferred Stock on an as-converted basis, but excluding the Series B-2 Preferred Stock) (the “B-1 Voting Threshold”), the Casdin Parties will not be permitted to exercise the voting rights with respect to any shares of Series B-1 Preferred Stock, as applicable, held by them in excess of the B-1 Voting Threshold and the Chief Financial Officer or General Counsel of Standard BioTools, each with full power of substitution and re-substitution, shall exercise the voting rights with respect to such shares of Series B-1 Preferred Stock in excess of the B-1 Voting Threshold in the same proportion as the outstanding Standard BioTools Common Stock (excluding any and all Standard BioTools Common Stock beneficially owned by the Casdin Parties and the Viking Parties (each as defined in the Series B-1 Certificate of Designations)) is voted on relevant matters.

The Series B-1 Certificate of Designations also provides that the holders of shares of the Series B-1 Preferred Stock have separate class approval rights over certain specified actions that would affect the rights of holders of the Series B-1 Preferred Stock and other specified matters. Specifically, the vote or written approval of the holders of at least 60% of the shares of Series B Preferred Stock outstanding at such time, voting or providing such approval together as a single class, and for the avoidance of doubt, without giving effect to limitations associated with the B-1 Voting Threshold, is generally required for the taking of the following actions: (i) any amendment to the Standard BioTools Charter to create any new series of securities of Standard BioTools with rights ranking senior to or on parity with the Series B-1 Preferred Stock or the Series B-2 Preferred Stock; (ii) the declaration or payment of any dividend or distribution on Standard BioTools’ capital stock; (iii) the purchase, redemption, or other acquisition of any Standard BioTools Common Stock or other capital stock of Standard BioTools ranking junior to the Series B-1 Preferred Stock, subject to certain exceptions; (iv) any amendment to the rights, powers, preferences, privileges or voting powers of the Series B-1 Preferred Stock or the Series B-2 Preferred Stock; and (v) any amendment to the Standard BioTools Charter or Standard BioTools Bylaws that would have an adverse effect on the rights, preferences, privileges, or voting power of the Series B-1 Preferred Stock.

In addition, for so long as Casdin Capital, LLC (“Casdin”) and its Permitted Transferees (as defined in the Series B-1 Certificate of Designations) continue to beneficially own shares of Series B-1 Preferred Stock that represent at least 7.5% of the outstanding shares of Standard BioTools Common Stock, on an as converted basis (the “Casdin Ownership Percentage”), on the terms and subject to the conditions set forth in the Series B-1 Certificate of

3

 

Designations, the holders of a majority of the outstanding shares of Series B-1 Preferred Stock will have the right to nominate for election and to elect one member to the Standard BioTools Board (the “Series B-1 Preferred Director”). Subject to applicable law and The Nasdaq Stock Market listing standards, the Series B-1 Preferred Director shall be offered the opportunity, with respect to each standing committee of the Standard BioTools Board, to sit on such committee. Further, the Series B-1 Preferred Director will hold office until the following year’s annual meeting of Standard BioTools’ stockholders and until his or her successor is duly elected or qualified or until his or her earlier death, resignation or removal. For purposes of clarity, the Series B-1 Preferred Director shall not be classified with the remaining members of the Board of Directors.

The Series B-1 Certificate of Designations also provides that for so long as the Casdin Ownership Percentage continues to be met or exceeded for the Series B-1 Preferred Stock, the Series B-1 Preferred Director will have certain consent rights over, among other things: (i) any increase in the number of directors on the Standard BioTools Board beyond seven; (ii) the hiring, promotion, demotion, or termination of Standard BioTools’ Chief Executive Officer; (iii) entering into or modifying (including by waiver) any transaction, agreement or arrangement with any Related Person (as such term is defined in the Certificates of Designations), subject to certain exceptions; (iv) any voluntary petition under any applicable federal or state bankruptcy or insolvency law effected by Standard BioTools or any of its subsidiaries; (v) any change in the principal business of Standard BioTools or entry by Standard BioTools into any material new line of business; and (vi) for a period of three years after the Original Issuance Date (as defined in the Series B-1 Certificate of Designations) or such shorter period ending immediately when the Series B-1 Preferred Stock percentage is less than 7.5%, (A) any acquisition (including by merger, consolidation or acquisition of stock or assets) of any assets, securities or property of any other person or (B) any sale, lease, license, transfer or other disposition of any assets of Standard BioTools or any of its subsidiaries, in each case, other than acquisitions or disposition of inventory or equipment in the ordinary course of business consistent with past practice, for consideration in excess of $50,000,000 in the aggregate in any six month period.

Series B-2 Preferred Stock

The following is a summary of the principal terms of the Series B-2 Preferred Stock.

The powers, preferences and rights, and the qualifications, limitations or restrictions of the Series B-2 Preferred Stock are set forth in the B-2 Certificate of Designations of Rights, Preferences and Privileges of Series B-2 Convertible Preferred Stock, Par Value $0.001, of Standard BioTools Inc., dated April 1, 2022 (the “Series B-2 Certificate of Designations”).

The Series B-2 Preferred Stock ranks senior to the Standard BioTools Common Stock, with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of Standard BioTools.

Dividend Rights

The holders of Series B-2 Preferred Stock are entitled to participate in all dividends declared on the Standard BioTools Common Stock on an as-converted basis, on the terms and subject to the conditions set forth in the Series B-2 Certificate of Designations.

Liquidation Rights

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of Standard BioTools, the Series B-2 Preferred Stock has a liquidation preference equal to the greater of (i) the Liquidation Preference (as defined in the Series B-2 Certificate of Designations) and (ii) the amount per share of Series B-2 Preferred Stock that such holder would have received had all holders of Series B Preferred Stock, immediately prior to such voluntary or involuntary liquidation, dissolution or winding up of the affairs of Standard BioTools, converted all shares of Series B Preferred Stock into Standard BioTools Common Stock pursuant to the terms of the Certificates of Designations, as applicable (without regard to any limitations on conversion contained therein).

Conversion and Redemption Rights

Subject to certain limitations contained in the Series B-2 Certificate of Designations, the Series B-2 Preferred Stock is convertible at the option of the holders thereof at any time into a number of shares of Standard BioTools Common Stock equal to the Conversion Rate (as defined in the Series B-2 Certificate of Designations), in each case subject to certain adjustments, provided that Viking Global Investors LP (“Viking”) and its affiliates shall not be permitted to voluntarily convert shares of its Series B-2 Preferred Stock if, as a result of such conversion, Viking,

4

 

together with its affiliates, would beneficially own more than 9.5% of the total number of shares of Standard BioTools Common Stock issued and outstanding after giving effect to such conversion (the “Cap”).

At any time after the fifth anniversary of the Original Issuance Date, if the Last Reported Sale Price of the Standard BioTools Common Stock is greater than the Mandatory Conversion Price for at least twenty consecutive Trading Days immediately preceding the date of the Notice of Mandatory Conversion (as such terms are defined in the Series B-2 Certificate of Designations), Standard BioTools may elect to convert all of the outstanding shares of Series B Preferred Stock into shares of Standard BioTools Common Stock at the Conversion Rate.

If Standard BioTools undergoes certain change of control transactions, each holder of outstanding Series B-2 Preferred Stock will have the option, subject to the holder’s right to convert all or a portion of the shares of Series B-2 Preferred Stock held by such holder into Standard BioTools Common Stock prior to such redemption, to require Standard BioTools to purchase all or a portion of such holder’s outstanding shares of Series B-2 Preferred Stock that have not been converted into Standard BioTools Common Stock at a purchase price per share of Series B-2 Preferred Stock, payable in cash, equal to the greater of (A) the Liquidation Preference of such share of Series B-2 Preferred Stock, and (B) the amount of cash and/or other assets that such holder would have been entitled to receive if such holder had converted such share of Series B-2 Preferred Stock into Standard BioTools Common Stock immediately prior to the change of control transaction (“B-2 Change of Control Put”). In the event of a change of control in which Standard BioTools is anticipated to merge with another person and will not be the surviving corporation or if the Standard BioTools Common Stock will no longer be listed on a U.S. national securities exchange, Standard BioTools will have a right to redeem, subject to the holder’s right to convert into Standard BioTools Common Stock prior to such redemption, all of such holder’s shares of Series B-2 Preferred Stock, or if a holder exercises the B-2 Change of Control Put in part, the remainder of such holder’s shares of Series B-2 Preferred Stock, at a redemption price per share payable in cash, equal to the greater of (A) the Liquidation Preference of such share of Series B-2 Preferred Stock, and (B) the amount of cash and/or other property that the holder would have received if such holder had converted such share of Series B-2 Preferred Stock into Standard BioTools Common Stock immediately prior to the change of control transaction.

After the seventh anniversary of the Original Issuance Date (as defined in the Series B-2 Certificate of Designations), subject to certain conditions, Standard BioTools may, at its option, redeem all of the outstanding shares of Series B Preferred Stock at a redemption price per share of Series B Preferred Stock, payable in cash, equal to the Liquidation Preference.

Voting Rights; Consent Rights

The holders of shares of Series B-2 Preferred Stock have voting power measured in a manner related to the conversion ratio of the shares of Series B-2 Preferred Stock and are entitled to vote as a single class with the holders of the Standard BioTools Common Stock and the holders of any other class or series of equity interest of Standard BioTools then entitled to vote with the Standard BioTools Common Stock on all matters submitted to a vote of the holders of Standard BioTools Common Stock; provided, among other things, that to the extent the Series B-2 Preferred Stock held by the Viking Parties (as defined in the Series B-2 Certificate of Designations) would, in the aggregate, represent voting rights with respect to more than 19.9% of the Standard BioTools Common Stock (including the Series B-2 Preferred Stock on an as-converted basis, but excluding the Series B-1 Preferred Stock) (the “B-2 Voting Threshold”), the Viking Parties will not be permitted to exercise the voting rights with respect to any shares of Series B-2 Preferred Stock, as applicable, held by them in excess of the B-2 Voting Threshold and the Chief Financial Officer or General Counsel of Standard BioTools, each with full power of substitution and re-substitution, shall exercise the voting rights with respect to such shares of Series B-2 Preferred Stock in excess of the B-2 Voting Threshold in the same proportion as the outstanding Standard BioTools Common Stock (excluding any and all Standard BioTools Common Stock beneficially owned by the Casdin Parties and the Viking Parties (each as defined in the Series B-2 Certificate of Designations)) is voted on relevant matters.

The Series B-2 Certificate of Designations also provides that the holders of shares of the Series B-2 Preferred Stock will have separate class approval rights over certain specified actions that would affect the rights of holders of the Series B-2 Preferred Stock and other specified matters. Specifically, the vote or written approval of the holders of at least 60% of the shares of Series B Preferred Stock outstanding at such time, voting or providing such approval together as a single class, and for the avoidance of doubt, without giving effect to limitations associated with the Cap or the B-2 Voting Threshold, is generally required for the taking of the following actions: (i) any amendment to the Standard BioTools Charter to create any new series of securities of Standard BioTools with rights ranking senior to or on parity with the Series B-1 Preferred Stock or the Series B-2 Preferred Stock; (ii) the declaration or payment of

5

 

any dividend or distribution on Standard BioTools’ capital stock; (iii) the purchase, redemption, or other acquisition of any Standard BioTools Common Stock or other capital stock of Standard BioTools ranking junior to the Series B-2 Preferred Stock, subject to certain exceptions; (iv) any amendment to the rights, powers, preferences, privileges or voting powers of the Series B-1 Preferred Stock or the Series B-2 Preferred Stock; and (v) any amendment to the Standard BioTools Charter or Standard BioTools Bylaws that would have an adverse effect on the rights, preferences, privileges, or voting power of the Series B-2 Preferred Stock.

In addition, for so long as Viking and its Permitted Transferees (as defined in the Series B-2 Certificate of Designations) continue to beneficially own shares of Series B-2 Preferred Stock that represent at least 7.5% of the outstanding shares of Standard BioTools Common Stock, on an as converted basis (the “Viking Ownership Percentage”), on the terms and subject to the conditions set forth in the Series B-2 Certificate of Designations, the holders of a majority of the outstanding shares of Series B-2 Preferred Stock, voting separately as a single class, and for the avoidance of doubt, without giving effect to limitations associated with the Cap or the B-2 Voting Threshold, will each have the right to nominate for election and to elect one member to the Standard BioTools Board (the “Series B-2 Preferred Director”). Subject to applicable law and The Nasdaq Stock Market listing standards, the Series B-2 Preferred Director shall be offered the opportunity, with respect to each standing committee of the Standard BioTools Board, to sit on such committee. The Series B-2 Preferred Director will hold office until the following year’s annual meeting of Standard BioTools’ stockholders and until his or her successor is duly elected or qualified or until his or her earlier death, resignation or removal. For purposes of clarity, the Series B-2 Preferred Director shall not be classified with the remaining members of the Standard BioTools Board.

The Series B-2 Certificate of Designations also provides that for so long as the Viking Ownership Percentage continues to be met or exceeded for the Series B-2 Preferred Stock, the Series B-2 Preferred Director will have certain consent rights over, among other things: (i) any increase in the number of directors on the Standard BioTools Board beyond seven; (ii) the hiring, promotion, demotion, or termination of Standard BioTools’ Chief Executive Officer; (iii) entering into or modifying (including by waiver) any transaction, agreement or arrangement with any Related Person (as such term is defined in the Certificates of Designations), subject to certain exceptions; (iv) any voluntary petition under any applicable federal or state bankruptcy or insolvency law effected by Standard BioTools or any of its subsidiaries; (v) any change in the principal business of Standard BioTools or entry by Standard BioTools into any material new line of business; and (vi) for a period of three years after the Original Issuance Date (as defined in the Series B-2 Certificate of Designations) or such shorter period ending immediately when the Series B-2 Preferred Stock percentage is less than 7.5%, (A) any acquisition (including by merger, consolidation or acquisition of stock or assets) of any assets, securities or property of any other person or (B) any sale, lease, license, transfer or other disposition of any assets of Standard BioTools or any of its subsidiaries, in each case, other than acquisitions or disposition of inventory or equipment in the ordinary course of business consistent with past practice, for consideration in excess of $50,000,000 in the aggregate in any six month period.

Registration Rights Agreement

On January 23, 2022, Standard BioTools entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P, Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP (collectively, the “Purchasers”), pursuant to which the Purchasers have certain customary registration rights with respect to shares issuable under (i) a Loan Agreement, dated and effective as of January 23, 2022, among the lenders party thereto affiliated with Casdin Private Growth Equity Fund II, L.P. and the Company, (ii) a Loan Agreement, dated and effective as of January 23, 2022, among the lenders party thereto affiliated with Viking and the Company, and (iii) separate Series B Convertible Preferred Stock Purchase Agreements, dated and effective as of January 23, 2022 (together, the “Purchase Agreements”) with each of the Purchasers, including (a) any shares of Standard BioTools Common Stock acquired by any Holder (as defined in the Registration Rights Agreement) pursuant to the conversion of the Series B Preferred Stock in accordance with the Certificates of Designations and (b) any shares of Standard BioTools Common Stock acquired by any Holder pursuant to preemptive rights under the Purchase Agreements.

Following the closing of the merger with SomaLogic, Inc. (“SomaLogic”) on January 5, 2024, Standard BioTools assumed certain registrations rights previously granted by SomaLogic, including (i) those certain resale registration and piggyback registration obligations under that certain Amended and Restated Registration Rights Agreement, dated as of September 1, 2021 and (ii) those certain registration obligations under that certain Agreement and Plan of Merger,

6

 

dated as of July 25, 2022, by and among SomaLogic, Panther Merger Subsidiary I, LLC, Panther Merger Subsidiary II, LLC, Palamedrix Inc., and Shareholders Representative Services, LLC, as the securityholder representative.

Preemptive Rights; Standstill; Transfer Restrictions

Pursuant to the Purchase Agreements, and subject to customary exceptions, if Standard BioTools intends to issue or sell new equity securities, then each of the Purchaser Parties (as defined in the Purchase Agreements) have the right to participate in such equity offering on a pro rata basis for so long as such Purchaser Parties (as defined under each of their applicable Purchase Agreements), collectively, continue to beneficially own at least 25% of the Acquired Shares (as defined in each of the Purchase Agreements) (including Underlying Shares (as defined in each of the Purchase Agreements) issued on conversion of such Acquired Shares). Pursuant to the Purchase Agreements, until the later of (x) the first anniversary of April 4, 2022 and (y) such time as such Purchaser beneficially owns securities representing less than 7.5% of the outstanding shares of Standard BioTools Common Stock (on an as-converted basis), each selling securityholder is subject to customary standstill restrictions. The selling securityholders are prohibited under the Purchase Agreements from transferring any shares of Series B Preferred Stock and any shares of Standard BioTools Common Stock issued or issuable upon conversion of such shares of Series B Preferred Stock to certain purchasers who may be activists, competitors, or other significant holders, with certain exceptions.

Anti-Takeover Effects of Delaware Law and the Standard BioTools Charter and Standard BioTools Bylaws

Certain provisions of Delaware law and the Standard BioTools Charter and Standard BioTools Bylaws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of Standard BioTools. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed in part to encourage anyone seeking to acquire control of us to first negotiate with the Board. We believe that the advantages gained by protecting the ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of the Standard BioTools Common Stock, because, among other reasons, the negotiation of such proposals could improve their terms.

Standard BioTools Charter and Standard BioTools Bylaws

The Standard BioTools Charter and Standard BioTools Bylaws include provisions that:

•
authorize the Standard BioTools Board to issue, without further action by the stockholders, additional shares of undesignated preferred stock;
•
require that any action to be taken by the stockholders be effected at a duly called annual or special meeting and not by written consent;
•
specify that special meetings of the stockholders can be called only by the Standard BioTools Board, the Chairperson of the Standard BioTools Board, the Secretary, the Chief Executive Officer or the President;
•
establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of the stockholders and an advance notice procedure for nominations of persons for election to the Standard BioTools Board at any stockholder meeting;
•
provide that directors may be removed only for cause; provided that, pursuant to the Certificates of Designations, the Series B-1 Director (as defined in the Series B-1 Certificate of Designations) and the Series B-2 Director (as defined in the Series B-2 Certificate of Designations) may only be removed by the holders of the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, respectively;
•
provide that (i) vacancies on the Standard BioTools Board resulting from one or more directors resignations from the Standard BioTools Board may be filled by a majority of directors then in office, including those who have so resigned; and (ii) vacancies on the Standard BioTools Board resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class may be filled only by a majority of the directors then in office, even though less than a quorum, or by a sole remaining director; provided that, pursuant to the Certificates of Designations, vacancies in directorships provided for the Series B-1 Director and the Series B-2 Director may be filled by a majority of the directors in office from time to time, but shall solely be filled with the approval of the holders of a majority of the outstanding shares of the Series B-1 Preferred Stock and Series B-2 Preferred Stock, respectively, voting as a single class;

7

 

•
subject to the rights of holders of any outstanding Preferred Stock, establish that the Standard BioTools Board is divided into three classes, Class I, Class II, and Class III, with each class serving staggered terms;
•
specify that no stockholder is permitted to cumulate votes at any election of the Standard BioTools Board; and
•
require the affirmative vote of a majority of the Standard BioTools Board and at least 66 2∕3% of the total voting power of outstanding voting securities, voting together as a single class, to amend the above-mentioned provisions.

Delaware Anti-Takeover Statute

We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers (“Section 203”). In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless:

•
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
•
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not for determining the outstanding voting stock owned by the interested stockholder, (i) voting stock owned by persons who are directors and also officers, and (ii) voting stock owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
•
at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2∕3% of the outstanding voting stock which is not owned by the interested stockholder.

Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with its affiliates and associates, owns, or is an affiliate or associate of the corporation and within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions the Standard BioTools Board does not approve in advance. We also anticipate that Section 203 may discourage business combinations or other attempts that might result in a premium over the market price for the shares of Standard BioTools Common Stock held by the stockholders.

The provisions of Delaware law and the Standard BioTools Charter and Standard BioTools Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of the Standard BioTools Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the Standard BioTools management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.

Transfer Agent and Registrar

The transfer agent and registrar for the Standard BioTools Common Stock is Computershare Trust Company, N.A. The transfer agent’s address is 462 South 4th Street, Suite 1600, Louisville, KY 40202, and its telephone number is (800) 662-7232 or (781) 575-2879.

Nasdaq Global Select Market Listing

The Standard BioTools Common Stock is traded on The Nasdaq Global Select Market under the trading symbol “LAB.”

 

8

 EX-10.2 3 lab-ex10_2.htm EX-10.2 EX-10.2

Exhibit 10.2

STANDARD BIOTOOLS INC. INDEMNIFICATION AGREEMENT

This Indemnification Agreement (“Agreement”) is made as of _______, 2024 by and between Standard BioTools Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).

 

WHEREAS, the Company and Indemnitee recognize the significant cost of directors’ and officers’ liability insurance and the general reductions in the coverage of such insurance;

 

 

WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve as officers and directors of the Company and to indemnify its officers and directors so as to provide them with the maximum protection permitted by law.

 

NOW, THEREFORE, in consideration for Indemnitee’s services as an officer or director of the Company, the Company and Indemnitee hereby agree as follows:

 

1.
Definitions.

 

(a)
A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

 

(i)
Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company’s then outstanding securities;

 

(ii)
Change in Board Composition. During any period of two consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Company’s board of directors, and any new directors (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 1(a)(i), 1(a)(iii) or 1(a)(iv)) whose election by the board of directors or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Company’s board of directors;

 

(iii)
Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;

 

(iv)
Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and

 

(v)
Other Events. Any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended, whether or not the Company is then subject to such reporting requirement.

 

For purposes of this Section 1(a), the following terms shall have the following meanings:

 

(1)
“Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended; provided, however, that “Person” shall exclude

(i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

(2)
“Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Securities Exchange Act of 1934, as amended; provided, however, that “Beneficial Owner” shall exclude any Person otherwise becoming a Beneficial Owner by reason of (i) the stockholders of the Company approving a merger of the Company with another entity or (ii) the Company’s board of directors approving a sale of securities by the Company to such Person.

 

(b)
“Corporate Status” describes the status of a person who is or was a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise.

 

(c)
“DGCL” means the General Corporation Law of the State of Delaware.

 

(d)
“Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

 

(e)
“Enterprise” means the Company and any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary.

 

(f)
“Expenses” include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees and costs of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also include

(i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond or other appeal bond or their equivalent, and (ii) for purposes of Section 12(d), Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

(g)
“Independent Counsel” means a law firm, or a partner or member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent (i) the Company or Indemnitee in any matter material to either such party (other than as Independent Counsel with respect to matters concerning Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict
of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement.

 

(h)
“Proceeding” means any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, including any appeal therefrom and including without limitation any such Proceeding pending as of the date of this Agreement, in which Indemnitee was, is or will be involved as a party, a potential party, a non-party witness or otherwise by reason of (i) the fact that Indemnitee is or was a director or officer of the Company, (ii) any action taken by Indemnitee or any action or inaction on Indemnitee’s part while acting as a director or officer of the Company, or (iii) the fact that he or she is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification or advancement of expenses can be provided under this Agreement.

 

(i)
Reference to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

2.
Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 2 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 2, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful.

 

3.
Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses and, to the fullest extent permitted by law, amounts paid in settlement actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with such Proceeding or any claim,

 

issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification shall be made under this Section 3 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court of Chancery or such other court shall deem proper.

 

4.
Indemnification for Expenses of a Party Who is Wholly or Partly Successful. To the extent that Indemnitee is a party to or a participant in and is successful (on the merits or otherwise) in defense of any Proceeding or any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses
actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection therewith. To the extent permitted by applicable law, if Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, in defense of one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with (a) each successfully resolved claim, issue or matter and (b) any claim, issue or matter related to any such successfully resolved claim, issuer or matter. For purposes of this section, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

5.
Indemnification for Expenses of a Witness. To the extent that Indemnitee is, by reason of his or her Corporate Status, a witness in any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified to the extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection therewith.

 

6.
Additional Indemnification.

 

(a)
Notwithstanding any limitation in Sections 2, 3 or 4, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with the Proceeding or any claim, issue or matter therein.

 

(b)
For purposes of Section 6(a), the meaning of the phrase “to the fullest extent permitted by applicable law” shall include, but not be limited to:

 

(i)
the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL; and

 

(ii)
the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.

 

7.
Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any Proceeding (or any part of any Proceeding):

 

(a)
for which payment has actually been made to or on behalf of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid;

 

(b)
for an accounting or disgorgement of profits pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of federal, state or local statutory law or common law, if Indemnitee is held liable therefor (including pursuant to any settlement arrangements);

 

(c)
for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or
the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements);

 

(d)
initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, agents or other indemnitees, unless (i) the Company’s board of directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law,

(iii) otherwise authorized in Section 12(d) or (iv) otherwise required by applicable law; or

 

(e)
if prohibited by applicable law.

 

8.
Advances of Expenses. The Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made as soon as reasonably practicable, but in any event no later than 30 days, after the receipt by the Company of a written statement or statements requesting such advances from time to time (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditure made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice). Advances shall be unsecured and interest free and made without regard to Indemnitee’s ability to repay such advances. Indemnitee hereby undertakes to repay any advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. This Section 8 shall not apply to the extent advancement is prohibited by law and shall not apply to any Proceeding for which indemnity is not permitted under this Agreement, but shall apply to any Proceeding referenced in Section 7(b) or 7(c) prior to a determination that Indemnitee is not entitled to be indemnified by the Company.

 

9.
Procedures for Notification and Defense of Claim.

 

(a)
Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee of notice thereof. The written notification to the Company shall include, in reasonable detail, a description of the nature of the Proceeding and the facts underlying the Proceeding. The

 

failure by Indemnitee to notify the Company will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights, except to the extent that such failure or delay materially prejudices the Company.

 

(b)
If, at the time of the receipt of a notice of a Proceeding pursuant to the terms hereof, the Company has directors’ and officers’ liability insurance in effect, the Company shall give prompt notice of the commencement of the Proceeding to the insurers in accordance with the procedures set forth in the applicable policies. The Company shall thereafter take all commercially-reasonable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.

 

(c)
In the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall be entitled to assume the defense of such Proceeding with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee for any fees or expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding. Notwithstanding the Company’s assumption of the defense of any such Proceeding, the Company shall be obligated to pay the
fees and expenses of Indemnitee’s counsel to the extent (i) the employment of counsel by Indemnitee is authorized by the Company, (ii) counsel for the Company or Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense such that Indemnitee needs to be separately represented, (iii) the Company is not financially or legally able to perform its indemnification obligations or (iv) the Company shall not have retained, or shall not continue to retain, such counsel to defend such Proceeding. The Company shall have the right to conduct such defense as it sees fit in its sole discretion. Regardless of any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding at Indemnitee’s personal expense. The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Company.

 

(d)
Indemnitee shall give the Company such information and cooperation in connection with the Proceeding as may be reasonably appropriate.

 

(e)
The Company shall not be liable to indemnify Indemnitee for any settlement of any Proceeding (or any part thereof) without the Company’s prior written consent, which shall not be unreasonably withheld.

 

(f)
The Company shall not settle any Proceeding (or any part thereof) without Indemnitee’s prior written consent, which shall not be unreasonably withheld.

 

10.
Procedures upon Application for Indemnification.

 

(a)
To obtain indemnification, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and as is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of the Proceeding. The Company shall, as soon as reasonably practicable after receipt of such a request for indemnification, advise the board of directors that Indemnitee has requested indemnification. Any delay in providing the request will not relieve the Company from its obligations under this Agreement, except to the extent such failure is prejudicial.

 

(b)
Upon written request by Indemnitee for indemnification pursuant to Section 10(a), a determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Company’s board of directors, a copy of which shall be delivered to Indemnitee or (ii) if a Change in Control shall not have occurred,

(A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Company’s board of directors, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Company’s board of directors, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Company’s board of directors, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Company’s board of directors, by the stockholders of the Company. If it is determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten days after such determination. Indemnitee shall cooperate with the person, persons or entity making the determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys’ fees and disbursements) reasonably incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company, to the extent permitted by applicable law.

 

(c)
In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 10(b), the Independent Counsel shall be selected as provided in this Section 10(c). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Company’s board of directors, and the Company shall give written notice to Indemnitee advising him or her of
the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Company’s board of directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 1 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after the later of (i) submission by Indemnitee of a written request for indemnification pursuant to Section 10(a) hereof and (ii) the final disposition of the Proceeding, the parties have not agreed upon an Independent Counsel, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 10(b) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 12(a) of this Agreement, the Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

 

(d)
The Company agrees to pay the reasonable fees and expenses of any Independent Counsel and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

11.
Presumptions and Effect of Certain Proceedings.

 

(a)
In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by such person, persons or entity of any determination contrary to that presumption.

 

(b)
The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.

 

(c)
For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith to the extent Indemnitee relied in good faith on (i) the records or books of account of the Enterprise, including financial statements, (ii) information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, (iii) the advice of legal counsel for the Enterprise or its board of directors or counsel selected by any committee of the board of directors or (iv) information or records given or reports made to the Enterprise by an independent certified public accountant, an appraiser, investment banker or other expert selected with reasonable care by the Enterprise or its board of directors or any committee of the board of directors. The provisions of this Section 11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.

 

(d)
Neither the knowledge, actions nor failure to act of any other director, officer, agent or employee of the Enterprise shall be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

12.
Remedies of Indemnitee.

 

(a)
Subject to Section 12(e), in the event that (i) a determination is made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement,

(ii) advancement of Expenses is not timely made pursuant to Section 8 or 12(d) of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 10 of this Agreement within 90 days after the later of the receipt by the Company of the request for indemnification or the final disposition of the Proceeding, (iv) payment of indemnification pursuant to this Agreement is not made

(A)
within ten days after a determination has been made that Indemnitee is entitled to indemnification or
(B)
with respect to indemnification pursuant to Sections 4, 5 and 12(d) of this Agreement, within 30 days after receipt by the Company of a written request therefor, or (v) the Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or proceeding designed to deny, or to recover from, Indemnitee the benefits provided or intended to be

 

provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of Expenses. Indemnitee shall commence such proceeding seeking an adjudication within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 4 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication in accordance with this Agreement.

 

(b)
Neither (i) the failure of the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders that Indemnitee has not met the applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has or has not met the applicable standard of conduct. In the event that a determination shall have been made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this Section 12 shall be conducted in all respects as a de novo trial, on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding commenced pursuant to this Section 12, the Company shall, to the fullest extent not prohibited by law, have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.

 

(c)
To the fullest extent not prohibited by law, the Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement. If a determination shall have been made pursuant to Section 10 of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statements not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

(d)
To the extent not prohibited by law, the Company shall indemnify Indemnitee against
all Expenses that are incurred by Indemnitee in connection with any action for indemnification or advancement of Expenses from the Company under this Agreement unless as a part of such action, the court of competent jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such action were not made in good faith or were frivolousor to the extent Indemnitee is successful in such action, and, if requested by Indemnitee, shall (as soon as reasonably practicable, but in any event no later than 30 days, after receipt by the Company of a written request therefor) advance such Expenses to Indemnitee, subject to the provisions of Section 8.

 

(e)
Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification shall be required to be made prior to the final disposition of the Proceeding.

 

13.
Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by Indemnitee, whether for Expenses, judgments, fines or amounts paid or to be paid in settlement, in connection with any claim relating to an indemnifiable event under this

 

Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the events and transactions giving rise to such Proceeding; and (ii) the relative fault of Indemnitee and the Company (and its other directors, officers, employees and agents) in connection with such events and transactions.

 

14.
Non-exclusivity. The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company’s certificate of incorporation or bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company’s certificate of incorporation and bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change, subject to the restrictions expressly set forth herein or therein. Except as expressly set forth herein, no right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. Except as expressly set forth herein, the assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

15.
Primary Responsibility. The Company acknowledges that Indemnitee has or may have certain rights to indemnification and advancement of expenses provided by other entities and/or organizations (collectively, the “Secondary Indemnitors”). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Secondary Indemnitors to advance Expenses or to provide indemnification for the same Expenses or liabilities incurred by Indemnitee in connection with a Proceeding are secondary), (ii) that it shall be required to advance the full amount of Expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the certificate of incorporation or bylaws of the Company (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Secondary Indemnitors, and (iii) that, to the extent not in contravention of any insurance policy or policies providing liability or other insurance for the Company or any director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise, it irrevocably waives, relinquishes and releases the Secondary Indemnitors from any and all claims against the Secondary Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Secondary Indemnitors on behalf of Indemnitee with respect to any claim for which indemnification is required under the terms of this Agreement shall affect the foregoing and the Secondary Indemnitors shall have
a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Secondary Indemnitors are express third party beneficiaries of the terms of this Section 15.

 

16.
No Duplication of Payments. The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received payment for such amounts under any insurance policy, contract, agreement or otherwise.

 

17.
Insurance. The Company shall, from time to time, make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or policies of insurance with reputable

 

insurance companies providing the officers and directors of the Company with coverage for losses from wrongful acts, or to ensure the Company’s performance of its indemnification obligations under this Agreement. Among other considerations, the Company will weigh the costs of obtaining such insurance coverage against the protection afforded by such coverage. In all policies of director and officer liability insurance, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s directors, if Indemnitee is a director; or of the Company’s officers, if Indemnitee is not a director of the Company but is an officer. Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such insurance if the Company determines in good faith that such insurance is not reasonably available, if the premium costs for such insurance are disproportionate to the amount of coverage provided, if the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance maintained by a subsidiary or parent of the Company.

 

18.
Subrogation. In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

19.
Services to the Company. Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company, as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders his or her resignation or is removed from such position. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that any employment with the Company (or any of its subsidiaries or any Enterprise) is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, with or without notice, except as may be otherwise expressly provided in any executed, written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies adopted by the Company’s board of directors or, with respect to service as a director or officer of the Company, the Company’s certificate of incorporation or bylaws or the DGCL. No such document shall be subject to any oral modification thereof.

 

20.
Successors. This Agreement shall be binding upon the Company and its successors and assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company, and shall inure to the benefit of Indemnitee and Indemnitee’s heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company, by written agreement, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.

 

21.
Severability. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to court order or other applicable law, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement containing any

 

such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (ii) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (iii) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

 

22.
Enforcement. The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.

 

23.
Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Company’s certificate of incorporation and bylaws and applicable law.

 

24.
Modification and Waiver. No supplement, modification or amendment to this Agreement shall be binding unless executed in writing by the parties hereto. No amendment, alteration or repeal of this Agreement shall adversely affect any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. No waiver of any of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this Agreement nor shall any waiver constitute a continuing waiver.

 

25.
Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed:

 

(a)
if to Indemnitee, to Indemnitee’s address, facsimile number or electronic mail address as shown on the signature page of this Agreement or in the Company’s records, as may be updated in accordance with the provisions hereof; or

 

(b)
if to the Company, to the attention of the Chief Executive Officer or Chief Financial Officer of the Company at 2 Tower Place, Suite 2000, South San Francisco, CA 94080, or at such other current address as the Company shall have furnished to Indemnitee.

 

Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or three days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if

sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day.

 

26.
Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, The Corporation Trust Company, Wilmington, Delaware as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware,

(iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.

 

27.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 

28.
Captions. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

 

 

 

(signature page follows)

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

 

STANDARD BIOTOOLS INC.

 

 

Signature of Authorized Signatory

 

Print Name

 

Title

 

Address: 2 Tower Place, Suite 2000

South San Francisco, CA 94080

 

AGREED TO AND ACCEPTED:

 

INDEMNITEE:

 

 

Signature

 

Print Name

 

Title

 

Address:

 

 

 EX-10.96 4 lab-ex10_96.htm EX-10.96 EX-10.96

Exhibit 10.96

STANDARD BIOTOOLS INC.

Outside Director Equity Compensation Policy

(as amended and restated effective August 9, 2022)

Standard BioTools Inc. (the “Company”) believes that the granting of equity compensation represents a powerful tool to attract, retain and reward members of its board of directors who are not Employees (“Outside Directors”) and to align the interests of our Outside Directors with those of our stockholders. This Outside Director Equity Compensation Policy (the “Policy”) is intended to formalize the Company’s policy regarding grants of equity compensation to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy have the meanings given such terms in the Company’s 2011 Equity Incentive Plan (the “Plan”).

This amended and restated Policy will be effective as of August 9, 2022 (the “Effective Date”). Outside Directors will be entitled to receive all types of Awards (except Incentive Stock Options) under the Plan, including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors pursuant to Sections (c) and (d) of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions:

(a) Type of Option. Options granted pursuant to this Policy will be Nonstatutory Stock Options and, except as otherwise provided herein, will be subject to the other terms and conditions of the Plan.

(b) No Discretion. No person will have any discretion to select which Outside Directors will be granted Awards under this Policy or to determine the number of Shares to be covered by such Awards (except as provided in Section (e) below and Section 13 of the Plan).

(c) Initial Award. Each person who first becomes an Outside Director following the Effective Date automatically will be granted the number of Restricted Stock Units having a Value of $148,500, rounded to the nearest whole share (the “Initial Award”) on the date on which such person first becomes an Outside Director following the Effective Date, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy; provided, however, that a Director who is an Employee (an “Inside Director”) who ceases to be an Inside Director, but who remains a Director, will not receive an Initial Award.

(d) Annual Award. Each Outside Director automatically will be granted (i) an Option having a Value of $57,500, rounded to the nearest whole share (the “Annual Option Award”) and (ii) the number of Restricted Stock Units having a Value of $57,500, rounded to the nearest whole share (the “Annual RSU Award,” and collectively, the “Annual Award”) on the date of each annual meeting of the stockholders of the Company; provided, however, that a Director who receives an Initial Award at any annual meeting of stockholders will not also receive an Annual Award on that date.

(e) Terms. The terms of each Award granted pursuant to this Policy will be as follows:

(i)
The term of each Option granted in accordance with the Policy will be ten (10) years.
(ii)
The exercise price per Share of each Option granted pursuant to this Policy will equal 100% of the Fair Market Value per share of the Common Stock on the date of grant.
(iii)
Subject to Section 13 of the Plan, the Initial Award will vest as to 25% of the total number of Shares subject thereto on each anniversary of the date of grant, provided that the Outside Director continues to serve as a Director through each such date.
(iv)
Subject to Section 13 of the Plan, the Annual Option Award will vest and become exercisable as to 1/12 of the Shares subject to the Annual Option Award each month after the date of grant, provided that the Outside Director continues to serve as a Director through each such date.
(v)
Subject to Section 13 of the Plan, the Annual RSU Award will fully vest on the earlier to occur of: (i) one day prior to the date of the Company’s next annual meeting of stockholders held after the date of grant or (ii) the anniversary of the date of grant, in each case, provided that the Outside Director continues to serve as a Director through the vesting date.
(vi)
For purposes of this Policy, “Value” means (i) with respect to an Option, the grant date fair value (as determined in accordance with U.S. generally accepted accounting principles and as reflected in the Company’s financial statements); and (ii) with respect to an RSU Award, the applicable dollar amount divided by average of the closing trading price of a Share for the 30-trading day period ending on the trading day prior to the date of grant.
(f)
Revisions. The Administrator in its discretion may change and otherwise revise the terms of Awards granted under this Policy, including, without limitation, the number or value of Shares therefor and the exercise prices thereof, for Awards granted on or after the date the Administrator determines to make any such change or revision.
(g)
Adjustments. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, share split, reverse share split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Policy, will adjust the number of Shares issuable pursuant to Initial Awards and Annual Awards to be granted under Sections (c) and (d) of the Policy.
(h)
Change in Control. In the event of a Change in Control, with respect to Awards granted to Outside Directors, the Participant will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Shares underlying such Awards, including those Shares which would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Performance Units and Performance Shares, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met.

* * *

 EX-21.1 5 lab-ex21_1.htm EX-21.1 EX-21.1

 

Exhibit 21.1

 

SUBSIDIARIES OF STANDARD BIOTOOLS INC.

 

 

 

 

Subsidiaries of Standard BioTools Inc. (Delaware):

 

SB Sciences Inc. (Delaware)

Standard BioTools (Shanghai) Instrument Technology Company Limited (China)

Standard BioTools K.K. (Japan)

Standard BioTools Europe B.V. (Netherlands)

Standard BioTools Singapore Pte. Ltd. (Singapore)

SomaLogic, Inc. (Delaware)

 

Subsidiaries of Standard BioTools Europe B.V. (Netherlands):

 

Standard BioTools France SARL (France)

Standard BioTools GmbH (Germany)

Standard BioTools Italy S.r.l. (Italy)

Standard BioTools UK Limited (United Kingdom)

 

Subsidiaries of SB Sciences Inc. (Delaware):

 

Standard BioTools Canada Inc. (Ontario, Canada)

 

Subsidiaries of SomaLogic, Inc. (Delaware):

 

SomaLogic Operating Co., Inc. (Delaware)

SomaLogic Limited (United Kingdom)

Panther Merger Subsidiary II, LLC (Delaware)

SomaLogic Singapore PTE. LTD. (Singapore)

 

 

 EX-23.1 6 lab-ex23_1.htm EX-23.1 EX-23.1

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-276628, 333-276626, 333-265010), Form S-8 (Nos. 333-264086, 333-256617, 333-172206, 333-180363, 333-187204, 333-202325, 333-209904, 333-215555, 333-219667, 333-222561, 333-229214, 333-232441, 333-239810, 333-272753, 333-276625, 333-276620) and Form S-8/S-3 (No.333-194084) of Standard BioTools Inc. of our report dated February 28, 2024 relating to the financial statements, which appears in this Form 10-K.

 

/s/ PricewaterhouseCoopers LLP

 

San Jose, California

March 1, 2024

 EX-31.1 7 lab-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

CERTIFICATION OF THE PRESIDENT AND CHIEF EXECUTIVE OFFICER

PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Egholm, Ph.D., certify that:

1.
I have reviewed this annual report on Form 10-K of Standard BioTools Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 1, 2024

By:

/s/ Michael Egholm, Ph.D.

 

 

Michael Egholm, Ph.D.

 

 

President and Chief Executive Officer

 

 

 EX-31.2 8 lab-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey Black, certify that:

1.
I have reviewed this annual report on Form 10-K of Standard BioTools Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 1, 2024

By:

/s/ Jeffrey Black

 

 

Jeffrey Black

 

 

Chief Financial Officer

 

 

 EX-32.1 9 lab-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Egholm, Ph.D., the chief executive officer of Standard BioTools Inc. (the “Company”), certify for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge,

1.
the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 1, 2024

By:

/s/ Michael Egholm, Ph.D.

 

Michael Egholm, Ph.D.

 

President and Chief Executive Officer

 

 

 

 

 EX-32.2 10 lab-ex32_2.htm EX-32.2 EX-32.2

 

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey Black, the chief financial officer of Standard BioTools Inc. (the “Company”), certify for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge,

1.
the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 1, 2024

By:

/s/ Jeffrey Black

 

Jeffrey Black

 

Chief Financial Officer

 

 

 

 

 EX-97.1 11 lab-ex97_1.htm EX-97.1 EX-97.1

 

Exhibit 97.1

STANDARD BIOTOOLS INC.

CLAWBACK POLICY

I.
Introduction

The Board of Directors (the “Board”) of Standard BioTools Inc.(the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this policy which provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the federal securities laws (the “Policy”). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and final rules and amendments adopted by the Securities and Exchange Commission (the “SEC”) to implement the aforementioned legislation.

II.
Administration

This Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee of the Board, in which case references herein to the Board shall be deemed references to the Compensation Committee. Any determinations made by the Board shall be final and binding on all affected individuals.

III.
Covered Executives

This Policy applies to the Company’s current and former executive officers, as determined by the Board in accordance with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the SEC and any national securities exchange on which the Company’s securities are listed, and such other employees who may from time to time be deemed subject to the Policy by the Board (“Covered Executives”).

IV.
Incentive-Based Compensation

For purposes of this Policy, incentive-based compensation (“Incentive-Based Compensation”) includes any compensation that is granted, earned, or vested based wholly or in part upon the attainment of any financial reporting measures that are determined and presented in accordance with the accounting principles (“GAAP Measures”) used in preparing the Company’s financial statements and any measures derived wholly or in part from such measures, as well as non-GAAP Measures, stock price, and total shareholder return (collectively, “Financial Reporting Measures”); however, it does not include: (i) base salaries; (ii) discretionary cash bonuses; (iii) awards (either cash or equity) that are solely based upon subjective, strategic or operational standards or standards unrelated to Financial Reporting Measures, and (iv) equity awards that vest solely on completion of a specified employment period or without any performance condition. Incentive-Based Compensation is considered received in the fiscal period during which the applicable reporting measure is attained, even if the payment or grant of such award occurs after the end of that period. If an award is subject to both time-based and performance-based vesting conditions, the award is considered received upon satisfaction of the performance-based conditions, even if such an award continues to be subject to the time-based vesting conditions.

For the purposes of this Policy, Incentive-Based Compensation may include, among other things, any of the following:

•
Annual bonuses and other short- and long-term cash incentives.
•
Stock options.
•
Stock appreciation rights.
•
Restricted stock or restricted stock units.
•
Performance shares or performance units.

 

For purposes of this Policy, Financial Reporting Measures may include, among other things, any of the following:

•
Company stock price.

 

 

•
Total shareholder return.
•
Revenues.
•
Net income.
•
Earnings before interest, taxes, depreciation, and amortization (EBITDA).
•
Funds from operations.
•
Liquidity measures such as working capital or operating cash flow.
•
Return measures such as return on invested capital or return on assets.
•
Earnings measures such as earnings per share.
V.
Recoupment; Accounting Restatement

In the event the Company is required to prepare an accounting restatement of its financial statements due to the Company’s material noncompliance with any financial reporting requirement under U.S. securities laws, including any required accounting restatement to correct an error in previously issued financial statements that (i) is material to the previously issued financial statements or (ii) is not material to previously issued financial statements, but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period, the Board will require reimbursement or forfeiture of any excess Incentive-Based Compensation received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare the accounting restatement (the “Look-Back Period”). For the purposes of this Policy, the date on which the Company is required to prepare an accounting restatement is the earlier of (i) the date the Board concludes or reasonably should have concluded that the Company is required to prepare a restatement to correct a material error, and (ii) the date a court, regulator, or other legally authorized body directs the Company to restate its previously issued financial statements to correct a material error. The Company’s obligation to recover erroneously awarded compensation is not dependent on if or when the restated financial statements are filed.

Recovery of the Incentive-Based Compensation is only required when the excess award is received by a Covered Executive (i) after the beginning of their service as a Covered Executive, (ii) who served as an executive officer at any time during the performance period for that Incentive-Based Compensation, (iii) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Look-Back Period immediately preceding the date on which the Company is required to prepare an accounting restatement.

VI.
Excess Incentive Compensation: Amount Subject to Recovery

The amount of Incentive-Based Compensation subject to recovery is the amount the Covered Executive received in excess of the amount of Incentive-Based Compensation that would have been paid to the Covered Executive had it been based on the restated financial statements, as determined by the Board. The amount subject to recovery will be calculated on a pre-tax basis.

For Incentive-Based Compensation received as cash awards, the erroneously awarded compensation is the difference between the amount of the cash award that was received (whether payable in a lump sum or over time) and the amount that should have been received applying the restated Financial Reporting Measure. For cash awards paid from bonus pools, the erroneously awarded Incentive-Based Compensation is the pro rata portion of any deficiency that results from the aggregate bonus pool that is reduced based on applying the restated Financial Reporting Measure.

For Incentive-Based Compensation received as equity awards that are still held at the time of recovery, the amount subject to recovery is the number of shares or other equity awards received or vested in excess of the number that should have been received or vested applying the restated Financial Reporting Measure. If the equity award has been exercised, but the underlying shares have not been sold, the erroneously awarded compensation is the number of shares underlying the award.

In instances where the Company is not able to determine the amount of erroneously awarded Incentive-Based Compensation directly from the information in the accounting restatement, the amount will be based on the Company’s reasonable estimate of the effect of the accounting restatement on the applicable measure. In such instances, the Company will maintain documentation of the determination of that reasonable estimate.

VII.
Method of Recoupment

The Board will determine, in its sole discretion, subject to applicable law, the method for recouping Incentive-Based Compensation hereunder, which may include, without limitation:

2

 

•
requiring reimbursement of cash Incentive-Based Compensation previously paid;
•
seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;
•
offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;
•
cancelling outstanding vested or unvested equity awards; and/or
•
taking any other remedial and recovery action permitted by law, as determined by the Board.
VIII.
No Indemnification; Successors

The Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive-Based Compensation. This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.

IX.
Exception to Enforcement

The Board shall recover any excess Incentive-Based Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Board in accordance with Rule 10D-1 of the Exchange Act and any applicable rules or standards adopted by the SEC and the listing standards of any national securities exchange on which the Company’s securities are listed.

X.
Interpretation

The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the SEC and any national securities exchange on which the Company’s securities are listed.

XI.
Effective Date

This Policy shall be effective as of the date it is adopted by the Board (the “Effective Date”) and shall apply to Incentive-Based Compensation that is received by a Covered Executive on or after October 2, 2023, as determined by the Board in accordance with applicable rules or standards adopted by the SEC and the listing standards of any national securities exchange on which the Company’s securities are listed.

XII.
Amendment; Termination

The Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to comply with any rules or standards adopted by the SEC and the listing standards of any national securities exchange on which the Company’s securities are listed. The Board may terminate this Policy at any time.

XIII.
Other Recoupment Rights

Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.

3

 GRAPHIC 12 img186398206_0.jpg GRAPHIC begin 644 img186398206_0.jpg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img186398206_1.jpg GRAPHIC begin 644 img186398206_1.jpg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end EX-101.SCH 14 lab-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 100010 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Operating Lease Maturity (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - NIH Contract link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Revenue and Geographic Area link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Goodwill and Intangible Assets, net link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Mezzanine Equity link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Shareholders' Deficit link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - 401(K) Plan link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Restructuring and Related Charges link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - NIH Contract (Tables) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Revenue and Geographic Area (Tables) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Goodwill and Intangible Assets, net (Tables) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Mezzanine Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Shareholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Restructuring and Related Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - NIH Contract - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - NIH Contract (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Business Combination - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Revenue and Geographic Area - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Revenue and Geographic Area - Long-lived Assets by Geographic Areas (Details) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Revenue and Geographic Area - Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Revenue and Geographic Area - Performance Obligation (Details1) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Goodwill and Intangible Assets, net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Goodwill and Intangible Assets, net - Changes in the Carrying Value of Goodwill by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Finite-lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Goodwill and Intangible Assets, net - Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Balance Sheet Details - Summary of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 100580 - Disclosure - Balance Sheet Details - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 100590 - Disclosure - Balance Sheet Details - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100600 - Disclosure - Balance Sheet Details - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100610 - Disclosure - Balance Sheet Details - Accrued Compensation and Related Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 100620 - Disclosure - Balance Sheet Details - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100630 - Disclosure - Debt - Schedule of Carrying Value of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 100640 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100650 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 100660 - Disclosure - Debt - Future Minimum Payments under Term Loan Facility including End of Term Fee Payment (Details) link:presentationLink link:calculationLink link:definitionLink 100670 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100680 - Disclosure - Commitments and Contingencies - Schedule of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 100690 - Disclosure - Commitments and Contingencies - Operating Lease Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 100700 - Disclosure - Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 100710 - Disclosure - Fair Value of Financial Instruments - Schedule of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 100720 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100730 - Disclosure - Mezzanine Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100740 - Disclosure - Mezzanine Equity - Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 100750 - Disclosure - Shareholders' Deficit - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100760 - Disclosure - Shareholders' Deficit - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 100770 - Disclosure - Stock-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100780 - Disclosure - Stock-based Compensation - Restricted and Performance Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 100790 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100800 - Disclosure - Stock-based Compensation - Weighted-average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 100810 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 100820 - Disclosure - Income Taxes - Loss Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 100830 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 100840 - Disclosure - Income Taxes - Reconciliation of Income Taxes at Statutory Rate (Details) link:presentationLink link:calculationLink link:definitionLink 100850 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100860 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100870 - Disclosure - Income Taxes - Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 100880 - Disclosure - Income Taxes - Aggregate Changes in Balance of Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 100890 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100900 - Disclosure - Segment Reporting - Schedule of Business Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 100910 - Disclosure - Restructuring and Related Charges - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100920 - Disclosure - Restructuring and Related Charges - Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100930 - Disclosure - Restructuring and Related Charges - Restructuring and Other Efficiency Costs (Details) link:presentationLink link:calculationLink link:definitionLink 100940 - Disclosure - 401(K) Plan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 100950 - Disclosure - Subsequent Event - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink Goodwill [Line Items] Goodwill [Line Items] Auditor Firm ID Auditor Firm ID Line Of Credit Facility, Maximum Borrowing Capacity, Percentage Of Eligible Inventory Line Of Credit Facility, Maximum Borrowing Capacity, Percentage Of Eligible Inventory Percentage of eligible inventory 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Document Transition Report Document Transition Report Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Weighted average expected volatility Deferred Tax Assets, in Process Research and Development Capitalized R&D costs Revenue, Remaining Performance Obligation, Amount Remaining performance obligation Defined Benefit Plan Disclosure [Line Items] Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Schedule of Nonvested Performance-Based Units Activity Money Market Funds [Member] Money market funds Less equity issuance costs Payments of Stock Issuance Costs Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] South San Francisco South San Francisco [Member] South San Francisco Geographical [Axis] Geographical [Axis] Lessor, Operating Lease, Payment to be Received Total future minimum payments (receipts) Accrued Vacation, Current Accrued vacation Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Award vesting period Estimated Fair Value Short-term investments Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale, Total Deferred Grant Revenue, Current Deferred Grant Revenue, Current Deferred grant income, current Other Liabilities, Noncurrent Other non-current liabilities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Restricted Stock Units Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Exchange ratio Exchange Ratio Exchange ratio. Quoted Prices in Active Markets For Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Entity Public Float Entity Public Float 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Phantom Share Units (PSUs) [Member] Phantom Share Units (PSUs) Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Temporary Equity, Shares Authorized Redeemable preferred stock, shares authorized (in shares) Income Tax, Policy [Policy Text Block] Income Taxes Property, Plant and Equipment, Useful Life Property and equipment, estimated useful lives Revenue from Contract with Customer, Excluding Assessed Tax Total revenue Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block] Series B Redeemable Preferred Stock Accrued commissions Accrued Sales Commission, Current Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Total unrecognized compensation cost related to stock-based compensation arrangements Disaggregation of Revenue [Table Text Block] Schedule of Disaggregation of Revenue Concentration Risk Type [Axis] Concentration Risk Type [Axis] Performance adjustment for 2020 awards (in shares) | shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period, Weighted Average Grant Date Fair Value ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Contract with Customer, Liability, Current Deferred revenue, current 2025 Lessee Net Operating Lease Liability Payments Due Year Two Lessee, net operating lease, liability payments due year two. Deferred Tax Liabilities, Operating Leases, Right-Of-Use Assets Deferred Tax Liabilities, Operating Leases, Right-Of-Use Assets Right-of-use assets Certain Employee [Member] Certain Employee [Member] Certain Employee Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Title of Individual [Domain] Title of Individual [Domain] Research And Development Arrangement, Contract To Perform For Others, Maximum Contract Value Research And Development Arrangement, Contract To Perform For Others, Maximum Contract Value Maximum contract value Subsequent Events [Text Block] Subsequent Event Deferred Tax Assets, Operating Leases, Right-Of-Use Liability Deferred Tax Assets, Operating Leases, Right-Of-Use Liability Right-of-use lease liabilities InstruNor AS [Member] InstruNor AS [Member] InstruNor AS Research And Development Arrangement, Contract To Perform For Others, Amount Research And Development Arrangement, Contract To Perform For Others, Amount Cumulative cash receipts from milestones achieved Research and Development [Abstract] Temporary Equity, Shares Issued Redeemable preferred stock, shares issued (in shares) Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Stock Repurchased During Period, Shares Repurchases of common shares Repurchase of common stock (in shares) Line Of Credit Facility, Maximum Borrowing Capacity, Percentage Of Eligible Receivables Line Of Credit Facility, Maximum Borrowing Capacity, Percentage Of Eligible Receivables Percentage of eligible receivables Schedule of Stock by Class [Table] Fair Value Measurement [Domain] Treasury stock at cost: 3,132 and 422 shares at December 31, 2023 and 2022, respectively Treasury Stock, Common, Value Number Of Additional Shares Issuable Under Make-Whole Premium, Maximum Number Of Additional Shares Issuable Under Make-Whole Premium, Maximum Maximum additional shares issuable (in shares) Two Thousand Seventeen Employee Stock Purchase Plan [Member] Two Thousand Seventeen Employee Stock Purchase Plan [Member] 2017 Employee Stock Purchase Plan 2017 Employee Stock Purchase Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of Nonvested and Outstanding Units Severance and other employee-related benefits Employee Severance [Member] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Class of Stock [Line Items] Service and other revenue Service and Other Revenue [Member] Service and other revenue. Balance Sheet Location [Axis] Assets, Current Total current assets Vesting [Domain] Vesting [Domain] 2027 Lessee Net Operating Lease Liability Payments Due Year Four Lessee, net operating lease, liability payments due year four. Total liabilities, mezzanine equity and stockholders' deficit Liabilities and Equity Entity Address, State or Province Entity Address, State or Province Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred: Revenue From Contract With Customer, Terms Of Payment Period Revenue From Contract With Customer, Terms Of Payment Period Terms of payment period Long-Term Debt [Text Block] Debt Deferred Income Tax Assets, Net Less deferred tax assets included in other long-term assets Portion Of Stock Options Vest On First Anniversary Portion Of Stock Options Vest On First Anniversary Rate at which outstanding options vest on the first anniversary of the option grant date Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Ending balance (in shares) Beginning balance (in shares) Percentage of headquarters subleased space Lessor Operating Lease Percentage Of Headquarters Subleased Lessor, operating lease, percentage of headquarters subleased. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average fair value per share (in dollars per share) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Share Based Compensation Arrangement By Share Based Payment Award, Options, Expected To Vest, Outstanding, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value Unvested awards Goodwill and Intangible Assets, Policy [Policy Text Block] Goodwill Trading Symbol Trading Symbol Deferred Tax Assets, Net of Valuation Allowance Total deferred tax assets, net of valuation allowance Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Payment of debt and equity issuance costs Payment of Financing and Stock Issuance Costs, Total Payment of Financing and Stock Issuance Costs Common Stock, Shares, Issued Common stock, shares issued (in shares) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Executive stock-based compensation Restrictions on Cash and Cash Equivalents [Table Text Block] Schedule of Restricted Cash 2025 Long-Term Debt, Maturity, Year Two Research And Development Arrangement, Contract To Perform For Others , Contract Income Research And Development Arrangement, Contract To Perform For Others , Contract Income Non-operating income Depreciation, Amortization and Accretion, Net, Total Depreciation, Amortization and Accretion, Net Depreciation and amortization Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] 401(K) Plan Compensation and Employee Benefit Plans [Text Block] Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price Vested (in dollars per share) Cash and cash equivalents Cash and Cash Equivalents [Member] Non-Cash Right -of-Use Assets and Lease Liabilities Non-Cash Right -of-Use Assets and Lease Liabilities Non-cash right-of-use assets and lease liabilities Lease expiration date Lease Expiration Date Schedule of Long-Term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Foreign Tax Authority [Member] Foreign Tax Authority 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Common Stock, Capital Shares Reserved for Future Issuance Number of remaining securities available for future issuance (in shares) Advertising Expense Advertising costs incurred Accum. Other Comp. (Loss) AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Business Combination Disclosure [Text Block] Business Combination 2024 Lessee Net Operating Lease Liability Payments Due Next Twelve Months Lessee, net operating lease, liability payments due next twelve months. 2026 Lessee Net Operating Lease Liability Payments Due Year Three Lessee, net operating lease, liability payments due year three. Term loan, current Long-Term Debt, Current Maturities, Total Long-Term Debt, Current Maturities Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustment Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Deferred Tax Liabilities, Property, Plant and Equipment Fixed assets and intangibles Entity Address, City or Town Entity Address, City or Town Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate per annum 2025 Lessor, Operating Lease, Payment to be Received, Year Two Inventory, LIFO Reserve, Period Charge Provision for excess and obsolete inventory 2019 and 2014 Notes Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Lessee, Operating Lease, Renewal Term Renewal term Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment, Net 2026 Lessor, Operating Lease, Payment to be Received, Year Three Subsequent Event Subsequent Event [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Share-Based Payment Arrangement, Tranche Two [Member] Tranche Two Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Increases in balances related to tax positions during a prior period Additional Paid-in Capital [Member] Additional Paid-in Capital Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Significant Components of Provision for Income Taxes Raw materials Inventory, Raw Materials, Gross Equity Incentive Plan [Member] Equity Incentive Plan [Member] Equity Incentive Plan Liabilities, Current [Abstract] Current liabilities: Assets, Current [Abstract] Current assets: Accounts Receivable, Allowance for Credit Loss, Current Accounts receivable, allowances Counterparty Name [Axis] Counterparty Name [Axis] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Additional advance payments received Bridge Loans Bridge Loan [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets, net Less: current portion of operating lease liabilities Operating Lease, Liability, Current Operating lease liabilities, current Advertising Cost [Policy Text Block] Advertising Costs SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account Charges to other accounts Total Term Loan Facility Total debt Long-Term Debt Long-term debt Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Class of Stock [Domain] Class of Stock [Domain] Restructuring and related charges Restructuring and related charges Restructuring Charges, Total Restructuring Charges Total restructuring and other related costs Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Weighted Average Remaining Contractual Term 1 Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term 1 Unvested awards Secured Debt, Total Secured Debt Term loan Credit losses on accounts receivable Accounts Receivable, Credit Loss Expense (Reversal) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Tax benefit at federal statutory rate Net Minimum Lease Payments for Operating Leases Net Operating Lease Liabilities Payments Due [Abstract] Net operating lease liabilities payments due. Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Scenario [Domain] Scenario [Domain] Treasury Stock, Common, Shares Treasury stock, ending balance (in shares) Treasury stock, beginning balance (in shares) Treasury stock (in shares) Combined Company Combined Company [Member] Combined company. SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Entity Central Index Key Entity Central Index Key Proceeds from exercise of stock options Proceeds From Exercise Of Stock Options Proceeds from exercise of stock options. Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock, net of shares withheld for taxes Plan Name [Domain] Plan Name [Domain] 2028 2028 Lessor, Operating Lease, Payment to be Received, Year Five CANADA Canada Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Weighted average remaining contractual terms Restricted Cash, Noncurrent Non-current restricted cash Total assets measured at fair value Total assets measured at fair value Assets, Fair Value Disclosure Lease option to extend Lessee, Operating Lease, Option to Extend Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, remaining performance obligation, expected timing of satisfaction, period Current Foreign Tax Expense (Benefit) Foreign Schedule of Goodwill [Table Text Block] Schedule of Goodwill Liabilities, Current Total current liabilities Entity Tax Identification Number Entity Tax Identification Number Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Financial Instruments [Domain] Financial Instruments [Domain] Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Stock-based compensation Asset Retirement Obligations Incurred But Not Yet Paid Asset Retirement Obligations Incurred But Not Yet Paid Asset retirement obligations Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted- Average Remaining Contractual Life (in Years) Corporate Headquarters (21st Floor) Corporate Headquarters Twenty First Floor [Member] Corporate headquarters twenty first floor. Grant [Member] Grant revenue Investment, Name [Axis] Research and Development Arrangement, Contract to Perform for Others, Capital Expenditures Research and Development Arrangement, Contract to Perform for Others, Capital Expenditures Capital expenditures SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Valuation Allowances [Roll Forward] Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under ESPP Award Type [Axis] Award Type [Axis] Lessee, Operating Leases [Text Block] Leases Research, Development, and Computer Software Disclosure [Text Block] NIH Contract Plan Name [Axis] Plan Name [Axis] Research and Development Arrangement, Contract to Perform for Others [Table Text Block] Research and Development Arrangement, Contract to Perform for Others Geographical [Domain] Geographical [Domain] Assets Total assets UNITED STATES United States Operating Lease, Right-of-Use Asset Operating lease right-of-use asset, net Total operating lease right-of-use assets, net Entity Registrant Name Entity Registrant Name Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit) Accumulated deficit Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information Loss on Bridge Loans Debt Securities, Gain (Loss) Loss on bridge loans Retained Earnings [Member] Accum. Deficit Class of Stock [Axis] Class of Stock [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Ending balance (in shares) Beginning balance (in shares) Awards outstanding Loss On Forward Sale Of Stock Loss On Forward Sale Of Stock Loss on forward sale of Series B Preferred Stock Change in fair value of Forward Purchase Agreements Loss on forward sale of Series B Preferred Stock Impairment of Intangible Assets, Finite-Lived Impairment of InstruNor developed technology intangible Deferred Income Tax Liabilities, Net Deferred tax liability Deferred tax liability per balance sheet Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under ESPP (in shares) Minimum [Member] Minimum Audit Information [Abstract] Audit Information [Abstract] Schedule of Available-for-Sale Securities Reconciliation Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Proteomics Proteomics [Member] Proteomics Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Temporary Equity [Abstract] Mezzanine equity: Operating Lease, Liability Total operating lease liabilities Forecast [Member] Forecast Share-Based Payment Arrangement, Tranche One [Member] Tranche One Revenue [Policy Text Block] Deferred Grant Income Accrued taxes Accrued Income Taxes, Current Equity Component [Domain] Equity Component [Domain] Defined Contribution Plan, Cost Employer matching contributions expense Segments [Axis] Segments [Axis] Securities To Be Issued Upon Exercise Of Options Employee Stock Option Employee Stock Option [Member] Secured Debt, Current Term loan, current Deferred Grant Revenue Deferred Grant Revenue Total deferred grant income Amortization of Debt Issuance Costs and Discounts, Total Amortization of Debt Issuance Costs and Discounts Amortization of debt discounts, premiums and issuance costs Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] Sublease income Sublease Income Goodwill, Foreign Currency Translation Gain (Loss) Foreign currency translation Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price per Option Debt Disclosure [Abstract] Debt Disclosure [Abstract] Additional interest rate Debt Instrument, Basis Spread on Variable Rate Basis spread on variable rate Entity Current Reporting Status Entity Current Reporting Status Common Stock, Shares Authorized Common stock, shares authorized (in shares) Research and Development Expense, Total Research and Development Expense Research and development Term Loan and Convertible Notes, net Debt, Policy [Policy Text Block] Deferred Tax Liabilities, Gross, Total Deferred Tax Liabilities, Gross Total deferred tax liabilities Deferred Foreign Income Tax Expense (Benefit) Foreign Proceeds from Issuance of Convertible Preferred Stock Proceeds from Purchase Agreements Proceeds from issuance of Series B Preferred Stock Stock repurchase program, authorized amount Stock Repurchase Program Authorized Dollar Amount Debt Instrument, Periodic Payment, Number Of Installments Debt Instrument, Periodic Payment, Number Of Installments Number of installments Assets [Abstract] ASSETS Assets: Revenue from Contract with Customer [Policy Text Block] Revenue Recognition 2027 Lessor, Operating Lease, Payment to be Received, Year Four Amortization of Intangible Assets Amortization of developed technology Accrued interest receivable related to short-term investments Interest Receivable, Current Convertible Preferred Stock [Member] Convertible Preferred Stock Series B Preferred Stock Common stock: $0.001 par value, 400,000 shares authorized at December 31, 2023 and 2022; 83,364 and 79,904 shares issued at December 31, 2023 and 2022, respectively; 80,232 and 79,482 shares outstanding at December 31, 2023 and 2022, respectively Common Stock, Value, Issued Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Change in valuation allowance Repayments of Long-Term Debt, Total Repayment of term loan Repayments of Long-Term Debt loss on the bridge loans loss on the bridge loans Restructuring Reserve, Total Restructuring Reserve Ending balance Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One Vested Contract with Customer, Liability, Revenue Recognized Revenue recognized Furniture and Fixtures [Member] Office furniture and fixtures Other accrued liabilities Accrued Liabilities, Current Other accrued liabilities Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Auditor Name Auditor Name Income (loss) from operations Operating Income (Loss) Loss from operations Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Number of shares issued in business combination (in shares) SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Realized gains and losses from sales of short-term investments Debt Securities, Available-for-Sale, Realized Gain (Loss) Debt Securities, Available-for-Sale, Realized Gain (Loss), Total Two Thousand And Eleven Equity Incentive Plan [Member] Two Thousand And Eleven Equity Incentive Plan [Member] 2011 Equity Incentive Plan Business Combination, Consideration Transferred, Total Business Combination, Consideration Transferred Aggregate purchase price Deferred Income Tax Expense (Benefit), Total Deferred Income Tax Expense (Benefit) Total deferred benefit Total benefit (expense) from income taxes Income tax benefit (expense) Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Research and development expense Research and Development Expense [Member] Research and development Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Unrecognized tax benefits, decrease resulting from prior period tax positions Decreases in balances related to tax positions taken during prior period Research And Development Arrangement, Contract To Perform For Others , Assets Placed In Service , Gross Research And Development Arrangement, Contract To Perform For Others , Assets Placed In Service , Gross Assets placed in service, gross Lessee, Leases [Policy Text Block] Leases Cash payments Payments for Restructuring Concentration Risk, Percentage Concentration risk, percentage Share-Based Payment Arrangement, Expense Total stock-based compensation Payment, Tax Withholding, Share-Based Payment Arrangement Payments for taxes related to net share settlement of equity awards and other Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Award vesting percentage Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value Vested Finite-Lived Intangible Assets, Net, Ending Balance Finite-Lived Intangible Assets, Net, Beginning Balance Finite-Lived Intangible Assets, Net Total Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Business Segment Information Revenue from Contract with Customer [Text Block] Revenue and Geographic Area Combined Subsidiaries Combined Subsidiaries [Member] Combined subsidiaries. Casdin Casdin [Member] Casdin Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Options granted (in shares) Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of foreign exchange rate fluctuations on cash and cash equivalents Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding License [Member] License and royalty revenue Debt Instrument, Face Amount Par Value Aggregate principal amount Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increases in balances related to tax positions taken during current period Measurement Basis [Axis] Debt Instrument, Covenant, Convertible Debt Threshold Debt Instrument, Covenant, Convertible Debt Threshold Convertible debt Other income (expense), net Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Other income, net Sale of Stock, Price Per Share Price per share (in dollars per share) Net Minimum Lease Payments for Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Minimum Lease Payments for Operating Leases Proceeds from Maturities, Prepayments and Calls of Other Investments Proceeds from sales and maturities of investments SomaLogic Inc. Somalogic Inc [Member] SomaLogic Inc. Net change in unrealized gain (loss) on investments Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Long-Term Debt, Type [Domain] Long-term Debt, Type [Domain] Entity Voluntary Filers Entity Voluntary Filers Subsequent Events [Abstract] Subsequent Events [Abstract] Senior Convertible Notes due 2034 [Member] Senior Convertible Notes Due 2034 [Member] 2014 Notes Income (Loss) from Continuing Operations before Income Taxes, Foreign International Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Other Assets, Noncurrent Other non-current assets Series B Preferred Stock Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Accrued other Other Accrued Liabilities, Current Shareholders' Deficit Equity [Text Block] Depreciation, Total Depreciation Depreciation Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Asia Pacific [Member] Asia-Pacific 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Additional Paid in Capital, Total Additional Paid in Capital Additional paid-in capital Unrealized Gains Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Undisclosed Customer Undisclosed Customer [Member] Undisclosed Customer Defined Contribution Plan, Employer Matching Contribution, Maximum Annual Match Per Employee, Amount Defined Contribution Plan, Employer Matching Contribution, Maximum Annual Match Per Employee, Amount Maximum annual employee contribution matched by employer Stockholders' deficit: Equity, Attributable to Parent [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Lessee, Operating Lease, Liability, to be Paid, after Year Five Thereafter Schedule of Operating Leases Lease, Cost [Table Text Block] Secured Debt [Member] Secured Debt Developed Technology Rights [Member] Developed technology Developed Technology Amortization Expense Entity [Domain] Entity [Domain] Restructuring and Related Cost, Expected Cost, Total Restructuring and Related Cost, Expected Cost Restructuring costs Line of Credit Facility, Maximum Borrowing Capacity Borrowing base Lessor, operating lease, term of contract Lessor, Operating Lease, Term of Contract Total cost of revenue Cost of Goods and Services Sold, Total Cost of Goods and Services Sold Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Loss Contingencies [Table] Investment, Name [Domain] Deferred Tax Liabilities, Net, Total Deferred Tax Liabilities, Net Net deferred tax liability Accounting Policies [Abstract] Accounting Policies [Abstract] Segments [Domain] Segments [Domain] Accrued Payroll Taxes, Current Accrued payroll taxes and other Deferred Tax Assets, Depreciation and Amortization Deferred Tax Assets Depreciation And Amortization Depreciation and amortization SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Ending balance Beginning balance Scenario [Axis] Scenario [Axis] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Business and Credit Risk Sale of Stock, Consideration Received on Transaction Sale of stock, consideration received on transaction Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility [Member] Revolving Credit Facility Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Customer Concentration Risk [Member] Customer Concentration Risk Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Components of Accumulated Other Comprehensive Loss Commitments and contingencies (Note 8) Commitments and Contingencies DVS Sciences, Inc. [Member] DVS Sciences, Inc. [Member] DVS Sciences, Inc. Transaction-related expenses Transaction-related expenses Business Combination, Acquisition Related Costs Income Statement [Abstract] Income Statement [Abstract] Debt Securities, Available-for-Sale, Current Short-term investments Performance Shares [Member] Performance Shares Operating Lease, Cost Operating lease cost (including variable costs) Retirement Benefits [Abstract] Restructuring Type [Axis] Restructuring Type [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Five Largest Customers [Member] Five Largest Customers [Member] Five Largest Customers Finite-Lived Intangible Assets Acquired Finite-lived intangible assets acquired Proceeds from Issuance of Debt Proceeds from issuance of debt Two Thousand And Seventeen Inducement Award Plan [Member] Two Thousand And Seventeen Inducement Award Plan [Member] 2017 Inducement Award Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Aggregate intrinsic value, vested and released All Award Types Award Type [Domain] Document Period End Date Document Period End Date Statistical Measurement [Axis] Statistical Measurement [Axis] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments Operating cash flows from operating leases Debt Instrument, Redemption Condition, Stock Value Exceeding Percentage of Conversion Price Debt Instrument, Redemption Condition, Stock Value Exceeding Percentage of Conversion Price Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price Debt Instrument, Redemption, Period Two [Member] Redemption, Period Two Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Product and Service [Domain] Product and Service [Domain] EMEA [Member] EMEA Cost of product revenue Cost of Sales [Member] Deferred Tax Assets, Operating Loss Carryforwards, Total Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carryforward Unrecognized Tax Benefits Ending balance Beginning balance SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Repayment of term loan and advances under revolving credit facility Repayments of Long-Term Lines of Credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Federal R&D credit Performance adjustment for 2020 awards (in shares) | shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Computer Equipment And Software [Member] Computer Equipment And Software [Member] Computer equipment and software Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Other Other Restructuring [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] CHINA China Fair Value, Recurring Fair Value, Recurring [Member] Number of Reportable Segments Number of reporting segments End of term fee and debt issuance costs Debt Related Commitment Fees and Debt Issuance Costs Research And Development Arrangement, Contract To Perform For Others, Other Income Recognized Research And Development Arrangement, Contract To Perform For Others, Other Income Recognized Surplus funding from NIH Contract Inventory, Policy [Policy Text Block] Inventories, net Future Minimum Payments under Term Loan Facility including End of Term Fee Payment Schedule of Maturities of Long-Term Debt [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Options Operating Loss Carryforward, Subject To Expiration Operating Loss Carryforward, Subject To Expiration Operating loss carryforwards, subject to expiration US Treasury Securities [Member] U.S. treasury securities Effective Income Tax Rate Reconciliation, Research and Development Credit, Percent Effective Income Tax Rate Reconciliation, Research and Development Credit, Percent R&D tax credits expiring unutilized Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] Payments for Repurchase of Common Stock Share repurchase amount Repurchase of common stock Increase (Decrease) in Deferred Compensation Accrued compensation and related benefits Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Mezzanine Equity Mezzanine Equity [Text Block] Mezzanine equity. Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Summary of Valuation Allowance [Table Text Block] Schedule of Summary of Valuation Allowance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock from stock option exercises (in shares) Option exercised (in shares) Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other, net LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT Liabilities and Equity [Abstract] Lessor, Operating Lease, Payment to be Received, after Year Five Lessor, Operating Lease, Payment to be Received, after Year Five Thereafter Entity Address, Postal Zip Code Entity Address, Postal Zip Code Debt Instrument, Convertible, Conversion Ratio Initial conversion rate of notes Entity Interactive Data Current Entity Interactive Data Current Defined Contribution Plan, Employer Matching Contribution, Percent of Match Percent of employee match Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits, that if recognized would affect effective tax rate Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Credit Facility [Domain] Credit Facility [Domain] Equity [Abstract] Equity [Abstract] Two Thousand And Twenty Two Inducement Equity Incentive Plan Two Thousand And Twenty Two Inducement Equity Incentive Plan [Member] 2022 Inducement Equity Incentive Plan Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Instruments [Member] Instruments [Member] Instruments Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options exercised (in dollars per share) Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Valuation Allowance, Deferred Tax Asset Equity Components [Axis] Equity Components [Axis] Summary of Income Tax Contingencies [Table Text Block] Schedule of Aggregate Changes in Balance of Gross Unrecognized Tax Benefits Increase (Decrease) in Accounts Receivable Accounts receivable, net Restructuring and Related Activities [Abstract] Increase (Decrease) in Other Operating Liabilities, Total Increase (Decrease) in Other Operating Liabilities Other liabilities Payments to Acquire Businesses, Gross Purchase price, cash Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Schedule of Expected Timing of Revenue Recognition Office Equipment [Member] Office furniture and fixtures Secured Long-Term Debt, Noncurrent Term loan, non-current Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Released (in dollars per share) Local Phone Number Local Phone Number Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Debt Conversion, Converted Instrument, Shares Issued Debt conversion, converted instrument, shares issued Allowance for excess and obsolete inventory Inventory Valuation Reserves Current Federal Tax Expense (Benefit) Federal Research Tax Credit Carryforward [Member] Research Tax Credit Carryforward Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock, net of shares withheld for taxes (in shares) Balance as of December 31, 2023 Balance as of December 31, 2022 Goodwill, Total Goodwill Goodwill Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Customer One Customer One [Member] Customer One Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment, net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Gross profit Gross profit Gross Profit Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Document Annual Report Document Annual Report Purchase commitment due in the next year Purchase Obligation, to be Paid, Year One Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Service [Member] Service revenue SINGAPORE Singapore Research And Development Arrangement, Contract To Perform For Others, Expenses Research And Development Arrangement, Contract To Perform For Others, Expenses Cumulative amounts applied against operating costs (excluding depreciation) Corporate Headquarters (18th Floor) Corporate Headquarters Eighteenth Floor [Member] Corporate headquarters eighteenth floor. Debt Instrument, Interest Rate, Stated Percentage Interest rate on notes Long-Lived Tangible Asset [Axis] Property, Plant and Equipment, Type [Axis] Senior Convertible Notes Due 2024 [Member] Senior Convertible Notes Due 2024 [Member] 2019 Notes Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Contractual term Securities to be issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] 2028 Lessee Net Operating Lease Liability Payments Due Year Five Lessee, net operating lease, liability payments due year five. Maximum [Member] Maximum Convertible notes, non-current Convertible Debt, Noncurrent Consolidation Items [Domain] Consolidation Items [Domain] Temporary Equity, Shares Outstanding Redeemable preferred stock, shares outstanding (in shares) Temporary Equity [Table Text Block] Schedule of Carrying Value of Preferred Stock Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Finite lived intangible assets acquired Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Treasury stock acquired, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Fair Value, Recurring and Nonrecurring [Table] Term loan advances percentage Debt Instrument, Incremental Payment, Percent Debt Instrument, Incremental Payment, Percent Term loan payment as a percentage of original principal amount of each advance Genomics Genomics [Member] Genomics Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash, cash equivalents and restricted cash Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number Unvested awards (in shares) RSUs, PSUs, stock options and ESPP shares Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract] Sublease Income Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Document Financial Statement Error Correction [Flag] Operating segments Operating Segments [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders Schedule of Inventory, Current [Table Text Block] Schedule of Inventories, Net Segment Reporting Disclosure [Text Block] Segment Reporting City Area Code City Area Code Deferred State and Local Income Tax Expense (Benefit) State Inventory, Net Inventories, net Total inventories, net Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Consolidation Items [Axis] Consolidation Items [Axis] Thereafter Lessee Net Operating Lease Liability Payments Due After Year Five Lessee, net operating lease, liability payments due after year five. Business Acquisition [Line Items] Business Acquisition [Line Items] Customer [Domain] Customer [Domain] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation and amortization Selling, general and administrative expense Selling, General and Administrative Expenses [Member] Selling, general and administrative Temporary Equity, Liquidation Preference Redeemable preferred stock, aggregate liquidation preference Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Shares used in computing net loss per share, basic (in shares) Work-in-process Inventory, Work in Process, Gross Employee Stock [Member] Employee Stock Employee stock purchase plan Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Research and Development Expense, Policy [Policy Text Block] Research and Development Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Activity Under Restricted Stock Units Statement [Table] Statement [Table] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Activity Under Stock Options Accounts Receivable [Member] Accounts Receivable Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Stock-Based Compensation Determined using Black-Sholes Option-Pricing Model and Weighted Average Assumptions Increase (Decrease) in Contract with Customer, Liability Deferred revenue Document Fiscal Period Focus Document Fiscal Period Focus Lessee, Operating Lease, Liability, to be Paid Total future minimum payments (receipts) Short-term Investments Investment, Policy [Policy Text Block] Revenue from Contract with Customer Benchmark [Member] Revenue from Contract with Customer 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Accrued legal expenses Accrued Professional Fees, Current Statement [Line Items] Statement [Line Items] Collaborative Arrangements, Annual Payments Receivable Under Development Agreement Collaborative Arrangements, Annual Payments Receivable Under Development Agreement Annual payments receivable Total future minimum payments (receipts) Lessee Net Operating Lease Liability Payments Due Lessee, net operating lease, liability payments due. Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Line Items] Effective Income Tax Rate Reconciliation, Net Operating Loss Carry Forward, Percent Effective Income Tax Rate Reconciliation, Net Operating Loss Carry Forward, Percent NOL carryforwards expiring unutilized Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions Decreases in balances related to tax positions taken during current period Estimated fair value Fair value of Bridge Loans Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure, Total Schedule Of Significant Accounting Policies [Line Items] Schedule Of Significant Accounting Policies [Line Items] Schedule Of Significant Accounting Policies [Line Items] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Schedule of Net Long-Lived Assets Consisting of Property and Equipment in Different Geographic Areas Schedule of Revenues from External Customers and Long-Lived Assets [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Lessee, Operating Lease, Remaining Term Of Contract Lessee, Operating Lease, Remaining Term Of Contract Remaining lease term Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Significant Components of Deferred Tax Assets and Liabilities Accounts receivable (net of allowances of $312 and $592 at December 31, 2023 and 2022, respectively) Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts Receivable, after Allowance for Credit Loss, Current Customer [Axis] Customer [Axis] Common Stock [Member] Common Stock Debt Instrument [Line Items] Debt Instrument [Line Items] Construction in Progress, Gross Construction-in-progress Temporary Equity, Par or Stated Value Per Share Redeemable preferred stock, par value (in dollars per share) Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Cash-unrestricted Stock Repurchased During Period, Value Repurchase of common stock Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Schedule of Stock-Based Compensation Expense Schedule of Common Stock Reserved for Future Issuance Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding (shares) Finished goods Inventory, Finished Goods, Gross Income (Loss) from Continuing Operations before Income Taxes, Domestic Domestic Return to provision Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Schedule of Carrying Value of Debt Schedule of Debt [Table Text Block] Schedule of Debt and Series B Convertible Preferred Stock Cover [Abstract] Cover [Abstract] Selling, General and Administrative Expense, Total Selling, General and Administrative Expense Selling, general and administrative Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price Unvested awards (in dollars per share) Vesting [Axis] Vesting [Axis] Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Current: Document Fiscal Year Focus Document Fiscal Year Focus Carrying value of assets Research And Development Arrangement, Contract To Perform For Others, Property and Equipment, Net Research And Development Arrangement, Contract To Perform For Others, Property and Equipment, Net Carrying value of property and equipment, net Product and Service, Other [Member] Other revenue Total other revenue Income Taxes Paid, Net, Total Income Taxes Paid, Net Cash paid for income taxes, net of refunds Shareholders' Equity [Table] Temporary Equity, by Class of Stock [Table] Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Proceeds from ESPP stock issuance and exercise of stock options Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Segment Reporting [Abstract] Segment Reporting [Abstract] Security Exchange Name Security Exchange Name Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Expiration period Domestic Tax Authority [Member] Domestic Tax Authority Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Change during the year Other comprehensive loss, net of tax Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Changes and Accounting Pronouncements Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Percentage Of Performance Units Expected To Vest Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Percentage Of Performance Units Expected To Vest Percentage of performance period Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross Property and equipment, gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Vested (in shares) Current State and Local Tax Expense (Benefit) State Options cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Convertible notes, current Convertible Debt, Current Legal Entity [Axis] Legal Entity [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Accrued warranties Accrued Warranties Current Accrued warranties current. Research And Development Arrangement, Contract To Perform For Others, Depreciation Expense Research And Development Arrangement, Contract To Perform For Others, Depreciation Expense Depreciation expenses Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock from stock option exercises Entity Emerging Growth Company Entity Emerging Growth Company Proceeds from Convertible Debt Proceeds from Bridge Loans Proceeds from bridge loans Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Options exercised Shareholders' Equity [Line Items] Temporary Equity [Line Items] Amendment Flag Amendment Flag Tax Credit Carryforward, Amount Tax credit carryforward Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Effective Income Tax Rate Reconciliation, Nondeductible Expense, Forward Sale Of Preferred Stock And Debt, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Forward Sale Of Preferred Stock And Debt, Percent Non-deductible loss on Forward Sale of Preferred Stock and Bridge Loans Research And Development Arrangement, Contract To Perform For Others, Construction in Progress, Gross Research And Development Arrangement, Contract To Perform For Others, Construction in Progress, Gross Construction-in-progress Unrealized Losses Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Basis of Accounting, Policy [Policy Text Block] Basis of Presentation and Consolidation Available-for-sale securities held Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss Equity ownership percentage Equity Method Investment, Ownership Percentage Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Estimated Future Intangible Asset Amortization Expense Deferred Tax Liabilities, Gross [Abstract] Deferred tax liabilities: Restructuring and Related Charges Restructuring and Related Activities Disclosure [Text Block] Leases [Abstract] Leases [Abstract] Variable Rate [Domain] Variable Rate [Domain] Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Schedule of Restructuring Liabilities Securities Act File Number Entity File Number Initial Conversion Price Of Stock Initial Conversion Price Of Stock Initial conversion price of stock (in dollars per share) Patents and License Agreements [Member] Patents and License Agreements [Member] Patents and licenses Patents and Licenses Amortization Expense Defined Contribution Plan Eligible Compensation Contributed By Employee Percentage Defined Contribution Plan Eligible Compensation Contributed By Employee Percentage Percentage of employees eligible compensation Deferred Tax Assets, Gross Total gross deferred tax assets Receivable [Policy Text Block] Accounts Receivable, net Lessor, Operating Lease, Sublease Income Expected Lessor, Operating Lease, Sublease Income Expected Lessor, operating lease, sublease income expected Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Long-Term Debt, Excluding Current Maturities, Total Long-Term Debt, Excluding Current Maturities Term loan, non-current Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total cash, cash equivalents, and restricted cash Total cash, cash equivalents, and restricted cash Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Viking Viking [Member] Viking Share-Based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Debt Instrument [Axis] Debt Instrument [Axis] Fair Value Estimate of Fair Value Measurement [Member] Americas [Member] Americas Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Ending balance (in dollars per share) Beginning balance (in dollars per share) Weighted - average grant date fair value Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent Non-deductible interest/premium Deferred Tax Assets, Valuation Allowance Valuation allowance Valuation allowance on deferred tax assets Total operating expenses Operating Expenses 2024 Long-Term Debt, Maturity, Year One Auditor Location Auditor Location Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Weighted average expected term Schedule of Defined Benefit Plans Disclosures [Table] Preferred stock: $0.001 par value, 9,744 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 Preferred Stock, Value, Issued Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Number of Operating Segments Number of operating segments Title of Individual [Axis] Title of Individual [Axis] Sale of Stock, Number of Shares Issued in Transaction Shares sold (in shares) Research And Development Arrangement, Contract To Perform For Others, Other Income Research And Development Arrangement, Contract To Perform For Others, Other Income Cumulative amounts recognized as non-operating income Cumulative amounts recognized as non-operating income Accrued Bonuses, Current Accrued severance and retention payments 2019 Notes, current Senior Convertible Notes Due 2024, Current [Member] Senior convertible notes due 2024, current. Amortization cost before recovery Debt Securities, Available-for-Sale, Allowance for Credit Loss, Sell before Recovery Revenues [Abstract] Revenue: Deferred Grant Income, Noncurrent Deferred Grant Income, Noncurrent Deferred grant income, non-current Deferred grant income, non-current Entity Address, Address Line One Entity Address, Address Line One Transaction-related Expenses Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block] Corporate Corporate Segment [Member] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Research And Development Arrangement, Contract To Perform For Others, Estimated Future Capital Expenditures Research And Development Arrangement, Contract To Perform For Others, Estimated Future Capital Expenditures Estimated future capital expenditures Laboratory And Manufacturing Equipment [Member] Laboratory And Manufacturing Equipment [Member] Laboratory and manufacturing equipment Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Details Finite-Lived Intangible Assets, Gross, Total Finite-Lived Intangible Assets, Gross Gross Amount Other Asia-Pacific Other Asia-Pacific [Member] Other Asia-Pacific Options, Performance Share Units And Restricted Stock Units [Member] Options, Performance Share Units And Restricted Stock Units [Member] RSUs, stock options and PSUs Subsequent Event Type [Domain] Subsequent Event Type [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Variable Lease, Cost Variable costs (including non-lease components) Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefit Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefit Unrecognized tax benefit Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Long-Term Debt, Type [Axis] Long-term Debt, Type [Axis] Restructuring and Related Charges Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Corporate expenses Corporate, Non-Segment [Member] Stockholders' Equity, Policy [Policy Text Block] Treasury Stock Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Product [Member] Product revenue Product revenue Research And Development Arrangement, Contract To Perform For Others, Capital Expenditures, To Be Incurred Research And Development Arrangement, Contract To Perform For Others, Capital Expenditures, To Be Incurred Capital expenditures expected to be incurred Share Price Share price (in dollars per share) Share price (in usd per share) Accrued interest Accrued Interest Current Accrued interest current. Total long term debt Long-Term Debt, Gross Principal amount Depreciation & amortization Depreciation, Depletion and Amortization, Total Depreciation, Depletion and Amortization Product and Service [Axis] Product and Service [Axis] Contract with Customer, Liability, Noncurrent Deferred revenue, non-current Title of 12(b) Security Title of 12(b) Security Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization and Impairment Redeemable preferred stock: $0.001 par value; 256 shares authorized, issued and outstanding at December 31, 2023 and 2022; aggregate liquidation preference of $255,559 at December 31, 2023 and 2022 Temporary Equity, Carrying Amount, Attributable to Parent Total Series B Redeemable Preferred Stock Prime Rate [Member] Prime Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Performance period Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Finite-Lived Intangible Assets One Genomics Customer One Genomics Customer [Member] One Genomics Customer Schedule of Company's Financial Instruments by Significant Investment Category Measured at Fair Value on a Recurring Basis Within the Fair Value Hierarchy Fair Value, Assets Measured on Recurring Basis [Table Text Block] Treasury Stock, Common [Member] Treasury Stock Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities State and Local Jurisdiction [Member] State and Local Jurisdiction Total Term Loan Facility Long-Term Line of Credit Line of credit outstanding Amount borrowed Goodwill, Impairment Loss Impairment of goodwill Segment Reporting, Policy [Policy Text Block] Segment Reporting Total Weighted Average Number of Shares Outstanding, Diluted, Adjustment Portion at Fair Value Measurement [Member] [Default] Portion at Fair Value Measurement [Member] Long-Lived Tangible Asset [Domain] Property, Plant and Equipment, Type [Domain] Subsequent Event [Table] Subsequent Event [Table] Inventories, net Increase (Decrease) in Inventories, Total Increase (Decrease) in Inventories Contract with Customer, Liability, Total Contract with Customer, Liability Deferred revenue Long-lived Assets Long-Lived Assets Lessee, Operating Lease, Existence of Option to Terminate [true false] Other Operating Activities, Cash Flow Statement Other non-cash items Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Goodwill and Intangible Asset Impairment, Total Goodwill and Intangible Asset Impairment Impairment of goodwill and intangibles Common Stock, Shares, Outstanding Ending balance (in shares) Beginning balance (in shares) Common stock, shares outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted average risk-free interest rate Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Stock-based Compensation Share-Based Payment Arrangement [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Goodwill [Roll Forward] Goodwill [Roll Forward] SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Charges to earnings Revenue From Contract With Customer, Performance Obligation Period Revenue From Contract With Customer, Performance Obligation Period Performance obligation period Business Combinations Policy [Policy Text Block] Business Combinations Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Increase (Decrease) In Fair Value Of Bridge Loans Increase (Decrease) In Fair Value Of Bridge Loans Change in fair value of Bridge Loans Change in the fair value of Bridge Loans Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-Average Grant Date Fair Value per Share Income Statement Location [Domain] Income Statement Location [Domain] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted (in dollars per share) Restricted Cash and Cash Equivalents, Current, Total Restricted Cash and Cash Equivalents, Current Restricted cash Business Combination and Asset Acquisition [Abstract] Business Combination and Asset Acquisition [Abstract] Document Type Document Type Line of Credit [Member] Line of Credit Accrued restructuring Accrued Restructuring, Current Accrued restructuring, current. 2019 Notes, non-current Senior Convertible Notes Due 2024, Non-current [Member] Senior convertible notes due 2024, non-current. Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Share-Based Payment Arrangement RSUs, PSUs, and stock options Share-Based Payment Arrangement [Member] Counterparty Name [Domain] Counterparty Name [Domain] Collaboration Revenue Collaboration Revenue [Member] Development revenue Development revenue Lease option to termination Lessee, Operating Lease, Option to Terminate Total inventory, gross Inventory, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (in shares) Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Short-term investments Short-Term Investments [Member] Entity Filer Category Entity Filer Category Customer advances Customer Advance, Current Customer advance, current Balance Sheet Location [Domain] Workers' Compensation Liability, Current Accrued incentive compensation Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Loss Before Income Taxes Geographic Concentration Risk [Member] Geographic Concentration Risk Variable Rate [Axis] Variable Rate [Axis] 2024 Lessor, Operating Lease, Payment to be Received, Year One Debt Instrument, Redemption, Period Three [Member] Redemption, Period Three Deferred Tax Assets, Tax Credit Carryforwards, Total Deferred Tax Assets, Tax Credit Carryforwards Tax credit carryforwards Transaction costs Effective Income Tax Rate Transaction Cost Effective income tax rate transaction cost. Liabilities Total liabilities Deferred Grant Income, Current Deferred Grant Income, Current Deferred grant income, current Foreign tax expense Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Property, Plant and Equipment [Table] Schedule of Property, Plant and Equipment [Table] Finite-Lived Intangible Assets, Remaining Amortization Period Weighted-Average Amortization Period Final payment fee and accrued interest due Debt Instrument Final Payment Fee And Accrued Interest Due Debt instrument, final payment fee and accrued interest due. Payments to Acquire Short-Term Investments Purchases of short-term investments Impairment charge Asset Impairment Charges, Total Asset Impairment Charges Asset impairment charges Total stockholders' deficit Equity, Attributable to Parent Ending balance Beginning balance Product And Service Product And Service [Member] Total product and service revenue Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference Intangible Assets, Net (Excluding Goodwill), Total Intangible Assets, Net (Excluding Goodwill) Developed technology, net Lessor, operating lease, remaining term of contract Lessor, Operating Lease, Remaining Term Of Contract1 Lessor, Operating Lease, Remaining Term Of Contract1 Net Income (Loss) Net loss Net loss Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Interest Expense, Total Interest Expense Interest expense Business Description and Basis of Presentation [Text Block] Description of Business Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State tax expense, net of federal benefit Uninvoiced receipts Uninvoiced Receipts Current Uninvoiced receipts current. Facility Costs Facility Closing [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Number Of Months To Vest Ratably After First Anniversary Of Vesting Commencement Number Of Months To Vest Ratably After First Anniversary Of Vesting Commencement Number of months over which options vest ratably Convertible Debt [Member] Convertible Debt Fair Value Measurement, Policy [Policy Text Block] Fair Value of Financial Instruments Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Shares used in computing net loss per share, diluted (in shares) Schedule of Reconciliation of Income Taxes at Statutory Rate to (Provision for)/Benefit (expense) from Income Taxes Recorded in Statements of Operations Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Credit Facility [Axis] Credit Facility [Axis] Effective Income Tax Rate Reconciliation, Percent Effective tax rate Deferred Federal Income Tax Expense (Benefit) Federal Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Reserves and accruals Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Accrued Compensation and Related Benefits Amortized Cost Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Accumulated depreciation expenses Research And Development Arrangement, Contract To Perform For Others, Accumulated Depreciation Expenses Research And Development Arrangement, Contract To Perform For Others, Accumulated Depreciation Expenses Cumulative amounts applied against depreciation expense for assets placed in service Cumulative amounts applied against depreciation expense for assets placed in service Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term (in years) Restructuring Reserve, Current Accrued restructuring Debt Instrument, Redemption Price, Percentage Debt instrument redemption price Use of Estimates, Policy [Policy Text Block] Use of Estimates Income Tax Disclosure [Text Block] Income Taxes Deferred Tax Assets, Net [Abstract] Deferred tax assets: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Ending balance (in dollars per share) Beginning balance (in dollars per share) Stock Option Grants Exercise Price Minimum Percentage On Fair Market Value Stock Option Grants Exercise Price Minimum Percentage On Fair Market Value Stock option grants exercise price minimum percentage on fair market value SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Leasehold Improvements [Member] Leasehold improvements Income Tax Authority [Axis] Income Tax Authority [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Cost of revenue: Costs and Expenses [Abstract] Debt Instrument, Redemption, Period One [Member] Redemption, Period One Total current tax expense Current Income Tax Expense (Benefit), Total Current Income Tax Expense (Benefit) Debt Instrument, Face Amount, Per Instrument Debt Instrument, Face Amount, Per Instrument Debt instrument, face amount, per instrument Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Domain] Proceeds from Research and Development Grant Proceeds from Research and Development Grant Proceeds from NIH Contract Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Type of Restructuring [Domain] Type of Restructuring [Domain] Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Consumables [Member] Consumables [Member] Consumables Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Released (in shares) Stock Issued During Period, Shares, New Issues Shares issued (in shares) Employee-related Liabilities, Current Accrued compensation and related benefits Accrued compensation and related benefits Business Acquisition [Axis] Business Acquisition [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Intangible Assets and Other Long-Lived Assets Operating Loss Carryforwards Operating loss carryforward XML 15 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Feb. 21, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Document Financial Statement Error Correction [Flag] false    
Entity File Number 001-34180    
Entity Registrant Name STANDARD BIOTOOLS INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 77-0513190    
Entity Address, Address Line One 2 Tower Place, Suite 2000    
Entity Address, City or Town South San Francisco,    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94080    
City Area Code 650    
Local Phone Number 266-6000    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol LAB    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 132.7
Entity Common Stock, Shares Outstanding (shares)   290,117,930  
Documents Incorporated by Reference

Portions of the registrant’s proxy statement in connection with the registrant’s annual meeting of stockholders, scheduled to be held in June 2024, are incorporated by reference in Part III of this report. Except as expressly incorporated by reference, such proxy statement shall not be deemed to be part of this report.

    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001162194    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location San Jose, California
Auditor Firm ID 238
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 51,704 $ 81,309
Short-term investments 63,191 84,475
Accounts receivable (net of allowances of $312 and $592 at December 31, 2023 and 2022, respectively) 19,660 17,280
Inventories, net 20,533 21,473
Prepaid expenses and other current assets 3,127 4,278
Total current assets 158,215 208,815
Property and equipment, net 24,187 25,652
Operating lease right-of-use asset, net 30,663 33,883
Other non-current assets 2,285 3,109
Developed technology, net 1,400 12,600
Goodwill 106,317 106,251
Total assets 323,067 390,310
Current liabilities:    
Accounts payable 9,236 7,914
Accrued compensation and related benefits 11,867 9,153
Operating lease liabilities, current 4,323 3,682
Deferred revenue, current 11,607 10,792
Deferred grant income, current 3,612 3,644
Other accrued liabilities 9,152 6,175
Term loan, current 5,000 2,083
Convertible notes, current 54,530 0
Total current liabilities 109,327 43,443
Convertible notes, non-current 569 54,615
Term loan, non-current 3,414 8,194
Deferred tax liability 841 1,055
Operating lease liabilities, non-current 30,374 34,081
Deferred revenue, non-current 3,520 3,816
Deferred grant income, non-current 10,755 14,359
Other non-current liabilities 1,065 961
Total liabilities 159,865 160,524
Commitments and contingencies (Note 8)
Mezzanine equity:    
Redeemable preferred stock: $0.001 par value; 256 shares authorized, issued and outstanding at December 31, 2023 and 2022; aggregate liquidation preference of $255,559 at December 31, 2023 and 2022 311,253 311,253
Stockholders' deficit:    
Preferred stock: $0.001 par value, 9,744 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 0 0
Common stock: $0.001 par value, 400,000 shares authorized at December 31, 2023 and 2022; 83,364 and 79,904 shares issued at December 31, 2023 and 2022, respectively; 80,232 and 79,482 shares outstanding at December 31, 2023 and 2022, respectively 83 80
Additional paid-in capital 860,816 847,008
Accumulated other comprehensive loss (2,221) (1,896)
Accumulated deficit (1,000,752) (926,096)
Treasury stock at cost: 3,132 and 422 shares at December 31, 2023 and 2022, respectively (5,977) (563)
Total stockholders' deficit (148,051) (81,467)
Total liabilities, mezzanine equity and stockholders' deficit $ 323,067 $ 390,310
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Accounts receivable, allowances $ 312 $ 592
Redeemable preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Redeemable preferred stock, shares authorized (in shares) 256,000 256,000
Redeemable preferred stock, shares issued (in shares) 256,000 256,000
Redeemable preferred stock, shares outstanding (in shares) 256,000 256,000
Redeemable preferred stock, aggregate liquidation preference $ 255,559 $ 255,559
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 9,744,000 9,744,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 400,000,000 400,000,000
Common stock, shares issued (in shares) 83,364,000 79,904,000
Common stock, shares outstanding (in shares) 80,232,000 79,482,000
Treasury stock (in shares) 3,132,000 422,000
Accumulated other comprehensive loss $ (2,221) $ (1,896)
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:    
Total revenue $ 106,340 $ 97,948
Cost of revenue:    
Total cost of revenue 55,890 60,897
Gross profit 50,450 37,051
Research and development 25,948 37,382
Selling, general and administrative 87,541 102,285
Restructuring and related charges 7,076 9,732
Transaction-related expenses 6,485 3,857
Total operating expenses 127,050 153,256
Loss from operations (76,600) (116,205)
Interest expense (4,567) (4,331)
Loss on forward sale of Series B Preferred Stock 0 (60,081)
Loss on Bridge Loans 0 (13,719)
Other income (expense), net 6,963 1,408
Loss before income taxes (74,204) (192,928)
Income tax benefit (expense) (452) 2,830
Net loss $ (74,656) $ (190,098)
Net loss per share, basic (in dollars per share) $ (0.94) $ (2.43)
Net loss per share, diluted (in dollars per share) $ (0.94) $ (2.43)
Shares used in computing net loss per share, basic (in shares) 79,160 78,305
Shares used in computing net loss per share, diluted (in shares) 79,160 78,305
Service revenue    
Revenue:    
Total revenue $ 25,980 $ 23,712
Product revenue    
Revenue:    
Total revenue 79,198 72,454
Cost of revenue:    
Total cost of revenue 44,942 52,555
Service and other revenue    
Revenue:    
Total revenue 27,142 25,494
Cost of revenue:    
Total cost of revenue 10,948 8,342
Other revenue    
Revenue:    
Total revenue $ 1,162 $ 1,782
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net loss $ (74,656) $ (190,098)
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustment (849) (487)
Net change in unrealized gain (loss) on investments 524 (502)
Other comprehensive income (loss), net of tax (325) (989)
Comprehensive loss $ (74,981) $ (191,087)
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accum. Other Comp. (Loss)
Accum. Deficit
Treasury Stock
Beginning balance (in shares) at Dec. 31, 2021   76,919,000        
Beginning balance at Dec. 31, 2021 $ 94,596 $ 77 $ 831,424 $ (907) $ (735,998)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of restricted stock, net of shares withheld for taxes (in shares)   2,373,000        
Issuance of restricted stock, net of shares withheld for taxes (211) $ 2 (213)      
Issuance of common stock under ESPP (in shares)   583,000        
Issuance of common stock under ESPP 820 $ 1 819      
Issuance of common stock from stock option exercises (in shares)   29,000        
Issuance of common stock from stock option exercises 98   98      
Stock-based compensation expense 14,880   14,880      
Repurchase of common stock (in shares)           (422,000)
Repurchase of common stock (563)         $ (563)
Net loss (190,098)       (190,098)  
Other comprehensive loss, net of tax $ (989)     (989) 0  
Ending balance (in shares) at Dec. 31, 2022 79,482,000 79,904,000        
Ending balance at Dec. 31, 2022 $ (81,467) $ 80 847,008 (1,896) (926,096) $ (563)
Treasury stock, ending balance (in shares) at Dec. 31, 2022 422,000         (422,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of restricted stock, net of shares withheld for taxes (in shares)   2,946,000        
Issuance of restricted stock, net of shares withheld for taxes $ (116) $ 3 (119)      
Issuance of common stock under ESPP (in shares)   470,000        
Issuance of common stock under ESPP $ 723   723      
Issuance of common stock from stock option exercises (in shares) 44,000 44,000        
Issuance of common stock from stock option exercises $ 81   81      
Stock-based compensation expense $ 13,123   13,123      
Repurchase of common stock (in shares) 2,709,703         (2,710,000)
Repurchase of common stock $ (5,414)         $ (5,414)
Net loss (74,656)       (74,656)  
Other comprehensive loss, net of tax $ (325)     (325)    
Ending balance (in shares) at Dec. 31, 2023 80,232,000 83,364,000        
Ending balance at Dec. 31, 2023 $ (148,051) $ 83 $ 860,816 $ (2,221) $ (1,000,752) $ (5,977)
Treasury stock, ending balance (in shares) at Dec. 31, 2023 3,132,000         (3,132,000)
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating activities    
Net loss $ (74,656) $ (190,098)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss on forward sale of Series B Preferred Stock 0 60,081
Loss on bridge loans 0 13,719
Stock-based compensation expense 13,123 14,880
Amortization of developed technology 11,200 11,528
Depreciation and amortization 3,980 3,499
Provision for excess and obsolete inventory 1,496 7,874
Impairment of InstruNor developed technology intangible 0 3,526
Amortization of debt discounts, premiums and issuance costs 770 830
Other non-cash items (987) 273
Changes in assets and liabilities:    
Accounts receivable, net (2,991) 1,063
Inventories, net (4,914) (8,470)
Prepaid expenses and other assets 960 33
Accounts payable 1,618 (2,776)
Accrued compensation and related benefits 3,018 4,113
Deferred revenue 884 (3,467)
Other liabilities 3,212 (5,978)
Net cash used in operating activities (43,287) (89,370)
Investing activities    
Purchases of short-term investments (94,896) (137,302)
Proceeds from sales and maturities of investments 117,964 53,000
Purchases of property and equipment (2,831) (3,825)
Net cash provided by (used in) investing activities 20,237 (88,127)
Financing activities    
Proceeds from bridge loans 0 25,000
Proceeds from issuance of Series B Preferred Stock 0 225,000
Repayment of term loan and advances under revolving credit facility (2,083) (6,838)
Payment of debt and equity issuance costs 0 (12,547)
Repurchase of common stock (5,414) (563)
Proceeds from ESPP stock issuance and exercise of stock options 827 917
Payments for taxes related to net share settlement of equity awards and other (139) (211)
Net cash provided by (used in) financing activities (6,809) 230,758
Effect of foreign exchange rate fluctuations on cash and cash equivalents 34 (404)
Net increase (decrease) in cash, cash equivalents and restricted cash (29,825) 52,857
Cash, cash equivalents and restricted cash at beginning of period 82,324 29,467
Cash, cash equivalents and restricted cash at end of period 52,499 82,324
Supplemental disclosures of cash flow information    
Cash paid for interest 3,819 3,493
Cash paid for income taxes, net of refunds 801 309
Non-cash right-of-use assets and lease liabilities 629 651
Asset retirement obligations $ 758 $ 718
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Description of Business
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

1. Description of Business

Standard BioTools Inc. (Standard BioTools or the Company), formerly known as Fluidigm Corporation, is a Delaware corporation headquartered in South San Francisco, California.

The Company has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company endeavors to provide reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy.

On January 5, 2024, the Company completed its previously announced merger (the Merger) with SomaLogic, Inc. (SomaLogic) a protein biomarker discovery company enabling researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. See Note 16 – Subsequent Events, for more information.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of the Company's wholly owned subsidiaries. As of December 31, 2023, the Company had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, Italy, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves, the carrying value of goodwill and other long-lived assets, and the potential outcome of uncertain tax positions that have been recognized in the Company's financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company's consolidated financial statements.

Foreign Currency

Assets and liabilities of non-U.S. subsidiaries that use their local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. Income and expense accounts are translated at monthly average exchange rates during the year. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity (deficit).

Revenue Recognition

The Company generates revenue primarily from the sale of its products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. The Company also generates revenue from product development agreements, license and royalty agreements, and grants. Revenue is reported net of any sales, use and value-added taxes the Company collects from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue.

The Company recognizes revenue based on the amount of consideration it expects to receive in exchange for the goods and services it transfers to the customer. The Company's commercial arrangements typically include multiple distinct products and services, and the Company allocates revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices

(SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price.

Product Revenue

The Company recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in 30 to 60 days.

The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.

Service and Other Revenue

The Company recognizes revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed.

Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally one to three years. The Company believes this time-elapsed approach is appropriate for service contracts because the Company provides services on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments made in advance of service are reported on the Company's consolidated balance sheet as deferred revenue.

Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.

The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC Topic 606, Revenue from Contracts with Customers, as the grant agreement is not with a customer. As there is no authoritative U.S. GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC Topic 958, Not-for-Profit Entities by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.

Significant Judgments

Applying the revenue recognition practices discussed above often requires significant judgment. Significant judgment is required when interpreting commercial terms in sales agreements and determining when control of goods and services passes to the customer. Judgment is also required when identifying performance obligations, estimating SSP and allocating purchase consideration in agreements that include multiple performance obligations. Any material changes created by errors in judgment could have a material effect on the Company's operating results and overall financial condition.

Cash and Cash Equivalents

The Company considers all highly liquid financial instruments with maturities at the time of purchase of three months or less to be cash equivalents. Cash and cash equivalents balance at December 31, 2023, and 2022 represent cash on deposit with banks and money market funds.

Short-term Investments

Short-term investments are comprised of U.S treasury securities that mature within one year. The Company classifies its short-term investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets. Any unrealized gains and losses from short-term investments are reported as a component of other comprehensive income (loss) within the consolidated statements of comprehensive loss and as a separate component of stockholders’ equity (deficit). The Company evaluates its short-term investments to assess whether investments with unrealized loss positions are other-than-temporarily impaired. An investment is

considered to be other-than-temporarily impaired if the impairment is related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of their cost basis. No investment has been assessed as other than temporarily impaired. Realized gains and losses are calculated on the specific identification method and are recorded as interest income (loss). There were no realized gains and losses from sales of short-term investments during any of the periods presented.

The Company excludes accrued interest from the fair value and amortized cost basis of its short-term investments.

Accounts Receivable, net

Trade accounts receivable are recorded at net invoice value. The Company reviews its exposure to accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The Company evaluates such allowances on a regular basis and adjust them as needed.

Concentrations of Business and Credit Risk

Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, short-term investments, and accounts receivable. The Company's cash, cash equivalents, and short-term investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of risk. Under the Company's investment policy, the Company invests exclusively in securities issued by the U.S. government or U.S. government agencies, or in government money-market funds. The goals of the Company's investment policy, in order of priority, are to: preserve capital, meet liquidity needs, and optimize returns. For these reasons, management believes that the Company is not exposed to significant credit risk.

The Company generally does not require collateral to support credit sales. To reduce credit risk, the Company performs credit evaluations of its customers.

The Company's products include components that are currently procured from a single source or a limited number of sources. The Company believes that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, the Company attempts to maintain an adequate supply of critical limited-source components.

Inventories, net

Inventories are stated at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company regularly reviews inventory for excess and obsolete products and components. Significant judgment is required in determining provisions for slow-moving, excess, and obsolete inventories which are recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, product expiration, discontinuance of product lines, and quality issues.

Property and Equipment, net

Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Accumulated depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The estimated useful lives of the Company's property and equipment are generally as follows: computer equipment and software, three to four years; laboratory and manufacturing equipment, two to seven years; and office furniture and fixtures, five years.

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. Lease terms are determined at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For its long-term operating leases, the Company recognizes a lease liability and a right-of-use asset (ROU) on its consolidated balance sheets. ROU assets represent the Company's right-to-use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The lease liability is determined at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a term similar to the lease arrangement. Significant judgment is required in determining the incremental

collateralized borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. Lease expense is recognized on a straight-line basis over the lease term. Sublease income from an operating lease is recognized on a straight-line basis over the sublease term. The Company does not have any finance leases.

The Company elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify, the Company will not recognize ROU assets or lease liabilities for leases with an initial lease term of one year or less. The Company also elected not to separate lease and nonlease components for the Company's building leases. The nonlease components are generally variable in nature and are expected to represent most of the Company's variable lease costs. Variable costs are expensed as incurred. The Company has taken a portfolio approach for its vehicle leases by country.

Business Combinations, Goodwill, Intangible Assets and Other Long-Lived Assets

The Company has completed acquisitions of businesses in the past and may acquire additional businesses or technologies in the future. The results of businesses acquired in a business combination are included in the Company's consolidated financial statements from the date of acquisition. The Company allocates the purchase price, which is the sum of the consideration provided in a business combination, to the identifiable assets and liabilities of the acquired business at their acquisition date fair values. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and estimates of future revenue.

Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The Company's intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Judgment is needed to assess the factors that could indicate an impairment of intangible assets.

Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that the Company will be required to recognize an impairment charge include, but are not limited to, declines in the Company's stock price or market capitalization, economic downturns and other macroeconomic events, declines in the Company's market share or revenues, or significant litigation. Any impairment charges could have a material adverse effect on the Company's operating results and net asset value in the period in which the Company recognizes the impairment charge.

In evaluating goodwill and intangible assets with indefinite lives for indications of impairment, the Company first conducts an assessment of qualitative factors to determine whether it is more likely than not that the fair value of each of the Company's reporting units is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of each of its reporting units is less than its carrying amount, the Company compares the fair value of each of its reporting units to its carrying value. If the fair value of each of the Company's reporting units exceeds its carrying value, goodwill is not considered impaired, and no further analysis is required. If the carrying value of each of the Company's reporting units exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill.

The Company evaluates its long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, the Company estimates the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly.

Series B Redeemable Preferred Stock

The Purchase Agreements (as described in Note 9) for the issuance of shares of Series B Redeemable Preferred Stock were accounted for as forward sales contracts at fair value in accordance with ASC Topic 480, Distinguishing Liabilities from Equities. The Series B Redeemable Preferred Stock was classified as mezzanine equity and recorded at fair value upon issuance, net of issuance costs, due to its redemption features that are outside of the Company’s control. Mezzanine equity is presented separately on the consolidated balance sheets between liabilities and shareholders’ equity because it shares characteristics of both. In the year ended December 31, 2022, the Company recognized a $60.1 million loss on the forward sales of Series B Preferred Stock and a $13.7 million loss on the Bridge Loans due to the increase in the price of the Company's common stock from January 23, 2022 (the date of the Purchase Agreements and the Bridge Loan agreements) to the Private Placement Closing Date. See Note 9 for additional information.

Restructuring and Related Charges

The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Costs for involuntary separation programs are recorded when management has approved the plan for separation, the employees are identified and made aware of the benefits they are entitled to, it is unlikely that the plan will change significantly, and if applicable, any required governmental notification is made. Costs associated with benefits that are contingent on the employee continuing to provide service are recognized over the required service period. Costs associated with leased facilities (net of sublease income, if applicable) that the Company has vacated as part of a restructuring plan are also included.

Transaction-related Expenses

The Company expensed certain costs incurred related to the merger agreement with SomaLogic, described further in Note 16, including legal, advisory, accounting and other transaction-related costs. The expenses in the prior period relate to the private placement whereby the Company issued and sold an aggregate of $225.0 million of convertible preferred stock in connection with the conversion of the bridge loans, which closed on April 4, 2022.

Deferred Grant Income

Proceeds from the NIH Contract have been principally recorded as capital expenditures and to offset applicable operating costs. The non-operating income recognized from the grant proceeds received in excess of the amounts spent for capital expenditures and operating expenses is reflected on the consolidated statement of operations as surplus funding from the NIH contract.

The NIH Contract met the definition of grants related to assets as the primary purpose for the payments was to fund the purchase and construction of capital assets to scale up production capacity. The Company elected to record the grants received as deferred income in accordance with International Accounting Standards (IAS) 20.

Deferred grant income related to production capacity expansion is being amortized for the related assets as a reduction of depreciation expense.

Term Loan, net

The term loan is recorded at its carrying value, which includes the outstanding principal amount and the cumulative accreted final payment, less unamortized debt issuance costs. Amortization of the debt issuance costs and accretion of the final payment are reflected in interest expense. The final payment is being accreted to the carrying value of the term loan through the expected maturity of July 1, 2025 using the effective interest method. Debt issuance costs were recorded as an offset to the carrying value of the loan and are amortized over the expected term also using the effective interest method.

Convertible Notes, net

The Company records the 2014 Notes and 2019 Notes (as described in Note 6) at their carrying values, which includes their principal amounts plus accrued and unpaid interest. Offering-related costs, including underwriting costs, on the 2014 Notes and 2019 Notes were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method.

Treasury Stock

The Company uses the cost method to account for the repurchases of its common stock in accordance with ASC 505-30, Equity-Treasury Stock. The direct costs associated with settled share repurchases, including trading commissions, are reported as treasury stock in the shareholders’ equity (deficit) section of the Company's consolidated balance sheets.

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of cash and cash equivalents, restricted cash, short-term investments, accounts receivable, accounts payable, term loan and convertible notes. The Company's cash equivalents, restricted cash, accounts receivable and accounts payable generally have short maturity or payment periods. Accordingly, their carrying values approximated their fair values at December 31, 2023 and 2022. The Company's short-term investments consist of U.S. treasury securities that are classified as available-for-sale and reported at fair value on the Company's consolidated balance sheets. The convertible notes and term loan are presented at their net carrying values.

As a basis for computing fair value, the Company follows a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level I: observable inputs such as quoted prices in active markets;

Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and

Level III: unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's cash equivalents, which include money market funds are classified as Level I because they are valued using quoted market prices. The Company's short-term investments, which include U.S. treasuries, are classified as Level II because they are valued using non-binding market consensus prices that were corroborated with observable market data, quoted market prices for similar instruments, or pricing models.

The Company's convertible notes are not regularly traded, and it is difficult to estimate a reliable and accurate market price for these securities. The estimated fair values of these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the Company's term loan also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's term loan was estimated using a discounted cash flows approach and current market interest rate data for similar loans. The carrying value of the Company's lines of term loan approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions.

Research and Development

The Company recognizes research and development expenses in the period incurred. Research and development (R&D) expenses generally consist of personnel costs, independent contractor costs, prototype and materials expenses, allocated facilities and information technology expenses, and related overhead expenses.

Advertising Costs

The Company expenses advertising costs as incurred. The Company incurred advertising costs of $2.0 million and $3.9 million during the years ended December 31, 2023 and 2022, respectively.

Stock-Based Compensation

The Company recognizes compensation costs for all stock-based awards, including stock options, Restricted Share Units (RSUs), Performance Share Units (PSUs) and stock purchased under the Company's Employee Share Purchase Plan (ESPP), based on the grant date fair value of the award. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service periods for non-performance-based awards. For RSUs, fair value is measured based on the closing fair market value of the Company's common stock on the date of grant. For PSUs with a market condition, the Company uses a Monte Carlo simulation pricing model to incorporate the market condition effects at the grant date. The Monte Carlo pricing model requires inputs which are subjective and generally requires judgment. For PSUs with performance conditions, stock-based compensation expense is recognized over the requisite service period when the achievement of each individual performance goal becomes probable.

The fair value of options and stock purchases under ESPP on the grant date is estimated using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions, including expected term, volatility, risk-free interest rate and the fair value of the Company's common stock. These assumptions generally require judgment. The Company determines the expected volatility based on the Company's historical stock price volatility generally commensurate with the estimated expected term of the stock awards. The expected term of an award is based on historical forfeiture experience, exercise activity, and the terms and conditions of the stock awards. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each grant’s expected term. The Company accounts for forfeitures as they occur.

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and

liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans and estimates. Should the actual amounts differ from the Company's estimates, the amount of the valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to the Company's tax provision in a period in which such estimates are changed, which in turn would affect net income or loss.

The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. Any interest and penalties related to uncertain tax positions are reflected in the income tax provision.

Segment Reporting

The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.

The Company's CEO, who is its Chief Operating Decision Maker (CODM), measures segment performance using gross profit which is determined by subtracting cost of product and service revenues from segment revenues. Depreciation and amortization expense is included in each segment’s gross profit.

Comprehensive Loss

Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on the Company's short-term investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of comprehensive loss.

Net Loss per Share

The Company's basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. RSUs, PSUs, stock options to purchase the Company's common stock, ESPP shares pending issuance, Series B Preferred Stock and convertible notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.

The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

RSUs, PSUs, stock options and ESPP shares

 

 

16,740

 

 

 

15,752

 

Series B Preferred Stock

 

 

75,164

 

 

 

75,164

 

2019 Notes(1)

 

 

18,966

 

 

 

18,966

 

2014 Notes

 

 

10

 

 

 

10

 

Total

 

 

110,880

 

 

 

109,892

 

 

(1)
The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to Note 6 for additional information on the 2019 Notes.

 

The 2,709,703 common shares that were repurchased during the year ended December 31, 2023 have also been excluded from the Company's earnings per share and diluted earnings per share calculations.

Recent Accounting Changes and Accounting Pronouncements

Adoption of New Accounting Guidance

From time to time, new accounting standards are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures, which requires disclosure of more detailed information about a reportable segment’s expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.

Reclassification

Certain amounts in the consolidated financial statements have been reclassified from their original presentation to conform to current year presentation.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Geographic Area
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue and Geographic Area

3. Revenue and Geographic Area

Disaggregation of Revenue by Product Type and Geographic Area

The following tables present the Company's revenue for the years ended December 31, 2023 and 2022, respectively, based on product type and the geographic location of customers’ facilities (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Instruments

 

$

37,459

 

 

$

25,664

 

Consumables

 

 

41,739

 

 

 

46,790

 

Total product revenue

 

 

79,198

 

 

 

72,454

 

Service revenue

 

 

25,980

 

 

 

23,712

 

Product and service revenue

 

 

105,178

 

 

 

96,166

 

Other revenue

 

 

1,162

 

 

 

1,782

 

Total revenue

 

$

106,340

 

 

$

97,948

 

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Americas

 

$

46,196

 

 

$

43,982

 

Europe, Middle East and Africa (EMEA)

 

 

36,201

 

 

 

33,136

 

Asia-Pacific

 

 

23,943

 

 

 

20,830

 

Total revenue

 

$

106,340

 

 

$

97,948

 

 

Most of the Company's principal operations, other than manufacturing, are located at its corporate headquarters in the United States. Revenue from customers in the United States represented $44.1 million, or 42%, of total revenues for the year ended December 31,

2023, and $41.0 million, or 42%, of total revenues for the year ended December 31, 2022. Refer to Note 13 for additional information on revenue by reporting segment.

Revenue from customers in China represented $15.8 million, or 15%, of total revenues for the year ended December 31, 2023, and 11% of total revenues for the year ended December 31, 2022. With the exception of China in 2023 and 2022, no foreign country or jurisdiction had revenue in excess of 10% of the Company's total revenue during the years ended December 31, 2023 and 2022.

One genomics customer accounted for 10% and 11% of the Company's total revenue for the years ended December 31, 2023 and 2022, respectively, and 14% and 16% of outstanding net trade receivables at December 31, 2023 and 2022, respectively. No other customer represented more than 10% of the Company's total revenue for the fiscal years ended December 31, 2023 and 2022. Revenue from the Company's five largest customers represented 24% of total revenue for the year ended December 31, 2023 and 19% of total revenue the year ended December 31, 2022.

Long-lived Assets by Geographical Area

The Company had long-lived assets consisting of property and equipment, net of accumulated depreciation, and operating lease ROU assets, net of accumulated amortization, in the following geographic areas for each year presented (in thousands):

 

 

December 31,

 

 

2023

 

 

2022

 

United States

 

$

29,646

 

 

$

31,785

 

Singapore

 

 

17,097

 

 

 

21,178

 

Canada

 

 

6,231

 

 

 

5,394

 

Other Asia-Pacific

 

 

889

 

 

 

875

 

EMEA

 

 

987

 

 

 

303

 

Total

 

$

54,850

 

 

$

59,535

 

Unfulfilled Performance Obligations

The consolidated balance sheets as of December 31, 2023 and 2022 included total deferred revenue of $15.1 million and $14.6 million, respectively. During the year ended December 31, 2023, $10.6 million of the opening deferred revenue balance was recognized as revenue and $11.1 million of net additional advance payments, primarily for instrument service contracts, were received from customers.

 

The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of December 31, 2023 in the following periods (in thousands):

 

Fiscal Year

 

Expected Revenue (1)

 

2024

 

 

13,253

 

2025

 

 

6,634

 

2026

 

 

3,061

 

Thereafter

 

 

1,112

 

Total

 

$

24,060

 
(1)
Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins.

The Company also has unsatisfied performance obligations for service contracts with an expected term of one year or less not included in the amounts above.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets, net
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, net

4. Goodwill and Intangible Assets, net

During the second quarter of 2022, the Company discontinued the sale of products that utilized the developed technology acquired from InstruNor and recorded a $3.5 million impairment charge to write-off the unamortized portion of the related intangible asset.

The Company assessed goodwill for impairment when it performed its annual testing at the end of the fourth quarter of 2023. A qualitative approach was employed which included assessing significant events and circumstances such as the Company's current results,

assumptions regarding future performance, strategic initiatives and overall macroeconomic factors to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of each of the Company's reporting units is less than their carrying value. The Company determined there was no impairment as of December 31, 2023.

The changes in the carrying value of goodwill by segment are as follows (in thousands):

 

 

Proteomics

 

 

Genomics

 

 

Total

 

Balance as of December 31, 2022

 

$

85,752

 

 

$

20,499

 

 

$

106,251

 

Foreign currency translation

 

 

46

 

 

 

20

 

 

 

66

 

Balance as of December 31, 2023

 

$

85,798

 

 

$

20,519

 

 

$

106,317

 

 

Intangible assets with finite lives include developed technology, patents and licenses. In the consolidated balance sheets, developed technology is reported separately while patents and licenses are reported in other non-current assets. Intangible assets, net, were as follows (in thousands):

 

 

 

December 31, 2023

 

 

Gross Amount

 

 

Accumulated
Amortization
and
Impairment

 

 

Net

 

 

Weighted-
Average
Amortization
Period

Developed technology

 

$

117,354

 

 

$

(115,954

)

 

$

1,400

 

 

10.0 years

Patents and licenses

 

$

11,250

 

 

$

(11,243

)

 

$

7

 

 

7.0 years

 

 

 

December 31, 2022

 

 

Gross Amount

 

 

Accumulated
Amortization

 

 

Net

 

 

Weighted-
Average
Amortization
Period

Developed technology

 

$

117,194

 

 

$

(104,594

)

 

$

12,600

 

 

10.0 years

Patents and licenses

 

$

11,247

 

 

$

(10,669

)

 

$

578

 

 

7.0 years

 

Total amortization expense of the Company's intangible assets was $11.8 million and $12.2 million for the years ended December 31, 2023 and 2022, respectively. The $3.5 million impairment charge for the InstruNor developed technology intangible asset was recorded in research and development expense in 2022 and it is reflected in accumulated amortization in the above table.

Based on the net carrying value of intangible assets at December 31, 2023, the Company expects annual amortization expense to be as follows (in thousands):

 

Fiscal Year

 

Developed
Technology
Amortization
Expense

 

 

Patents and
Licenses
Amortization
Expense

 

 

Total

 

2024

 

 

1,400

 

 

 

7

 

 

 

1,407

 

Total

 

$

1,400

 

 

$

7

 

 

$

1,407

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details
 12 Months Ended
Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Details

5. Balance Sheet Details

Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Cash and cash equivalents

 

$

51,704

 

 

$

81,309

 

Restricted cash

 

 

795

 

 

 

1,015

 

Total cash, cash equivalents and restricted cash

 

$

52,499

 

 

$

82,324

 

 

 

Restricted cash of $0.8 and $1.0 million is included in other non-current assets on the consolidated balance sheets as of December 31, 2023 and 2022, respectively.

Inventories, net

Inventories, net consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Raw materials

 

$

15,539

 

 

$

16,866

 

Work-in-process

 

 

282

 

 

 

945

 

Finished goods

 

 

11,753

 

 

 

15,245

 

Total inventory, gross

 

 

27,574

 

 

 

33,056

 

Allowance for excess and obsolete inventory

 

 

(7,041

)

 

 

(11,583

)

Total inventories, net

 

$

20,533

 

 

$

21,473

 

 

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Laboratory and manufacturing equipment

 

$

35,563

 

 

$

33,329

 

Leasehold improvements

 

 

13,785

 

 

 

12,234

 

Computer equipment and software

 

 

6,232

 

 

 

5,793

 

Office furniture and fixtures

 

 

1,762

 

 

 

1,713

 

Property and equipment, gross

 

 

57,342

 

 

 

53,069

 

Less accumulated depreciation and amortization

 

 

(35,489

)

 

 

(29,029

)

Construction-in-progress

 

 

2,334

 

 

 

1,612

 

Property and equipment, net

 

$

24,187

 

 

$

25,652

 

 

Depreciation expense was $3.4 million and $2.8 million for the years ended December 31, 2023 and 2022, respectively.

Accrued Compensation and Related Benefits

Accrued compensation and related benefits, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Accrued incentive compensation

 

$

7,337

 

 

$

1,170

 

Accrued vacation

 

 

2,711

 

 

 

2,795

 

Accrued payroll taxes and other

 

 

994

 

 

 

1,174

 

Accrued restructuring

 

 

825

 

 

 

4,014

 

Accrued compensation and related benefits

 

$

11,867

 

 

$

9,153

 

 

Refer to Note 14 for additional information on restructuring.

Other Accrued Liabilities

Other accrued liabilities, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Accrued commissions

 

$

1,010

 

 

$

800

 

Accrued interest

 

 

295

 

 

 

318

 

Accrued legal expenses

 

 

964

 

 

 

349

 

Accrued taxes

 

 

1,230

 

 

 

1,443

 

Uninvoiced receipts

 

 

1,516

 

 

 

1,078

 

Accrued warranties

 

 

2,593

 

 

 

678

 

Customer advances

 

 

447

 

 

 

577

 

Accrued restructuring

 

 

—

 

 

 

19

 

Accrued other

 

 

1,097

 

 

 

913

 

Other accrued liabilities

 

$

9,152

 

 

$

6,175

 

Deferred Grant Income

In September 2020, the Company executed a contract with the National Institutes of Health (NIH) under NIH’s Rapid Acceleration of Diagnostics program to support the expansion of the Company’s production capacity for its COVID-19 test products. Under the now-completed contract, the Company received $34.0 million of funding from the NIH and used $22.2 million on capital expenditures for their Singapore manufacturing facility. The amortization of the deferred income, which is offset against depreciation, was $3.6 million and $3.5 million for the years ended December 31, 2023 and 2022, respectively. Cumulative amounts amortized and offsetting against depreciation expense for these assets placed in service were $7.8 million and $4.2 million as of December 31, 2023 and 2022, respectively, and the carrying values of these assets were $14.4 million and $18.0 million, respectively, as of these same dates.

The current portion of deferred grant income on the Company’s consolidated balance sheets represents amounts expected to be offset against depreciation expense over the next twelve months. The non-current portion of deferred grant income includes amounts expected to be offset against depreciation expense in later periods.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Debt

6. Debt

The carrying value of debt consists of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Convertible notes:

 

 

 

 

 

 

2014 Notes

 

$

569

 

 

$

568

 

2019 Notes, non-current

 

 

—

 

 

 

54,047

 

2019 Notes, current

 

 

54,530

 

 

 

—

 

Total convertible notes, net

 

 

55,099

 

 

 

54,615

 

Term loan, non-current

 

 

3,414

 

 

 

8,194

 

Term loan, current

 

 

5,000

 

 

 

2,083

 

Total debt

 

$

63,513

 

 

$

64,892

 

 

Convertible Notes

In February 2014, the Company closed an underwritten public offering of 2014 Senior Convertible Notes (2014 Notes), which will mature on February 1, 2034, unless earlier converted, redeemed or repurchased in accordance with the terms of the 2014 Notes. Holders may require the Company to repurchase all or a portion of their 2014 Notes on each of February 6, 2024 and February 6, 2029, at a repurchase price in cash equal to 100% of the principal amount of the 2014 Notes plus accrued and unpaid interest. On February 6, 2024, one holder of the 2014 Notes exercised their repurchase right, and the Company repurchased an immaterial amount of principal and accrued interest.

 

In November 2019, the Company issued $55.0 million aggregate principal amount of 2019 Senior Convertible Notes (2019 Notes). Net proceeds from the 2019 Notes issuance of $52.7 million, after deductions for commissions and other debt issuance costs, were used to retire all but $1.1 million of the aggregate principal value of the 2014 Notes then outstanding. The 2019 Notes bear interest at 5.25% per annum, payable semiannually on June 1 and December 1 of each year. The 2019 Notes will mature on December 1, 2024, unless

earlier repurchased or converted pursuant to their terms. The 2019 Notes will be convertible at the option of the holder at any point prior to the close of business on the second scheduled trading day preceding the maturity date. The initial conversion rate of the 2019 Notes is 344.8276 shares of the Company’s common stock per $1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately $2.90 per share). The conversion rate is subject to adjustment upon the occurrence of certain specified events. Those certain specified events include voluntary conversion of the 2019 Notes prior to the Company’s exercise of the Issuer’s Conversion Option (as defined therein) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2019 Notes. The conversion rate will not be adjusted for any accrued and unpaid interest. The 2019 Notes are convertible at the Company’s option in whole but not in part into shares of the Company’s common stock upon certain conditions if the volume-weighted average price of the Company’s common stock has equaled or exceeded 130% of the conversion price then in effect for a specified number of days.

Offering-related costs related to both notes were capitalized as debt issuance costs and are recorded as an offset to the carrying value of the 2019 Notes.

Revolving Credit Facility

On August 2, 2018, the Company entered into a revolving credit facility with Silicon Valley Bank (as amended, the Revolving Credit Facility) in an aggregate principal amount of up to the lesser of (i) $15.0 million or (ii) the sum of (a) 85% of eligible receivables and (b) 50% of eligible inventory, in each case, subject to certain limitations (Borrowing Base), provided that the amount of eligible inventory that may be counted towards the Borrowing Base shall be subject to a cap as set forth in the Revolving Credit Facility. The Revolving Credit Facility was collateralized by substantially all the Company’s property, other than intellectual property and contained certain financial covenants. There were no borrowings under the Revolving Credit Facility and it expired on August 2, 2023.

Term Loan Facility, net

On August 2, 2021, the Company amended its Revolving Credit Facility to, amongst other things, provide for a new $10.0 million term loan facility (the Term Loan Facility). As of December 31, 2023, the Term Loan Facility was fully drawn with an outstanding principal balance of $7.9 million and a carrying value of $8.4 million. The interest rate on the Term Loan Facility is the greater of 4.0% per annum or a floating per annum rate equal to the prime rate plus 0.75%. Interest on any outstanding term loan advances is due and payable monthly. In addition to the monthly interest payments, a final payment equal to 6.5% of the original principal amount of each advance is due the earlier of the maturity date or the date the advance is repaid. Principal balances are required to be repaid in 24 equal installments which began on August 1, 2023. The stated maturity of the Term Loan Facility is July 1, 2025. However, if the principal amount of the Company’s convertible debt exceeds $0.6 million as of June 1, 2024 or if the maturity date of the 2019 Notes has not been extended beyond January 1, 2026 by June 1, 2024, then the maturity date of the Term Loan Facility will be June 1, 2024. As there were no contractual requirement to repay the loan as of the balance sheet date, $3.4 million of the Term Loan Facility's carrying value is classified as non-current, consistent with its terms, on the Company’s balance sheet as of December 31, 2023.

On October 26, 2023, the Company entered into an amendment to the Term Loan Facility agreement which removed certain collateral covenants related to the Revolving Credit Facility due to its expiration on August 2, 2023.

Future minimum payments under the Term Loan Facility including the end of term fee payment as of December 31, 2023, are as follows (in thousands):

 

2024

 

$

5,000

 

2025

 

 

2,917

 

 

 

7,917

 

End of term fee and debt issuance costs

 

 

497

 

Total Term Loan Facility

 

$

8,414

 

Bridge Loans

On January 23, 2022, the Company entered into separate loan agreements (collectively, the Bridge Loan Agreements) with various investors for a $25.0 million term loan (collectively, the Bridge Loans). The Bridge Loans were fully drawn on January 24, 2022, and automatically converted into Series B Preferred Stock upon the subsequent closing of the Private Placement (as defined below) on April 4, 2022 (the Private Placement Closing Date).

Applying the guidance in ASC 825 Financial Instruments, the Company elected to record the Bridge Loans at their fair value using a probability‐weighted expected return method for the valuation analysis of the Bridge Loans. This resulted in a $13.7 million change

in fair value of the Bridge Loans from $25.0 million at inception to $38.7 million as of the Private Placement Closing Date, including the portion attributable to accrued interest, which is reflected as a non-operating unrealized loss on the Bridge Loans in the accompanying consolidated statements of operations for the year ended December 31, 2022. See Note 9 for further detail.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

7. Commitments and Contingencies

Leases

The Company has operating leases for buildings, equipment and vehicles. Existing leases have remaining terms ranging from less than one year to approximately 6 years. Some leases contain options to extend the lease, usually for up to five years, along with termination options. The Company’s facility lease has an expiration date of April 30, 2030 and contains an option to extend the lease, for up to five years, along with termination options. The Company is utilizing one floor (19th floor) for its corporate operations with all expense for this floor included within selling, general and administrative expense on the Company’s consolidated statement of operations for the years ended December 31, 2023 and 2022.

As part of the Company’s restructuring plan discussed further in Note 14, in August 2022, the Company entered into an agreement to sublease approximately 25% of its corporate headquarters space (18th floor) in South San Francisco, California for a period of 39 months. As of December 31, 2023, 24 months were remaining on the sublease. The Company expects to recognize $4.8 million of sublease income over the lease term that commenced in October 2022. At December 31, 2023, $2.9 million sublease income is expected to be recognized over the remaining lease term. In addition, on February 28, 2023, the Company signed a second agreement to sublease an additional 25% of its corporate headquarters (21st floor) for a period of 77 months, which commenced on December 1, 2023. The Company expects to recognize additional sublease income of $9.1 million over the lease term. At December 31, 2023, $9.0 million sublease income is expected to be recognized over the remaining lease term.

Rent expense, net of sublease income, is reported within restructuring and related charges for the year ended December 31, 2023, in the consolidated statements of operations. The Company is currently in the process of fully vacating and potentially subleasing an additional floor (20th floor).

Information about the Company's operating leases is as follows:

 

 

December 31, 2023

 

 

December 31, 2022

 

Weighted average remaining lease term (in years)

 

5.9 years

 

 

6.8 years

 

Weighted average discount rate per annum

 

 

11.8

%

 

 

11.8

%

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Operating lease cost (including variable costs)

 

$

11,159

 

 

$

10,917

 

Variable costs (including non-lease components)

 

$

3,164

 

 

$

2,930

 

Sublease income

 

$

2,679

 

 

$

189

 

Cash paid for amounts included in the measurement of
   operating lease liabilities

 

$

7,931

 

 

$

7,540

 

 

Future minimum lease payments and sublease income as of December 31, 2023 under commenced non-cancelable operating leases are as follows (in thousands):

 

Fiscal Year

 

Minimum Lease
Payments for
Operating Leases

 

 

Sublease Income

 

 

Net Minimum Lease Payments for Operating Leases

 

2024

 

$

8,086

 

 

$

(2,877

)

 

$

5,209

 

2025

 

 

8,135

 

 

 

(2,952

)

 

 

5,183

 

2026

 

 

7,821

 

 

 

(1,381

)

 

 

6,440

 

2027

 

 

7,395

 

 

 

(1,430

)

 

 

5,965

 

2028

 

 

7,355

 

 

 

(1,480

)

 

 

5,875

 

Thereafter

 

 

10,225

 

 

 

(2,058

)

 

 

8,167

 

Total future minimum payments (receipts)

 

 

49,017

 

 

$

(12,178

)

 

$

36,839

 

Imputed interest

 

 

(14,320

)

 

 

 

 

 

 

Total operating lease liabilities

 

 

34,697

 

 

 

 

 

 

 

Less: current portion of operating lease liabilities

 

 

4,323

 

 

 

 

 

 

 

Operating lease liabilities, net of current portion

 

$

30,374

 

 

 

 

 

 

 

Other Commitments

In the normal course of business, the Company enters into various contractual and legally binding purchase commitments. As of December 31, 2023, the Company's open commitments totaled $9.7 million. Capital expenditure commitments as of December 31, 2023 were immaterial.

The Company has entered into several license and patent agreements. Under these agreements, the Company pays annual license maintenance fees, non-refundable license issuance fees, and royalties as a percentage of net sales for the sale or sublicense of products using the licensed technology. Future payments related to these license agreements have not been included in the open commitments above, as the period of time over which the future license payments will be required to be made, and the amount of such payments, are indeterminable. The Company does not expect the license payments to be material in any particular year.

Indemnification

From time to time, the Company has entered into indemnification provisions under certain of its agreements in the ordinary course of business, typically with business partners, customers and suppliers. Pursuant to these agreements, the Company may indemnify, hold harmless and agree to reimburse the indemnified parties on a case-by-case basis for losses suffered or incurred by the indemnified parties in connection with any patent or other intellectual property infringement claim by any third party with respect to the Company’s products. The term of these indemnification provisions is generally perpetual from the time of the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is typically not limited to a specific amount. In addition, the Company has entered into indemnification agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding.

Litigation

On November 28, 2023, a purported stockholder filed a complaint against the Company and the members of the Company’s Board in the United States District Court for the Northern District of California. The complaint has since been voluntarily dismissed. On December 12, 2023 two separate shareholder complaints were filed in the District of Delaware, The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. The Company is reviewing the complaints and has not yet formally responded to them. On December 13, 2023, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed transaction, which was denied by the Court on January 4, 2024. The non-injunctive claims, including breach of fiduciary duty, are still being litigated. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs’ claim is successful, this type of litigation may result in significant costs and divert management’s attention and resources, which could adversely affect the operation of the Company.

Between October 24, 2023 and January 3, 2024, SomaLogic received 16 letters from purported shareholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement.

Additional lawsuits against the Company and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, the Company will not necessarily announce such additional filings.

In the normal course of business, the Company is from time to time involved in legal proceedings or potential legal proceedings, including matters involving employment, intellectual property, or others. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of any currently pending matters would not have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

8. Fair Value of Financial Instruments

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy (in thousands):

 

 

 

 

 

 

Fair Value Measurements At Reporting Date Using

 

 

 

Total

 

 

Quoted Prices in Active Markets For Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

As of December 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

35,385

 

 

$

35,385

 

 

$

—

 

 

$

—

 

Total cash and cash equivalents

 

$

35,385

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

63,191

 

 

$

—

 

 

$

63,191

 

 

$

—

 

Total short-term investments

 

$

63,191

 

 

$

—

 

 

$

63,191

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets measured at fair value

 

$

98,576

 

 

$

35,385

 

 

$

63,191

 

 

$

—

 

 

 

 

 

 

 

Fair Value Measurements At Reporting Date Using

 

 

 

Total

 

 

Quoted Prices in Active Markets For Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

As of December 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

53,894

 

 

$

53,894

 

 

$

—

 

 

$

—

 

Total cash and cash equivalents

 

$

53,894

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

84,475

 

 

$

84,475

 

 

$

—

 

 

$

—

 

Total short-term investments

 

$

84,475

 

 

$

84,475

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets measured at fair value

 

$

138,369

 

 

$

138,369

 

 

$

—

 

 

$

—

 

 

There were no transfers within the hierarchy and no changes in the valuation techniques used during the year ended December 31, 2023.

The following table summarizes available-for-sale-securities (in thousands):

 

 

 

 

 

 

 

 

As of December 31, 2023

 

 

 

Maturity (in years)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

$

35,385

 

Total cash and cash equivalents

 

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

$

35,385

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

1 or less

 

$

63,169

 

 

$

22

 

 

$

—

 

 

$

63,191

 

Total short-term investments

 

 

 

$

63,169

 

 

$

22

 

 

$

—

 

 

$

63,191

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total available-for-sale securities

 

 

 

$

98,554

 

 

$

22

 

 

$

—

 

 

$

98,576

 

 

 

 

 

 

 

 

 

As of December 31, 2022

 

 

 

Maturity (in years)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

$

53,894

 

Total cash and cash equivalents

 

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

$

53,894

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

1 or less

 

$

84,977

 

 

$

—

 

 

$

(502

)

 

$

84,475

 

Total short-term investments

 

 

 

$

84,977

 

 

$

—

 

 

$

(502

)

 

$

84,475

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total available-for-sale securities

 

 

 

$

138,871

 

 

$

—

 

 

$

(502

)

 

$

138,369

 

As of December 31, 2023, none of the available-for-sale securities held have been in an unrealized loss position for greater than 12 months. The Company does not intend to sell these investments and it is not likely that the Company will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recorded.

Debt

The 2014 Notes and 2019 Notes (collectively, the Convertible Notes) are not regularly traded. The estimated fair values for these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the 2019 Notes was $58.2 million and $48.4 million as of December 31, 2023 and 2022, respectively. The carrying value of the 2014 Notes approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions.

The estimated fair value of the Term Loan Facility also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's Term Loan Facility was estimated using a discounted cash flow model and current market interest rate data for similar loans. The carrying value of the Company's lines of Term Loan Facility approximates fair value as interest rates applied to the underlying debt are adjusted quarterly to market interest rates.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Mezzanine Equity
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Mezzanine Equity . Mezzanine Equity

Series B Redeemable Preferred Stock

On January 23, 2022, the Company entered into separate Series B Convertible Preferred Stock Purchase Agreements (collectively, the Purchase Agreements) with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, Casdin), and Viking Global Opportunities Illiquid Investments Sub Master LP and Viking Global Opportunities Drawdown LP (together, Viking, and together with Casdin, the Lenders), whereby the Company issued and sold an aggregate of $225.0 million of convertible preferred stock, consisting of: (i) 112,500 shares of the Company’s Series B-1 Convertible Preferred Stock, par value $0.001 per share (the Series B-1 Preferred Stock), at a purchase price of $1,000 per share; and (ii) 112,500 shares of the Company’s Series B-2 Convertible Preferred Stock, par value $0.001 per share (the Series B-2 Preferred Stock, and together with the Series B-1 Preferred Stock, the Series B Preferred Stock or the Series B Redeemable Preferred Stock) at a purchase price of $1,000 per share (together with the issuance of shares of Series B Preferred Stock in connection with the conversion of the Bridge Loans, the Private Placement). On the Private Placement Closing Date, 225,000 shares of Series B Preferred Stock were issued in accordance with the Purchase Agreements and the Bridge Loans

converted into 30,559 shares of Series B Preferred Stock, for a total of 255,559 shares of Series B Preferred Stock. The Company recorded the Series B Preferred Stock as mezzanine equity at its fair value upon issuance, net of any issuance costs, on the consolidated balance sheets as it has features, such as change of control and liquidation preference, which are outside of the Company’s control.

The Purchase Agreements were accounted for as forward sales contracts at fair value in accordance with the authoritative accounting guidance as the Series B Preferred Stock included certain contingent redemption features that created an obligation for the Company to repurchase its shares. The fair value of the payable portion of the forward sales contracts was determined using a Monte Carlo Simulation, which relies on significant assumptions regarding the estimated yield and term of the Series B Preferred Stock.

The components of the carrying value of the Series B Preferred Stock as of December 31, 2023 and 2022 were as follows (in thousands):

 

Proceeds from Purchase Agreements

 

$

225,000

 

Proceeds from Bridge Loans

 

 

25,000

 

Change in fair value of Forward Purchase Agreements

 

 

60,081

 

Change in the fair value of Bridge Loans

 

 

13,719

 

Less equity issuance costs

 

 

(12,547

)

Total Series B Redeemable Preferred Stock

 

$

311,253

 

 

The Series B Preferred Stock ranks senior to the Company's common stock with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The holders of Series B Preferred Stock are entitled to participate in all dividends declared on the Company's common stock on an as-converted basis.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Deficit
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Shareholders' Deficit

10. Shareholders' Deficit

Stock Repurchase Program

On November 23, 2022, the Company’s board of directors authorized the repurchase of up to $20.0 million in shares of the Company’s common stock in the open market or in negotiated transactions through December 31, 2023. The Company repurchased a total of 2,709,703 shares of common stock under the program at a cost of $5.4 million, excluding commission fees, for an average of $1.98 per share for the year ended December 31, 2023. Repurchases under the program were able to be suspended or discontinued at any time at the Company’s discretion, and on October 4, 2023, the Company terminated the program in connection with the announcement of the merger agreement with SomaLogic.

Common Shares Reserved

As of December 31, 2023, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

 

 

 

Securities To Be Issued Upon Exercise Of Options

 

 

Securities To Be Issued Upon Release Of Restricted Stock

 

 

Number Of Remaining Securities Available For Future Issuance

 

2022 Inducement Equity Incentive Plan

 

 

7,595

 

 

 

1,277

 

 

 

208

 

2011 Equity Incentive Plan

 

 

1,640

 

 

 

5,964

 

 

 

4,656

 

2017 Inducement Award Plan

 

 

59

 

 

 

2

 

 

 

—

 

2017 Employee Stock Purchase Plan

 

 

—

 

 

 

—

 

 

 

1,581

 

Total common stock reserved for future issuance

 

 

9,294

 

 

 

7,243

 

 

 

6,445

 
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation

11. Stock-based Compensation

Equity Compensation Plans

2011 Equity Incentive Plan

In January 2011, the Company's board of directors adopted the 2011 Equity Incentive Plan (2011 Plan) under which incentive stock options, non-statutory stock options, RSUs, stock appreciation rights, PSUs, and performance shares may be granted to its employees, directors, and consultants.

2022 Inducement Equity Incentive Plan

In April 2022, the Company's board of directors adopted the 2022 Inducement Plan and reserved 9.5 million shares of common stock for the issuance of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares and PSUs. In accordance with Nasdaq listing rules, equity awards issued under the 2022 Inducement Plan are restricted to individuals who are not already employees or directors of the Company. The terms and conditions of the 2022 Inducement Plan are substantially similar to those of the 2011 Plan.

The Company's board of directors sets the terms, conditions, and restrictions related to the grant of stock options, RSUs and performance-based awards under its stock-based plans, as well as employee participation in the 2017 Employee Stock Purchase Plan (ESPP). The Company's board of directors determines the number of awards to grant and also sets vesting criteria. In general, RSUs vest on a quarterly basis over a period of four years from the date of grant at a rate of 25% on the first anniversary of the grant date and ratably each quarter over the remaining 12 quarters, or ratably over 16 quarters, subject to the employees’ continued employment. The Company may grant RSUs with different vesting terms from time to time. Stock options granted under the Company's 2022 Inducement Plan and 2011 Plan have a term of no more than ten years from the date of grant and an exercise price of at least 100% of the fair market value of the underlying common stock on the date of grant. Generally, options vest at a rate of either 25% on the first anniversary of the option grant date and ratably each month over the remaining period of 36 months, or ratably each month over 48 months. The Company may grant options with different vesting terms from time to time. For performance-based share awards, the Company's board of directors sets the performance objectives and other vesting provisions in determining the number of shares or value of performance units and performance shares that will be paid out. Such payout will be a function of the extent to which performance objectives or other vesting provisions have been achieved.

Restricted Stock Units

 

 

 

Number of Units
 (in thousands)

 

 

Weighted-Average
Grant Date Fair Value per Unit

 

Balance at December 31, 2022

 

 

7,120

 

 

$

2.58

 

RSU granted

 

 

3,728

 

 

$

2.32

 

RSU released

 

 

(2,970

)

 

$

2.68

 

RSU forfeited

 

 

(945

)

 

$

2.17

 

Balance at December 31, 2023

 

 

6,933

 

 

$

2.46

 

 

As of December 31, 2023, the unrecognized compensation costs related to outstanding unvested RSUs under the Company’s equity incentive plans were $13.9 million. The Company expects to recognize those costs over a weighted-average period of 2.5 years.

Stock Options

 

 

 

Number of
Options (in thousands)

 

 

Weighted-Average
Exercise Price
per Option

 

 

Weighted-
Average Remaining Contractual Life (in years)

 

 

Aggregate
Intrinsic
Value (1) (in thousands)

 

Balance at December 31, 2022

 

 

7,882

 

 

$

4.43

 

 

 

7.9

 

 

$

—

 

Options granted

 

 

2,609

 

 

$

2.57

 

 

 

 

 

 

 

Options exercised

 

 

(44

)

 

$

1.84

 

 

 

 

 

 

 

Options cancelled

 

 

(1,153

)

 

$

6.84

 

 

 

 

 

 

 

Balance at December 31, 2023

 

 

9,294

 

 

$

3.62

 

 

 

8.5

 

 

$

439

 

Vested at December 31, 2023

 

 

3,497

 

 

$

3.98

 

 

 

8.2

 

 

$

78

 

Unvested awards at December 31, 2023

 

 

5,797

 

 

$

3.40

 

 

 

8.7

 

 

$

361

 

 

 

Aggregate intrinsic value as of December 31, 2023 was calculated as the difference between the closing price per share of the Company’s common stock on the last trading day of December, which was $2.21, and the exercise price of the options, multiplied by the number of in-the-money options.

The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022 was immaterial. The total intrinsic value of options vested during the years ended December 31, 2023 and 2022 was $0.1 million and zero, respectively. As of December 31,

2023, the unrecognized compensation costs related to outstanding unvested options under the Company’s equity incentive plans were $12.4 million. The Company expects to recognize those costs over a weighted-average period of 2.3 years.

The weighted average assumptions used to estimate the fair value of options granted were as follows:

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Stock options

 

 

 

 

 

 

Weighted average expected volatility

 

 

97.1

%

 

 

91.8

%

Weighted average expected term

 

4.7 years

 

 

4.3 years

 

Weighted average risk-free interest rate

 

 

3.9

%

 

 

2.6

%

Dividend yield

 

 

—

 

 

 

—

 

Weighted-average fair value per share

 

$

1.49

 

 

$

2.21

 

Expected Term—The expected term of options granted represents the period of time that the options are expected to be outstanding and is derived by analyzing historical exercise behavior.

Expected Volatility—The estimated volatility was based on the historical volatility of the common stock of the Company.

Risk-Free Interest Rate—The risk-free interest rate is the implied yield in effect at the time of the option grant based on U.S. Treasury securities with contract maturities similar to the expected term of the Company’s stock options.

Dividend Rate—The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used.

Performance-based Awards

The Company previously granted PSUs to certain executive officers and senior-level employees with the number of PSUs ultimately earned under these awards being calculated by comparing the Total Shareholder Return (TSR) of the Company’s common stock over the applicable three-year period against the TSR of a defined group of peer companies. The Company’s relative performance against its peer group determined the payout, which could range from 0% to 200% of the base awards. As these awards required continuous service in order to vest and these officers and senior level employees are no longer with the Company, they were canceled as of June 30, 2023.

In July 2023, the Company granted performance-based restricted stock units to certain executive officers that will vest in the first quarter of 2024 based upon the achievement of specified revenue and EBITDA targets for the twelve months ended December 31, 2023, and the executive’s continued employment with the Company. Stock-based compensation expense is being recognized over the requisite service period, as it is deemed probable the Company will satisfy the performance measures.

Activity under the performance-based awards was as follows:

 

 

 

Number of Units
(in thousands)

 

 

Weighted-Average
Grant Date Fair Value per Unit

 

Balance at December 31, 2022

 

 

453

 

 

$

4.81

 

PSU granted

 

 

309

 

 

$

2.42

 

PSU released

 

 

(52

)

 

$

9.60

 

Performance adjustment for 2020 awards

 

 

(401

)

 

$

4.19

 

Balance at December 31, 2023

 

 

309

 

 

$

2.42

 

Stock-based Compensation Expense

Stock-based compensation expense is reported in the Company's consolidated statement of operations as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Cost of product revenue

 

$

811

 

 

$

592

 

Research and development expense

 

 

1,671

 

 

 

2,481

 

Selling, general and administrative expense

 

 

10,641

 

 

 

11,807

 

Total stock-based compensation expense

 

$

13,123

 

 

$

14,880

 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

12. Income Taxes

The Company' loss before income taxes consists of the following (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Domestic

 

$

(40,587

)

 

$

(174,041

)

International

 

 

(33,617

)

 

 

(18,887

)

Loss before income taxes

 

$

(74,204

)

 

$

(192,928

)

 

Significant components of the Company's benefit (expense) from income taxes are as follows (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Current:

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

State

 

 

(197

)

 

 

(87

)

Foreign

 

 

(373

)

 

 

(405

)

Total current tax expense

 

 

(570

)

 

 

(492

)

Deferred:

 

 

 

 

 

 

Federal

 

 

—

 

 

 

—

 

State

 

 

—

 

 

 

—

 

Foreign

 

 

118

 

 

 

3,322

 

Total deferred benefit

 

 

118

 

 

 

3,322

 

Total benefit (expense) from income taxes

 

$

(452

)

 

$

2,830

 

 

Reconciliation of income taxes at the statutory rate to the benefit (expense) from income taxes recorded in the statements of operations is as follows:

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Tax benefit at federal statutory rate

 

 

21.0

%

 

 

21.0

%

State tax expense, net of federal benefit

 

 

1.3

 

 

 

0.8

 

Foreign tax expense

 

 

8.1

 

 

 

0.8

 

NOL carryforwards expiring unutilized

 

 

(5.5

)

 

 

(22.8

)

Change in valuation allowance

 

 

(21.9

)

 

 

17.1

 

Federal R&D credit

 

 

0.2

 

 

 

0.2

 

Unrecognized tax benefit

 

 

—

 

 

 

0.9

 

Non-deductible interest/premium

 

 

—

 

 

 

(0.3

)

Non-deductible loss on Forward Sale of Preferred Stock and
   Bridge Loans

 

 

—

 

 

 

(8.0

)

R&D tax credits expiring unutilized

 

 

—

 

 

 

(5.2

)

Transaction costs

 

 

(1.5

)

 

 

—

 

Executive stock-based compensation

 

 

(2.6

)

 

 

(0.8

)

Return to provision

 

 

2.5

 

 

 

—

 

Other, net

 

 

(2.0

)

 

 

(2.2

)

Effective tax rate

 

 

(0.4

)%

 

 

1.5

%

 

 

Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforward

 

$

96,242

 

 

$

85,182

 

Reserves and accruals

 

 

3,152

 

 

 

3,943

 

Depreciation and amortization

 

 

564

 

 

 

563

 

Capitalized R&D costs

 

 

5,962

 

 

 

3,840

 

Tax credit carryforwards

 

 

15,463

 

 

 

14,456

 

Stock-based compensation

 

 

1,143

 

 

 

2,064

 

Right-of-use lease liabilities

 

 

7,782

 

 

 

8,663

 

Total gross deferred tax assets

 

 

130,308

 

 

 

118,711

 

Valuation allowance on deferred tax assets

 

 

(124,124

)

 

 

(107,893

)

Total deferred tax assets, net of valuation allowance

 

 

6,184

 

 

 

10,818

 

Deferred tax liabilities:

 

 

 

 

 

 

Fixed assets and intangibles

 

 

(54

)

 

 

(3,913

)

Right-of-use assets

 

 

(6,836

)

 

 

(7,729

)

Total deferred tax liabilities

 

 

(6,890

)

 

 

(11,642

)

Net deferred tax liability

 

$

(706

)

 

$

(824

)

 

 

 

 

 

 

 

Deferred tax liability per balance sheet

 

$

(841

)

 

$

(1,055

)

Less deferred tax assets included in other long-term assets

 

 

135

 

 

 

231

 

Net deferred tax liability

 

$

(706

)

 

$

(824

)

 

Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company completed its Section 382 Study through December 31, 2022 and determined that an ownership change occurred on April 4, 2022 due to the issuance of preferred equity. As a result of this ownership change, a portion of net operating loss (NOL) carryforwards and all R&D credits will expire unutilized. Further limitations are also expected as a result of the merger with SomaLogic that occurred on January 5, 2024.

The Company establishes a valuation allowance for deferred tax assets if the Company determines it is more likely than not the related tax benefit will not be realized. The Company relies on several factors when assessing the realizability of deferred tax assets, including historical financial results, the Company's ability to recover net operating loss carry-forwards, the projected future operating results, and the Company's ability to use tax planning strategies.

The valuation allowances of $124.1 million and $107.9 million as of December 31, 2023 and 2022, respectively, primarily relate to temporary tax differences, net operating losses and research and development credits generated in the current and prior years. The Company believes it is more likely than not that U.S. federal and state, Canada and Netherlands deferred tax assets relating to temporary differences, net operating losses and research and development credits are not realizable. As such, full valuation allowances have been applied against the deferred tax assets relating to jurisdictions of the U.S. federal and state, Canada and Netherlands.

A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended December 31, 2023 and 2022 is as follows (in thousands):

 

 

Valuation Allowance

 

December 31, 2021

 

$

141,087

 

Charges to earnings

 

 

—

 

Charges to other accounts

 

 

(33,194

)

December 31, 2022

 

 

107,893

 

Charges to earnings

 

 

—

 

Charges to other accounts

 

 

16,231

 

December 31, 2023

 

$

124,124

 

 

As of December 31, 2023, the Company had net operating loss carryforwards for U.S. federal income tax purposes of $363.5 million, and U.S. federal research and development tax credits of $0.5 million, which begin expiring in 2042. As of December 31, 2023, the

Company had net operating loss carryforwards for state income tax purposes of $220.4 million, which will expire through 2043, and California research and development tax credits of $14.0 million, which do not expire. As of December 31, 2023, we had foreign net loss carryforwards of $36.6 million, which will begin to expire in 2041, and foreign tax credit carryforwards of $6.9 million, which begin to expire in 2037.

The aggregate changes in the balance of the Company's gross unrecognized tax benefits during 2023, and 2022 were as follows (in thousands):

 

December 31, 2021

 

$

8,515

 

Increases in balances related to tax positions during a prior
   period

 

 

154

 

Increases in balances related to tax positions taken during
   current period

 

 

—

 

Decreases in balances related to tax positions taken during prior
   period

 

 

(1,697

)

December 31, 2022

 

 

6,972

 

Increases in balances related to tax positions during a prior
   period

 

 

105

 

Decreases in balances related to tax positions taken during
   current period

 

 

(138

)

December 31, 2023

 

$

6,939

 

 

As of December 31, 2023, there were no unrecognized tax benefits that, if recognized, would reduce the Company's effective tax rate. The Company does not anticipate that existing unrecognized tax benefits will significantly increase or decrease within the next 12 months.

Accrued interest and penalties related to unrecognized tax benefits was included in the income tax provision. The amount was immaterial as of December 31, 2023 and 2022.

The Company files income tax returns in the United States, its various states, and in certain foreign jurisdictions. As a consequence of having operating loss carryforwards, all tax years are open to federal and state examination in the United States. Tax years from 2012 are open to examination in various foreign countries.

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Segment Reporting

13. Segment Reporting

The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.

During 2023, the CODM began using gross profit to measure the operating performance of the segments. The Company determines each segment’s gross profit by subtracting cost of product and service revenues from segment revenues.

The Company does not prepare or report segmented balance sheet information as the CODM does not use the information to assess segment operating performance. The segments adhere to the same accounting policies as the Company as a whole.

The Company's business segment information was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Revenue:

 

 

 

 

 

 

Proteomics

 

$

63,883

 

 

$

52,502

 

Genomics

 

 

42,457

 

 

 

45,446

 

Total revenue

 

$

106,340

 

 

$

97,948

 

 

 

 

 

 

 

 

Gross profit:

 

 

 

 

 

 

Proteomics

 

$

26,239

 

 

$

20,041

 

Genomics

 

 

24,211

 

 

 

17,010

 

Total gross profit

 

$

50,450

 

 

$

37,051

 

 

 

 

 

 

 

 

Depreciation & amortization:

 

 

 

 

 

 

Proteomics

 

$

12,072

 

 

$

12,223

 

Genomics

 

 

601

 

 

 

230

 

Total depreciation & amortization

 

$

12,673

 

 

$

12,453

 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
401(K) Plan
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
401(K) Plan

15. 401(k) Plan

The Company sponsors a 401(k) savings plan for its employees in the United States that stipulates that eligible employees may elect to contribute to the plan, subject to certain limitations, up to the lesser of 90% of eligible compensation or the maximum amount allowed by the U.S. Internal Revenue Service. In 2019 and onward, the employee match formula was 100% up to $3,000 annually. Employer matching contributions to the 401(k) plan were $0.5 million and $0.6 million for the years ended December 31, 2023 and 2022.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Related Charges
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring and Related Charges

14. Restructuring and Related Charges

Beginning with the appointment of the Company’s new management team in April 2022 and as further announced in August 2022, the Company has implemented a restructuring plan, including a reduction in force, to improve operational efficiency, achieve cost savings and align the Company’s workforce to the future needs of the business. In addition to the reduction in force, the Company is reducing leased office space, optimizing its manufacturing footprint and streamlining support functions. The Company is developing a more disciplined cost management culture throughout its organization by investing in training and advanced information systems.

The Company records restructuring and related charges as incurred. These items are classified within restructuring and related charges in the consolidated statements of operations for the year ended December 31, 2023, and primarily include severance costs as well as facility costs (net of sublease income) for leased space in South San Francisco that the Company has vacated as part of the restructuring plan. The Company recognized restructuring and related charges of $7.1 million and $9.7 million for the years ended December 31, 2023 and 2022, respectively.

The Company expects to relieve the majority of the existing liability for restructuring charges primarily related to employee severance in 2024. Ongoing restructuring charges will continue to be incurred for facility related costs through the termination of the facility leases. These estimates are subject to a number of assumptions, and actual results may differ.

The following table summarizes the change in the Company’s restructuring and other related liabilities for the years ended December 31, 2023 and 2022 (in thousands):

 

 

 

Severance
and other
employee-
related
benefits(1)

 

 

Facility
Costs

 

 

Other(2)

 

 

Total

 

Balance at December 31, 2021

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Restructuring and related charges

 

 

5,849

 

 

 

2,885

 

 

 

998

 

 

 

9,732

 

Cash payments

 

 

(1,835

)

 

 

(2,885

)

 

 

(979

)

 

 

(5,699

)

Balance at December 31, 2022

 

$

4,014

 

 

$

—

 

 

$

19

 

 

$

4,033

 

Restructuring and related charges

 

 

2,379

 

 

 

4,160

 

 

 

537

 

 

 

7,076

 

Cash payments

 

 

(5,568

)

 

 

(4,160

)

 

 

(556

)

 

 

(10,284

)

Balance at December 31, 2023

 

$

825

 

 

$

—

 

 

$

—

 

 

$

825

 

 

(1)
Restructuring liabilities are recorded in accrued compensation and related benefits on the consolidated balance sheets.
(2)
Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the consolidated balance sheets.

The Company’s restructuring and related charges by segment and corporate were as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Restructuring:

 

 

 

 

 

 

Proteomics

 

$

1,010

 

 

$

1,363

 

Genomics

 

 

714

 

 

 

1,273

 

Corporate expenses

 

 

5,352

 

 

 

7,096

 

Total restructuring and related charges

 

$

7,076

 

 

$

9,732

 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Event
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Event

16. Subsequent Event

SomaLogic Merger

On January 5, 2024, the Company completed the previously announced Merger pursuant to the Agreement and Plan of Merger, dated as of October 4, 2023 (the “Merger Agreement”), by and among the Company, SomaLogic, and Martis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub). Pursuant to the Merger Agreement, Merger Sub merged with and into SomaLogic, with SomaLogic surviving as a wholly owned subsidiary of Standard BioTools. At the consummation of the Merger, each issued and outstanding share of common stock of SomaLogic, was converted into the right to receive 1.11 shares of common stock of Standard BioTools, and cash in lieu of fractional shares. At the effective time of the Merger, SomaLogic’s common stockholders owned approximately 57%, and the Company’s common stockholders owned approximately 43%, of the outstanding shares of common stock of the combined company on a fully diluted basis.

In addition, as of the effective time of the Merger, the Company assumed each SomaLogic stock incentive plan, outstanding option to purchase shares of SomaLogic common stock and outstanding restricted stock units convertible into shares of SomaLogic common stock, whether vested or unvested. In addition, as of the Effective Time, each SomaLogic warrant was treated in accordance with its terms.

Due to the limited time between the Merger date and the filing of this Annual Report, it is not practicable for the Company to disclose the preliminary allocation of the purchase price to assets acquired and liabilities assumed.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Consolidation

Basis of Presentation and Consolidation

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of the Company's wholly owned subsidiaries. As of December 31, 2023, the Company had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, Italy, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves, the carrying value of goodwill and other long-lived assets, and the potential outcome of uncertain tax positions that have been recognized in the Company's financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company's consolidated financial statements.

Foreign Currency

Foreign Currency

Assets and liabilities of non-U.S. subsidiaries that use their local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. Income and expense accounts are translated at monthly average exchange rates during the year. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity (deficit).

Revenue Recognition

Revenue Recognition

The Company generates revenue primarily from the sale of its products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. The Company also generates revenue from product development agreements, license and royalty agreements, and grants. Revenue is reported net of any sales, use and value-added taxes the Company collects from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue.

The Company recognizes revenue based on the amount of consideration it expects to receive in exchange for the goods and services it transfers to the customer. The Company's commercial arrangements typically include multiple distinct products and services, and the Company allocates revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices

(SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price.

Product Revenue

The Company recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in 30 to 60 days.

The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.

Service and Other Revenue

The Company recognizes revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed.

Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally one to three years. The Company believes this time-elapsed approach is appropriate for service contracts because the Company provides services on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments made in advance of service are reported on the Company's consolidated balance sheet as deferred revenue.

Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.

The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC Topic 606, Revenue from Contracts with Customers, as the grant agreement is not with a customer. As there is no authoritative U.S. GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC Topic 958, Not-for-Profit Entities by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.

Significant Judgments

Applying the revenue recognition practices discussed above often requires significant judgment. Significant judgment is required when interpreting commercial terms in sales agreements and determining when control of goods and services passes to the customer. Judgment is also required when identifying performance obligations, estimating SSP and allocating purchase consideration in agreements that include multiple performance obligations. Any material changes created by errors in judgment could have a material effect on the Company's operating results and overall financial condition.
Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid financial instruments with maturities at the time of purchase of three months or less to be cash equivalents. Cash and cash equivalents balance at December 31, 2023, and 2022 represent cash on deposit with banks and money market funds.
Short-term Investments

Short-term Investments

Short-term investments are comprised of U.S treasury securities that mature within one year. The Company classifies its short-term investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets. Any unrealized gains and losses from short-term investments are reported as a component of other comprehensive income (loss) within the consolidated statements of comprehensive loss and as a separate component of stockholders’ equity (deficit). The Company evaluates its short-term investments to assess whether investments with unrealized loss positions are other-than-temporarily impaired. An investment is

considered to be other-than-temporarily impaired if the impairment is related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of their cost basis. No investment has been assessed as other than temporarily impaired. Realized gains and losses are calculated on the specific identification method and are recorded as interest income (loss). There were no realized gains and losses from sales of short-term investments during any of the periods presented.

The Company excludes accrued interest from the fair value and amortized cost basis of its short-term investments.
Accounts Receivable, net

Accounts Receivable, net

Trade accounts receivable are recorded at net invoice value. The Company reviews its exposure to accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The Company evaluates such allowances on a regular basis and adjust them as needed.
Concentrations of Business and Credit Risk

Concentrations of Business and Credit Risk

Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, short-term investments, and accounts receivable. The Company's cash, cash equivalents, and short-term investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of risk. Under the Company's investment policy, the Company invests exclusively in securities issued by the U.S. government or U.S. government agencies, or in government money-market funds. The goals of the Company's investment policy, in order of priority, are to: preserve capital, meet liquidity needs, and optimize returns. For these reasons, management believes that the Company is not exposed to significant credit risk.

The Company generally does not require collateral to support credit sales. To reduce credit risk, the Company performs credit evaluations of its customers.

The Company's products include components that are currently procured from a single source or a limited number of sources. The Company believes that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, the Company attempts to maintain an adequate supply of critical limited-source components.
Inventories, net

Inventories, net

Inventories are stated at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company regularly reviews inventory for excess and obsolete products and components. Significant judgment is required in determining provisions for slow-moving, excess, and obsolete inventories which are recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, product expiration, discontinuance of product lines, and quality issues.
Property and Equipment, net

Property and Equipment, net

Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Accumulated depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The estimated useful lives of the Company's property and equipment are generally as follows: computer equipment and software, three to four years; laboratory and manufacturing equipment, two to seven years; and office furniture and fixtures, five years.
Leases

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. Lease terms are determined at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For its long-term operating leases, the Company recognizes a lease liability and a right-of-use asset (ROU) on its consolidated balance sheets. ROU assets represent the Company's right-to-use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The lease liability is determined at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a term similar to the lease arrangement. Significant judgment is required in determining the incremental

collateralized borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. Lease expense is recognized on a straight-line basis over the lease term. Sublease income from an operating lease is recognized on a straight-line basis over the sublease term. The Company does not have any finance leases.

The Company elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify, the Company will not recognize ROU assets or lease liabilities for leases with an initial lease term of one year or less. The Company also elected not to separate lease and nonlease components for the Company's building leases. The nonlease components are generally variable in nature and are expected to represent most of the Company's variable lease costs. Variable costs are expensed as incurred. The Company has taken a portfolio approach for its vehicle leases by country.
Business Combinations

The Company has completed acquisitions of businesses in the past and may acquire additional businesses or technologies in the future. The results of businesses acquired in a business combination are included in the Company's consolidated financial statements from the date of acquisition. The Company allocates the purchase price, which is the sum of the consideration provided in a business combination, to the identifiable assets and liabilities of the acquired business at their acquisition date fair values. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and estimates of future revenue.

Goodwill

Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The Company's intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Judgment is needed to assess the factors that could indicate an impairment of intangible assets.

Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that the Company will be required to recognize an impairment charge include, but are not limited to, declines in the Company's stock price or market capitalization, economic downturns and other macroeconomic events, declines in the Company's market share or revenues, or significant litigation. Any impairment charges could have a material adverse effect on the Company's operating results and net asset value in the period in which the Company recognizes the impairment charge.

In evaluating goodwill and intangible assets with indefinite lives for indications of impairment, the Company first conducts an assessment of qualitative factors to determine whether it is more likely than not that the fair value of each of the Company's reporting units is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of each of its reporting units is less than its carrying amount, the Company compares the fair value of each of its reporting units to its carrying value. If the fair value of each of the Company's reporting units exceeds its carrying value, goodwill is not considered impaired, and no further analysis is required. If the carrying value of each of the Company's reporting units exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill.
Intangible Assets and Other Long-Lived Assets

The Company evaluates its long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, the Company estimates the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly.
Series B Redeemable Preferred Stock

Series B Redeemable Preferred Stock

The Purchase Agreements (as described in Note 9) for the issuance of shares of Series B Redeemable Preferred Stock were accounted for as forward sales contracts at fair value in accordance with ASC Topic 480, Distinguishing Liabilities from Equities. The Series B Redeemable Preferred Stock was classified as mezzanine equity and recorded at fair value upon issuance, net of issuance costs, due to its redemption features that are outside of the Company’s control. Mezzanine equity is presented separately on the consolidated balance sheets between liabilities and shareholders’ equity because it shares characteristics of both. In the year ended December 31, 2022, the Company recognized a $60.1 million loss on the forward sales of Series B Preferred Stock and a $13.7 million loss on the Bridge Loans due to the increase in the price of the Company's common stock from January 23, 2022 (the date of the Purchase Agreements and the Bridge Loan agreements) to the Private Placement Closing Date. See Note 9 for additional information.
Restructuring and Related Charges

Restructuring and Related Charges

The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Costs for involuntary separation programs are recorded when management has approved the plan for separation, the employees are identified and made aware of the benefits they are entitled to, it is unlikely that the plan will change significantly, and if applicable, any required governmental notification is made. Costs associated with benefits that are contingent on the employee continuing to provide service are recognized over the required service period. Costs associated with leased facilities (net of sublease income, if applicable) that the Company has vacated as part of a restructuring plan are also included.
Transaction-related Expenses

Transaction-related Expenses

The Company expensed certain costs incurred related to the merger agreement with SomaLogic, described further in Note 16, including legal, advisory, accounting and other transaction-related costs. The expenses in the prior period relate to the private placement whereby the Company issued and sold an aggregate of $225.0 million of convertible preferred stock in connection with the conversion of the bridge loans, which closed on April 4, 2022.
Deferred Grant Income

Deferred Grant Income

Proceeds from the NIH Contract have been principally recorded as capital expenditures and to offset applicable operating costs. The non-operating income recognized from the grant proceeds received in excess of the amounts spent for capital expenditures and operating expenses is reflected on the consolidated statement of operations as surplus funding from the NIH contract.

The NIH Contract met the definition of grants related to assets as the primary purpose for the payments was to fund the purchase and construction of capital assets to scale up production capacity. The Company elected to record the grants received as deferred income in accordance with International Accounting Standards (IAS) 20.

Deferred grant income related to production capacity expansion is being amortized for the related assets as a reduction of depreciation expense.

Term Loan and Convertible Notes, net

Term Loan, net

The term loan is recorded at its carrying value, which includes the outstanding principal amount and the cumulative accreted final payment, less unamortized debt issuance costs. Amortization of the debt issuance costs and accretion of the final payment are reflected in interest expense. The final payment is being accreted to the carrying value of the term loan through the expected maturity of July 1, 2025 using the effective interest method. Debt issuance costs were recorded as an offset to the carrying value of the loan and are amortized over the expected term also using the effective interest method.

Convertible Notes, net

The Company records the 2014 Notes and 2019 Notes (as described in Note 6) at their carrying values, which includes their principal amounts plus accrued and unpaid interest. Offering-related costs, including underwriting costs, on the 2014 Notes and 2019 Notes were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method.
Treasury Stock

Treasury Stock

The Company uses the cost method to account for the repurchases of its common stock in accordance with ASC 505-30, Equity-Treasury Stock. The direct costs associated with settled share repurchases, including trading commissions, are reported as treasury stock in the shareholders’ equity (deficit) section of the Company's consolidated balance sheets.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of cash and cash equivalents, restricted cash, short-term investments, accounts receivable, accounts payable, term loan and convertible notes. The Company's cash equivalents, restricted cash, accounts receivable and accounts payable generally have short maturity or payment periods. Accordingly, their carrying values approximated their fair values at December 31, 2023 and 2022. The Company's short-term investments consist of U.S. treasury securities that are classified as available-for-sale and reported at fair value on the Company's consolidated balance sheets. The convertible notes and term loan are presented at their net carrying values.

As a basis for computing fair value, the Company follows a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level I: observable inputs such as quoted prices in active markets;

Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and

Level III: unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's cash equivalents, which include money market funds are classified as Level I because they are valued using quoted market prices. The Company's short-term investments, which include U.S. treasuries, are classified as Level II because they are valued using non-binding market consensus prices that were corroborated with observable market data, quoted market prices for similar instruments, or pricing models.

The Company's convertible notes are not regularly traded, and it is difficult to estimate a reliable and accurate market price for these securities. The estimated fair values of these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the Company's term loan also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's term loan was estimated using a discounted cash flows approach and current market interest rate data for similar loans. The carrying value of the Company's lines of term loan approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions.
Research and Development

Research and Development

The Company recognizes research and development expenses in the period incurred. Research and development (R&D) expenses generally consist of personnel costs, independent contractor costs, prototype and materials expenses, allocated facilities and information technology expenses, and related overhead expenses.
Advertising Costs

Advertising Costs

The Company expenses advertising costs as incurred. The Company incurred advertising costs of $2.0 million and $3.9 million during the years ended December 31, 2023 and 2022, respectively.
Stock-Based Compensation

Stock-Based Compensation

The Company recognizes compensation costs for all stock-based awards, including stock options, Restricted Share Units (RSUs), Performance Share Units (PSUs) and stock purchased under the Company's Employee Share Purchase Plan (ESPP), based on the grant date fair value of the award. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service periods for non-performance-based awards. For RSUs, fair value is measured based on the closing fair market value of the Company's common stock on the date of grant. For PSUs with a market condition, the Company uses a Monte Carlo simulation pricing model to incorporate the market condition effects at the grant date. The Monte Carlo pricing model requires inputs which are subjective and generally requires judgment. For PSUs with performance conditions, stock-based compensation expense is recognized over the requisite service period when the achievement of each individual performance goal becomes probable.

The fair value of options and stock purchases under ESPP on the grant date is estimated using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions, including expected term, volatility, risk-free interest rate and the fair value of the Company's common stock. These assumptions generally require judgment. The Company determines the expected volatility based on the Company's historical stock price volatility generally commensurate with the estimated expected term of the stock awards. The expected term of an award is based on historical forfeiture experience, exercise activity, and the terms and conditions of the stock awards. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each grant’s expected term. The Company accounts for forfeitures as they occur.

Income Taxes

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and

liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans and estimates. Should the actual amounts differ from the Company's estimates, the amount of the valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to the Company's tax provision in a period in which such estimates are changed, which in turn would affect net income or loss.

The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. Any interest and penalties related to uncertain tax positions are reflected in the income tax provision.
Segment Reporting

Segment Reporting

The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.

The Company's CEO, who is its Chief Operating Decision Maker (CODM), measures segment performance using gross profit which is determined by subtracting cost of product and service revenues from segment revenues. Depreciation and amortization expense is included in each segment’s gross profit.
Comprehensive Loss

Comprehensive Loss

Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on the Company's short-term investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of comprehensive loss.
Net Loss per Share

Net Loss per Share

The Company's basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. RSUs, PSUs, stock options to purchase the Company's common stock, ESPP shares pending issuance, Series B Preferred Stock and convertible notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.

The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

RSUs, PSUs, stock options and ESPP shares

 

 

16,740

 

 

 

15,752

 

Series B Preferred Stock

 

 

75,164

 

 

 

75,164

 

2019 Notes(1)

 

 

18,966

 

 

 

18,966

 

2014 Notes

 

 

10

 

 

 

10

 

Total

 

 

110,880

 

 

 

109,892

 

 

(1)
The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to Note 6 for additional information on the 2019 Notes.

 

The 2,709,703 common shares that were repurchased during the year ended December 31, 2023 have also been excluded from the Company's earnings per share and diluted earnings per share calculations.

Recent Accounting Changes and Accounting Pronouncements

Recent Accounting Changes and Accounting Pronouncements

Adoption of New Accounting Guidance

From time to time, new accounting standards are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures, which requires disclosure of more detailed information about a reportable segment’s expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.
Reclassification

Reclassification

Certain amounts in the consolidated financial statements have been reclassified from their original presentation to conform to current year presentation.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders

The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

RSUs, PSUs, stock options and ESPP shares

 

 

16,740

 

 

 

15,752

 

Series B Preferred Stock

 

 

75,164

 

 

 

75,164

 

2019 Notes(1)

 

 

18,966

 

 

 

18,966

 

2014 Notes

 

 

10

 

 

 

10

 

Total

 

 

110,880

 

 

 

109,892

 

 

(1)
The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to Note 6 for additional information on the 2019 Notes.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Geographic Area (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue

The following tables present the Company's revenue for the years ended December 31, 2023 and 2022, respectively, based on product type and the geographic location of customers’ facilities (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Instruments

 

$

37,459

 

 

$

25,664

 

Consumables

 

 

41,739

 

 

 

46,790

 

Total product revenue

 

 

79,198

 

 

 

72,454

 

Service revenue

 

 

25,980

 

 

 

23,712

 

Product and service revenue

 

 

105,178

 

 

 

96,166

 

Other revenue

 

 

1,162

 

 

 

1,782

 

Total revenue

 

$

106,340

 

 

$

97,948

 

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Americas

 

$

46,196

 

 

$

43,982

 

Europe, Middle East and Africa (EMEA)

 

 

36,201

 

 

 

33,136

 

Asia-Pacific

 

 

23,943

 

 

 

20,830

 

Total revenue

 

$

106,340

 

 

$

97,948

 
Schedule of Net Long-Lived Assets Consisting of Property and Equipment in Different Geographic Areas

The Company had long-lived assets consisting of property and equipment, net of accumulated depreciation, and operating lease ROU assets, net of accumulated amortization, in the following geographic areas for each year presented (in thousands):

 

 

December 31,

 

 

2023

 

 

2022

 

United States

 

$

29,646

 

 

$

31,785

 

Singapore

 

 

17,097

 

 

 

21,178

 

Canada

 

 

6,231

 

 

 

5,394

 

Other Asia-Pacific

 

 

889

 

 

 

875

 

EMEA

 

 

987

 

 

 

303

 

Total

 

$

54,850

 

 

$

59,535

 
Schedule of Expected Timing of Revenue Recognition

The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of December 31, 2023 in the following periods (in thousands):

 

Fiscal Year

 

Expected Revenue (1)

 

2024

 

 

13,253

 

2025

 

 

6,634

 

2026

 

 

3,061

 

Thereafter

 

 

1,112

 

Total

 

$

24,060

 
(1)
Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets, net (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill

The changes in the carrying value of goodwill by segment are as follows (in thousands):

 

 

Proteomics

 

 

Genomics

 

 

Total

 

Balance as of December 31, 2022

 

$

85,752

 

 

$

20,499

 

 

$

106,251

 

Foreign currency translation

 

 

46

 

 

 

20

 

 

 

66

 

Balance as of December 31, 2023

 

$

85,798

 

 

$

20,519

 

 

$

106,317

 

 
Schedule of Finite-Lived Intangible Assets

Intangible assets with finite lives include developed technology, patents and licenses. In the consolidated balance sheets, developed technology is reported separately while patents and licenses are reported in other non-current assets. Intangible assets, net, were as follows (in thousands):

 

 

 

December 31, 2023

 

 

Gross Amount

 

 

Accumulated
Amortization
and
Impairment

 

 

Net

 

 

Weighted-
Average
Amortization
Period

Developed technology

 

$

117,354

 

 

$

(115,954

)

 

$

1,400

 

 

10.0 years

Patents and licenses

 

$

11,250

 

 

$

(11,243

)

 

$

7

 

 

7.0 years

 

 

 

December 31, 2022

 

 

Gross Amount

 

 

Accumulated
Amortization

 

 

Net

 

 

Weighted-
Average
Amortization
Period

Developed technology

 

$

117,194

 

 

$

(104,594

)

 

$

12,600

 

 

10.0 years

Patents and licenses

 

$

11,247

 

 

$

(10,669

)

 

$

578

 

 

7.0 years

 
Schedule of Estimated Future Intangible Asset Amortization Expense

Based on the net carrying value of intangible assets at December 31, 2023, the Company expects annual amortization expense to be as follows (in thousands):

 

Fiscal Year

 

Developed
Technology
Amortization
Expense

 

 

Patents and
Licenses
Amortization
Expense

 

 

Total

 

2024

 

 

1,400

 

 

 

7

 

 

 

1,407

 

Total

 

$

1,400

 

 

$

7

 

 

$

1,407

 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Schedule of Cash and Cash Equivalents

Cash, cash equivalents and restricted cash consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Cash and cash equivalents

 

$

51,704

 

 

$

81,309

 

Restricted cash

 

 

795

 

 

 

1,015

 

Total cash, cash equivalents and restricted cash

 

$

52,499

 

 

$

82,324

 

 
Schedule of Restricted Cash

Cash, cash equivalents and restricted cash consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Cash and cash equivalents

 

$

51,704

 

 

$

81,309

 

Restricted cash

 

 

795

 

 

 

1,015

 

Total cash, cash equivalents and restricted cash

 

$

52,499

 

 

$

82,324

 

 

 
Schedule of Inventories, Net

Inventories, net consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Raw materials

 

$

15,539

 

 

$

16,866

 

Work-in-process

 

 

282

 

 

 

945

 

Finished goods

 

 

11,753

 

 

 

15,245

 

Total inventory, gross

 

 

27,574

 

 

 

33,056

 

Allowance for excess and obsolete inventory

 

 

(7,041

)

 

 

(11,583

)

Total inventories, net

 

$

20,533

 

 

$

21,473

 
Schedule of Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Laboratory and manufacturing equipment

 

$

35,563

 

 

$

33,329

 

Leasehold improvements

 

 

13,785

 

 

 

12,234

 

Computer equipment and software

 

 

6,232

 

 

 

5,793

 

Office furniture and fixtures

 

 

1,762

 

 

 

1,713

 

Property and equipment, gross

 

 

57,342

 

 

 

53,069

 

Less accumulated depreciation and amortization

 

 

(35,489

)

 

 

(29,029

)

Construction-in-progress

 

 

2,334

 

 

 

1,612

 

Property and equipment, net

 

$

24,187

 

 

$

25,652

 
Schedule of Accrued Compensation and Related Benefits

Accrued compensation and related benefits, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Accrued incentive compensation

 

$

7,337

 

 

$

1,170

 

Accrued vacation

 

 

2,711

 

 

 

2,795

 

Accrued payroll taxes and other

 

 

994

 

 

 

1,174

 

Accrued restructuring

 

 

825

 

 

 

4,014

 

Accrued compensation and related benefits

 

$

11,867

 

 

$

9,153

 
Other Accrued Liabilities

Other Accrued Liabilities

Other accrued liabilities, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Accrued commissions

 

$

1,010

 

 

$

800

 

Accrued interest

 

 

295

 

 

 

318

 

Accrued legal expenses

 

 

964

 

 

 

349

 

Accrued taxes

 

 

1,230

 

 

 

1,443

 

Uninvoiced receipts

 

 

1,516

 

 

 

1,078

 

Accrued warranties

 

 

2,593

 

 

 

678

 

Customer advances

 

 

447

 

 

 

577

 

Accrued restructuring

 

 

—

 

 

 

19

 

Accrued other

 

 

1,097

 

 

 

913

 

Other accrued liabilities

 

$

9,152

 

 

$

6,175

 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Carrying Value of Debt

The carrying value of debt consists of the following (in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Convertible notes:

 

 

 

 

 

 

2014 Notes

 

$

569

 

 

$

568

 

2019 Notes, non-current

 

 

—

 

 

 

54,047

 

2019 Notes, current

 

 

54,530

 

 

 

—

 

Total convertible notes, net

 

 

55,099

 

 

 

54,615

 

Term loan, non-current

 

 

3,414

 

 

 

8,194

 

Term loan, current

 

 

5,000

 

 

 

2,083

 

Total debt

 

$

63,513

 

 

$

64,892

 
Future Minimum Payments under Term Loan Facility including End of Term Fee Payment

Future minimum payments under the Term Loan Facility including the end of term fee payment as of December 31, 2023, are as follows (in thousands):

 

2024

 

$

5,000

 

2025

 

 

2,917

 

 

 

7,917

 

End of term fee and debt issuance costs

 

 

497

 

Total Term Loan Facility

 

$

8,414

 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Operating Leases

Information about the Company's operating leases is as follows:

 

 

December 31, 2023

 

 

December 31, 2022

 

Weighted average remaining lease term (in years)

 

5.9 years

 

 

6.8 years

 

Weighted average discount rate per annum

 

 

11.8

%

 

 

11.8

%

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Operating lease cost (including variable costs)

 

$

11,159

 

 

$

10,917

 

Variable costs (including non-lease components)

 

$

3,164

 

 

$

2,930

 

Sublease income

 

$

2,679

 

 

$

189

 

Cash paid for amounts included in the measurement of
   operating lease liabilities

 

$

7,931

 

 

$

7,540

 
Schedule of Future Minimum Lease Payments

Future minimum lease payments and sublease income as of December 31, 2023 under commenced non-cancelable operating leases are as follows (in thousands):

 

Fiscal Year

 

Minimum Lease
Payments for
Operating Leases

 

 

Sublease Income

 

 

Net Minimum Lease Payments for Operating Leases

 

2024

 

$

8,086

 

 

$

(2,877

)

 

$

5,209

 

2025

 

 

8,135

 

 

 

(2,952

)

 

 

5,183

 

2026

 

 

7,821

 

 

 

(1,381

)

 

 

6,440

 

2027

 

 

7,395

 

 

 

(1,430

)

 

 

5,965

 

2028

 

 

7,355

 

 

 

(1,480

)

 

 

5,875

 

Thereafter

 

 

10,225

 

 

 

(2,058

)

 

 

8,167

 

Total future minimum payments (receipts)

 

 

49,017

 

 

$

(12,178

)

 

$

36,839

 

Imputed interest

 

 

(14,320

)

 

 

 

 

 

 

Total operating lease liabilities

 

 

34,697

 

 

 

 

 

 

 

Less: current portion of operating lease liabilities

 

 

4,323

 

 

 

 

 

 

 

Operating lease liabilities, net of current portion

 

$

30,374

 

 

 

 

 

 

 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Company's Financial Instruments by Significant Investment Category Measured at Fair Value on a Recurring Basis Within the Fair Value Hierarchy

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy (in thousands):

 

 

 

 

 

 

Fair Value Measurements At Reporting Date Using

 

 

 

Total

 

 

Quoted Prices in Active Markets For Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

As of December 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

35,385

 

 

$

35,385

 

 

$

—

 

 

$

—

 

Total cash and cash equivalents

 

$

35,385

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

63,191

 

 

$

—

 

 

$

63,191

 

 

$

—

 

Total short-term investments

 

$

63,191

 

 

$

—

 

 

$

63,191

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets measured at fair value

 

$

98,576

 

 

$

35,385

 

 

$

63,191

 

 

$

—

 

 

 

 

 

 

 

Fair Value Measurements At Reporting Date Using

 

 

 

Total

 

 

Quoted Prices in Active Markets For Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

As of December 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

53,894

 

 

$

53,894

 

 

$

—

 

 

$

—

 

Total cash and cash equivalents

 

$

53,894

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$

84,475

 

 

$

84,475

 

 

$

—

 

 

$

—

 

Total short-term investments

 

$

84,475

 

 

$

84,475

 

 

$

—

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets measured at fair value

 

$

138,369

 

 

$

138,369

 

 

$

—

 

 

$

—

 
Schedule of Available-for-Sale Securities Reconciliation

The following table summarizes available-for-sale-securities (in thousands):

 

 

 

 

 

 

 

 

As of December 31, 2023

 

 

 

Maturity (in years)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

$

35,385

 

Total cash and cash equivalents

 

 

 

$

35,385

 

 

$

—

 

 

$

—

 

 

$

35,385

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

1 or less

 

$

63,169

 

 

$

22

 

 

$

—

 

 

$

63,191

 

Total short-term investments

 

 

 

$

63,169

 

 

$

22

 

 

$

—

 

 

$

63,191

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total available-for-sale securities

 

 

 

$

98,554

 

 

$

22

 

 

$

—

 

 

$

98,576

 

 

 

 

 

 

 

 

 

As of December 31, 2022

 

 

 

Maturity (in years)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

$

53,894

 

Total cash and cash equivalents

 

 

 

$

53,894

 

 

$

—

 

 

$

—

 

 

$

53,894

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

1 or less

 

$

84,977

 

 

$

—

 

 

$

(502

)

 

$

84,475

 

Total short-term investments

 

 

 

$

84,977

 

 

$

—

 

 

$

(502

)

 

$

84,475

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total available-for-sale securities

 

 

 

$

138,871

 

 

$

—

 

 

$

(502

)

 

$

138,369

 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Mezzanine Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Carrying Value of Preferred Stock

The components of the carrying value of the Series B Preferred Stock as of December 31, 2023 and 2022 were as follows (in thousands):

 

Proceeds from Purchase Agreements

 

$

225,000

 

Proceeds from Bridge Loans

 

 

25,000

 

Change in fair value of Forward Purchase Agreements

 

 

60,081

 

Change in the fair value of Bridge Loans

 

 

13,719

 

Less equity issuance costs

 

 

(12,547

)

Total Series B Redeemable Preferred Stock

 

$

311,253

 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Deficit (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Common Stock Reserved for Future Issuance

As of December 31, 2023, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

 

 

 

Securities To Be Issued Upon Exercise Of Options

 

 

Securities To Be Issued Upon Release Of Restricted Stock

 

 

Number Of Remaining Securities Available For Future Issuance

 

2022 Inducement Equity Incentive Plan

 

 

7,595

 

 

 

1,277

 

 

 

208

 

2011 Equity Incentive Plan

 

 

1,640

 

 

 

5,964

 

 

 

4,656

 

2017 Inducement Award Plan

 

 

59

 

 

 

2

 

 

 

—

 

2017 Employee Stock Purchase Plan

 

 

—

 

 

 

—

 

 

 

1,581

 

Total common stock reserved for future issuance

 

 

9,294

 

 

 

7,243

 

 

 

6,445

 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Activity Under Restricted Stock Units

Restricted Stock Units

 

 

 

Number of Units
 (in thousands)

 

 

Weighted-Average
Grant Date Fair Value per Unit

 

Balance at December 31, 2022

 

 

7,120

 

 

$

2.58

 

RSU granted

 

 

3,728

 

 

$

2.32

 

RSU released

 

 

(2,970

)

 

$

2.68

 

RSU forfeited

 

 

(945

)

 

$

2.17

 

Balance at December 31, 2023

 

 

6,933

 

 

$

2.46

 
Schedule of Activity Under Stock Options

Stock Options

 

 

 

Number of
Options (in thousands)

 

 

Weighted-Average
Exercise Price
per Option

 

 

Weighted-
Average Remaining Contractual Life (in years)

 

 

Aggregate
Intrinsic
Value (1) (in thousands)

 

Balance at December 31, 2022

 

 

7,882

 

 

$

4.43

 

 

 

7.9

 

 

$

—

 

Options granted

 

 

2,609

 

 

$

2.57

 

 

 

 

 

 

 

Options exercised

 

 

(44

)

 

$

1.84

 

 

 

 

 

 

 

Options cancelled

 

 

(1,153

)

 

$

6.84

 

 

 

 

 

 

 

Balance at December 31, 2023

 

 

9,294

 

 

$

3.62

 

 

 

8.5

 

 

$

439

 

Vested at December 31, 2023

 

 

3,497

 

 

$

3.98

 

 

 

8.2

 

 

$

78

 

Unvested awards at December 31, 2023

 

 

5,797

 

 

$

3.40

 

 

 

8.7

 

 

$

361

 

 

 

Aggregate intrinsic value as of December 31, 2023 was calculated as the difference between the closing price per share of the Company’s common stock on the last trading day of December, which was $2.21, and the exercise price of the options, multiplied by the number of in-the-money options.
Schedule of Stock-Based Compensation Determined using Black-Sholes Option-Pricing Model and Weighted Average Assumptions

The weighted average assumptions used to estimate the fair value of options granted were as follows:

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Stock options

 

 

 

 

 

 

Weighted average expected volatility

 

 

97.1

%

 

 

91.8

%

Weighted average expected term

 

4.7 years

 

 

4.3 years

 

Weighted average risk-free interest rate

 

 

3.9

%

 

 

2.6

%

Dividend yield

 

 

—

 

 

 

—

 

Weighted-average fair value per share

 

$

1.49

 

 

$

2.21

 
Schedule of Nonvested Performance-Based Units Activity

Activity under the performance-based awards was as follows:

 

 

 

Number of Units
(in thousands)

 

 

Weighted-Average
Grant Date Fair Value per Unit

 

Balance at December 31, 2022

 

 

453

 

 

$

4.81

 

PSU granted

 

 

309

 

 

$

2.42

 

PSU released

 

 

(52

)

 

$

9.60

 

Performance adjustment for 2020 awards

 

 

(401

)

 

$

4.19

 

Balance at December 31, 2023

 

 

309

 

 

$

2.42

 
Schedule of Stock-Based Compensation Expense

Stock-based compensation expense is reported in the Company's consolidated statement of operations as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Cost of product revenue

 

$

811

 

 

$

592

 

Research and development expense

 

 

1,671

 

 

 

2,481

 

Selling, general and administrative expense

 

 

10,641

 

 

 

11,807

 

Total stock-based compensation expense

 

$

13,123

 

 

$

14,880

 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Loss Before Income Taxes loss before income taxes consists of the following (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Domestic

 

$

(40,587

)

 

$

(174,041

)

International

 

 

(33,617

)

 

 

(18,887

)

Loss before income taxes

 

$

(74,204

)

 

$

(192,928

)
Schedule of Significant Components of Provision for Income Taxes

Significant components of the Company's benefit (expense) from income taxes are as follows (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Current:

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

State

 

 

(197

)

 

 

(87

)

Foreign

 

 

(373

)

 

 

(405

)

Total current tax expense

 

 

(570

)

 

 

(492

)

Deferred:

 

 

 

 

 

 

Federal

 

 

—

 

 

 

—

 

State

 

 

—

 

 

 

—

 

Foreign

 

 

118

 

 

 

3,322

 

Total deferred benefit

 

 

118

 

 

 

3,322

 

Total benefit (expense) from income taxes

 

$

(452

)

 

$

2,830

 
Schedule of Reconciliation of Income Taxes at Statutory Rate to (Provision for)/Benefit (expense) from Income Taxes Recorded in Statements of Operations

Reconciliation of income taxes at the statutory rate to the benefit (expense) from income taxes recorded in the statements of operations is as follows:

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Tax benefit at federal statutory rate

 

 

21.0

%

 

 

21.0

%

State tax expense, net of federal benefit

 

 

1.3

 

 

 

0.8

 

Foreign tax expense

 

 

8.1

 

 

 

0.8

 

NOL carryforwards expiring unutilized

 

 

(5.5

)

 

 

(22.8

)

Change in valuation allowance

 

 

(21.9

)

 

 

17.1

 

Federal R&D credit

 

 

0.2

 

 

 

0.2

 

Unrecognized tax benefit

 

 

—

 

 

 

0.9

 

Non-deductible interest/premium

 

 

—

 

 

 

(0.3

)

Non-deductible loss on Forward Sale of Preferred Stock and
   Bridge Loans

 

 

—

 

 

 

(8.0

)

R&D tax credits expiring unutilized

 

 

—

 

 

 

(5.2

)

Transaction costs

 

 

(1.5

)

 

 

—

 

Executive stock-based compensation

 

 

(2.6

)

 

 

(0.8

)

Return to provision

 

 

2.5

 

 

 

—

 

Other, net

 

 

(2.0

)

 

 

(2.2

)

Effective tax rate

 

 

(0.4

)%

 

 

1.5

%

 
Schedule of Significant Components of Deferred Tax Assets and Liabilities

Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands):

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforward

 

$

96,242

 

 

$

85,182

 

Reserves and accruals

 

 

3,152

 

 

 

3,943

 

Depreciation and amortization

 

 

564

 

 

 

563

 

Capitalized R&D costs

 

 

5,962

 

 

 

3,840

 

Tax credit carryforwards

 

 

15,463

 

 

 

14,456

 

Stock-based compensation

 

 

1,143

 

 

 

2,064

 

Right-of-use lease liabilities

 

 

7,782

 

 

 

8,663

 

Total gross deferred tax assets

 

 

130,308

 

 

 

118,711

 

Valuation allowance on deferred tax assets

 

 

(124,124

)

 

 

(107,893

)

Total deferred tax assets, net of valuation allowance

 

 

6,184

 

 

 

10,818

 

Deferred tax liabilities:

 

 

 

 

 

 

Fixed assets and intangibles

 

 

(54

)

 

 

(3,913

)

Right-of-use assets

 

 

(6,836

)

 

 

(7,729

)

Total deferred tax liabilities

 

 

(6,890

)

 

 

(11,642

)

Net deferred tax liability

 

$

(706

)

 

$

(824

)

 

 

 

 

 

 

 

Deferred tax liability per balance sheet

 

$

(841

)

 

$

(1,055

)

Less deferred tax assets included in other long-term assets

 

 

135

 

 

 

231

 

Net deferred tax liability

 

$

(706

)

 

$

(824

)
Schedule of Summary of Valuation Allowance

A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended December 31, 2023 and 2022 is as follows (in thousands):

 

 

Valuation Allowance

 

December 31, 2021

 

$

141,087

 

Charges to earnings

 

 

—

 

Charges to other accounts

 

 

(33,194

)

December 31, 2022

 

 

107,893

 

Charges to earnings

 

 

—

 

Charges to other accounts

 

 

16,231

 

December 31, 2023

 

$

124,124

 
Schedule of Aggregate Changes in Balance of Gross Unrecognized Tax Benefits

The aggregate changes in the balance of the Company's gross unrecognized tax benefits during 2023, and 2022 were as follows (in thousands):

 

December 31, 2021

 

$

8,515

 

Increases in balances related to tax positions during a prior
   period

 

 

154

 

Increases in balances related to tax positions taken during
   current period

 

 

—

 

Decreases in balances related to tax positions taken during prior
   period

 

 

(1,697

)

December 31, 2022

 

 

6,972

 

Increases in balances related to tax positions during a prior
   period

 

 

105

 

Decreases in balances related to tax positions taken during
   current period

 

 

(138

)

December 31, 2023

 

$

6,939

 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of Business Segment Information

The Company's business segment information was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Revenue:

 

 

 

 

 

 

Proteomics

 

$

63,883

 

 

$

52,502

 

Genomics

 

 

42,457

 

 

 

45,446

 

Total revenue

 

$

106,340

 

 

$

97,948

 

 

 

 

 

 

 

 

Gross profit:

 

 

 

 

 

 

Proteomics

 

$

26,239

 

 

$

20,041

 

Genomics

 

 

24,211

 

 

 

17,010

 

Total gross profit

 

$

50,450

 

 

$

37,051

 

 

 

 

 

 

 

 

Depreciation & amortization:

 

 

 

 

 

 

Proteomics

 

$

12,072

 

 

$

12,223

 

Genomics

 

 

601

 

 

 

230

 

Total depreciation & amortization

 

$

12,673

 

 

$

12,453

 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Related Charges (Tables)
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Liabilities

The following table summarizes the change in the Company’s restructuring and other related liabilities for the years ended December 31, 2023 and 2022 (in thousands):

 

 

 

Severance
and other
employee-
related
benefits(1)

 

 

Facility
Costs

 

 

Other(2)

 

 

Total

 

Balance at December 31, 2021

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Restructuring and related charges

 

 

5,849

 

 

 

2,885

 

 

 

998

 

 

 

9,732

 

Cash payments

 

 

(1,835

)

 

 

(2,885

)

 

 

(979

)

 

 

(5,699

)

Balance at December 31, 2022

 

$

4,014

 

 

$

—

 

 

$

19

 

 

$

4,033

 

Restructuring and related charges

 

 

2,379

 

 

 

4,160

 

 

 

537

 

 

 

7,076

 

Cash payments

 

 

(5,568

)

 

 

(4,160

)

 

 

(556

)

 

 

(10,284

)

Balance at December 31, 2023

 

$

825

 

 

$

—

 

 

$

—

 

 

$

825

 

 

(1)
Restructuring liabilities are recorded in accrued compensation and related benefits on the consolidated balance sheets.
(2)
Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the consolidated balance sheets.

The Company’s restructuring and related charges by segment and corporate were as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Restructuring:

 

 

 

 

 

 

Proteomics

 

$

1,010

 

 

$

1,363

 

Genomics

 

 

714

 

 

 

1,273

 

Corporate expenses

 

 

5,352

 

 

 

7,096

 

Total restructuring and related charges

 

$

7,076

 

 

$

9,732

 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Narrative (Details)
 12 Months Ended
Apr. 04, 2022
USD ($)
Dec. 31, 2023
USD ($)
Segment
shares
Dec. 31, 2022
USD ($)
Schedule Of Significant Accounting Policies [Line Items]      
Realized gains and losses from sales of short-term investments   $ 0 $ 0
Advertising costs incurred   $ 2,000,000 3,900,000
Number of reporting segments | Segment   2  
Loss on forward sale of Series B Preferred Stock   $ 0 60,081,000
Loss on bridge loans   $ 0 13,719,000
Repurchase of common stock (in shares) | shares   2,709,703  
Bridge Loans      
Schedule Of Significant Accounting Policies [Line Items]      
Loss on bridge loans     13,700,000
Convertible Preferred Stock      
Schedule Of Significant Accounting Policies [Line Items]      
Sale of stock, consideration received on transaction $ 225,000,000    
Loss on forward sale of Series B Preferred Stock   $ 60,081,000 $ 60,081,000
Office furniture and fixtures      
Schedule Of Significant Accounting Policies [Line Items]      
Property and equipment, estimated useful lives   5 years  
Minimum | Computer equipment and software      
Schedule Of Significant Accounting Policies [Line Items]      
Property and equipment, estimated useful lives   3 years  
Minimum | Laboratory and manufacturing equipment      
Schedule Of Significant Accounting Policies [Line Items]      
Property and equipment, estimated useful lives   2 years  
Maximum | Computer equipment and software      
Schedule Of Significant Accounting Policies [Line Items]      
Property and equipment, estimated useful lives   4 years  
Maximum | Laboratory and manufacturing equipment      
Schedule Of Significant Accounting Policies [Line Items]      
Property and equipment, estimated useful lives   7 years  
Product revenue | Minimum      
Schedule Of Significant Accounting Policies [Line Items]      
Terms of payment period   30 days  
Product revenue | Maximum      
Schedule Of Significant Accounting Policies [Line Items]      
Terms of payment period   60 days  
Service revenue | Minimum      
Schedule Of Significant Accounting Policies [Line Items]      
Performance obligation period   1 year  
Service revenue | Maximum      
Schedule Of Significant Accounting Policies [Line Items]      
Performance obligation period   3 years  
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
RSUs, PSUs, stock options and ESPP shares 16,740,000 15,752,000
Series B Preferred Stock 75,164,000 75,164,000
Total 110,880,000 109,892,000
Maximum additional shares issuable (in shares) 4,741,374  
2019 Notes | Convertible Debt    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
2019 and 2014 Notes 18,966,000 18,966,000
2014 Notes | Convertible Debt    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
2019 and 2014 Notes 10,000 10,000
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
NIH Contract - Narrative (Details)
Sep. 30, 2020
USD ($)
Research and Development [Abstract]  
Maximum contract value $ 34,000,000
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
NIH Contract (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Research and Development [Abstract]    
Cumulative amounts applied against depreciation expense for assets placed in service $ (7,800) $ (4,200)
Cumulative amounts applied against depreciation expense for assets placed in service (7,800) (4,200)
Carrying value of property and equipment, net 14,400 18,000
Deferred grant income, non-current $ 10,755 $ 14,359
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combination - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Share price (in dollars per share)   $ 2.21  
Goodwill   $ 106,317 $ 106,251
Impairment of InstruNor developed technology intangible   $ 0 3,526
InstruNor AS | Developed technology      
Business Acquisition [Line Items]      
Impairment of InstruNor developed technology intangible $ 3,500   $ 3,500
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]    
Total revenue $ 106,340 $ 97,948
Americas    
Disaggregation of Revenue [Line Items]    
Total revenue 46,196 43,982
EMEA    
Disaggregation of Revenue [Line Items]    
Total revenue 36,201 33,136
Asia-Pacific    
Disaggregation of Revenue [Line Items]    
Total revenue 23,943 20,830
Instruments    
Disaggregation of Revenue [Line Items]    
Total revenue 37,459 25,664
Consumables    
Disaggregation of Revenue [Line Items]    
Total revenue 41,739 46,790
Product revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 79,198 72,454
Service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 25,980 23,712
Total product and service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 105,178 96,166
Total other revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 1,162 $ 1,782
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Geographic Area - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]    
Total revenue $ 106,340 $ 97,948
Deferred revenue 15,100 $ 14,600
Revenue recognized 10,600  
Additional advance payments received $ 11,100  
Revenue from Contract with Customer | Customer Concentration Risk | One Genomics Customer    
Disaggregation of Revenue [Line Items]    
Concentration risk, percentage 10.00% 11.00%
Revenue from Contract with Customer | Customer Concentration Risk | Five Largest Customers    
Disaggregation of Revenue [Line Items]    
Concentration risk, percentage 24.00% 19.00%
Accounts Receivable | Customer Concentration Risk | Customer One    
Disaggregation of Revenue [Line Items]    
Concentration risk, percentage 14.00% 16.00%
United States | Revenue from Contract with Customer | Geographic Concentration Risk    
Disaggregation of Revenue [Line Items]    
Total revenue $ 44,100 $ 41,000
Concentration risk, percentage 42.00% 42.00%
China | Revenue from Contract with Customer | Geographic Concentration Risk    
Disaggregation of Revenue [Line Items]    
Total revenue $ 15,800  
Concentration risk, percentage 15.00% 11.00%
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Geographic Area - Long-lived Assets by Geographic Areas (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]    
Long-lived Assets $ 54,850 $ 59,535
United States    
Segment Reporting Information [Line Items]    
Long-lived Assets 29,646 31,785
Singapore    
Segment Reporting Information [Line Items]    
Long-lived Assets 17,097 21,178
Canada    
Segment Reporting Information [Line Items]    
Long-lived Assets 6,231 5,394
Other Asia-Pacific    
Segment Reporting Information [Line Items]    
Long-lived Assets 889 875
EMEA    
Segment Reporting Information [Line Items]    
Long-lived Assets $ 987 $ 303
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Geographic Area - Performance Obligations (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation $ 24,060 [1]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation $ 13,253 [1]
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation $ 6,634 [1]
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation $ 3,061 [1]
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation $ 1,112 [1]
Revenue, remaining performance obligation, expected timing of satisfaction, period
[1] Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins.
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Geographic Area - Performance Obligation (Details1)
$ in Thousands
Dec. 31, 2023
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation $ 24,060 [1]
[1] Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins.
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets, net - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2023
Jun. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]        
Goodwill $ 106,317,000   $ 106,317,000 $ 106,251,000
Impairment of InstruNor developed technology intangible     0 3,526,000
Impairment of goodwill $ 0      
Amortization of developed technology     11,200,000 11,528,000
Developed technology        
Finite-Lived Intangible Assets [Line Items]        
Amortization of developed technology     $ 11,800,000 12,200,000
InstruNor AS | Developed technology        
Finite-Lived Intangible Assets [Line Items]        
Impairment of InstruNor developed technology intangible   $ 3,500,000   $ 3,500,000
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets, net - Changes in the Carrying Value of Goodwill by Segment (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Goodwill [Roll Forward]  
Balance as of December 31, 2022 $ 106,251
Foreign currency translation 66
Balance as of December 31, 2023 106,317
Proteomics  
Goodwill [Roll Forward]  
Balance as of December 31, 2022 85,752
Foreign currency translation 46
Balance as of December 31, 2023 85,798
Genomics  
Goodwill [Roll Forward]  
Balance as of December 31, 2022 20,499
Foreign currency translation 20
Balance as of December 31, 2023 $ 20,519
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets, net - Schedule of Finite-lived Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total $ 1,407  
Developed technology    
Finite-Lived Intangible Assets [Line Items]    
Gross Amount 117,354 $ 117,194
Accumulated Amortization and Impairment (115,954) (104,594)
Total $ 1,400 $ 12,600
Weighted-Average Amortization Period 10 years 10 years
Patents and licenses    
Finite-Lived Intangible Assets [Line Items]    
Gross Amount $ 11,250 $ 11,247
Accumulated Amortization and Impairment (11,243) (10,669)
Total $ 7 $ 578
Weighted-Average Amortization Period 7 years 7 years
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets, net - Future Amortization Expense (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
2024 $ 1,407  
Total 1,407  
Developed Technology Amortization Expense    
Finite-Lived Intangible Assets [Line Items]    
2024 1,400  
Total 1,400 $ 12,600
Patents and Licenses Amortization Expense    
Finite-Lived Intangible Assets [Line Items]    
2024 7  
Total $ 7 $ 578
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details - Summary of Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]      
Cash and cash equivalents $ 51,704 $ 81,309  
Restricted cash 795 1,015  
Total cash, cash equivalents, and restricted cash 52,499 82,324 $ 29,467
Non-current restricted cash $ 800 $ 1,000  
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details - Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Raw materials $ 15,539 $ 16,866
Work-in-process 282 945
Finished goods 11,753 15,245
Total inventory, gross 27,574 33,056
Allowance for excess and obsolete inventory (7,041) (11,583)
Total inventories, net $ 20,533 $ 21,473
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details - Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 57,342 $ 53,069
Less accumulated depreciation and amortization (35,489) (29,029)
Construction-in-progress 2,334 1,612
Property and equipment, net 24,187 25,652
Laboratory and manufacturing equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 35,563 33,329
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 13,785 12,234
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 6,232 5,793
Office furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,762 $ 1,713
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]      
Depreciation   $ 3,400,000 $ 2,800,000
Maximum contract value $ 34,000,000    
Capital expenditures $ 22,200,000    
Depreciation expenses   3,600,000 3,500,000
Accumulated depreciation expenses   7,800,000 4,200,000
Carrying value of assets   $ 14,400,000 $ 18,000,000
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details - Accrued Compensation and Related Benefits (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Accrued incentive compensation $ 7,337 $ 1,170
Accrued vacation 2,711 2,795
Accrued payroll taxes and other 994 1,174
Accrued restructuring 825 4,014
Accrued compensation and related benefits $ 11,867 $ 9,153
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details - Other Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Accrued commissions $ 1,010 $ 800
Accrued interest 295 318
Accrued legal expenses 964 349
Accrued taxes 1,230 1,443
Uninvoiced receipts 1,516 1,078
Accrued warranties 2,593 678
Customer advances 447 577
Accrued restructuring 0 19
Accrued other 1,097 913
Other accrued liabilities $ 9,152 $ 6,175
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt - Schedule of Carrying Value of Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Total debt $ 63,513 $ 64,892
Line of credit outstanding 8,414  
Convertible Debt    
Debt Instrument [Line Items]    
Total debt 55,099 54,615
Secured Debt    
Debt Instrument [Line Items]    
Term loan, non-current 3,414 8,194
Term loan, current 5,000 2,083
2014 Notes | Convertible Debt    
Debt Instrument [Line Items]    
Total debt 569 568
2019 Notes, non-current | Convertible Debt    
Debt Instrument [Line Items]    
Total debt 0 54,047
2019 Notes, current | Convertible Debt    
Debt Instrument [Line Items]    
Total debt $ 54,530 $ 0
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt - Narrative (Details)
 1 Months Ended 2 Months Ended 12 Months Ended
Aug. 02, 2018
USD ($)
Nov. 30, 2019
USD ($)
$ / shares
shares
Feb. 28, 2014
Mar. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
MonthlyInstallment
Dec. 31, 2022
USD ($)
Apr. 04, 2022
USD ($)
Jan. 23, 2022
USD ($)
Aug. 02, 2021
USD ($)
Debt Instrument [Line Items]                  
Principal amount         $ 7,917,000        
Line of credit outstanding         8,414,000        
Convertible Debt | 2014 Notes                  
Debt Instrument [Line Items]                  
Principal amount   $ 1,100,000              
Convertible Debt | 2019 Notes                  
Debt Instrument [Line Items]                  
Aggregate principal amount   55,000,000              
Proceeds from issuance of debt   $ 52,700,000              
Interest rate on notes   5.25%              
Initial conversion rate of notes   0.3448276              
Debt conversion, converted instrument, shares issued | shares   344.8276              
Initial conversion price of stock (in dollars per share) | $ / shares   $ 2.9              
Convertible Debt | Redemption, Period Two | 2019 Notes                  
Debt Instrument [Line Items]                  
Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price   130.00%              
Convertible Debt | Redemption, Period Three | 2014 Notes                  
Debt Instrument [Line Items]                  
Debt instrument redemption price     100.00%            
Secured Debt                  
Debt Instrument [Line Items]                  
Aggregate principal amount         $ 7,900,000       $ 10,000,000
Interest rate on notes         4.00%        
Convertible debt         $ 600,000        
Term loan         $ 8,400,000        
Term loan advances percentage         6.50%        
Number of installments | MonthlyInstallment         24        
Term loan, non-current         $ 3,414,000 $ 8,194,000      
Secured Debt | Prime Rate                  
Debt Instrument [Line Items]                  
Additional interest rate         0.75%        
Line of Credit | Revolving Credit Facility                  
Debt Instrument [Line Items]                  
Borrowing base $ 15,000,000                
Percentage of eligible receivables 85.00%                
Percentage of eligible inventory 50.00%                
Line of credit outstanding         $ 0        
Bridge Loans                  
Debt Instrument [Line Items]                  
Debt instrument, face amount, per instrument               $ 25,000,000  
Change in fair value of Bridge Loans       $ 13,700,000          
Fair value of Bridge Loans             $ 38,700,000 $ 25,000,000  
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt - Future Minimum Payments under Term Loan Facility including End of Term Fee Payment (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Debt Disclosure [Abstract]  
2024 $ 5,000
2025 2,917
Total long term debt 7,917
End of term fee and debt issuance costs 497
Total Term Loan Facility $ 8,414
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Feb. 28, 2023
Aug. 31, 2022
Dec. 31, 2023
Lessee, Lease, Description [Line Items]      
Renewal term     5 years
Lease expiration date     Apr. 30, 2030
Lease option to extend     contains an option to extend the lease
Lessee, Operating Lease, Existence of Option to Extend [true false]     true
Lease option to termination     along with termination options
Lessee, Operating Lease, Existence of Option to Terminate [true false]     true
Purchase commitment due in the next year     $ 9.7
South San Francisco      
Lessee, Lease, Description [Line Items]      
Percentage of headquarters subleased space 25.00% 25.00%  
Lessor, operating lease, term of contract 77 months 39 months  
Lessor, operating lease, remaining term of contract     24 months
Lessor, operating lease, sublease income expected $ 9.1 $ 4.8  
Corporate Headquarters (18th Floor) | South San Francisco      
Lessee, Lease, Description [Line Items]      
Lessor, operating lease, sublease income expected     $ 2.9
Corporate Headquarters (21st Floor)      
Lessee, Lease, Description [Line Items]      
Lessor, operating lease, sublease income expected     $ 9.0
Minimum      
Lessee, Lease, Description [Line Items]      
Remaining lease term     1 year
Maximum      
Lessee, Lease, Description [Line Items]      
Remaining lease term     6 years
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Schedule of Operating Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Weighted average remaining lease term (in years) 5 years 10 months 24 days 6 years 9 months 18 days
Weighted average discount rate per annum 11.80% 11.80%
Operating lease cost (including variable costs) $ 11,159 $ 10,917
Variable costs (including non-lease components) 3,164 2,930
Sublease income 2,679 189
Cash paid for amounts included in the measurement of operating lease liabilities $ 7,931 $ 7,540
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Operating Lease Maturity (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Minimum Lease Payments for Operating Leases    
2024 $ 8,086  
2025 8,135  
2026 7,821  
2027 7,395  
2028 7,355  
Thereafter 10,225  
Total future minimum payments (receipts) 49,017  
Imputed interest (14,320)  
Total operating lease liabilities 34,697  
Less: current portion of operating lease liabilities 4,323 $ 3,682
Operating lease liabilities, net of current portion 30,374 $ 34,081
Sublease Income    
2024 (2,877)  
2025 (2,952)  
2026 (1,381)  
2027 (1,430)  
2028 (1,480)  
Thereafter (2,058)  
Total future minimum payments (receipts) (12,178)  
Net Minimum Lease Payments for Operating Leases    
2024 5,209  
2025 5,183  
2026 6,440  
2027 5,965  
2028 5,875  
Thereafter 8,167  
Total future minimum payments (receipts) $ 36,839  
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Short-term investments $ 98,576 $ 138,369
Fair Value, Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash and cash equivalents 35,385 53,894
Short-term investments 63,191 84,475
Total assets measured at fair value 98,576 138,369
Fair Value, Recurring | Quoted Prices in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash and cash equivalents 35,385 53,894
Short-term investments 0 84,475
Total assets measured at fair value 35,385 138,369
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash and cash equivalents 0 0
Short-term investments 63,191 0
Total assets measured at fair value 63,191 0
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash and cash equivalents 0 0
Short-term investments 0 0
Total assets measured at fair value 0 0
U.S. treasury securities | Fair Value, Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Short-term investments 63,191 84,475
U.S. treasury securities | Fair Value, Recurring | Quoted Prices in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Short-term investments 0 84,475
U.S. treasury securities | Fair Value, Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Short-term investments 63,191 0
U.S. treasury securities | Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Short-term investments 0 0
Money market funds | Fair Value, Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash and cash equivalents 35,385 53,894
Money market funds | Fair Value, Recurring | Quoted Prices in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash and cash equivalents 35,385 53,894
Money market funds | Fair Value, Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash and cash equivalents 0 0
Money market funds | Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash and cash equivalents $ 0 $ 0
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments - Schedule of Available-for-Sale Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Amortized Cost $ 98,554 $ 138,871
Unrealized Gains 22 0
Unrealized Losses 0 (502)
Estimated Fair Value 98,576 138,369
Cash and cash equivalents    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Amortized Cost 35,385 53,894
Unrealized Gains 0 0
Unrealized Losses 0 0
Estimated Fair Value 35,385 53,894
Short-term investments    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Amortized Cost 63,169 84,977
Unrealized Gains 22 0
Unrealized Losses 0 (502)
Estimated Fair Value 63,191 84,475
Money market funds | Cash and cash equivalents    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Amortized Cost 35,385 53,894
Unrealized Gains 0 0
Unrealized Losses 0 0
Estimated Fair Value 35,385 53,894
U.S. treasury securities | Short-term investments    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Amortized Cost 63,169 84,977
Unrealized Gains 22 0
Unrealized Losses 0 (502)
Estimated Fair Value $ 63,191 $ 84,475
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities held $ 0  
Amortization cost before recovery 0  
Allowance for credit loss 0  
Fair Value | Significant Unobservable Inputs (Level 3) | Convertible Debt | 2019 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Estimated fair value $ 58,200,000 $ 48,400,000
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Mezzanine Equity - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
Apr. 04, 2022
Dec. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]      
Preferred stock, par value (in dollars per share)   $ 0.001 $ 0.001
Series B Preferred Stock      
Debt Instrument [Line Items]      
Sale of stock, consideration received on transaction $ 225.0    
Shares sold (in shares) 225,000    
Debt conversion, converted instrument, shares issued 30,559    
Shares issued (in shares) 255,559    
Series B Preferred Stock | Casdin      
Debt Instrument [Line Items]      
Shares sold (in shares) 112,500    
Preferred stock, par value (in dollars per share) $ 0.001    
Price per share (in dollars per share) $ 1,000    
Series B Preferred Stock | Viking      
Debt Instrument [Line Items]      
Shares sold (in shares) 112,500    
Preferred stock, par value (in dollars per share) $ 0.001    
Price per share (in dollars per share) $ 1,000    
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
Mezzanine Equity - Preferred Stock (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Shareholders' Equity [Line Items]    
Proceeds from Purchase Agreements $ 0 $ 225,000
Proceeds from Bridge Loans 0 25,000
Change in fair value of Forward Purchase Agreements 0 60,081
Total Series B Redeemable Preferred Stock 311,253 311,253
Series B Preferred Stock    
Shareholders' Equity [Line Items]    
Proceeds from Purchase Agreements 225,000 225,000
Proceeds from Bridge Loans 25,000 25,000
Change in fair value of Forward Purchase Agreements 60,081 60,081
Change in fair value of Bridge Loans 13,719 13,719
Less equity issuance costs (12,547) (12,547)
Total Series B Redeemable Preferred Stock $ 311,253 $ 311,253
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Deficit - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Nov. 23, 2022
Equity [Abstract]      
Stock repurchase program, authorized amount     $ 20,000,000
Repurchase of common stock (in shares) 2,709,703    
Share repurchase amount $ 5,414,000 $ 563,000  
Treasury stock acquired, average cost per share (in dollars per share) $ 1.98    
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Deficit - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details) - shares
shares in Thousands
Dec. 31, 2023
Apr. 30, 2022
Class of Stock [Line Items]    
Number of remaining securities available for future issuance (in shares) 6,445  
2022 Inducement Equity Incentive Plan    
Class of Stock [Line Items]    
Number of remaining securities available for future issuance (in shares) 208 9,500
2011 Equity Incentive Plan    
Class of Stock [Line Items]    
Number of remaining securities available for future issuance (in shares) 4,656  
2017 Inducement Award Plan    
Class of Stock [Line Items]    
Number of remaining securities available for future issuance (in shares) 0  
2017 Employee Stock Purchase Plan    
Class of Stock [Line Items]    
Number of remaining securities available for future issuance (in shares) 1,581  
Securities To Be Issued Upon Exercise Of Options    
Class of Stock [Line Items]    
Securities to be issued (in shares) 9,294  
Securities To Be Issued Upon Exercise Of Options | 2022 Inducement Equity Incentive Plan    
Class of Stock [Line Items]    
Securities to be issued (in shares) 7,595  
Securities To Be Issued Upon Exercise Of Options | 2011 Equity Incentive Plan    
Class of Stock [Line Items]    
Securities to be issued (in shares) 1,640  
Securities To Be Issued Upon Exercise Of Options | 2017 Inducement Award Plan    
Class of Stock [Line Items]    
Securities to be issued (in shares) 59  
Securities To Be Issued Upon Exercise Of Options | 2017 Employee Stock Purchase Plan    
Class of Stock [Line Items]    
Securities to be issued (in shares) 0  
Restricted Stock Units    
Class of Stock [Line Items]    
Securities to be issued (in shares) 7,243  
Restricted Stock Units | 2022 Inducement Equity Incentive Plan    
Class of Stock [Line Items]    
Securities to be issued (in shares) 1,277  
Restricted Stock Units | 2011 Equity Incentive Plan    
Class of Stock [Line Items]    
Securities to be issued (in shares) 5,964  
Restricted Stock Units | 2017 Inducement Award Plan    
Class of Stock [Line Items]    
Securities to be issued (in shares) 2  
Restricted Stock Units | 2017 Employee Stock Purchase Plan    
Class of Stock [Line Items]    
Securities to be issued (in shares) 0  
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Apr. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of remaining securities available for future issuance (in shares) 6,445    
Share price (in dollars per share) $ 2.21    
2011 Equity Incentive Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of remaining securities available for future issuance (in shares) 4,656    
Equity Incentive Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Aggregate intrinsic value, vested and released $ 100,000 $ 0  
Total unrecognized compensation cost related to stock-based compensation arrangements $ 12,400,000    
Weighted average remaining contractual terms 2 years 3 months 18 days    
2017 Employee Stock Purchase Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of remaining securities available for future issuance (in shares) 1,581    
2022 Inducement Equity Incentive Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of remaining securities available for future issuance (in shares) 208   9,500
Tranche One      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of months over which options vest ratably 36 months    
Tranche Two      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of months over which options vest ratably 48 months    
Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Award vesting period 4 years    
Award vesting percentage 25.00%    
Total unrecognized compensation cost related to stock-based compensation arrangements $ 13,900,000    
Weighted average remaining contractual terms 2 years 6 months    
Restricted Stock Units (RSUs) | Tranche One      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Rate at which outstanding options vest on the first anniversary of the option grant date 25.00%    
Share-Based Payment Arrangement      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expiration period 10 years    
Stock option grants exercise price minimum percentage on fair market value 100.00%    
Performance Shares      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Performance period 3 years    
Performance Shares | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percentage of performance period 0.00%    
Performance Shares | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percentage of performance period 200.00%    
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation - Restricted and Performance Stock Units (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Restricted Stock Units (RSUs)  
Number of Nonvested and Outstanding Units  
Beginning balance (in shares) | shares 7,120
Granted (in shares) | shares 3,728
Released (in shares) | shares (2,970)
Forfeited (in shares) | shares (945)
Ending balance (in shares) | shares 6,933
Weighted-Average Grant Date Fair Value per Share  
Beginning balance (in dollars per share) | $ / shares $ 2.58
Granted (in dollars per share) | $ / shares 2.32
Released (in dollars per share) | $ / shares 2.68
Forfeited (in dollars per share) | $ / shares 2.17
Ending balance (in dollars per share) | $ / shares $ 2.46
Performance Shares  
Number of Nonvested and Outstanding Units  
Beginning balance (in shares) | shares 453
Granted (in shares) | shares 309
Released (in shares) | shares (52)
Performance adjustment for 2020 awards (in shares) | shares | shares (401)
Ending balance (in shares) | shares 309
Weighted-Average Grant Date Fair Value per Share  
Beginning balance (in dollars per share) | $ / shares $ 4.81
Granted (in dollars per share) | $ / shares 2.42
Released (in dollars per share) | $ / shares 9.6
Performance adjustment for 2020 awards (in shares) | shares | $ / shares 4.19
Ending balance (in dollars per share) | $ / shares $ 2.42
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Number of Options    
Beginning balance (in shares) 7,882  
Options granted (in shares) 2,609  
Option exercised (in shares) (44)  
Options cancelled (in shares) (1,153)  
Ending balance (in shares) 9,294 7,882
Vested (in shares) 3,497  
Unvested awards (in shares) 5,797  
Weighted-Average Exercise Price per Option    
Beginning balance (in dollars per share) $ 4.43  
Options granted (in dollars per share) 2.57  
Options exercised (in dollars per share) 1.84  
Options cancelled (in dollars per share) 6.84  
Ending balance (in dollars per share) 3.62 $ 4.43
Vested (in dollars per share) 3.98  
Unvested awards (in dollars per share) $ 3.4  
Weighted- Average Remaining Contractual Life (in Years)    
Contractual term 8 years 6 months 7 years 10 months 24 days
Vested 8 years 2 months 12 days  
Unvested awards 8 years 8 months 12 days  
Aggregate Intrinsic Value    
Outstanding $ 439 $ 0
Vested 78  
Unvested awards $ 361  
Share price (in usd per share) $ 2.21  
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation - Weighted-average Assumptions (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Weighted average expected volatility 97.10% 91.80%
Weighted average expected term 4 years 8 months 12 days 4 years 3 months 18 days
Weighted average risk-free interest rate 3.90% 2.60%
Dividend yield 0.00% 0.00%
Weighted-average fair value per share (in dollars per share) $ 1.49 $ 2.21
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation $ 13,123 $ 14,880
Cost of product revenue    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation 811 592
Research and development expense    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation 1,671 2,481
Selling, general and administrative expense    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation $ 10,641 $ 11,807
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Loss Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Domestic $ (40,587) $ (174,041)
International (33,617) (18,887)
Loss before income taxes $ (74,204) $ (192,928)
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Current:    
Federal $ 0 $ 0
State (197) (87)
Foreign (373) (405)
Total current tax expense (570) (492)
Deferred:    
Federal 0 0
State 0 0
Foreign 118 3,322
Total deferred benefit 118 3,322
Total benefit (expense) from income taxes $ (452) $ 2,830
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Reconciliation of Income Taxes at Statutory Rate (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Tax benefit at federal statutory rate 21.00% 21.00%
State tax expense, net of federal benefit 1.30% 0.80%
Foreign tax expense 8.10% 0.80%
NOL carryforwards expiring unutilized (5.50%) (22.80%)
Change in valuation allowance (21.90%) 17.10%
Federal R&D credit 0.20% 0.20%
Unrecognized tax benefit 0.00% 0.90%
Non-deductible interest/premium 0.00% (0.30%)
Non-deductible loss on Forward Sale of Preferred Stock and Bridge Loans 0.00% (8.00%)
R&D tax credits expiring unutilized 0.00% (5.20%)
Transaction costs (1.50%) 0.00%
Executive stock-based compensation (2.60%) (0.80%)
Return to provision 2.50% 0.00%
Other, net (2.00%) (2.20%)
Effective tax rate (0.40%) 1.50%
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets:    
Net operating loss carryforward $ 96,242 $ 85,182
Reserves and accruals 3,152 3,943
Depreciation and amortization 564 563
Capitalized R&D costs 5,962 3,840
Tax credit carryforwards 15,463 14,456
Stock-based compensation 1,143 2,064
Right-of-use lease liabilities 7,782 8,663
Total gross deferred tax assets 130,308 118,711
Valuation allowance on deferred tax assets (124,124) (107,893)
Total deferred tax assets, net of valuation allowance 6,184 10,818
Deferred tax liabilities:    
Fixed assets and intangibles (54) (3,913)
Right-of-use assets (6,836) (7,729)
Total deferred tax liabilities (6,890) (11,642)
Net deferred tax liability (706) (824)
Deferred tax liability per balance sheet (841) (1,055)
Less deferred tax assets included in other long-term assets $ 135 $ 231
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2023
Income Taxes [Line Items]    
Valuation allowance $ 107,893,000 $ 124,124,000
Unrecognized tax benefits, that if recognized would affect effective tax rate   0
Unrecognized tax benefits, decrease resulting from prior period tax positions $ 1,697,000  
Domestic Tax Authority    
Income Taxes [Line Items]    
Operating loss carryforward   363,500,000
Domestic Tax Authority | Research Tax Credit Carryforward    
Income Taxes [Line Items]    
Tax credit carryforward   500,000
State and Local Jurisdiction    
Income Taxes [Line Items]    
Operating loss carryforward   220,400,000
State and Local Jurisdiction | Research Tax Credit Carryforward    
Income Taxes [Line Items]    
Tax credit carryforward   14,000,000
Foreign Tax Authority    
Income Taxes [Line Items]    
Operating loss carryforward   36,600,000
Tax credit carryforward   $ 6,900,000
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Valuation Allowance (Details) - Valuation Allowance, Deferred Tax Asset - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Valuation Allowances [Roll Forward]    
Beginning balance $ 107,893 $ 141,087
Charges to earnings 0 0
Charges to other accounts 16,231 (33,194)
Ending balance $ 124,124 $ 107,893
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Aggregate Changes in Balance of Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
Beginning balance $ 6,972 $ 8,515
Increases in balances related to tax positions during a prior period 105 154
Increases in balances related to tax positions taken during current period   0
Decreases in balances related to tax positions taken during current period (138)  
Decreases in balances related to tax positions taken during prior period   (1,697)
Ending balance $ 6,939 $ 6,972
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting - Narrative (Details)
 12 Months Ended
Dec. 31, 2023
Segment
Segment Reporting Information [Line Items]  
Number of reporting segments 2
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting - Schedule of Business Segment Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]    
Total revenue $ 106,340 $ 97,948
Gross profit 50,450 37,051
Depreciation & amortization 12,673 12,453
Proteomics    
Segment Reporting Information [Line Items]    
Total revenue 63,883 52,502
Gross profit 26,239 20,041
Depreciation & amortization 12,072 12,223
Genomics    
Segment Reporting Information [Line Items]    
Total revenue 42,457 45,446
Gross profit 24,211 17,010
Depreciation & amortization $ 601 $ 230
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Related Charges - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]    
Restructuring and related charges $ 7,076 $ 9,732
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Related Charges - Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Restructuring Reserve [Roll Forward]    
Beginning balance $ 4,033 $ 0
Restructuring and related charges 7,076 9,732
Cash payments (10,284) (5,699)
Ending balance 825 4,033
Severance and other employee-related benefits    
Restructuring Reserve [Roll Forward]    
Beginning balance 4,014 0
Restructuring and related charges 2,379 5,849
Cash payments (5,568) (1,835)
Ending balance 825 4,014
Facility Costs    
Restructuring Reserve [Roll Forward]    
Beginning balance 0 0
Restructuring and related charges 4,160 2,885
Cash payments (4,160) (2,885)
Ending balance 0 0
Other    
Restructuring Reserve [Roll Forward]    
Beginning balance 19 0
Restructuring and related charges 537 998
Cash payments (556) (979)
Ending balance $ 0 $ 19
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Related Charges - Restructuring and Other Efficiency Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]    
Total restructuring and other related costs $ 7,076 $ 9,732
Corporate expenses    
Restructuring Cost and Reserve [Line Items]    
Total restructuring and other related costs 5,352 7,096
Proteomics | Operating segments    
Restructuring Cost and Reserve [Line Items]    
Total restructuring and other related costs 1,010 1,363
Genomics | Operating segments    
Restructuring Cost and Reserve [Line Items]    
Total restructuring and other related costs $ 714 $ 1,273
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
401(K) Plan - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]      
Percent of employee match     100.00%
Maximum annual employee contribution matched by employer     $ 3,000
Employer matching contributions expense $ 500,000 $ 600,000  
Maximum      
Defined Benefit Plan Disclosure [Line Items]      
Percentage of employees eligible compensation 90.00%    
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Event - Narrative (Details) - Subsequent Event - Common Stock
Jan. 05, 2024
Combined Company  
Subsequent Event [Line Items]  
Equity ownership percentage 57.00%
Combined Subsidiaries  
Subsequent Event [Line Items]  
Equity ownership percentage 43.00%
SomaLogic Inc.  
Subsequent Event [Line Items]  
Exchange ratio 1.11%
EXCEL 106 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 107 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 108 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 110 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 263 484 1 true 96 0 false 6 false false R1.htm 100000 - Document - Cover Sheet http://www.standardbio.com/20231231/taxonomy/role/Cover Cover Cover 1 false false R2.htm 100010 - Document - Audit Information Sheet http://www.standardbio.com/20231231/taxonomy/role/AuditInformation Audit Information Cover 2 false false R3.htm 100030 - Statement - Consolidated Balance Sheets Sheet http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 100040 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 100050 - Statement - Consolidated Statements of Operations Sheet http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 100060 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 6 false false R7.htm 100070 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) Statements 7 false false R8.htm 100080 - Statement - Consolidated Statements of Cash Flows Sheet http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 100090 - Disclosure - Description of Business Sheet http://www.standardbio.com/20231231/taxonomy/role/DescriptionofBusiness Description of Business Notes 9 false false R10.htm 100100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 100130 - Disclosure - Revenue and Geographic Area Sheet http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicArea Revenue and Geographic Area Notes 11 false false R12.htm 100140 - Disclosure - Goodwill and Intangible Assets, net Sheet http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnet Goodwill and Intangible Assets, net Notes 12 false false R13.htm 100150 - Disclosure - Balance Sheet Details Sheet http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetails Balance Sheet Details Notes 13 false false R14.htm 100160 - Disclosure - Debt Sheet http://www.standardbio.com/20231231/taxonomy/role/Debt Debt Notes 14 false false R15.htm 100180 - Disclosure - Commitments and Contingencies Sheet http://www.standardbio.com/20231231/taxonomy/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 100190 - Disclosure - Fair Value of Financial Instruments Sheet http://www.standardbio.com/20231231/taxonomy/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 16 false false R17.htm 100200 - Disclosure - Mezzanine Equity Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquity1 Mezzanine Equity Notes 17 false false R18.htm 100210 - Disclosure - Shareholders' Deficit Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficit Shareholders' Deficit Notes 18 false false R19.htm 100220 - Disclosure - Stock-based Compensation Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation Stock-based Compensation Notes 19 false false R20.htm 100230 - Disclosure - Income Taxes Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 100240 - Disclosure - Segment Reporting Sheet http://www.standardbio.com/20231231/taxonomy/role/SegmentReporting Segment Reporting Notes 21 false false R22.htm 100250 - Disclosure - 401(K) Plan Sheet http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlan 401(K) Plan Notes 22 false false R23.htm 100260 - Disclosure - Restructuring and Related Charges Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedCharges Restructuring and Related Charges Notes 23 false false R24.htm 100270 - Disclosure - Subsequent Event Sheet http://www.standardbio.com/20231231/taxonomy/role/SubsequentEvent Subsequent Event Notes 24 false false R25.htm 100280 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 100290 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 100310 - Disclosure - Revenue and Geographic Area (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaTables Revenue and Geographic Area (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicArea 27 false false R28.htm 100320 - Disclosure - Goodwill and Intangible Assets, net (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetTables Goodwill and Intangible Assets, net (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnet 28 false false R29.htm 100330 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetails 29 false false R30.htm 100340 - Disclosure - Debt (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/DebtTables Debt (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/Debt 30 false false R31.htm 100350 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/CommitmentsandContingencies 31 false false R32.htm 100360 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/FairValueofFinancialInstruments 32 false false R33.htm 100370 - Disclosure - Mezzanine Equity (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityTables Mezzanine Equity (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquity1 33 false false R34.htm 100380 - Disclosure - Shareholders' Deficit (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitTables Shareholders' Deficit (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficit 34 false false R35.htm 100390 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables Stock-based Compensation (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation 35 false false R36.htm 100400 - Disclosure - Income Taxes (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxes 36 false false R37.htm 100410 - Disclosure - Segment Reporting (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/SegmentReporting 37 false false R38.htm 100420 - Disclosure - Restructuring and Related Charges (Tables) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesTables Restructuring and Related Charges (Tables) Tables http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedCharges 38 false false R39.htm 100430 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 39 false false R40.htm 100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo Summary of Significant Accounting Policies - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details) Details 40 false false R41.htm 100450 - Disclosure - NIH Contract - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/NIHContractNarrativeDetails NIH Contract - Narrative (Details) Details 41 false false R42.htm 100460 - Disclosure - NIH Contract (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails NIH Contract (Details) Details 42 false false R43.htm 100470 - Disclosure - Business Combination - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails Business Combination - Narrative (Details) Details 43 false false R44.htm 100480 - Disclosure - Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details) Details 44 false false R45.htm 100490 - Disclosure - Revenue and Geographic Area - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails Revenue and Geographic Area - Narrative (Details) Details 45 false false R46.htm 100500 - Disclosure - Revenue and Geographic Area - Long-lived Assets by Geographic Areas (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails Revenue and Geographic Area - Long-lived Assets by Geographic Areas (Details) Details 46 false false R47.htm 100510 - Disclosure - Revenue and Geographic Area - Performance Obligations (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaPerformanceObligationsDetails Revenue and Geographic Area - Performance Obligations (Details) Details 47 false false R48.htm 100520 - Disclosure - Revenue and Geographic Area - Performance Obligation (Details1) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1 Revenue and Geographic Area - Performance Obligation (Details1) Details 48 false false R49.htm 100530 - Disclosure - Goodwill and Intangible Assets, net - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails Goodwill and Intangible Assets, net - Narrative (Details) Details 49 false false R50.htm 100540 - Disclosure - Goodwill and Intangible Assets, net - Changes in the Carrying Value of Goodwill by Segment (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails Goodwill and Intangible Assets, net - Changes in the Carrying Value of Goodwill by Segment (Details) Details 50 false false R51.htm 100550 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Finite-lived Intangible Assets (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails Goodwill and Intangible Assets, net - Schedule of Finite-lived Intangible Assets (Details) Details 51 false false R52.htm 100560 - Disclosure - Goodwill and Intangible Assets, net - Future Amortization Expense (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails Goodwill and Intangible Assets, net - Future Amortization Expense (Details) Details 52 false false R53.htm 100570 - Disclosure - Balance Sheet Details - Summary of Cash and Cash Equivalents (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails Balance Sheet Details - Summary of Cash and Cash Equivalents (Details) Details 53 false false R54.htm 100580 - Disclosure - Balance Sheet Details - Inventories (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails Balance Sheet Details - Inventories (Details) Details 54 false false R55.htm 100590 - Disclosure - Balance Sheet Details - Property and Equipment (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails Balance Sheet Details - Property and Equipment (Details) Details 55 false false R56.htm 100600 - Disclosure - Balance Sheet Details - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsNarrativeDetails Balance Sheet Details - Narrative (Details) Details 56 false false R57.htm 100610 - Disclosure - Balance Sheet Details - Accrued Compensation and Related Benefits (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails Balance Sheet Details - Accrued Compensation and Related Benefits (Details) Details 57 false false R58.htm 100620 - Disclosure - Balance Sheet Details - Other Accrued Liabilities (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails Balance Sheet Details - Other Accrued Liabilities (Details) Details 58 false false R59.htm 100630 - Disclosure - Debt - Schedule of Carrying Value of Debt (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails Debt - Schedule of Carrying Value of Debt (Details) Details 59 false false R60.htm 100640 - Disclosure - Debt - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails Debt - Narrative (Details) Details 60 false false R61.htm 100660 - Disclosure - Debt - Future Minimum Payments under Term Loan Facility including End of Term Fee Payment (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails Debt - Future Minimum Payments under Term Loan Facility including End of Term Fee Payment (Details) Details 61 false false R62.htm 100670 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 62 false false R63.htm 100680 - Disclosure - Commitments and Contingencies - Schedule of Operating Leases (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails Commitments and Contingencies - Schedule of Operating Leases (Details) Details 63 false false R64.htm 100690 - Disclosure - Commitments and Contingencies - Operating Lease Maturity (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3 Commitments and Contingencies - Operating Lease Maturity (Details) Details 64 false false R65.htm 100700 - Disclosure - Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details) Details 65 false false R66.htm 100710 - Disclosure - Fair Value of Financial Instruments - Schedule of Available-for-Sale Securities (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails Fair Value of Financial Instruments - Schedule of Available-for-Sale Securities (Details) Details 66 false false R67.htm 100720 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 67 false false R68.htm 100730 - Disclosure - Mezzanine Equity - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails Mezzanine Equity - Narrative (Details) Details 68 false false R69.htm 100740 - Disclosure - Mezzanine Equity - Preferred Stock (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails Mezzanine Equity - Preferred Stock (Details) Details 69 false false R70.htm 100750 - Disclosure - Shareholders' Deficit - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitNarrativeDetails Shareholders' Deficit - Narrative (Details) Details 70 false false R71.htm 100760 - Disclosure - Shareholders' Deficit - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails Shareholders' Deficit - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details) Details 71 false false R72.htm 100770 - Disclosure - Stock-based Compensation - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails Stock-based Compensation - Narrative (Details) Details 72 false false R73.htm 100780 - Disclosure - Stock-based Compensation - Restricted and Performance Stock Units (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails Stock-based Compensation - Restricted and Performance Stock Units (Details) Details 73 false false R74.htm 100790 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails Stock-based Compensation - Stock Option Activity (Details) Details 74 false false R75.htm 100800 - Disclosure - Stock-based Compensation - Weighted-average Assumptions (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsDetails Stock-based Compensation - Weighted-average Assumptions (Details) Details 75 false false R76.htm 100810 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails Stock-based Compensation - Stock-based Compensation Expense (Details) Details 76 false false R77.htm 100820 - Disclosure - Income Taxes - Loss Before Income Taxes (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesLossBeforeIncomeTaxesDetails Income Taxes - Loss Before Income Taxes (Details) Details 77 false false R78.htm 100830 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails Income Taxes - Components of Provision for Income Taxes (Details) Details 78 false false R79.htm 100840 - Disclosure - Income Taxes - Reconciliation of Income Taxes at Statutory Rate (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails Income Taxes - Reconciliation of Income Taxes at Statutory Rate (Details) Details 79 false false R80.htm 100850 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) Details 80 false false R81.htm 100860 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 81 false false R82.htm 100870 - Disclosure - Income Taxes - Valuation Allowance (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails Income Taxes - Valuation Allowance (Details) Details 82 false false R83.htm 100880 - Disclosure - Income Taxes - Aggregate Changes in Balance of Gross Unrecognized Tax Benefits (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesAggregateChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails Income Taxes - Aggregate Changes in Balance of Gross Unrecognized Tax Benefits (Details) Details 83 false false R84.htm 100890 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 84 false false R85.htm 100900 - Disclosure - Segment Reporting - Schedule of Business Segment Information (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails Segment Reporting - Schedule of Business Segment Information (Details) Details 85 false false R86.htm 100910 - Disclosure - Restructuring and Related Charges - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesNarrativeDetails Restructuring and Related Charges - Narrative (Details) Details 86 false false R87.htm 100920 - Disclosure - Restructuring and Related Charges - Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails Restructuring and Related Charges - Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) Details 87 false false R88.htm 100930 - Disclosure - Restructuring and Related Charges - Restructuring and Other Efficiency Costs (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails Restructuring and Related Charges - Restructuring and Other Efficiency Costs (Details) Details 88 false false R89.htm 100940 - Disclosure - 401(K) Plan - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails 401(K) Plan - Narrative (Details) Details 89 false false R90.htm 100950 - Disclosure - Subsequent Event - Narrative (Details) Sheet http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails Subsequent Event - Narrative (Details) Details 90 false false All Reports Book All Reports lab-20231231.htm lab-20231231.xsd img186398206_0.jpg img186398206_1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 false false JSON 113 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lab-20231231.htm": { "nsprefix": "lab", "nsuri": "http://www.standardbio.com/20231231", "dts": { "inline": { "local": [ "lab-20231231.htm" ] }, "schema": { "local": [ "lab-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 417, "keyCustom": 67, "axisStandard": 37, "axisCustom": 0, "memberStandard": 64, "memberCustom": 31, "hidden": { "total": 13, "http://xbrl.sec.gov/dei/2023": 3, "http://fasb.org/us-gaap/2023": 9, "http://www.standardbio.com/20231231": 1 }, "contextCount": 263, "entityCount": 1, "segmentCount": 96, "elementCount": 808, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 962, "http://xbrl.sec.gov/dei/2023": 38 }, "report": { "R1": { "role": "http://www.standardbio.com/20231231/taxonomy/role/Cover", "longName": "100000 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.standardbio.com/20231231/taxonomy/role/AuditInformation", "longName": "100010 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "longName": "100030 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R4": { "role": "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical", "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "longName": "100050 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R6": { "role": "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss", "longName": "100060 - Statement - Consolidated Statements of Comprehensive Loss", "shortName": "Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R7": { "role": "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit", "longName": "100070 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_90cdd76f-4617-43dc-9843-6f207ea85de8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_90cdd76f-4617-43dc-9843-6f207ea85de8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "longName": "100080 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R9": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DescriptionofBusiness", "longName": "100090 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPolicies", "longName": "100100 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicArea", "longName": "100130 - Disclosure - Revenue and Geographic Area", "shortName": "Revenue and Geographic Area", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnet", "longName": "100140 - Disclosure - Goodwill and Intangible Assets, net", "shortName": "Goodwill and Intangible Assets, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetails", "longName": "100150 - Disclosure - Balance Sheet Details", "shortName": "Balance Sheet Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.standardbio.com/20231231/taxonomy/role/Debt", "longName": "100160 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.standardbio.com/20231231/taxonomy/role/CommitmentsandContingencies", "longName": "100180 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.standardbio.com/20231231/taxonomy/role/FairValueofFinancialInstruments", "longName": "100190 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquity1", "longName": "100200 - Disclosure - Mezzanine Equity", "shortName": "Mezzanine Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "lab:MezzanineEquityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "lab:MezzanineEquityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficit", "longName": "100210 - Disclosure - Shareholders' Deficit", "shortName": "Shareholders' Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation", "longName": "100220 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxes", "longName": "100230 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SegmentReporting", "longName": "100240 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlan", "longName": "100250 - Disclosure - 401(K) Plan", "shortName": "401(K) Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedCharges", "longName": "100260 - Disclosure - Restructuring and Related Charges", "shortName": "Restructuring and Related Charges", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SubsequentEvent", "longName": "100270 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables", "longName": "100290 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaTables", "longName": "100310 - Disclosure - Revenue and Geographic Area (Tables)", "shortName": "Revenue and Geographic Area (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetTables", "longName": "100320 - Disclosure - Goodwill and Intangible Assets, net (Tables)", "shortName": "Goodwill and Intangible Assets, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsTables", "longName": "100330 - Disclosure - Balance Sheet Details (Tables)", "shortName": "Balance Sheet Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DebtTables", "longName": "100340 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "longName": "100350 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.standardbio.com/20231231/taxonomy/role/FairValueofFinancialInstrumentsTables", "longName": "100360 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityTables", "longName": "100370 - Disclosure - Mezzanine Equity (Tables)", "shortName": "Mezzanine Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:TemporaryEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:TemporaryEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitTables", "longName": "100380 - Disclosure - Shareholders' Deficit (Tables)", "shortName": "Shareholders' Deficit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables", "longName": "100390 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesTables", "longName": "100400 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingTables", "longName": "100410 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesTables", "longName": "100420 - Disclosure - Restructuring and Related Charges (Tables)", "shortName": "Restructuring and Related Charges (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "100430 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:InvestmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:InvestmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo", "longName": "100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.standardbio.com/20231231/taxonomy/role/NIHContractNarrativeDetails", "longName": "100450 - Disclosure - NIH Contract - Narrative (Details)", "shortName": "NIH Contract - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_25f5fe61-2dc2-435a-9872-db5b3c6dff9d", "name": "lab:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails", "longName": "100460 - Disclosure - NIH Contract (Details)", "shortName": "NIH Contract (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "lab:ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "longName": "100470 - Disclosure - Business Combination - Narrative (Details)", "shortName": "Business Combination - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:SharePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails", "longName": "100480 - Disclosure - Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details)", "shortName": "Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_786a528e-fcec-44da-a140-015bea689ac4", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R45": { "role": "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "longName": "100490 - Disclosure - Revenue and Geographic Area - Narrative (Details)", "shortName": "Revenue and Geographic Area - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R46": { "role": "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails", "longName": "100500 - Disclosure - Revenue and Geographic Area - Long-lived Assets by Geographic Areas (Details)", "shortName": "Revenue and Geographic Area - Long-lived Assets by Geographic Areas (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:NoncurrentAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:NoncurrentAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaPerformanceObligationsDetails", "longName": "100510 - Disclosure - Revenue and Geographic Area - Performance Obligations (Details)", "shortName": "Revenue and Geographic Area - Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_75da9976-18a5-42d6-9829-befddf33daa3", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R48": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1", "longName": "100520 - Disclosure - Revenue and Geographic Area - Performance Obligation (Details1)", "shortName": "Revenue and Geographic Area - Performance Obligation (Details1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "longName": "100530 - Disclosure - Goodwill and Intangible Assets, net - Narrative (Details)", "shortName": "Goodwill and Intangible Assets, net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_93ad71fc-1717-4fcd-a827-00037fa812a8", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R50": { "role": "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails", "longName": "100540 - Disclosure - Goodwill and Intangible Assets, net - Changes in the Carrying Value of Goodwill by Segment (Details)", "shortName": "Goodwill and Intangible Assets, net - Changes in the Carrying Value of Goodwill by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_6cc4f038-bbd2-427e-9210-29f04ae4154c", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R51": { "role": "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails", "longName": "100550 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Finite-lived Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets, net - Schedule of Finite-lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c2065a29-1ff1-4ae3-a74b-c6ede0699a40", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R52": { "role": "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails", "longName": "100560 - Disclosure - Goodwill and Intangible Assets, net - Future Amortization Expense (Details)", "shortName": "Goodwill and Intangible Assets, net - Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails", "longName": "100570 - Disclosure - Balance Sheet Details - Summary of Cash and Cash Equivalents (Details)", "shortName": "Balance Sheet Details - Summary of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R54": { "role": "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails", "longName": "100580 - Disclosure - Balance Sheet Details - Inventories (Details)", "shortName": "Balance Sheet Details - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails", "longName": "100590 - Disclosure - Balance Sheet Details - Property and Equipment (Details)", "shortName": "Balance Sheet Details - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsNarrativeDetails", "longName": "100600 - Disclosure - Balance Sheet Details - Narrative (Details)", "shortName": "Balance Sheet Details - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails", "longName": "100610 - Disclosure - Balance Sheet Details - Accrued Compensation and Related Benefits (Details)", "shortName": "Balance Sheet Details - Accrued Compensation and Related Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:WorkersCompensationLiabilityCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:WorkersCompensationLiabilityCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails", "longName": "100620 - Disclosure - Balance Sheet Details - Other Accrued Liabilities (Details)", "shortName": "Balance Sheet Details - Other Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:AccruedSalesCommissionCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:AccruedSalesCommissionCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "longName": "100630 - Disclosure - Debt - Schedule of Carrying Value of Debt (Details)", "shortName": "Debt - Schedule of Carrying Value of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:LongTermDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:LongTermDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "longName": "100640 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8e71a47f-b202-4345-88f0-6f0f87cb750e", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R61": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails", "longName": "100660 - Disclosure - Debt - Future Minimum Payments under Term Loan Facility including End of Term Fee Payment (Details)", "shortName": "Debt - Future Minimum Payments under Term Loan Facility including End of Term Fee Payment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "longName": "100670 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails", "longName": "100680 - Disclosure - Commitments and Contingencies - Schedule of Operating Leases (Details)", "shortName": "Commitments and Contingencies - Schedule of Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3", "longName": "100690 - Disclosure - Commitments and Contingencies - Operating Lease Maturity (Details)", "shortName": "Commitments and Contingencies - Operating Lease Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails", "longName": "100700 - Disclosure - Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details)", "shortName": "Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1c41f808-26d5-4fe4-bfb7-2ff047a06f69", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R66": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails", "longName": "100710 - Disclosure - Fair Value of Financial Instruments - Schedule of Available-for-Sale Securities (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Available-for-Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "longName": "100720 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails", "longName": "100730 - Disclosure - Mezzanine Equity - Narrative (Details)", "shortName": "Mezzanine Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a5a86634-55a3-4106-a4fb-0279eedb99d5", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R69": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails", "longName": "100740 - Disclosure - Mezzanine Equity - Preferred Stock (Details)", "shortName": "Mezzanine Equity - Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e757a59b-1a44-404c-89d0-2fb3160f7927", "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R70": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitNarrativeDetails", "longName": "100750 - Disclosure - Shareholders' Deficit - Narrative (Details)", "shortName": "Shareholders' Deficit - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_f2db7db9-6b61-4ae4-9cf0-6f8b06f65145", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f2db7db9-6b61-4ae4-9cf0-6f8b06f65145", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "longName": "100760 - Disclosure - Shareholders' Deficit - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details)", "shortName": "Shareholders' Deficit - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cf81ad02-d232-4f70-a316-27e8a58eb243", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R72": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "longName": "100770 - Disclosure - Stock-based Compensation - Narrative (Details)", "shortName": "Stock-based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2b5c832f-81d9-4785-842c-7af2d689177e", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R73": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails", "longName": "100780 - Disclosure - Stock-based Compensation - Restricted and Performance Stock Units (Details)", "shortName": "Stock-based Compensation - Restricted and Performance Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_51d29f38-596f-4a12-b7bb-3f43206d5a43", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_51d29f38-596f-4a12-b7bb-3f43206d5a43", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails", "longName": "100790 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)", "shortName": "Stock-based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_6cc4f038-bbd2-427e-9210-29f04ae4154c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R75": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsDetails", "longName": "100800 - Disclosure - Stock-based Compensation - Weighted-average Assumptions (Details)", "shortName": "Stock-based Compensation - Weighted-average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails", "longName": "100810 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)", "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesLossBeforeIncomeTaxesDetails", "longName": "100820 - Disclosure - Income Taxes - Loss Before Income Taxes (Details)", "shortName": "Income Taxes - Loss Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails", "longName": "100830 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)", "shortName": "Income Taxes - Components of Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails", "longName": "100840 - Disclosure - Income Taxes - Reconciliation of Income Taxes at Statutory Rate (Details)", "shortName": "Income Taxes - Reconciliation of Income Taxes at Statutory Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails", "longName": "100850 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)", "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails", "longName": "100860 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C_6cc4f038-bbd2-427e-9210-29f04ae4154c", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3e62e889-e530-4ce6-9acc-d396fdfb5322", "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R82": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails", "longName": "100870 - Disclosure - Income Taxes - Valuation Allowance (Details)", "shortName": "Income Taxes - Valuation Allowance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "C_1dafab6c-3258-4982-8d39-f91758dc44ad", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2dae6dac-e1cf-446a-9a31-ddc80f3ae82b", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R83": { "role": "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesAggregateChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails", "longName": "100880 - Disclosure - Income Taxes - Aggregate Changes in Balance of Gross Unrecognized Tax Benefits (Details)", "shortName": "Income Taxes - Aggregate Changes in Balance of Gross Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "C_6cc4f038-bbd2-427e-9210-29f04ae4154c", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eaef6f84-019e-41b3-9401-2abe272c3cb3", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R84": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails", "longName": "100890 - Disclosure - Segment Reporting - Narrative (Details)", "shortName": "Segment Reporting - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": null }, "R85": { "role": "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails", "longName": "100900 - Disclosure - Segment Reporting - Schedule of Business Segment Information (Details)", "shortName": "Segment Reporting - Schedule of Business Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R86": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesNarrativeDetails", "longName": "100910 - Disclosure - Restructuring and Related Charges - Narrative (Details)", "shortName": "Restructuring and Related Charges - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RestructuringCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": null }, "R87": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails", "longName": "100920 - Disclosure - Restructuring and Related Charges - Summary of the Changes in Our Restructuring and Other Related Liabilities (Details)", "shortName": "Restructuring and Related Charges - Summary of the Changes in Our Restructuring and Other Related Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "C_6cc4f038-bbd2-427e-9210-29f04ae4154c", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eaef6f84-019e-41b3-9401-2abe272c3cb3", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R88": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails", "longName": "100930 - Disclosure - Restructuring and Related Charges - Restructuring and Other Efficiency Costs (Details)", "shortName": "Restructuring and Related Charges - Restructuring and Other Efficiency Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "C_70e42c9a-4836-489a-bf3e-8e5c00aa26cf", "name": "us-gaap:RestructuringCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4447fd97-884e-437f-9834-a890acb77811", "name": "us-gaap:RestructuringCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "unique": true } }, "R89": { "role": "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails", "longName": "100940 - Disclosure - 401(K) Plan - Narrative (Details)", "shortName": "401(K) Plan - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "C_afa4ad85-6564-467c-9458-273ee6fffd7f", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_afa4ad85-6564-467c-9458-273ee6fffd7f", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails", "longName": "100950 - Disclosure - Subsequent Event - Narrative (Details)", "shortName": "Subsequent Event - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "C_b09faa55-a25c-4d3d-85c6-097980c36b61", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b09faa55-a25c-4d3d-85c6-097980c36b61", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "lab-20231231.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36", "r936" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r876" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable (net of allowances of $312 and $592 at December 31, 2023 and 2022, respectively)", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r358", "r359" ] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Bonuses, Current", "terseLabel": "Accrued severance and retention payments", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued taxes", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r139", "r205" ] }, "lab_AccruedInterestCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "AccruedInterestCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued interest", "label": "Accrued Interest Current", "documentation": "Accrued interest current." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other accrued liabilities", "label": "Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Payroll Taxes, Current", "terseLabel": "Accrued payroll taxes and other", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued legal expenses", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "lab_AccruedRestructuringCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "AccruedRestructuringCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued restructuring", "label": "Accrued Restructuring, Current", "documentation": "Accrued restructuring, current." } } }, "auth_ref": [] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued commissions", "label": "Accrued Sales Commission, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39", "r895" ] }, "us-gaap_AccruedVacationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedVacationCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Vacation, Current", "terseLabel": "Accrued vacation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39", "r100" ] }, "lab_AccruedWarrantiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "AccruedWarrantiesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued warranties", "label": "Accrued Warranties Current", "documentation": "Accrued warranties current." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r86", "r238", "r738" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r49", "r50", "r154", "r248", "r734", "r770", "r771" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Accum. Other Comp. (Loss)", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r22", "r50", "r633", "r636", "r680", "r766", "r767", "r987", "r988", "r989", "r1006", "r1007", "r1008" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Additional Paid in Capital, Total", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r146", "r936", "r1114" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r579", "r580", "r581", "r784", "r1006", "r1007", "r1008", "r1090", "r1116" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r109", "r110", "r541" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r216" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Advertising Expense", "terseLabel": "Advertising costs incurred", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r588" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r574", "r587" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, allowances", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r249", "r360", "r398" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AmericasMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Americas [Member]", "terseLabel": "Americas" } } }, "auth_ref": [ "r1118", "r1119", "r1120", "r1121" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discounts, premiums and issuance costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r485", "r663", "r916", "r917", "r995" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of developed technology", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r79", "r83" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia-Pacific" } } }, "auth_ref": [ "r1118", "r1119", "r1120", "r1121" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Impairment charge", "totalLabel": "Asset Impairment Charges, Total", "label": "Asset Impairment Charges", "terseLabel": "Asset impairment charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r11", "r84" ] }, "lab_AssetRetirementObligationsIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "AssetRetirementObligationsIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Asset Retirement Obligations Incurred But Not Yet Paid", "label": "Asset Retirement Obligations Incurred But Not Yet Paid", "terseLabel": "Asset retirement obligations" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r203", "r242", "r274", "r322", "r343", "r349", "r395", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r628", "r630", "r652", "r728", "r821", "r936", "r949", "r1050", "r1051", "r1099" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r233", "r252", "r274", "r395", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r628", "r630", "r652", "r936", "r1050", "r1051", "r1099" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets measured at fair value", "terseLabel": "Total assets measured at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r125" ] }, "lab_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "documentation": "Audit Information [Abstract]", "label": "Audit Information [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r954", "r955", "r956" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "auth_ref": [ "r954", "r955", "r956" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "auth_ref": [ "r954", "r955", "r956" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Gains", "verboseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r366" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses", "verboseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r367" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "verboseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r363", "r405", "r727" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated Fair Value", "terseLabel": "Short-term investments", "label": "Debt Securities, Available-for-Sale", "totalLabel": "Debt Securities, Available-for-Sale, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r364", "r405", "r722", "r1021" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Short-term investments", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r361", "r405" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r545", "r546", "r547", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r569", "r570", "r571", "r572", "r573" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r123", "r124" ] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Consolidation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BridgeLoanMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridge Loans", "label": "Bridge Loan [Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r625", "r929", "r930" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r119", "r120", "r625", "r929", "r930" ] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Number of shares issued in business combination (in shares)", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": [ "r199" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r625" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Transaction-related expenses", "terseLabel": "Transaction-related expenses", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r118" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]", "terseLabel": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Business Combination, Consideration Transferred, Total", "label": "Business Combination, Consideration Transferred", "terseLabel": "Aggregate purchase price", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombination" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r197", "r626" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Finite lived intangible assets acquired", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r121", "r122" ] }, "us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Transaction-related Expenses", "label": "Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for business combinations and other business acquisition transactions not accounted for using the purchase method, such as an exchange of shares between entities under common control." } } }, "auth_ref": [ "r1", "r2" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r117" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DescriptionofBusiness" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Description of Business", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r137", "r168", "r169" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CA", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Canada" } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CN", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "auth_ref": [] }, "lab_CasdinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CasdinMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Casdin", "label": "Casdin [Member]", "terseLabel": "Casdin" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "netLabel": "Cash-unrestricted", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r57", "r236", "r893" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r236" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r58" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "terseLabel": "Total cash, cash equivalents, and restricted cash", "totalLabel": "Total cash, cash equivalents, and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r57", "r165", "r271" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r6", "r165" ] }, "lab_CertainEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CertainEmployeeMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Certain Employee [Member]", "label": "Certain Employee [Member]", "terseLabel": "Certain Employee" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r229", "r245", "r246", "r247", "r274", "r303", "r307", "r311", "r313", "r316", "r317", "r395", "r457", "r460", "r461", "r462", "r468", "r469", "r490", "r491", "r494", "r497", "r504", "r652", "r778", "r779", "r780", "r781", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r809", "r830", "r849", "r869", "r870", "r871", "r872", "r873", "r961", "r997", "r1010" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r245", "r246", "r247", "r316", "r490", "r491", "r492", "r494", "r497", "r502", "r504", "r778", "r779", "r780", "r781", "r918", "r961", "r997" ] }, "lab_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CollaborationRevenueMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaboration Revenue", "label": "Collaboration Revenue [Member]", "terseLabel": "Development revenue", "verboseLabel": "Development revenue" } } }, "auth_ref": [] }, "lab_CollaborativeArrangementsAnnualPaymentsReceivableUnderDevelopmentAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CollaborativeArrangementsAnnualPaymentsReceivableUnderDevelopmentAgreement", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements, Annual Payments Receivable Under Development Agreement", "label": "Collaborative Arrangements, Annual Payments Receivable Under Development Agreement", "terseLabel": "Annual payments receivable" } } }, "auth_ref": [] }, "lab_CombinedCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CombinedCompanyMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Combined Company", "label": "Combined Company [Member]", "documentation": "Combined company." } } }, "auth_ref": [] }, "lab_CombinedSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CombinedSubsidiariesMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Combined Subsidiaries", "label": "Combined Subsidiaries [Member]", "documentation": "Combined subsidiaries." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 8)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r45", "r133", "r730", "r808" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r177", "r449", "r450", "r877", "r1045" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of remaining securities available for future issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r46" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r939", "r940", "r941", "r943", "r944", "r945", "r946", "r1006", "r1007", "r1090", "r1113", "r1116" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r145" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r145", "r809" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r145" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r23", "r145", "r809", "r827", "r1116", "r1117" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock: $0.001 par value, 400,000 shares authorized at December 31, 2023 and 2022; 83,364 and 79,904 shares issued at December 31, 2023 and 2022, respectively; 80,232 and 79,482 shares outstanding at December 31, 2023 and 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r145", "r732", "r936" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlan" ], "lang": { "en-us": { "role": { "terseLabel": "401(K) Plan", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r185", "r186", "r187", "r188" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r51", "r255", "r257", "r263", "r723", "r743" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "lab_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Computer Equipment And Software [Member]", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer equipment and software" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r64", "r67", "r127", "r128", "r357", "r876" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r64", "r67", "r127", "r128", "r357", "r772", "r876" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r64", "r67", "r127", "r128", "r357", "r876", "r967" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Business and Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r135", "r219" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r64", "r67", "r127", "r128", "r357" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r64", "r67", "r127", "r128", "r357", "r876" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r279", "r324", "r341", "r342", "r343", "r344", "r345", "r347", "r351", "r457", "r458", "r459", "r460", "r462", "r463", "r465", "r467", "r468", "r1050", "r1051" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r279", "r324", "r341", "r342", "r343", "r344", "r345", "r347", "r351", "r457", "r458", "r459", "r460", "r462", "r463", "r465", "r467", "r468", "r1050", "r1051" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress, Gross", "terseLabel": "Construction-in-progress", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r174" ] }, "lab_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ConsumablesMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Consumables [Member]", "label": "Consumables [Member]", "terseLabel": "Consumables" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Liability, Total", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r506", "r507", "r526" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r506", "r507", "r526" ] }, "lab_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Increase From Cash Receipts", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "terseLabel": "Additional advance payments received" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, non-current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r506", "r507", "r526" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r527" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, current", "label": "Convertible Debt, Current", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r138" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r179", "r470", "r471", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485", "r913", "r914", "r915", "r916", "r917" ] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, non-current", "label": "Convertible Debt, Noncurrent", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock", "verboseLabel": "Series B Preferred Stock", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r490", "r491", "r494", "r943", "r944", "r945", "r946" ] }, "lab_CorporateHeadquartersEighteenthFloorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CorporateHeadquartersEighteenthFloorMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Headquarters (18th Floor)", "label": "Corporate Headquarters Eighteenth Floor [Member]", "documentation": "Corporate headquarters eighteenth floor." } } }, "auth_ref": [] }, "lab_CorporateHeadquartersTwentyFirstFloorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CorporateHeadquartersTwentyFirstFloorMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Headquarters (21st Floor)", "label": "Corporate Headquarters Twenty First Floor [Member]", "documentation": "Corporate headquarters twenty first floor." } } }, "auth_ref": [] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r1013" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate expenses", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r29", "r342", "r343", "r344", "r345", "r351", "r1015" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Total cost of revenue", "totalLabel": "Cost of Goods and Services Sold, Total", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r159", "r718" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Charges", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations." } } }, "auth_ref": [ "r32", "r175", "r176" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r277", "r278", "r473", "r492", "r681", "r896", "r898" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal Tax Expense (Benefit)", "negatedTerseLabel": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r969", "r1000", "r1088" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Current Foreign Tax Expense (Benefit)", "negatedTerseLabel": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r969", "r1000" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total current tax expense", "totalLabel": "Current Income Tax Expense (Benefit), Total", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r196", "r613", "r619", "r1000" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "negatedTerseLabel": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r969", "r1000", "r1088" ] }, "lab_CustomerAdvanceCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CustomerAdvanceCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer advances", "label": "Customer Advance, Current", "documentation": "Customer advance, current" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r65", "r357" ] }, "lab_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "CustomerOneMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer One", "label": "Customer One [Member]", "terseLabel": "Customer One" } } }, "auth_ref": [] }, "lab_DVSSciencesInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DVSSciencesInc.Member", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "DVS Sciences, Inc. [Member]", "label": "DVS Sciences, Inc. [Member]", "terseLabel": "DVS Sciences, Inc." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Debt conversion, converted instrument, shares issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r60", "r61" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r34", "r138", "r139", "r204", "r207", "r279", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r664", "r913", "r914", "r915", "r916", "r917", "r998" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails": { "parentTag": "us-gaap_LineOfCredit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total long term debt", "label": "Long-Term Debt, Gross", "terseLabel": "Principal amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r34", "r207", "r487" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Initial conversion rate of notes", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r42", "r94", "r182", "r183", "r472" ] }, "lab_DebtInstrumentCovenantConvertibleDebtThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DebtInstrumentCovenantConvertibleDebtThreshold", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Convertible Debt Threshold", "label": "Debt Instrument, Covenant, Convertible Debt Threshold", "terseLabel": "Convertible debt" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Par Value", "verboseLabel": "Aggregate principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r130", "r132", "r470", "r664", "r914", "r915" ] }, "lab_DebtInstrumentFaceAmountPerInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DebtInstrumentFaceAmountPerInstrument", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Face Amount, Per Instrument", "label": "Debt Instrument, Face Amount, Per Instrument", "terseLabel": "Debt instrument, face amount, per instrument" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated fair value", "terseLabel": "Fair value of Bridge Loans", "label": "Debt Instrument, Fair Value Disclosure", "totalLabel": "Debt Instrument, Fair Value Disclosure, Total", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r478", "r651", "r914", "r915" ] }, "lab_DebtInstrumentFinalPaymentFeeAndAccruedInterestDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DebtInstrumentFinalPaymentFeeAndAccruedInterestDue", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final payment fee and accrued interest due", "label": "Debt Instrument Final Payment Fee And Accrued Interest Due", "documentation": "Debt instrument, final payment fee and accrued interest due." } } }, "auth_ref": [] }, "lab_DebtInstrumentIncrementalPaymentPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DebtInstrumentIncrementalPaymentPercent", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Term loan advances percentage", "documentation": "Debt Instrument, Incremental Payment, Percent", "label": "Debt Instrument, Incremental Payment, Percent", "terseLabel": "Term loan payment as a percentage of original principal amount of each advance" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate on notes", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r41", "r471" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r279", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r664", "r913", "r914", "r915", "r916", "r917", "r998" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r43", "r279", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r664", "r913", "r914", "r915", "r916", "r917", "r998" ] }, "lab_DebtInstrumentPeriodicPaymentNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DebtInstrumentPeriodicPaymentNumberOfInstallments", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment, Number Of Installments", "label": "Debt Instrument, Periodic Payment, Number Of Installments", "terseLabel": "Number of installments" } } }, "auth_ref": [] }, "lab_DebtInstrumentRedemptionConditionStockValueExceedingPercentageofConversionPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DebtInstrumentRedemptionConditionStockValueExceedingPercentageofConversionPrice", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Redemption Condition, Stock Value Exceeding Percentage of Conversion Price", "label": "Debt Instrument, Redemption Condition, Stock Value Exceeding Percentage of Conversion Price", "terseLabel": "Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information about timing of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Redemption, Period One", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodThreeMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Redemption, Period Three", "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Redemption, Period Two", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt instrument redemption price", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r43", "r94", "r97", "r129", "r130", "r132", "r134", "r181", "r183", "r279", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r664", "r913", "r914", "r915", "r916", "r917", "r998" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan and Convertible Notes, net", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "End of term fee and debt issuance costs", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses." } } }, "auth_ref": [ "r161" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Allowance for credit loss", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r365", "r405", "r409", "r411" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization cost before recovery", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Sell before Recovery", "documentation": "Amount of decrease in allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) from intent to sell or more likely than not will be required to sell before recovery of amortized cost basis." } } }, "auth_ref": [ "r410" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Available-for-sale securities held", "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss", "documentation": "Amount of cumulative unrecognized loss on investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1022", "r1023" ] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gains and losses from sales of short-term investments", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "totalLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1024" ] }, "us-gaap_DebtSecuritiesGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesGainLoss", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on Bridge Loans", "label": "Debt Securities, Gain (Loss)", "negatedTerseLabel": "Loss on bridge loans", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r746", "r990", "r991" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Expense (Benefit)", "negatedTerseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1000", "r1087", "r1088" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Foreign Income Tax Expense (Benefit)", "negatedTerseLabel": "Foreign", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r196", "r1000", "r1087" ] }, "lab_DeferredGrantIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DeferredGrantIncomeCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails": { "parentTag": "lab_DeferredGrantRevenue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Grant Income, Current", "label": "Deferred Grant Income, Current", "terseLabel": "Deferred grant income, current" } } }, "auth_ref": [] }, "lab_DeferredGrantIncomeNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DeferredGrantIncomeNoncurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails": { "parentTag": "lab_DeferredGrantRevenue", "weight": 1.0, "order": 1.0 }, "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Grant Income, Noncurrent", "label": "Deferred Grant Income, Noncurrent", "terseLabel": "Deferred grant income, non-current", "verboseLabel": "Deferred grant income, non-current" } } }, "auth_ref": [] }, "lab_DeferredGrantRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DeferredGrantRevenue", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Grant Revenue", "label": "Deferred Grant Revenue", "totalLabel": "Total deferred grant income" } } }, "auth_ref": [] }, "lab_DeferredGrantRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DeferredGrantRevenueCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Deferred Grant Revenue, Current", "label": "Deferred Grant Revenue, Current", "terseLabel": "Deferred grant income, current" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Less deferred tax assets included in other long-term assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r596", "r597" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Income Tax Expense (Benefit), Total", "label": "Deferred Income Tax Expense (Benefit)", "negatedTotalLabel": "Total deferred benefit", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r11", "r196", "r226", "r618", "r619", "r1000" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Liabilities, Gross, Total", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r140", "r141", "r206", "r607" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 0.0 }, "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "negatedTerseLabel": "Deferred tax liability per balance sheet", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r596", "r597", "r729" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "negatedTerseLabel": "State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1000", "r1087", "r1088" ] }, "lab_DeferredTaxAssetsDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DeferredTaxAssetsDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Depreciation and Amortization", "label": "Deferred Tax Assets Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total gross deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r608" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Capitalized R&D costs", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r116", "r1086" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets, net of valuation allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1085" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "auth_ref": [] }, "lab_DeferredTaxAssetsOperatingLeasesRightOfUseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DeferredTaxAssetsOperatingLeasesRightOfUseLiability", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Operating Leases, Right-Of-Use Liability", "label": "Deferred Tax Assets, Operating Leases, Right-Of-Use Liability", "terseLabel": "Right-of-use lease liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r116", "r1086" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r115", "r116", "r1086" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock-based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r116", "r1086" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Reserves and accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r116", "r1086" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails", "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Valuation allowance", "negatedLabel": "Valuation allowance on deferred tax assets", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r609" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Liabilities, Net, Total", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r111", "r1085" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "lab_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Operating Leases, Right-Of-Use Assets", "label": "Deferred Tax Liabilities, Operating Leases, Right-Of-Use Assets", "negatedTerseLabel": "Right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Fixed assets and intangibles", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r116", "r1086" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "terseLabel": "Employer matching contributions expense", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r536" ] }, "lab_DefinedContributionPlanEligibleCompensationContributedByEmployeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DefinedContributionPlanEligibleCompensationContributedByEmployeePercentage", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan Eligible Compensation Contributed By Employee Percentage", "label": "Defined Contribution Plan Eligible Compensation Contributed By Employee Percentage", "terseLabel": "Percentage of employees eligible compensation" } } }, "auth_ref": [] }, "lab_DefinedContributionPlanEmployerMatchingContributionMaximumAnnualMatchPerEmployeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "DefinedContributionPlanEmployerMatchingContributionMaximumAnnualMatchPerEmployeeAmount", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Employer Matching Contribution, Maximum Annual Match Per Employee, Amount", "label": "Defined Contribution Plan, Employer Matching Contribution, Maximum Annual Match Per Employee, Amount", "terseLabel": "Maximum annual employee contribution matched by employer" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Percent of employee match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r85" ] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Amortization and Accretion, Net, Total", "label": "Depreciation, Amortization and Accretion, Net", "verboseLabel": "Depreciation and amortization", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation & amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r11", "r327" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology", "verboseLabel": "Developed Technology Amortization Expense", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r198" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r525", "r919", "r920", "r921", "r922", "r923", "r924", "r925" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r525", "r919", "r920", "r921", "r922", "r923", "r924", "r925" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1053" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r539", "r544", "r575", "r576", "r578", "r932" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense", "verboseLabel": "Schedule of Common Stock Reserved for Future Issuance", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r15", "r105" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "terseLabel": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r954", "r955", "r956" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r954", "r955", "r956", "r958" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r957" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r952" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "EMEA [Member]", "terseLabel": "EMEA", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1118", "r1119", "r1120", "r1121" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r264", "r292", "r293", "r294", "r295", "r296", "r301", "r303", "r311", "r312", "r313", "r314", "r641", "r642", "r724", "r744", "r902" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r264", "r292", "r293", "r294", "r295", "r296", "r303", "r311", "r312", "r313", "r314", "r641", "r642", "r724", "r744", "r902" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r62", "r63" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of foreign exchange rate fluctuations on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r654" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r599" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Tax benefit at federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r276", "r599", "r621" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r1084", "r1089" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign tax expense", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r1084", "r1089" ] }, "lab_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwardPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwardPercent", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Net Operating Loss Carry Forward, Percent", "label": "Effective Income Tax Rate Reconciliation, Net Operating Loss Carry Forward, Percent", "negatedTerseLabel": "NOL carryforwards expiring unutilized" } } }, "auth_ref": [] }, "lab_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForwardSaleOfPreferredStockAndDebtPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForwardSaleOfPreferredStockAndDebtPercent", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Forward Sale Of Preferred Stock And Debt, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Forward Sale Of Preferred Stock And Debt, Percent", "negatedLabel": "Non-deductible loss on Forward Sale of Preferred Stock and Bridge Loans" } } }, "auth_ref": [] }, "lab_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent", "negatedTerseLabel": "Non-deductible interest/premium" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "negatedTerseLabel": "Executive stock-based compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r1084", "r1089" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "negatedTerseLabel": "Other, net", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1084", "r1089" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Return to provision", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense." } } }, "auth_ref": [ "r1084", "r1089" ] }, "lab_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCreditPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCreditPercent", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Research and Development Credit, Percent", "label": "Effective Income Tax Rate Reconciliation, Research and Development Credit, Percent", "negatedLabel": "R&D tax credits expiring unutilized" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State tax expense, net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r1084", "r1089" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Federal R&D credit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1084", "r1089" ] }, "lab_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefit": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefit", "label": "Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefit", "terseLabel": "Unrecognized tax benefit" } } }, "auth_ref": [] }, "lab_EffectiveIncomeTaxRateTransactionCost": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "EffectiveIncomeTaxRateTransactionCost", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesReconciliationofIncomeTaxesatStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Effective Income Tax Rate Transaction Cost", "documentation": "Effective income tax rate transaction cost." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and related benefits", "totalLabel": "Accrued compensation and related benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost related to stock-based compensation arrangements", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r577" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance and other employee-related benefits", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock [Member]", "terseLabel": "Employee Stock", "verboseLabel": "Employee stock purchase plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Securities To Be Issued Upon Exercise Of Options", "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r951" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (shares)", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r951" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r951" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r959" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "terseLabel": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r951" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r951" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r951" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r951" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r960" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r23", "r230", "r259", "r260", "r261", "r287", "r288", "r289", "r291", "r297", "r299", "r315", "r396", "r397", "r505", "r579", "r580", "r581", "r614", "r615", "r632", "r633", "r634", "r635", "r636", "r637", "r640", "r655", "r656", "r657", "r658", "r659", "r660", "r680", "r766", "r767", "r768", "r784", "r849" ] }, "lab_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "EquityIncentivePlanMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan [Member]", "label": "Equity Incentive Plan [Member]", "terseLabel": "Equity Incentive Plan" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r392", "r393", "r394" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r392" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r478", "r651", "r914", "r915" ] }, "lab_ExchangeRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ExchangeRatio", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange ratio", "label": "Exchange Ratio", "documentation": "Exchange ratio." } } }, "auth_ref": [] }, "us-gaap_FacilityClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FacilityClosingMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility Costs", "label": "Facility Closing [Member]", "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r644", "r645", "r648" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r644", "r645", "r648" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Company's Financial Instruments by Significant Investment Category Measured at Fair Value on a Recurring Basis Within the Fair Value Hierarchy", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r125", "r201" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r24", "r126" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r478", "r530", "r531", "r532", "r533", "r534", "r535", "r645", "r688", "r689", "r690", "r914", "r915", "r926", "r927", "r928" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r30", "r125", "r478", "r914", "r915" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r644", "r645", "r646", "r647", "r649" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r478", "r914", "r915" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r643" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets For Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r478", "r530", "r535", "r645", "r688", "r926", "r927", "r928" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r478", "r530", "r535", "r645", "r689", "r914", "r915", "r926", "r927", "r928" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r478", "r530", "r531", "r532", "r533", "r534", "r535", "r645", "r690", "r914", "r915", "r926", "r927", "r928" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r478", "r530", "r531", "r532", "r533", "r534", "r535", "r688", "r689", "r690", "r914", "r915", "r926", "r927", "r928" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r643", "r649" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r399", "r400", "r402", "r403", "r404", "r406", "r407", "r408", "r486", "r502", "r638", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r742", "r907", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r1024", "r1025", "r1026", "r1027" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization and Impairment", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r240", "r432" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r173" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r429", "r431", "r432", "r433", "r719", "r720" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finite-Lived Intangible Assets, Gross, Total", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross Amount", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r172", "r720" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r719" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r80", "r82" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r172", "r719" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted-Average Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r719" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Finite-lived intangible assets acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r430" ] }, "lab_FiveLargestCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "FiveLargestCustomersMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Five Largest Customers [Member]", "label": "Five Largest Customers [Member]", "terseLabel": "Five Largest Customers" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r653" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Office furniture and fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "lab_GenomicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "GenomicsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Genomics", "label": "Genomics [Member]", "terseLabel": "Genomics" } } }, "auth_ref": [] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r66", "r876" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance as of December 31, 2023", "periodStartLabel": "Balance as of December 31, 2022", "totalLabel": "Goodwill, Total", "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r239", "r415", "r721", "r908", "r936", "r1030", "r1037" ] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Goodwill and Intangible Asset Impairment, Total", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Impairment of goodwill and intangibles", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r17", "r77" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r423" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Impairment Loss", "terseLabel": "Impairment of goodwill", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r11", "r416", "r422", "r427", "r908" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r908" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Grant [Member]", "terseLabel": "Grant revenue", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r1054" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross profit", "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r158", "r274", "r322", "r342", "r348", "r351", "r395", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r652", "r904", "r1050" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r954", "r955", "r956" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Impairment of InstruNor developed technology intangible", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r995", "r1040" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets and Other Long-Lived Assets", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r275", "r620" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesLossBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r3", "r156", "r209", "r322", "r342", "r348", "r351", "r725", "r740", "r904" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r275", "r620" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r434", "r440", "r833" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r440", "r833" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r19" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r276", "r592", "r600", "r605", "r611", "r616", "r622", "r623", "r624", "r783" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total benefit (expense) from income taxes", "negatedLabel": "Income tax benefit (expense)", "totalLabel": "Income Tax Expense (Benefit), Total", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r213", "r227", "r298", "r299", "r330", "r598", "r617", "r747" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r258", "r594", "r595", "r605", "r606", "r610", "r612", "r777" ] }, "lab_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "IncomeTaxesLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Income Taxes [Line Items]", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Income Taxes Paid, Net, Total", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes, net of refunds", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r59" ] }, "lab_IncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "IncomeTaxesTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Income Taxes [Table]", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r716", "r994" ] }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredCompensation", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Accrued compensation and related benefits", "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future." } } }, "auth_ref": [ "r10" ] }, "lab_IncreaseDecreaseInFairValueOfBridgeLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "IncreaseDecreaseInFairValueOfBridgeLoans", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Fair Value Of Bridge Loans", "label": "Increase (Decrease) In Fair Value Of Bridge Loans", "verboseLabel": "Change in fair value of Bridge Loans", "negatedLabel": "Change in the fair value of Bridge Loans" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories, net", "totalLabel": "Increase (Decrease) in Inventories, Total", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo" ], "lang": { "en-us": { "role": { "terseLabel": "2019 and 2014 Notes", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": [ "r308", "r309", "r313" ] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo" ], "lang": { "en-us": { "role": { "terseLabel": "Series B Preferred Stock", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method." } } }, "auth_ref": [ "r308", "r309", "r313" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs, PSUs, stock options and ESPP shares", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r304", "r305", "r306", "r313", "r543" ] }, "lab_InitialConversionPriceOfStock": { "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "InitialConversionPriceOfStock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial Conversion Price Of Stock", "label": "Initial Conversion Price Of Stock", "terseLabel": "Initial conversion price of stock (in dollars per share)" } } }, "auth_ref": [] }, "lab_InstruNorASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "InstruNorASMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "InstruNor AS [Member]", "label": "InstruNor AS [Member]", "terseLabel": "InstruNor AS" } } }, "auth_ref": [] }, "lab_InstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "InstrumentsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Instruments [Member]", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnet" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets, net", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r428" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Developed technology, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r78", "r81" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Total", "label": "Interest Expense", "negatedLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r131", "r211", "r262", "r326", "r662", "r834", "r947", "r1115" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r267", "r269", "r270" ] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest receivable related to short-term investments", "label": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r981" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r982" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total inventory, gross", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r985" ] }, "us-gaap_InventoryLIFOReservePeriodCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLIFOReservePeriodCharge", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory, LIFO Reserve, Period Charge", "terseLabel": "Provision for excess and obsolete inventory", "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period." } } }, "auth_ref": [ "r171" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total inventories, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r251", "r894", "r936" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories, net", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r215", "r235", "r250", "r412", "r413", "r414", "r717", "r899" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r984" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Allowance for excess and obsolete inventory", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r76", "r985" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r983" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r745", "r773", "r774", "r775", "r776", "r857", "r858" ] }, "lab_LaboratoryAndManufacturingEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LaboratoryAndManufacturingEquipmentMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Laboratory And Manufacturing Equipment [Member]", "label": "Laboratory And Manufacturing Equipment [Member]", "terseLabel": "Laboratory and manufacturing equipment" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Operating Leases", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1095" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseExpirationDate1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease expiration date", "label": "Lease Expiration Date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r174" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r670" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r669" ] }, "lab_LesseeNetOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LesseeNetOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum payments (receipts)", "label": "Lessee Net Operating Lease Liability Payments Due", "documentation": "Lessee, net operating lease, liability payments due." } } }, "auth_ref": [] }, "lab_LesseeNetOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LesseeNetOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "lab_LesseeNetOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee Net Operating Lease Liability Payments Due After Year Five", "documentation": "Lessee, net operating lease, liability payments due after year five." } } }, "auth_ref": [] }, "lab_LesseeNetOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LesseeNetOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "lab_LesseeNetOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee Net Operating Lease Liability Payments Due Next Twelve Months", "documentation": "Lessee, net operating lease, liability payments due next twelve months." } } }, "auth_ref": [] }, "lab_LesseeNetOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LesseeNetOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "lab_LesseeNetOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee Net Operating Lease Liability Payments Due Year Five", "documentation": "Lessee, net operating lease, liability payments due year five." } } }, "auth_ref": [] }, "lab_LesseeNetOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LesseeNetOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "lab_LesseeNetOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee Net Operating Lease Liability Payments Due Year Four", "documentation": "Lessee, net operating lease, liability payments due year four." } } }, "auth_ref": [] }, "lab_LesseeNetOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LesseeNetOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "lab_LesseeNetOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee Net Operating Lease Liability Payments Due Year Three", "documentation": "Lessee, net operating lease, liability payments due year three." } } }, "auth_ref": [] }, "lab_LesseeNetOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LesseeNetOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "lab_LesseeNetOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee Net Operating Lease Liability Payments Due Year Two", "documentation": "Lessee, net operating lease, liability payments due year two." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r671" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]", "documentation": "Indicates (true false) whether lessee has option to terminate operating lease." } } }, "auth_ref": [ "r671" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Future Minimum Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1096" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum payments (receipts)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "verboseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "negatedLabel": "Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease option to extend", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r671" ] }, "us-gaap_LesseeOperatingLeaseOptionToTerminate": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToTerminate", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease option to termination", "label": "Lessee, Operating Lease, Option to Terminate", "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r671" ] }, "lab_LesseeOperatingLeaseRemainingTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LesseeOperatingLeaseRemainingTermOfContract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Remaining Term Of Contract", "label": "Lessee, Operating Lease, Remaining Term Of Contract", "terseLabel": "Remaining lease term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1094" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Leases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r665" ] }, "lab_LessorOperatingLeasePaymentToBeReceivedAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LessorOperatingLeasePaymentToBeReceivedAfterYearFive", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "documentation": "Lessor, Operating Lease, Payment to be Received, after Year Five", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "negatedTerseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]", "terseLabel": "Sublease Income" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Payment to be Received", "negatedTotalLabel": "Total future minimum payments (receipts)", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r679" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "2028", "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r679" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r679" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r679" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r679" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r679" ] }, "lab_LessorOperatingLeasePercentageOfHeadquartersSubleased": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LessorOperatingLeasePercentageOfHeadquartersSubleased", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of headquarters subleased space", "label": "Lessor Operating Lease Percentage Of Headquarters Subleased", "documentation": "Lessor, operating lease, percentage of headquarters subleased." } } }, "auth_ref": [] }, "lab_LessorOperatingLeaseRemainingTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LessorOperatingLeaseRemainingTermOfContract1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, operating lease, remaining term of contract", "label": "Lessor, Operating Lease, Remaining Term Of Contract1", "documentation": "Lessor, Operating Lease, Remaining Term Of Contract1" } } }, "auth_ref": [] }, "lab_LessorOperatingLeaseSubleaseIncomeExpected": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LessorOperatingLeaseSubleaseIncomeExpected", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessor, Operating Lease, Sublease Income Expected", "label": "Lessor, Operating Lease, Sublease Income Expected", "terseLabel": "Lessor, operating lease, sublease income expected" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lessor, operating lease, term of contract", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1097" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r38", "r274", "r395", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r629", "r630", "r631", "r652", "r807", "r903", "r949", "r1050", "r1099", "r1100" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, mezzanine equity and stockholders' deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r150", "r208", "r736", "r936", "r999", "r1028", "r1091" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r40", "r234", "r274", "r395", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r629", "r630", "r631", "r652", "r936", "r1050", "r1099", "r1100" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "License [Member]", "verboseLabel": "License and royalty revenue", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r1054" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Term Loan Facility", "label": "Long-Term Line of Credit", "terseLabel": "Line of credit outstanding", "verboseLabel": "Amount borrowed", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r34", "r207", "r1109" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Borrowing base", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r37" ] }, "lab_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleInventory": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleInventory", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Percentage Of Eligible Inventory", "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Percentage Of Eligible Inventory", "terseLabel": "Percentage of eligible inventory" } } }, "auth_ref": [] }, "lab_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleReceivables": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleReceivables", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Percentage Of Eligible Receivables", "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Percentage Of Eligible Receivables", "terseLabel": "Percentage of eligible receivables" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "terseLabel": "Line of Credit", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DebtScheduleofDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total Term Loan Facility", "totalLabel": "Total debt", "label": "Long-Term Debt", "terseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r34", "r207", "r477", "r488", "r914", "r915", "r1109" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DebtScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, current", "totalLabel": "Long-Term Debt, Current Maturities, Total", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r243" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r279", "r481" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsUnderTermLoanFacilityIncludingEndOfTermFeePaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r279", "r481" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DebtScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Term loan, non-current", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r244" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Debt" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r178" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r43" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r43", "r89" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r451", "r452", "r453", "r456", "r1046", "r1047" ] }, "lab_LossOnForwardSaleOfStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LossOnForwardSaleOfStock", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 }, "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Loss On Forward Sale Of Stock", "label": "Loss On Forward Sale Of Stock", "terseLabel": "Loss on forward sale of Series B Preferred Stock", "verboseLabel": "Change in fair value of Forward Purchase Agreements", "negatedTerseLabel": "Loss on forward sale of Series B Preferred Stock" } } }, "auth_ref": [] }, "lab_LossOnTheBridgeLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "LossOnTheBridgeLoans", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "loss on the bridge loans", "documentation": "loss on the bridge loans" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "auth_ref": [ "r357", "r921", "r1053", "r1111", "r1112" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r537", "r715", "r765", "r799", "r800", "r855", "r859", "r861", "r862", "r864", "r887", "r888", "r906", "r918", "r931", "r938", "r1052", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "lab_MezzanineEquityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "MezzanineEquityTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquity1" ], "lang": { "en-us": { "role": { "verboseLabel": "Mezzanine Equity", "label": "Mezzanine Equity [Text Block]", "documentation": "Mezzanine equity." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r537", "r715", "r765", "r799", "r800", "r855", "r859", "r861", "r862", "r864", "r887", "r888", "r906", "r918", "r931", "r938", "r1052", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1055" ] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "Valuation Allowances [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "auth_ref": [ "r357", "r921", "r1053", "r1111", "r1112" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r268" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r268" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r165", "r166", "r167" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r157", "r167", "r210", "r232", "r253", "r256", "r261", "r274", "r290", "r292", "r293", "r294", "r295", "r298", "r299", "r310", "r322", "r342", "r348", "r351", "r395", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r642", "r652", "r741", "r829", "r847", "r848", "r904", "r947", "r1050" ] }, "lab_NetOperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "NetOperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "Net Minimum Lease Payments for Operating Leases", "label": "Net Operating Lease Liabilities Payments Due [Abstract]", "documentation": "Net operating lease liabilities payments due." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Changes and Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "lab_NonCashRightOfUseAssetsAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "NonCashRightOfUseAssetsAndLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Non-Cash Right -of-Use Assets and Lease Liabilities", "label": "Non-Cash Right -of-Use Assets and Lease Liabilities", "terseLabel": "Non-cash right-of-use assets and lease liabilities" } } }, "auth_ref": [] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived Assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r356" ] }, "lab_NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum": { "xbrltype": "sharesItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo" ], "lang": { "en-us": { "role": { "documentation": "Number Of Additional Shares Issuable Under Make-Whole Premium, Maximum", "label": "Number Of Additional Shares Issuable Under Make-Whole Premium, Maximum", "terseLabel": "Maximum additional shares issuable (in shares)" } } }, "auth_ref": [] }, "lab_NumberOfMonthsToVestRatablyAfterFirstAnniversaryOfVestingCommencement": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "NumberOfMonthsToVestRatablyAfterFirstAnniversaryOfVestingCommencement", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of Months To Vest Ratably After First Anniversary Of Vesting Commencement", "label": "Number Of Months To Vest Ratably After First Anniversary Of Vesting Commencement", "terseLabel": "Number of months over which options vest ratably" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1014" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1014" ] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "terseLabel": "Office furniture and fixtures", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "lab_OneGenomicsCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "OneGenomicsCustomerMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "One Genomics Customer", "label": "One Genomics Customer [Member]", "terseLabel": "One Genomics Customer" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r322", "r342", "r348", "r351", "r904" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost (including variable costs)", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r672", "r935" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "terseLabel": "Net Minimum Lease Payments for Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "verboseLabel": "Minimum Lease Payments for Operating Leases" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r667" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails2": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 }, "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: current portion of operating lease liabilities", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r667" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails2": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturityDetails3" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r667" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r668", "r675" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset, net", "totalLabel": "Total operating lease right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r666" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate per annum", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r677", "r935" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r676", "r935" ] }, "lab_OperatingLossCarryforwardSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "OperatingLossCarryforwardSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforward, Subject To Expiration", "label": "Operating Loss Carryforward, Subject To Expiration", "terseLabel": "Operating loss carryforwards, subject to expiration" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforward", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r115" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r345", "r351" ] }, "lab_OptionsPerformanceShareUnitsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "OptionsPerformanceShareUnitsAndRestrictedStockUnitsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Options, Performance Share Units And Restricted Stock Units [Member]", "label": "Options, Performance Share Units And Restricted Stock Units [Member]", "terseLabel": "RSUs, stock options and PSUs" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r39" ] }, "lab_OtherAsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "OtherAsiaPacificMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Asia-Pacific", "label": "Other Asia-Pacific [Member]", "terseLabel": "Other Asia-Pacific" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r241" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net change in unrealized gain (loss) on investments", "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r9", "r21", "r200" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r9", "r21", "r200" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Change during the year", "verboseLabel": "Other comprehensive loss, net of tax", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r9", "r21", "r200", "r254", "r257" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r44" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Other income (expense), net", "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r162" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash items", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestructuringMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r909", "r910", "r911", "r912" ] }, "lab_PatentsandLicenseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "PatentsandLicenseAgreementsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Patents and License Agreements [Member]", "label": "Patents and License Agreements [Member]", "terseLabel": "Patents and licenses", "verboseLabel": "Patents and Licenses Amortization Expense" } } }, "auth_ref": [] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt and equity issuance costs", "totalLabel": "Payment of Financing and Stock Issuance Costs, Total", "label": "Payment of Financing and Stock Issuance Costs", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": [ "r54" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "verboseLabel": "Share repurchase amount", "negatedTerseLabel": "Repurchase of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r55" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r439", "r993" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less equity issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r54" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Payments for taxes related to net share settlement of equity awards and other", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r266" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "verboseLabel": "Purchase price, cash", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r52", "r627" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r164" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Purchases of short-term investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r163" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "terseLabel": "Performance Shares", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PhantomShareUnitsPSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PhantomShareUnitsPSUsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Phantom Share Units (PSUs) [Member]", "terseLabel": "Phantom Share Units (PSUs)", "documentation": "Share-based payment arrangement awarded as phantom share or unit." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "axisDefault": "Portion at Fair Value Measurement [Member] [Default]", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r650" ] }, "lab_PortionOfStockOptionsVestOnFirstAnniversary": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "PortionOfStockOptionsVestOnFirstAnniversary", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Portion Of Stock Options Vest On First Anniversary", "label": "Portion Of Stock Options Vest On First Anniversary", "terseLabel": "Rate at which outstanding options vest on the first anniversary of the option grant date" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r144", "r490" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r144", "r809" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r144", "r490" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r144", "r809", "r827", "r1116", "r1117" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock: $0.001 par value, 9,744 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r144", "r731", "r936" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r986" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "terseLabel": "Prime Rate", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r977" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from Bridge Loans", "verboseLabel": "Proceeds from bridge loans", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r53" ] }, "lab_ProceedsFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ProceedsFromExerciseOfStockOptions", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds From Exercise Of Stock Options", "documentation": "Proceeds from exercise of stock options." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from Purchase Agreements", "verboseLabel": "Proceeds from issuance of Series B Preferred Stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r992" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from ESPP stock issuance and exercise of stock options", "totalLabel": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r8", "r27" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Maturities, Prepayments and Calls of Other Investments", "terseLabel": "Proceeds from sales and maturities of investments", "documentation": "The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy." } } }, "auth_ref": [ "r964" ] }, "lab_ProceedsFromResearchAndDevelopmentGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ProceedsFromResearchAndDevelopmentGrant", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from Research and Development Grant", "label": "Proceeds from Research and Development Grant", "terseLabel": "Proceeds from NIH Contract" } } }, "auth_ref": [] }, "lab_ProductAndServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ProductAndServiceMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Product And Service", "label": "Product And Service [Member]", "terseLabel": "Total product and service revenue" } } }, "auth_ref": [] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "terseLabel": "Other revenue", "verboseLabel": "Total other revenue", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r1054" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "terseLabel": "Product revenue", "verboseLabel": "Product revenue", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r919" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "auth_ref": [ "r353", "r718", "r759", "r760", "r761", "r762", "r763", "r764", "r890", "r919", "r937", "r968", "r1048", "r1049", "r1053", "r1111" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "auth_ref": [ "r353", "r718", "r759", "r760", "r761", "r762", "r763", "r764", "r890", "r919", "r937", "r968", "r1048", "r1049", "r1053", "r1111" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r174", "r237", "r739" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r726", "r739", "r936" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, net", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r12", "r220", "r225", "r737" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r174" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "lab_ProteomicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ProteomicsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Proteomics", "label": "Proteomics [Member]", "terseLabel": "Proteomics" } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit losses on accounts receivable", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r265", "r401" ] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchase commitment due in the next year", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r529", "r537", "r570", "r571", "r572", "r691", "r715", "r765", "r799", "r800", "r855", "r859", "r861", "r862", "r864", "r887", "r888", "r906", "r918", "r931", "r938", "r941", "r1041", "r1052", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r529", "r537", "r570", "r571", "r572", "r691", "r715", "r765", "r799", "r800", "r855", "r859", "r861", "r862", "r864", "r887", "r888", "r906", "r918", "r931", "r938", "r941", "r1041", "r1052", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable, net", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r1017", "r1018", "r1019", "r1020" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesAggregateChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Repayments of Long-Term Debt, Total", "terseLabel": "Repayment of term loan", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r56", "r781" ] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of term loan and advances under revolving credit facility", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r56" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r277", "r278", "r473", "r492", "r681", "r897", "r898" ] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails": { "parentTag": "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation expenses", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Accumulated Depreciation Expenses", "label": "Research And Development Arrangement, Contract To Perform For Others, Accumulated Depreciation Expenses", "negatedLabel": "Cumulative amounts applied against depreciation expense for assets placed in service", "negatedTerseLabel": "Cumulative amounts applied against depreciation expense for assets placed in service" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAmount", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Amount", "label": "Research And Development Arrangement, Contract To Perform For Others, Amount", "terseLabel": "Cumulative cash receipts from milestones achieved" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersAssetsPlacedInServiceGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAssetsPlacedInServiceGross", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails": { "parentTag": "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others , Assets Placed In Service , Gross", "label": "Research And Development Arrangement, Contract To Perform For Others , Assets Placed In Service , Gross", "terseLabel": "Assets placed in service, gross" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Research and Development Arrangement, Contract to Perform for Others, Capital Expenditures", "label": "Research and Development Arrangement, Contract to Perform for Others, Capital Expenditures", "terseLabel": "Capital expenditures" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpendituresToBeIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpendituresToBeIncurred", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Capital Expenditures, To Be Incurred", "label": "Research And Development Arrangement, Contract To Perform For Others, Capital Expenditures, To Be Incurred", "terseLabel": "Capital expenditures expected to be incurred" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersConstructionInProgressGross", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails": { "parentTag": "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Construction in Progress, Gross", "label": "Research And Development Arrangement, Contract To Perform For Others, Construction in Progress, Gross", "terseLabel": "Construction-in-progress" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersContractIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersContractIncome", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others , Contract Income", "label": "Research And Development Arrangement, Contract To Perform For Others , Contract Income", "terseLabel": "Non-operating income" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Depreciation Expense", "label": "Research And Development Arrangement, Contract To Perform For Others, Depreciation Expense", "terseLabel": "Depreciation expenses" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersEstimatedFutureCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersEstimatedFutureCapitalExpenditures", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Estimated Future Capital Expenditures", "label": "Research And Development Arrangement, Contract To Perform For Others, Estimated Future Capital Expenditures", "terseLabel": "Estimated future capital expenditures" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersExpenses", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Expenses", "label": "Research And Development Arrangement, Contract To Perform For Others, Expenses", "negatedTerseLabel": "Cumulative amounts applied against operating costs (excluding depreciation)" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/NIHContractNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Maximum Contract Value", "label": "Research And Development Arrangement, Contract To Perform For Others, Maximum Contract Value", "terseLabel": "Maximum contract value" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncome", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails", "http://www.standardbio.com/20231231/taxonomy/role/NIHContractNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Other Income", "label": "Research And Development Arrangement, Contract To Perform For Others, Other Income", "terseLabel": "Cumulative amounts recognized as non-operating income", "negatedTerseLabel": "Cumulative amounts recognized as non-operating income" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncomeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncomeRecognized", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Other Income Recognized", "label": "Research And Development Arrangement, Contract To Perform For Others, Other Income Recognized", "terseLabel": "Surplus funding from NIH Contract" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/NIHContractDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of assets", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Property and Equipment, Net", "label": "Research And Development Arrangement, Contract To Perform For Others, Property and Equipment, Net", "totalLabel": "Carrying value of property and equipment, net" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContractTables" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others", "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate." } } }, "auth_ref": [ "r1082", "r1083" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r136", "r590", "r1107" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development expense", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r589" ] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/NIHContract" ], "lang": { "en-us": { "role": { "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "NIH Contract", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": [ "r212", "r591" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r114" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r57", "r236", "r271" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r236" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Non-current restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r214", "r979", "r996" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedCharges" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Charges", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r436", "r437", "r439", "r442", "r448" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Restructuring and Related Cost, Expected Cost, Total", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring costs", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r438", "r441", "r445", "r447" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Restructuring and related charges", "terseLabel": "Restructuring and related charges", "totalLabel": "Restructuring Charges, Total", "label": "Restructuring Charges", "verboseLabel": "Total restructuring and other related costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r11", "r443", "r445", "r1042" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r438", "r439", "r445", "r446" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r438", "r439", "r440", "r441", "r445", "r446", "r447" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Reserve, Total", "label": "Restructuring Reserve", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r439", "r444" ] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Current", "terseLabel": "Accrued restructuring", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r980", "r1043", "r1044" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r147", "r184", "r735", "r769", "r771", "r782", "r810", "r936" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accum. Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r230", "r287", "r288", "r289", "r291", "r297", "r299", "r396", "r397", "r579", "r580", "r581", "r614", "r615", "r632", "r634", "r635", "r637", "r640", "r766", "r768", "r784", "r1116" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r323", "r324", "r341", "r346", "r347", "r353", "r355", "r357", "r524", "r525", "r718" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r357", "r966" ] }, "lab_RevenueFromContractWithCustomerPerformanceObligationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "RevenueFromContractWithCustomerPerformanceObligationPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Performance Obligation Period", "label": "Revenue From Contract With Customer, Performance Obligation Period", "terseLabel": "Performance obligation period" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r228", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r889" ] }, "lab_RevenueFromContractWithCustomerTermsOfPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "RevenueFromContractWithCustomerTermsOfPaymentPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Terms Of Payment Period", "label": "Revenue From Contract With Customer, Terms Of Payment Period", "terseLabel": "Terms of payment period" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicArea" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue and Geographic Area", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r228", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r528" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Deferred Grant Income", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r831", "r889", "r900" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r223" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r224" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r224" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaTables" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]", "terseLabel": "Schedule of Expected Timing of Revenue Recognition", "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [ "r965" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "country_SG": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "SG", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "SINGAPORE", "terseLabel": "Singapore" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock, consideration received on transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Shares sold (in shares)", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (in dollars per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "auth_ref": [ "r538", "r1009" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "auth_ref": [ "r300", "r538", "r962", "r1009" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Compensation and Related Benefits", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r50", "r1092", "r1093" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Available-for-Sale Securities Reconciliation", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r119", "r120", "r625" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r108" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Significant Components of Provision for Income Taxes", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r193" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Value of Debt", "label": "Schedule of Debt [Table Text Block]", "verboseLabel": "Schedule of Debt and Series B Convertible Preferred Stock", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Significant Components of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r192" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Disclosure401kPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r16", "r101", "r102", "r103", "r104" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Income Taxes at Statutory Rate to (Provision for)/Benefit (expense) from Income Taxes Recorded in Statements of Operations", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r191" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r108" ] }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "terseLabel": "Schedule of Net Long-Lived Assets Consisting of Property and Equipment in Different Geographic Areas", "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area." } } }, "auth_ref": [ "r75" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r392", "r393", "r394" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetFutureAmortizationExpenseDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetScheduleofFinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r80", "r82", "r719" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r80", "r82" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r908" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r908", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Loss Before Income Taxes", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1000" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories, Net", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r35", "r151", "r152", "r153" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Future Minimum Payments under Term Loan Facility including End of Term Fee Payment", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Performance-Based Units Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of Activity Under Restricted Stock Units", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Restricted Cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r31", "r202", "r1110" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r438", "r439", "r440", "r441", "r445", "r446", "r447" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring Liabilities", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r87", "r88" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r74", "r155" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r71", "r72", "r73", "r77" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Business Segment Information", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r71", "r72", "r73", "r77" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r540", "r542", "r545", "r546", "r547", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r569", "r570", "r571", "r572", "r573" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Activity Under Stock Options", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r25", "r26", "r106" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Determined using Black-Sholes Option-Pricing Model and Weighted Average Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r190" ] }, "lab_ScheduleOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ScheduleOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule Of Significant Accounting Policies [Line Items]", "label": "Schedule Of Significant Accounting Policies [Line Items]", "terseLabel": "Schedule Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "lab_ScheduleOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ScheduleOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule Of Significant Accounting Policies [Table]", "label": "Schedule Of Significant Accounting Policies [Table]", "terseLabel": "Schedule Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r181", "r183", "r184", "r245", "r246", "r247", "r316", "r490", "r491", "r492", "r494", "r497", "r502", "r504", "r778", "r779", "r780", "r781", "r918", "r961", "r997" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Estimated Future Intangible Asset Amortization Expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r82" ] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebt", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Secured Debt, Total", "label": "Secured Debt", "terseLabel": "Term loan", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r34", "r207", "r1109" ] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Secured Debt, Current", "terseLabel": "Term loan, current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r138", "r204" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "terseLabel": "Secured Debt", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredLongTermDebt", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Secured Long-Term Debt, Noncurrent", "terseLabel": "Term loan, non-current", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": [ "r43" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r950" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r953" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r319", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r357", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r441", "r447", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r908", "r968", "r1111" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "auth_ref": [ "r355", "r356", "r796", "r797", "r798", "r856", "r860", "r863", "r865", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r891", "r920", "r941", "r1053", "r1111" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SegmentReporting" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r334", "r345", "r349", "r350", "r351", "r352", "r353", "r354", "r357" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r335", "r336", "r337", "r338", "r339", "r340", "r355", "r905" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Selling, General and Administrative Expense, Total", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r160" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Selling, general and administrative expense", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "lab_SeniorConvertibleNotesDue2024CurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "SeniorConvertibleNotesDue2024CurrentMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Notes, current", "label": "Senior Convertible Notes Due 2024, Current [Member]", "documentation": "Senior convertible notes due 2024, current." } } }, "auth_ref": [] }, "lab_SeniorConvertibleNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "SeniorConvertibleNotesDue2024Member", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Senior Convertible Notes Due 2024 [Member]", "label": "Senior Convertible Notes Due 2024 [Member]", "terseLabel": "2019 Notes" } } }, "auth_ref": [] }, "lab_SeniorConvertibleNotesDue2024NonCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "SeniorConvertibleNotesDue2024NonCurrentMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Notes, non-current", "label": "Senior Convertible Notes Due 2024, Non-current [Member]", "documentation": "Senior convertible notes due 2024, non-current." } } }, "auth_ref": [] }, "lab_SeniorConvertibleNotesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "SeniorConvertibleNotesDue2034Member", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Senior Convertible Notes due 2034 [Member]", "label": "Senior Convertible Notes Due 2034 [Member]", "terseLabel": "2014 Notes" } } }, "auth_ref": [] }, "lab_ServiceAndOtherRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ServiceAndOtherRevenueMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Service and other revenue", "label": "Service and Other Revenue [Member]", "documentation": "Service and other revenue." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Service [Member]", "terseLabel": "Service revenue", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r919" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r932" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r562" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r562" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r560" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r560" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Awards outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r557", "r558" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Nonvested and Outstanding Units", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)", "terseLabel": "Weighted - average grant date fair value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r557", "r558" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contractual terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r189" ] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfPerformanceUnitsExpectedToVest": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfPerformanceUnitsExpectedToVest", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Percentage Of Performance Units Expected To Vest", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Percentage Of Performance Units Expected To Vest", "terseLabel": "Percentage of performance period" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentInPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance adjustment for 2020 awards (in shares) | shares", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance adjustment for 2020 awards (in shares) | shares", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Released (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r561" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r561" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r571" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Weighted average expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r570" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted average risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r572" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r540", "r542", "r545", "r546", "r547", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r569", "r570", "r571", "r572", "r573" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities to be issued (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r934" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted- Average Remaining Contractual Life (in Years)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r564" ] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Expected To Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value", "verboseLabel": "Unvested awards" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number", "terseLabel": "Unvested awards (in shares)" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price", "terseLabel": "Unvested awards (in dollars per share)" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Weighted Average Remaining Contractual Term 1", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term 1", "terseLabel": "Unvested awards" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Options cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r555" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options granted (in shares)", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r1063" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per share (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r563" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r105" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r549", "r550" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r549", "r550" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price per Option" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested, Aggregate Intrinsic Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value", "verboseLabel": "Vested" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price", "terseLabel": "Vested (in dollars per share)" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One", "verboseLabel": "Vested" } } }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period", "terseLabel": "Performance period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r545", "r546", "r547", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r569", "r570", "r571", "r572", "r573" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r554" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r555" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r553" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Tranche One", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Tranche Two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r539", "r548", "r567", "r568", "r569", "r570", "r573", "r582", "r583", "r584", "r585" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BusinessCombinationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Share price (in dollars per share)", "verboseLabel": "Share price (in usd per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1056" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate intrinsic value, vested and released", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r933" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Weighted average expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r569" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationRestrictedAndPerformanceStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value per Share" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Contractual term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r565" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested (in shares)", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r866", "r867", "r868", "r892" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r168", "r272" ] }, "lab_SomalogicIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "SomalogicIncMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SomaLogic Inc.", "label": "Somalogic Inc [Member]", "documentation": "SomaLogic Inc." } } }, "auth_ref": [] }, "lab_SouthSanFranciscoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "SouthSanFranciscoMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "South San Francisco", "label": "South San Francisco [Member]", "terseLabel": "South San Francisco" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails", "http://www.standardbio.com/20231231/taxonomy/role/GoodwillandIntangibleAssetsnetChangesintheCarryingValueofGoodwillbySegmentDetails", "http://www.standardbio.com/20231231/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r231", "r319", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r357", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r435", "r441", "r447", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r908", "r968", "r1111" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r229", "r245", "r246", "r247", "r274", "r303", "r307", "r311", "r313", "r316", "r317", "r395", "r457", "r460", "r461", "r462", "r468", "r469", "r490", "r491", "r494", "r497", "r504", "r652", "r778", "r779", "r780", "r781", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r809", "r830", "r849", "r869", "r870", "r871", "r872", "r873", "r961", "r997", "r1010" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r23", "r47", "r230", "r259", "r260", "r261", "r287", "r288", "r289", "r291", "r297", "r299", "r315", "r396", "r397", "r505", "r579", "r580", "r581", "r614", "r615", "r632", "r633", "r634", "r635", "r636", "r637", "r640", "r655", "r656", "r657", "r658", "r659", "r660", "r680", "r766", "r767", "r768", "r784", "r849" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "auth_ref": [ "r355", "r356", "r796", "r797", "r798", "r856", "r860", "r863", "r865", "r875", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r891", "r920", "r941", "r1053", "r1111" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r287", "r288", "r289", "r315", "r718", "r773", "r795", "r801", "r802", "r803", "r804", "r805", "r806", "r809", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r822", "r823", "r824", "r825", "r826", "r828", "r831", "r832", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r849", "r942" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "auth_ref": [ "r300", "r538", "r962", "r963", "r1009" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r287", "r288", "r289", "r315", "r718", "r773", "r795", "r801", "r802", "r803", "r804", "r805", "r806", "r809", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r822", "r823", "r824", "r825", "r826", "r828", "r831", "r832", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r849", "r942" ] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Payment Arrangement", "terseLabel": "RSUs, PSUs, and stock options", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r1012" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under ESPP (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r23", "r144", "r145", "r184" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Shares issued (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r23", "r144", "r145", "r184", "r778", "r849", "r870" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock, net of shares withheld for taxes (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r23", "r144", "r145", "r184" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock from stock option exercises (in shares)", "negatedLabel": "Option exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r23", "r144", "r145", "r184", "r554" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under ESPP", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r23", "r144", "r145", "r184" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock, net of shares withheld for taxes", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r23", "r184" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock from stock option exercises", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r23", "r47", "r184" ] }, "lab_StockOptionGrantsExercisePriceMinimumPercentageOnFairMarketValue": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "StockOptionGrantsExercisePriceMinimumPercentageOnFairMarketValue", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock Option Grants Exercise Price Minimum Percentage On Fair Market Value", "label": "Stock Option Grants Exercise Price Minimum Percentage On Fair Market Value", "terseLabel": "Stock option grants exercise price minimum percentage on fair market value" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Stock Repurchase Program Authorized Dollar Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "terseLabel": "Repurchases of common shares", "verboseLabel": "Repurchase of common stock (in shares)", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r23", "r144", "r145", "r184", "r781", "r849", "r872" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r23", "r144", "r145", "r184", "r784", "r849", "r872", "r948" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' deficit", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r145", "r148", "r149", "r170", "r811", "r827", "r850", "r851", "r936", "r949", "r999", "r1028", "r1091", "r1116" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' deficit:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Deficit", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r180", "r273", "r489", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r503", "r505", "r639", "r852", "r854", "r874" ] }, "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]", "terseLabel": "Series B Redeemable Preferred Stock", "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value." } } }, "auth_ref": [ "r0", "r142", "r143" ] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Treasury Stock", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r14", "r853" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r674", "r935" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r661", "r683" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r661", "r683" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r661", "r683" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r661", "r683" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSubsequentEventNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r661", "r683" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SubsequentEvent" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r682", "r684" ] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Schedule of Aggregate Changes in Balance of Gross Unrecognized Tax Benefits", "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r20", "r194", "r195" ] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Schedule of Summary of Valuation Allowance", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r113" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r978" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r115" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r114" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r114" ] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAbstract", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]", "terseLabel": "Mezzanine equity:" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityByClassOfStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityByClassOfStockTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shareholders' Equity [Table]", "label": "Temporary Equity, by Class of Stock [Table]", "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable." } } }, "auth_ref": [ "r33", "r90" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable preferred stock: $0.001 par value; 256 shares authorized, issued and outstanding at December 31, 2023 and 2022; aggregate liquidation preference of $255,559 at December 31, 2023 and 2022", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "verboseLabel": "Total Series B Redeemable Preferred Stock", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r457", "r460", "r461", "r462", "r468", "r469", "r586", "r733" ] }, "us-gaap_TemporaryEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityPreferredStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shareholders' Equity [Line Items]", "label": "Temporary Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityLiquidationPreference": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLiquidationPreference", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Redeemable preferred stock, aggregate liquidation preference", "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Redeemable preferred stock, par value (in dollars per share)", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r33", "r90" ] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Authorized", "terseLabel": "Redeemable preferred stock, shares authorized (in shares)", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r142" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Issued", "terseLabel": "Redeemable preferred stock, shares issued (in shares)", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r142" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Redeemable preferred stock, shares outstanding (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r142" ] }, "us-gaap_TemporaryEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityTableTextBlock", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityTables" ], "lang": { "en-us": { "role": { "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedule of Carrying Value of Preferred Stock", "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r33", "r90" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "auth_ref": [ "r1016", "r1098" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r486", "r502", "r638", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r742", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r1024", "r1025", "r1026", "r1027" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock acquired, average cost per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r98" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r98" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical", "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Treasury stock, ending balance (in shares)", "periodStartLabel": "Treasury stock, beginning balance (in shares)", "terseLabel": "Treasury stock (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r98" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock at cost: 3,132 and 422 shares at December 31, 2023 and 2022, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r48", "r98", "r99" ] }, "lab_TwoThousandAndElevenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "TwoThousandAndElevenEquityIncentivePlanMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Eleven Equity Incentive Plan [Member]", "label": "Two Thousand And Eleven Equity Incentive Plan [Member]", "verboseLabel": "2011 Equity Incentive Plan" } } }, "auth_ref": [] }, "lab_TwoThousandAndSeventeenInducementAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "TwoThousandAndSeventeenInducementAwardPlanMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Seventeen Inducement Award Plan [Member]", "label": "Two Thousand And Seventeen Inducement Award Plan [Member]", "verboseLabel": "2017 Inducement Award Plan" } } }, "auth_ref": [] }, "lab_TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Twenty Two Inducement Equity Incentive Plan", "label": "Two Thousand And Twenty Two Inducement Equity Incentive Plan [Member]", "terseLabel": "2022 Inducement Equity Incentive Plan" } } }, "auth_ref": [] }, "lab_TwoThousandSeventeenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "TwoThousandSeventeenEmployeeStockPurchasePlanMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureShareholdersDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Seventeen Employee Stock Purchase Plan [Member]", "label": "Two Thousand Seventeen Employee Stock Purchase Plan [Member]", "terseLabel": "2017 Employee Stock Purchase Plan", "verboseLabel": "2017 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureRestructuringAndRelatedChargesSummaryOfTheChangesInOurRestructuringAndOtherRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r438", "r439", "r445", "r446" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaLonglivedAssetsbyGeographicAreasDetails", "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury securities", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r901", "r926", "r928", "r1108" ] }, "lab_UndisclosedCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "UndisclosedCustomerMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Undisclosed Customer", "label": "Undisclosed Customer [Member]", "terseLabel": "Undisclosed Customer" } } }, "auth_ref": [] }, "lab_UninvoicedReceiptsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "UninvoicedReceiptsCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uninvoiced receipts", "label": "Uninvoiced Receipts Current", "documentation": "Uninvoiced receipts current." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesAggregateChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r593", "r601" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesAggregateChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions", "negatedTerseLabel": "Decreases in balances related to tax positions taken during current period", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r112" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesAggregateChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails", "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "terseLabel": "Unrecognized tax benefits, decrease resulting from prior period tax positions", "negatedLabel": "Decreases in balances related to tax positions taken during prior period", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r602" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesAggregateChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "verboseLabel": "Increases in balances related to tax positions taken during current period", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r603" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesAggregateChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases in balances related to tax positions during a prior period", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r602" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits, that if recognized would affect effective tax rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r604" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r68", "r69", "r70", "r217", "r218", "r221", "r222" ] }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "Valuation Allowance, Deferred Tax Asset", "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward." } } }, "auth_ref": [ "r1001", "r1002", "r1003", "r1004", "r1005" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r280", "r286" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charges to earnings", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account", "terseLabel": "Charges to other accounts", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense." } } }, "auth_ref": [ "r284" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r280", "r281", "r282", "r285", "r286" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r280", "r281", "r282", "r285", "r286" ] }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "auth_ref": [ "r280", "r281", "r282", "r285", "r286" ] }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsDisclosureTable", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/IncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "auth_ref": [ "r280", "r281", "r282", "r285", "r286" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable costs (including non-lease components)", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r673", "r935" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081" ] }, "lab_VikingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20231231", "localname": "VikingMember", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureMezzanineEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Viking", "label": "Viking [Member]", "terseLabel": "Viking" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommo" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1011" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Shares used in computing net loss per share, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r302", "r313" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Shares used in computing net loss per share, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r301", "r313" ] }, "us-gaap_WorkersCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WorkersCompensationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.standardbio.com/20231231/taxonomy/role/BalanceSheetDetailsAccruedCompensationandRelatedBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Workers' Compensation Liability, Current", "terseLabel": "Accrued incentive compensation", "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481288/505-10-05-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479455/805-10-15-4" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "6", "SubTopic": "50", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-6" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "SubTopic": "10", "Topic": "420", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//985-730/tableOfContent" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r961": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r962": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r963": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 114 0000950170-24-023845-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-023845-xbrl.zip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�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

Z'8%ZW%1 M-+QT\_) "ML=%T4BK^YA<(Y&HA-&IP=53/JI6&R1ZQV'##$�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

!J9<.=L0[ZC-@&H6*] M>(C4JA>,-+ MD! P>/:<$W@Z=UGG]N2Q]LORQ>:]41TXNW5P>=_='AEE3=]%-&RU^8'\)84' MNJ7QE9FCR;4901T.30*@.GG!BC#S;Y"!/QCP@$8M0 2,$9(TA(>?"3E'.+TK MB0*IA\9T"@V_OU4(QUZ$9L"H$9F5.>@>1AL^'*X=L ;$D-)_%.[XU^JM"<_HI+WY[PEPLY];K.FF1U085 :='HO M69LBHJ"5HW&_E+J0%R<@I@!,5URP9>@/O)[6B(SW]'G()8\'8)/(,W>R.LEC MTI/J=@.,,_;!<4O/#>,'3W0H:EHZV5=]E MC^=^GX >T2^E7UL8*MHY1(2X_:=->U7L1?^Z,:P\]HJT64&G.'_ ;DXX/>*3 MTTC]Y,?%OKJ(4T-B5Y\%(^GDAZ H]\ /#(]Q-X9 */_/G;QC : M)PM'"19N'>.:O)VKP]-Y9A^#< :A[BUM8#&BMR5ATY3"2]6$XQA'P1/G16#I M:MK.!BP %D3P>IB@#,%E)#T?>-X(YJ28H3F.?L#G,E@85!_DV[A/M^$>,4^I M+/R=(CU-.!6H%7M-S9)@W,RWJY>[<6A[EMV&Z[IH9&ZY=R<@T^-TF?QDDET7 MU3>MA()]G_'YI*BMS'BY+8=&90A.QRQ?+XQBSHU=C',PBWV =-Z+P%'<*452 M_,E7_Z$/=-?L +=OVFI!P[6B$+#KVYIPW_*U+:9SE"G?6UHI!4 AA405 4$& MLZ\E)()X(#Z.9+OUF6.YH<<_KM51.]SFI1GG'Y$'YKZT&4+PT4^7X/Z9BJ!9 MH'!WD]HNME:>+O-=LDBC;J+:^&$T--0PH5_3?V,L)"Y0D9_Q[RSHSP0U;9VX M#2LQC>5D0-.<]!!8$-O"/F-1^K0!JL%'BKSLS9I=ML7&878S#4)31 YVMO2EUV2=S F=T^_\GD=CO? V']/STX?V^/&'>U0GV<_-%;QSCBW];[W?FD[OOFW]%<@4 M6KGS/5EJIY!][K7%;9&T<75U!5*M-ZTQBE1.?43"W[GSZT5:?GJD2UB9AP./ M+2VP 4^Y5K*Y"P@NT>.TOS,=?))Y_QT11G).BC(!?TZ0(R%Q 3:F>'JK.L>:+$5H29]WO@V\?VQX.MVMU4(C7M M*!LA4&ZE1K&^IJ2*0E%VL3PTK8F!^]!W<8)"-;C%>"G@$=L8F$5P?)##FXNK MB3Z-]CNR;V%^8#/B:I\,:^Y\["-B*3KMZYPDT\C=<1="*&OPI,'$4BT*U M[QSIL?BC+-KBJM93!7'#Y#JB!@J^4^$C(X@K_ L##)*%8()IBB;DE=?/_QBH MH2%KKT&C%D/@I;=R'.TDNR!,N8\J&N(+#Y/:ASD9PP8(&"G6!8B?SJR/XDX1 M?7>O(JW6!ER#@4H\59D+V@3!T M%Y )N@( 0XI[LDD*K@9Z">F:##-\9F2.>Q6\+7>T1+%B0^E?9>?IN\.V!W@( MH"L0Q-7TS%UDX7=MHVXXME;H6FGRX]>_P[0M0"=<56XZ$\A(1OHE@_M". _1 MLZ-M"C4TM=DWMBAL<#)ZSEQFNZ57(TPBIU3QU8J,W"*DI5]V M8/6\[9]8N\)H/EFP((8$MAP1!?J8&7%.*5I.3D87K8Y8#EBM&YW<)/_0*;M2 M3-('M0G4]KZ\?_KMR=>A1N%OG.L2JZJ9F1H$ 6?^UO.PJH]<3X]'K@)[*,*N M$$0K\$2[OB;8*T1&HZL!@.!+H8GR\&]\P$L+0@Q3T M\)D?#YCES+S5DAD\+UK_]*D(E!!"6$ 4- M>F M7Y/\Q\CZS>UZTZS*R&N07TE-K1-7V9*6$N([:(5V)\2;L9BB(YT<(FFF+?8?B^%P?^X, Z# M_P@@N 7DK V([*/7%L]9RJW1B>/W[^RVV1O-ACQ-L M$;);9Q>_W Z&1P9ZD7S^T'\NX/2+7]0)S-P\2B%1FB6>@%0Q3K^-IIR>\06' MK4^TK0A.Y;YBJ5ZI)/,/8!4^,@690;>+4'&^^UMG#X"&U9H8=\;'F$$EM/>Y M !#LG&IP:"X:5(Q=WRF^=(YP1?5&$PGAO?_L7SFY,5 *2-L< FXNOKTO_COS;H7=IUC1C MJ$TY9D89:J-CXY'GTW>72'V#+ M\1%>EROZ QL)PWM548953.1[7+V)T1F%+L1(H>.#HO"KL D0]1"6+9<+6N1! M=]C_ISSKH$O,>6?\*U 7)]D3:$D:^3.M.,#'&9L1K1[_H)_ZN,?:#%L8?;WD M*'Q9MH)^#L)F>7A0$AYR3'+40[/@$B]B$UP:X1 Q>*6BR= MAM0$# 8$":5?(UN=LJ&:PU;VIP,1(:8VR=,&A%;S!L'N[X.OZ*I+I]3I=SRF MWHET@-$VM)_FX@V)X5WJH^0ZK^HXH98DR55!0$]>*S33QF!,0W"/B@5096C^ ML=U*X*65%[VT&Q0('?#*J'W]V!;_*S+O?RO\9>6IJ W\_=:J96N4P^)62]UI7C:C7?NP MY7?N0&,K=+2L[0YF"4A!*3P)*XQGIN1T$(MC_Q"#C4;WW!^03#+B$(\#W8:" MA LY#6\-A$KC J9*Y2GUFO6UJOU%CX[O"9M:B@#0Q_ENX(/(^P4[S5J!A(_& MJ:'J@%9^ #53:6U">-UDA->]NQ/":T)X_?G;KD48*@\9.A.[[2 : X8%9L&- MA1(1[6/]6H9L2=N ][?E. ")62L,[DFA$"$)TK^2W(G^$0';0HKQ@CZ+-+@$ ML2Z[.*=-6PN7\34#Z6NC2M@ST66JGR%%X"D=41")T;=5V+#XH]R GQ!YEB%A$H)X MXE .N;3M/Z/&G*9W/\0KX-(H]0"5W_N^9!O^/R(L['Z$@\,=^,^HD*_BVDDCG1)K;!ELJ)KL.H^)&W;DH'\>(ZU#]>ET$OJ\ W.RB?YI\]] MA5/#QP?+&S%61&(EXD,R)I@SE:YX M+*$R<\F32PN/ V<6^ZX)G>-5("5?)!UG)\H]?C%;Y7%1#A).G0J7M M U_J"!?L/#LG*F6N G WII3^ \7'4<@+_UHOGYXK:>E^O;,BBFJ=XZ/)XN/)X\Q7-3 SQTN@/DMG,RL4G;P3- MX0B*0Q0^=) ]EA@'V Y<*^M",LWR?E[)1G!%CP=-J#Q68J^2Z?R3\,[#%[JF MTJ?2N9BW#_T!7FZ>T0NA,^.Q#I@>'B]Q-J6[/HQC7*>%0M$B&+J!^4C=5[Y* M6VP>]]?#@?VPL,2*NDI F2T=P?%GB:5FTOU$ M@6=;"6O'DA4.!-7_&!P6IP].LA=0$'[$._*)0/MOT(;SK*>"B$.5F@/B02TY M?65!55ST^I@?0PN28#FO7!CPC.M5([14?+XJ-AML0RA)-J_+.87Q;=L@#A/# MFI70<_$?G60'5SHPIMAZ83MQYOQZ&'%5<_%LLE+5KHCGO7/NU<&R,6Q)(OHG MHJ>X<8*'*6$DB@50N0[D&^'6N3)\B9J"._R4"MQ8 ;$G5>R&.YG/7KJ-WVH- M&!6KM:@)GX&0N%;7J<+8Q9Q3$(ZT=T447^5,8@TL V_A]5["[X+47O_91R(\ M>"1S(_XQ"<]W[)<'&OP.31Y<1AJ11-(<9=H,9U6Y@&-7%W9_$5BWVS%V;V(3 MZ1)9'VTRB!FE7H@$I8*YW.AX^R<'L9;M6D:=;2/Y!CG!AWV >50%[.FJ85:> M'!H1QMH$5ZI&U (!V3,55URWU_',(ACG^)Q_R5H].D=A0APGVH8_?U]_\1=(?L"63T T5H0G,)!/>O7W]S\GUZ@.^N/\ ]0ZHE(]7X M+L!J=RJZ ]3]A1V?UOGQXLBA/FY,#U/6V\__A2 M13J1K#E 1!"$92@9,(";BJ7:?_-1-KJO?H5UB]^45QA0H8!UU_ MQE>]X^NZ261CFJ6W)!Z7Q.HEU[0UE]6T"SWBYQFPK$77OJ*4.6N>P*Q(&O@HAKF-G2[ P@F MZ(.YW? "GQ2O_;YO*+#'3N3W5R?'/H'6+@?UE%Y(I,^R,#U3L6)0E'=>PX=, M'Y;@#\Y^6Y?^>%?.N 644BPALPW4(1;8Q^:8D M$N9'W:#[?U7X1US+! @UXNDTOWMZ12%"M( MS&S*T'(W+P30ENRB*LFFHL;X/RC>S1U1W^L,H9WA&03QS#0KA;. TN3]-'XK M+A%9:<2%$&V?6U39LB#,J5R"7_]:Q^2>7IJ81/PGBH,2?\G\19N,ARP32X?FM;[04Z7]?-I8S_T<@&4L-N@!&AX!3D*\!Y M-UPH/[@EW9E)]U8+3S<)VBLH@8*?0'=GT=(&:_'W]+9F )0@;$=?=L7VM9 ? MT1&BA DJ:(>V@^8Z=WAH7*;U+U_FZ:DY2'D-=O"E#@V@'.CW@ T'.7*FH'>6 M#!K+<(C&07G,'W*A:@)XGJCT 9RB3CP5(??9VE5;G;EN%JX*6'.VLWG5HX5$ ML\V2!%V1""[%< K\I2@,E1"Y2FK_TJ'97\5^^X\T(!J:_FCHXP/#=G>?C/R.OX--]P-BYK[>U]^^]6W][Z.]U[6N/H[] BNN67LS-_=N_=-V)K- MD^63G-Z].SSJ!ZI*R*(Q^T2P"L02,:+X8];QS60E=_73\+=&S_NKTN_@MU T(44WBL>!XH[=\XV%8EK_C M 0UY(CL]#S2&SWB>NQ/6&52]FQLU%_%R;66&>-)&5B!3^_XO=N_(']]K]WB/E_K]]^? M^(U=OD\R/MO._:! 2'_Y_MC^X*%D#AH !D/^H-^6+_EO+=*8X6M_9"ZE7__A M__/%KAV>1TKK]-1'WPS*(ER[_X$K^/B#?>E$&3!R;7*O4LG?HEA7E8M,S4 ^ M;K6R?^P+%&B.?:ZM OG"W>_*^OXE)/KF1267YL]]/_0(M,-S]$!Z*72DM^LG M?/-1>)=C*^)IL7%)$V&W>.=O:7H+;WH+SQM60!U[$Q]D14Y+[EUMZ&_#PGNX M0[_EDIS6W!]?<]FTV#[=MWR4(]^G*86KLO/5NJDV>?9\??+P9%I,[_HQ/U=^ M%J)A]>/E]?5HS"F(NMJ6DF? MWZO^N:C_V:!D ^:9OY>;:3']>Q;3,Q[6K%?38OKT7_6?2+>>-O6=MHFRY2Z%CX#\VZ)NB@7B=WYK6U*?] MXA^YVE79DY/LO&K*:5V]\RH1>,00!SXOVEW-$Y'/_[/8;.\_T0$"_:C+LU]^ M.9O6V.=G!.=5Z5]VY^]E6F#OW'\US*XMHA0.',Z XM.@B"1?Q U'SU_7'"TU MT4<@ 3B(G>[EI[[_K):F HB^\M(DB:CGKV_.?R0?;3 M^=/SEX_/+K*+!WF6'.D?T#E\Z\/]XG;=3VYWMG;S5V[A5__\).T( ,/U_^]9 MD:BCSZ=5_OG9XM^+W7J?_5S.9E-YY=]4U+3R5K']1M)\7_H%]V04W3.MJT_[ MU3]JB_H5]'%JMY^:W/^FAQS;!9HF^CWKP0;;'[/-I8GB=>O,_R] GSMA"F@/B>MBT8#CD>2 M6GFV]I&9U9T+$F;165YG:JC1PYR?Z.OW$X)-#"HZH_@([-NW;2[.^00 M Z<%?@:VC,LX+,;,%B3]0@,\4+9@:K%YT3%+.9CYH9E38%REJC*9Q IBD]G: M%=6.O^N_L(1_GR[Z;K]9[70>:K"K/F,\[SRY%F7O5-OTVJ\JE(TE-X=G. MA>XB\'\O7"'G\5]BE\ZRU]@G<.G)1<*)?W7W]-:KVRR@ ?)@FHX)HUM^]U % M2>\OF?@_SK EE.G$1F*%4_T[,3*I/!.V+7PLNB:BWSTK=/@K,>-T.Z$&##N: MTIL06UF\0!J(@P*@G(O&SK9.K(8$[3^B[>AS7J[/B..1=&A)4YY?*M1J1D(7 M$+,0B:.JJ00!+UZD1(MWDOT(GCP2N&IH:I'IC83RD4S++%,AD$Z"&!.R\"JG MM9VN="4DXN EYU!*")B@QN/4W[B%GRWO_1MM36O:X0FF4F9,15>$[MIUW83_/ MLP^W?@ZGWC_<\Y0]CR*09=/M6*/5Z,$.A;C]GUB03QFQP&<5M%V'SK&@8,DQ MP?_6+AVK"R-Y)DN:\$9+_Z:=>.&@F,#2?!-7U8VG&F$M!K^%+OHY:=>ILF*9 MD@YZ]\ *F;*76MNC73AF.Q-]S0VW*8WT4B-IFRL?.39;<"'WM2@FU:3PZEH: M>7)%!S6%@G@+2^0*5YIJS$&EUD!BQ/^ "6 J5[3$NT'WEDA7798%=.F[KFV: MS1?0/X%)[]H>'=([5#=KF;3#_ZRA)_6%NQ,.Z$_4TQ&OW*RLB_:+R[(EK7OS MJUG%&NSZ(UXXR1W/&P2R]>I^-BV-:6FD2R-&!%V0;;1A04RS0.GJ+5;TN*CN MV[$W[K8-"A@:/50DMJF$G5GMW*)+RAHL&V"%!4,>Q23J+'D[&>MDK*FQ^KR; M4_J>G+=2&EE[#7HQ-@[UINF_;JB#;C!Q&=.601D(Z^\QD^#>*!6W![L/F.9^ M1-EI/D(AOE#KR)4?64JO7)Y&;:YU2^4X:.2\H MS //L]]X*MIMF,B\(.7JRL=-*Z6Y%GIHZ7"Z>E6LW(+N"S%6<(;UJ@=%JD)G%HGSY3+9W$0%HW;WMSI.B\\A#L66D18G>;*H4? M"/*@+6L2;0H223=3$_,WH4WTRTR?"['\G?EK\\^C]AF0_]>38I^=?O_]]XC_ MGNS]LG&[MGR=Z:.D]A35\0464!<;2O4?57VY*%<;^TT<[\&V+:OLWMV[IXI0 M&)[_H:N*JX(N+/M;[Q>L__*W)]DS_2TSN]UC^?,S:OCLPR6@IT:70(MS]"+\ MQ1W6^P!S)4H^?XIZ7FY15!M0SJ7*E]['O;QJLI;9U=^!<) M%-B\[.9-;A_G]U_=_>XNGV;G*K==@U52E+^\3[KUS==W;V?WOOGFSC?^O?/W M?/[H_9)#D;4EMGL?C5]=G:BXSZQL3OP[(4^W*5Y9W:]&>/'Y /!6CK7627*7 MMY '=8VD](5#4-;A)X_0[SR]>^?O>?9?K-#G7\#(Y_^5JXC8P:??X<>J_.M? M1;W@GFSHVK7\ VI&=IBN+[ WD?#AK-IKHXAN@J "M/$$[7D24EI"?2S15Z9T MAX1.E[U_V-T:6]"N82NY\&^RY7H!"=F_9G.!]6Q*2K:S6Q?G9[?YF?O_TFLD MI8R9DX("LOYUV_0KSJM4PR"J'F1 .>CFJJ_.6,QZM]O^\,470?S@\#T"!83S M4RM5%9<[W@W]C=9NE[$][-@.W/QDU5SRGDL"R_AV>,"@^MQ+/2[R3T99U=PT M9\ >3>(6,A@SV8B1M^-NBF?P!Y.%4:83L6]I%>,P]-8CTYTU=[6^8^@L_']8]=ZDC'_'_\* LN"8! M>3>OFHX[Z^(> >K8]K.JG"_R"WB-.*$=!W-WXWZW$Q?'X&'S4 M"[?JV?%ECQZ"L=B[X_@C]/E]H#YS"F]9#+8D.1+5,N[>)U+<_USM[LL\&KPC M?71Z/U6>B\HQW9IDXS?>%^U$GD8.%@ZA1^@8 #A8+3GK[<7V922@98T][+C> MN3NH^N5TSQA\H^HMU6KY>?H7IY8*G]@)TF=&JH,?D4^<<)$? !?YY82+_)AP MD>\BE\W*Q?_[%U2<_^>T^)^V[%[]#]1'O;?Y.++XP5XG117MM>#L2V_(3X\M9N&[>EC/\SE50P9.(F4[JXT___T@M(EL22/&9 M>32(9RE?,^C873@PR^WR,]W$2#H@57/.8WT$QT5&>O,AH\Q5/3AS_BDV&PXW M^.GC0Y8PZ9IYV6R;JJ21,%0P20><\CYDC8H3LN_G4=_B0O(0 "'DIBO&;<]5 M(9RZAS4'HAE%65P?CE^P(-UR$TP*9J8@:NX5ZD?5WMH;_B46EYA;O-8\J\I_ MH9 CK0\?VG),C&N9NZO+Q\<<=10N61P:-K^OV"Z70]L 5<1 M=FU!.3&=64/)+I86^!<+-T>_C2/$O5\$>! 5ZAYDQJTF9OBLE6@V*0J_G\KL MGPN*WO'N<-%O:.[)/Y47?VZG^!-/9"R*^4#/XP49\0LX 4Z182H_!D-^7"_\ MKM9*O^4" \9NM?_]3^ON)QGP_7$HP=T)2/"I @FPWT8OK9Z<&PA^M^N=HL-: MTB6B^(: KMZ%^Y=3+OW&2+L5]07^Q:5M;Q1WY#_96[N"_H;_Y;4%WXWM<.8X MB.EV5/)"4().X'PWE#9Z%XB7R4P_63/UT0B:%=1_)@ W1S[%W,%+T4%)2Z) (4\Q,6[3/>WNDSAB9!:B( P;)F3E)GFQJ MLBDA'L4(ZF"X0,,_074Q%EHBO\ER)LL)[7B,YF?=G("!,LW,<"$A6['CCU3" M,JX+%>!LY^;KVE_NB@IX#$^9+&RR,,TJ$/ C'BK:^5KGA!;]?#>&EL\6#7DM MSI*1A@#MZMHYUUXO2XJIY \CH]>A(_" 'RCBI._,-PN1J*6P!KY'Z;55$F] M1PJJH>T_K.^ZQ630DT'':@ZGQEU/T#KT4!9NZP@.D/5;Z3X)TPG!LE]O":R& M!%DGE(C.1=H<9,XNJ_W)A9ID*LU,-G?@1(/;6Q9E9:E">%ONB"\-79\2N_E. M-G,"@&YWS*'#OIBKCI.SFPSOK6J"0W.CJ9+7,K02*]ODXG0O+:I(%-5H###G MKFM1UPW:Y[0+TUPR\]> J,F@>F.EL41.0\,VW M=XZ?_'\ M=M;M.V"6N']^+2Q@M/?-T^0J;@9+?-3F8045DVS<"D*R.3 M$/ZH3> 6MEU&'S;00*"B/()G1((DXY)]K>QT0-VL".0UU@"2D)>@3M-D\QC< MX5G,)O'P_2=EP8, V>V(1ZF+SX"/)?9K&^^ -M1B7OC5M)_VR\F21O9++K30Q&924[3&U>$K,"JA M9%4V+,R2N, //1"08DQTT= /H*BN\PZ$G\ M![9*.5G<9'$V$A0LJN:9_G/H ''>2KX.!C0KYJ^J9D4CW5JHG@QI,B3FT*KW MP$.%+5LR!=V#NW6YW=( -(3*EG>JAF=>FD'W) Z1U4<&Q\9F:HXVC2?SG,SS M,$\Q 2&G+-P8WJT5P]S3Q*2@'F+T6:Q8M(*(KTTO1!2/B"(LI-2+C%4S:U=- M5CA98;#"!90;1=L!D/P E!>!%7 G9%U!++_+TM&L(($'=7($?6-*@)H6Y%$; M_V085Q]ZRWY[WCBW2U,=X<%D]M7)(B>+Y+9;)(+Q_JW:\Z O-\Z0"(=$>;?? M"C,3#(@T&7Q"L@90!@T,OQ_[Z\ N7*P(_SPU=B<+XQE<'F2FF2$2E,+_R2T W$^?-N>K@3//A@*BV*D%]J0;?3]1;];-P@[)X.?##[HTBO<2R;!.;G@A@=H2GFZ M=T2-I@V,I)UD'I'+4]>#__98@?&J::L% 5;9+<\+Y-M]ER &436L9>0DYCBE M-_"WS'%N=@QXKA1F9X'"C![ELP"Y++*?>#I;R8ZF@'#R=I^SM_O-"<$?MN^$ M#@.E9 .JT8&CA-!/F/0:46&.1'_!PWF/U8!5HV<1O$CU9VGQ=#?.L\ AF-LI M%,/]R'6?P$4X<<),QFQZR]((C@R5VE96S@VRFSUUCU-:+H#IK9V3=H$_>B)U M/[6.)^O[/:PPRPIC<45BB4ZU/\CE"B:+TID%J+A:9<2G1(5#S'GIIH .3_A1 MW 5>%J]Y38*;OR<^,:+NG *VR.F#,+[Y6FN M=K*[/X S;AUA1<@[D5"HIJ*KIED0[T68H(!QUBO26R^ZSDVX]1LDO;/F6 M49P^V2MT%$)F@PZTIAJEL(VC1$S(7X$N*)+?*BH>7"V5E%0V"$Y]QGCE%G(T MKBC/#9@OUSUX#I24&/E9Z_QZ9B"Z50"$ZMVK*D3$ MS$7*<4$.D)W:CE0#2=6SAC]UBZE5=:Q5]=A_4J'3#K6@YRW*C;OWJ; QU38F M%_)!:AN&<7';-CM-%$N['K:R'A1\LFU+MX-^3V"QW8//,51#ICUJ,C";79(F M+%$TTND>T@36= FE=%N>F"GEW#>29K\#F5$+IJFWI%1%T\GM\$663,$7J'N$*X MT!8+AW2OG2H?DRT:6Y2A5

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end XML 115 lab-20231231_htm.xml IDEA: XBRL DOCUMENT 0001162194 lab:OneGenomicsCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001162194 us-gaap:CommonStockMember 2021-12-31 0001162194 lab:CorporateHeadquartersTwentyFirstFloorMember 2023-01-01 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2034Member us-gaap:ConvertibleDebtMember 2022-12-31 0001162194 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001162194 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-08-02 0001162194 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001162194 srt:MaximumMember lab:ComputerEquipmentAndSoftwareMember 2023-12-31 0001162194 us-gaap:EmployeeSeveranceMember 2023-12-31 0001162194 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-12-31 0001162194 us-gaap:FacilityClosingMember 2022-01-01 2022-12-31 0001162194 us-gaap:OtherRestructuringMember 2021-12-31 0001162194 lab:CombinedCompanyMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-01-05 0001162194 lab:InstruNorASMember us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-12-31 0001162194 srt:AmericasMember 2023-01-01 2023-12-31 0001162194 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001162194 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2024NonCurrentMember us-gaap:ConvertibleDebtMember 2023-12-31 0001162194 us-gaap:SecuredDebtMember 2021-08-02 0001162194 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-12-31 0001162194 srt:AsiaPacificMember 2023-01-01 2023-12-31 0001162194 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001162194 srt:MaximumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001162194 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001162194 us-gaap:EmployeeStockOptionMember lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember 2023-12-31 0001162194 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001162194 us-gaap:ServiceMember srt:MinimumMember 2023-01-01 2023-12-31 0001162194 lab:TwoThousandAndElevenEquityIncentivePlanMember 2023-12-31 0001162194 2022-12-31 0001162194 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001162194 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0001162194 lab:PatentsandLicenseAgreementsMember 2023-12-31 0001162194 us-gaap:ServiceMember srt:MaximumMember 2023-01-01 2023-12-31 0001162194 us-gaap:StockCompensationPlanMember 2023-01-01 2023-12-31 0001162194 srt:MinimumMember lab:LaboratoryAndManufacturingEquipmentMember 2023-12-31 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001162194 us-gaap:RetainedEarningsMember 2023-12-31 0001162194 us-gaap:SecuredDebtMember 2023-12-31 0001162194 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001162194 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-12-31 0001162194 2022-11-23 0001162194 srt:AmericasMember 2022-01-01 2022-12-31 0001162194 us-gaap:OperatingSegmentsMember lab:GenomicsMember 2022-01-01 2022-12-31 0001162194 country:SG 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2034Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0001162194 lab:ComputerEquipmentAndSoftwareMember 2022-12-31 0001162194 country:CA 2022-12-31 0001162194 lab:GenomicsMember 2022-01-01 2022-12-31 0001162194 us-gaap:OfficeEquipmentMember 2022-12-31 0001162194 lab:LaboratoryAndManufacturingEquipmentMember 2022-12-31 0001162194 us-gaap:RetainedEarningsMember 2021-12-31 0001162194 lab:FiveLargestCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001162194 lab:ServiceAndOtherRevenueMember 2022-01-01 2022-12-31 0001162194 us-gaap:ConvertiblePreferredStockMember 2023-12-31 0001162194 us-gaap:OtherRestructuringMember 2022-01-01 2022-12-31 0001162194 2023-12-31 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001162194 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001162194 srt:MinimumMember 2023-01-01 2023-12-31 0001162194 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001162194 us-gaap:DomesticCountryMember 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2024Member us-gaap:ConvertibleDebtMember 2019-11-30 0001162194 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0001162194 us-gaap:ForeignCountryMember 2023-12-31 0001162194 us-gaap:EmployeeStockOptionMember lab:TwoThousandSeventeenEmployeeStockPurchasePlanMember 2023-12-31 0001162194 lab:CombinedSubsidiariesMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-01-05 0001162194 lab:OneGenomicsCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001162194 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001162194 lab:EquityIncentivePlanMember 2023-12-31 0001162194 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001162194 lab:CasdinMember us-gaap:ConvertiblePreferredStockMember 2022-04-04 0001162194 us-gaap:EmployeeSeveranceMember 2021-12-31 0001162194 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001162194 us-gaap:OfficeEquipmentMember 2023-12-31 0001162194 us-gaap:TreasuryStockCommonMember 2023-12-31 0001162194 lab:TwoThousandSeventeenEmployeeStockPurchasePlanMember 2023-12-31 0001162194 lab:OtherAsiaPacificMember 2022-12-31 0001162194 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-01-01 2022-12-31 0001162194 2023-06-30 0001162194 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001162194 us-gaap:SecuredDebtMember 2022-12-31 0001162194 lab:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001162194 srt:AsiaPacificMember 2022-01-01 2022-12-31 0001162194 2024-01-01 2023-12-31 0001162194 2022-01-01 2022-12-31 0001162194 2020-09-01 2020-09-30 0001162194 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 us-gaap:CommonStockMember us-gaap:SubsequentEventMember lab:SomalogicIncMember 2024-01-05 2024-01-05 0001162194 lab:ConsumablesMember 2022-01-01 2022-12-31 0001162194 us-gaap:DevelopedTechnologyRightsMember 2023-01-01 2023-12-31 0001162194 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2034Member us-gaap:ConvertibleDebtMember 2019-11-30 0001162194 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 us-gaap:OperatingSegmentsMember lab:ProteomicsMember 2022-01-01 2022-12-31 0001162194 us-gaap:SecuredDebtMember us-gaap:PrimeRateMember 2023-01-01 2023-12-31 0001162194 us-gaap:PerformanceSharesMember 2023-12-31 0001162194 us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001162194 srt:MaximumMember lab:LaboratoryAndManufacturingEquipmentMember 2023-12-31 0001162194 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-01-01 2023-12-31 0001162194 lab:FiveLargestCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2034Member us-gaap:ConvertibleDebtMember 2023-12-31 0001162194 srt:MinimumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001162194 lab:VikingMember us-gaap:ConvertiblePreferredStockMember 2022-04-04 2022-04-04 0001162194 us-gaap:EMEAMember 2022-12-31 0001162194 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 us-gaap:EmployeeStockOptionMember lab:TwoThousandAndElevenEquityIncentivePlanMember 2023-12-31 0001162194 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001162194 lab:SouthSanFranciscoMember lab:CorporateHeadquartersEighteenthFloorMember 2023-01-01 2023-12-31 0001162194 lab:ComputerEquipmentAndSoftwareMember 2023-12-31 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001162194 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001162194 us-gaap:EMEAMember 2023-12-31 0001162194 us-gaap:PerformanceSharesMember 2022-12-31 0001162194 lab:InstruNorASMember us-gaap:DevelopedTechnologyRightsMember 2022-04-01 2022-06-30 0001162194 lab:SeniorConvertibleNotesDue2024Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0001162194 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-08-02 2018-08-02 0001162194 us-gaap:ConvertiblePreferredStockMember 2022-04-04 2022-04-04 0001162194 us-gaap:ProductMember 2022-01-01 2022-12-31 0001162194 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001162194 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001162194 lab:SeniorConvertibleNotesDue2024NonCurrentMember us-gaap:ConvertibleDebtMember 2022-12-31 0001162194 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001162194 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001162194 us-gaap:OperatingSegmentsMember lab:ProteomicsMember 2023-01-01 2023-12-31 0001162194 lab:TwoThousandAndSeventeenInducementAwardPlanMember 2023-12-31 0001162194 lab:ConsumablesMember 2023-01-01 2023-12-31 0001162194 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001162194 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001162194 us-gaap:ProductMember srt:MinimumMember 2023-01-01 2023-12-31 0001162194 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001162194 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001162194 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001162194 lab:VikingMember us-gaap:ConvertiblePreferredStockMember 2022-04-04 0001162194 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-12-31 0001162194 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001162194 lab:LaboratoryAndManufacturingEquipmentMember 2023-12-31 0001162194 2025-01-01 2023-12-31 0001162194 us-gaap:ConvertibleDebtMember 2022-12-31 0001162194 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001162194 lab:SeniorConvertibleNotesDue2024Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2019-11-01 2019-11-30 0001162194 srt:MinimumMember lab:ComputerEquipmentAndSoftwareMember 2023-12-31 0001162194 lab:ProteomicsMember 2023-01-01 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2024Member us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2023-12-31 0001162194 us-gaap:EmployeeStockOptionMember 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2024CurrentMember us-gaap:ConvertibleDebtMember 2022-12-31 0001162194 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001162194 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2024Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0001162194 us-gaap:SecuredDebtMember 2023-01-01 2023-12-31 0001162194 us-gaap:CashAndCashEquivalentsMember 2022-12-31 0001162194 lab:PatentsandLicenseAgreementsMember 2022-12-31 0001162194 us-gaap:EmployeeStockOptionMember lab:TwoThousandAndSeventeenInducementAwardPlanMember 2023-12-31 0001162194 us-gaap:FacilityClosingMember 2022-12-31 0001162194 lab:SouthSanFranciscoMember 2022-08-01 2022-08-31 0001162194 country:CN us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001162194 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001162194 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 us-gaap:BridgeLoanMember 2022-02-01 2022-03-31 0001162194 lab:CasdinMember us-gaap:ConvertiblePreferredStockMember 2022-04-04 2022-04-04 0001162194 lab:GenomicsMember 2023-01-01 2023-12-31 0001162194 lab:EquityIncentivePlanMember 2023-01-01 2023-12-31 0001162194 country:US 2022-12-31 0001162194 us-gaap:ConvertibleDebtMember 2023-12-31 0001162194 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001162194 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 2020-09-30 0001162194 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-12-31 0001162194 us-gaap:RestrictedStockUnitsRSUMember lab:TwoThousandAndSeventeenInducementAwardPlanMember 2023-12-31 0001162194 lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember 2023-12-31 0001162194 us-gaap:EMEAMember 2022-01-01 2022-12-31 0001162194 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0001162194 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001162194 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001162194 us-gaap:BridgeLoanMember 2022-04-04 0001162194 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-12-31 0001162194 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001162194 srt:MaximumMember 2023-01-01 2023-12-31 0001162194 lab:InstrumentsMember 2022-01-01 2022-12-31 0001162194 lab:GenomicsMember 2023-12-31 0001162194 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001162194 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001162194 us-gaap:CommonStockMember 2022-12-31 0001162194 2026-01-01 2023-12-31 0001162194 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001162194 us-gaap:EmployeeSeveranceMember 2022-12-31 0001162194 lab:InstrumentsMember 2023-01-01 2023-12-31 0001162194 lab:SouthSanFranciscoMember 2023-01-01 2023-12-31 0001162194 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0001162194 us-gaap:BridgeLoanMember 2022-01-01 2022-12-31 0001162194 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 2023-01-01 2023-12-31 0001162194 us-gaap:OperatingSegmentsMember lab:GenomicsMember 2023-01-01 2023-12-31 0001162194 us-gaap:OtherRestructuringMember 2022-12-31 0001162194 lab:SeniorConvertibleNotesDue2034Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:ConvertibleDebtMember 2014-02-01 2014-02-28 0001162194 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0001162194 country:CN us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001162194 2021-12-31 0001162194 us-gaap:ShortTermInvestmentsMember 2022-12-31 0001162194 2023-12-31 2023-12-31 0001162194 us-gaap:OtherRestructuringMember 2023-01-01 2023-12-31 0001162194 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001162194 us-gaap:FacilityClosingMember 2021-12-31 0001162194 2027-01-01 2023-12-31 0001162194 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001162194 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001162194 lab:SouthSanFranciscoMember 2022-08-31 0001162194 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001162194 us-gaap:ProductMember srt:MaximumMember 2023-01-01 2023-12-31 0001162194 us-gaap:CommonStockMember 2023-12-31 0001162194 country:CA 2023-12-31 0001162194 lab:SouthSanFranciscoMember 2023-02-28 0001162194 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001162194 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001162194 us-gaap:TreasuryStockCommonMember 2022-12-31 0001162194 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001162194 us-gaap:RestrictedStockUnitsRSUMember lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember 2023-12-31 0001162194 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-12-31 0001162194 lab:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001162194 lab:ProteomicsMember 2022-01-01 2022-12-31 0001162194 2019-01-01 2019-12-31 0001162194 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001162194 2024-02-21 0001162194 lab:ServiceAndOtherRevenueMember 2023-01-01 2023-12-31 0001162194 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001162194 lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember 2022-04-30 0001162194 us-gaap:RestrictedStockUnitsRSUMember lab:TwoThousandAndElevenEquityIncentivePlanMember 2023-12-31 0001162194 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001162194 us-gaap:OtherRestructuringMember 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2024Member us-gaap:ConvertibleDebtMember 2019-11-01 2019-11-30 0001162194 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0001162194 country:US 2023-12-31 0001162194 us-gaap:BridgeLoanMember 2022-01-23 0001162194 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001162194 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0001162194 lab:EquityIncentivePlanMember 2022-01-01 2022-12-31 0001162194 country:SG 2022-12-31 0001162194 lab:SeniorConvertibleNotesDue2024Member us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2022-12-31 0001162194 us-gaap:FacilityClosingMember 2023-12-31 0001162194 us-gaap:RestrictedStockUnitsRSUMember lab:TwoThousandSeventeenEmployeeStockPurchasePlanMember 2023-12-31 0001162194 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001162194 lab:SouthSanFranciscoMember 2023-02-28 2023-02-28 0001162194 us-gaap:ProductMember 2023-01-01 2023-12-31 0001162194 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-12-31 0001162194 lab:ProductAndServiceMember 2023-01-01 2023-12-31 0001162194 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001162194 us-gaap:RetainedEarningsMember 2022-12-31 0001162194 lab:SeniorConvertibleNotesDue2034Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001162194 us-gaap:EMEAMember 2023-01-01 2023-12-31 0001162194 lab:ProteomicsMember 2023-12-31 0001162194 us-gaap:ServiceMember 2023-01-01 2023-12-31 0001162194 us-gaap:FacilityClosingMember 2023-01-01 2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2024CurrentMember us-gaap:ConvertibleDebtMember 2023-12-31 0001162194 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001162194 lab:ProductAndServiceMember 2022-01-01 2022-12-31 0001162194 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001162194 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 lab:OtherAsiaPacificMember 2023-12-31 0001162194 lab:GenomicsMember 2022-12-31 0001162194 us-gaap:EmployeeSeveranceMember 2022-01-01 2022-12-31 0001162194 lab:ProteomicsMember 2022-12-31 pure shares iso4217:USD shares lab:MonthlyInstallment lab:Segment iso4217:USD false FY 0001162194 P1Y P3Y P2Y P1Y P1Y P1Y 0.3448276 10-K true 2023-12-31 --12-31 2023 false 001-34180 STANDARD BIOTOOLS INC. DE 77-0513190 2 Tower Place, Suite 2000 South San Francisco, CA 94080 650 266-6000 Common Stock, $0.001 par value per share LAB NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 132700000 290117930 <p style="text-indent:4.173%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant’s proxy statement in connection with the registrant’s annual meeting of stockholders, scheduled to be held in June 2024, are incorporated by reference in Part III of this report. Except as expressly incorporated by reference, such proxy statement shall not be deemed to be part of this report.</span></p> 238 PricewaterhouseCoopers LLP San Jose, California 51704000 81309000 63191000 84475000 312000 592000 19660000 17280000 20533000 21473000 3127000 4278000 158215000 208815000 24187000 25652000 30663000 33883000 2285000 3109000 1400000 12600000 106317000 106251000 323067000 390310000 9236000 7914000 11867000 9153000 4323000 3682000 11607000 10792000 3612000 3644000 9152000 6175000 5000000 2083000 54530000 0 109327000 43443000 569000 54615000 3414000 8194000 841000 1055000 30374000 34081000 3520000 3816000 10755000 14359000 1065000 961000 159865000 160524000 0.001 0.001 256000 256000 256000 256000 256000 256000 255559000 255559000 311253000 311253000 0.001 0.001 9744000 9744000 0 0 0 0 0 0 0.001 0.001 400000000 400000000 83364000 79904000 80232000 79482000 83000 80000 860816000 847008000 -2221000 -1896000 -1000752000 -926096000 3132000 422000 5977000 563000 -148051000 -81467000 323067000 390310000 79198000 72454000 27142000 25494000 106340000 97948000 44942000 52555000 10948000 8342000 55890000 60897000 50450000 37051000 25948000 37382000 87541000 102285000 7076000 9732000 6485000 3857000 127050000 153256000 -76600000 -116205000 4567000 4331000 0 60081000 0 -13719000 6963000 1408000 -74204000 -192928000 452000 -2830000 -74656000 -190098000 -0.94 -0.94 -2.43 -2.43 79160000 79160000 78305000 78305000 -74656000 -190098000 -849000 -487000 524000 -502000 -325000 -989000 -74981000 -191087000 76919000 77000 831424000 -907000 -735998000 94596000 2373000 2000 -213000 -211000 583000 1000 819000 820000 29000 98000 98000 14880000 14880000 -422000 563000 563000 -190098000 -190098000 -989000 0 -989000 79904000 80000 847008000 -1896000 -926096000 -422000 -563000 -81467000 2946000 3000 -119000 -116000 44000 81000 81000 470000 723000 723000 13123000 13123000 -2710000 5414000 5414000 -74656000 -74656000 -325000 -325000 83364000 83000 860816000 -2221000 -1000752000 -3132000 -5977000 -148051000 -74656000 -190098000 0 60081000 0 -13719000 13123000 14880000 11200000 11528000 3980000 3499000 1496000 7874000 0 3526000 770000 830000 -987000 273000 2991000 -1063000 4914000 8470000 -960000 -33000 1618000 -2776000 3018000 4113000 884000 -3467000 3212000 -5978000 -43287000 -89370000 94896000 137302000 117964000 53000000 2831000 3825000 20237000 -88127000 0 25000000 0 225000000 2083000 6838000 0 12547000 5414000 563000 827000 917000 139000 211000 -6809000 230758000 34000 -404000 -29825000 52857000 82324000 29467000 52499000 82324000 3819000 3493000 801000 309000 629000 651000 758000 718000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Standard BioTools Inc. (Standard BioTools or the Company), formerly known as Fluidigm Corporation, is a Delaware corporation headquartered in South San Francisco, California.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company endeavors to provide reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 5, 2024, the Company completed its previously announced merger (the Merger) with SomaLogic, Inc. (SomaLogic) a protein biomarker discovery company enabling researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. See Note 16 – Subsequent Events, for more information.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of the Company's wholly owned subsidiaries. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, Italy, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves, the carrying value of goodwill and other long-lived assets, and the potential outcome of uncertain tax positions that have been recognized in the Company's financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company's consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities of non-U.S. subsidiaries that use their local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. Income and expense accounts are translated at monthly average exchange rates during the year. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity (deficit).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue primarily from the sale of its products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. The Company also generates revenue from product development agreements, license and royalty agreements, and grants. Revenue is reported net of any sales, use and value-added taxes the Company collects from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue based on the amount of consideration it expects to receive in exchange for the goods and services it transfers to the customer. The Company's commercial arrangements typically include multiple distinct products and services, and the Company allocates revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Service and Other Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a672786e-a172-48cb-9ca9-7d4b067c4876;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company believes this time-elapsed approach is appropriate for service contracts because the Company provides services on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments made in advance of service are reported on the Company's consolidated balance sheet as deferred revenue.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as the grant agreement is not with a customer. As there is no authoritative U.S. GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC Topic 958, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Not-for-Profit Entities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Judgments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applying the revenue recognition practices discussed above often requires significant judgment. Significant judgment is required when interpreting commercial terms in sales agreements and determining when control of goods and services passes to the customer. Judgment is also required when identifying performance obligations, estimating SSP and allocating purchase consideration in agreements that include multiple performance obligations. Any material changes created by errors in judgment could have a material effect on the Company's operating results and overall financial condition.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid financial instruments with maturities at the time of purchase of three months or less to be cash equivalents. Cash and cash equivalents balance at December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> represent cash on deposit with banks and money market funds.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investments are comprised of U.S treasury securities that mature within one year. The Company classifies its short-term investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets. Any unrealized gains and losses from short-term investments are reported as a component of other comprehensive income (loss) within the consolidated statements of comprehensive loss and as a separate component of stockholders’ equity (deficit). The Company evaluates its short-term investments to assess whether investments with unrealized loss positions are other-than-temporarily impaired. An investment is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">considered </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to be other-than-temporarily impaired if the impairment is related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of their cost basis. No investment has been assessed as other than temporarily impaired. Realized gains and losses are calculated on the specific identification method and are recorded as interest income (loss). There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains and losses from sales of short-term investments during any of the periods presented.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excludes accrued interest from the fair value and amortized cost basis of its short-term investments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trade accounts receivable are recorded at net invoice value. The Company reviews its exposure to accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The Company evaluates such allowances on a regular basis and adjust them as needed.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Business and Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, short-term investments, and accounts receivable. The Company's cash, cash equivalents, and short-term investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of risk. Under the Company's investment policy, the Company invests exclusively in securities issued by the U.S. government or U.S. government agencies, or in government money-market funds. The goals of the Company's investment policy, in order of priority, are to: preserve capital, meet liquidity needs, and optimize returns. For these reasons, management believes that the Company is not exposed to significant credit risk.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generally does not require collateral to support credit sales. To reduce credit risk, the Company performs credit evaluations of its customers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's products include components that are currently procured from a single source or a limited number of sources. The Company believes that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, the Company attempts to maintain an adequate supply of critical limited-source components.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories are stated at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company regularly reviews inventory for excess and obsolete products and components. Significant judgment is required in determining provisions for slow-moving, excess, and obsolete inventories which are recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, product expiration, discontinuance of product lines, and quality issues.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Accumulated depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The estimated useful lives of the Company's property and equipment are generally as follows: computer equipment and software, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_19f8079b-4c08-44e0-aad5-5c7e979235d0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; laboratory and manufacturing equipment, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3da92a74-6815-434d-91af-6f8ebc86d6a3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; and office furniture and fixtures, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. Lease terms are determined at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For its long-term operating leases, the Company recognizes a lease liability and a right-of-use asset (ROU) on its consolidated balance sheets. ROU assets represent the Company's right-to-use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The lease liability is determined at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a term similar to the lease arrangement. Significant judgment is required in determining the incremental</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collateralized borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. Lease expense is recognized on a straight-line basis over the lease term. Sublease income from an operating lease is recognized on a straight-line basis over the sublease term. The Company does not have any finance leases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify, the Company will not recognize ROU assets or lease liabilities for leases with an initial lease term of one year or less. The Company also elected not to separate lease and nonlease components for the Company's building leases. The nonlease components are generally variable in nature and are expected to represent most of the Company's variable lease costs. Variable costs are expensed as incurred. The Company has taken a portfolio approach for its vehicle leases by country.</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combinations, Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has completed acquisitions of businesses in the past and may acquire additional businesses or technologies in the future. The results of businesses acquired in a business combination are included in the Company's consolidated financial statements from the date of acquisition. The Company allocates the purchase price, which is the sum of the consideration provided in a business combination, to the identifiable assets and liabilities of the acquired business at their acquisition date fair values. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and estimates of future revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The Company's intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Judgment is needed to assess the factors that could indicate an impairment of intangible assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that the Company will be required to recognize an impairment charge include, but are not limited to, declines in the Company's stock price or market capitalization, economic downturns and other macroeconomic events, declines in the Company's market share or revenues, or significant litigation. Any impairment charges could have a material adverse effect on the Company's operating results and net asset value in the period in which the Company recognizes the impairment charge.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In evaluating goodwill and intangible assets with indefinite lives for indications of impairment, the Company first conducts an assessment of qualitative factors to determine whether it is more likely than not that the fair value of each of the Company's reporting units is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of each of its reporting units is less than its carrying amount, the Company compares the fair value of each of its reporting units to its carrying value. If the fair value of each of the Company's reporting units exceeds its carrying value, goodwill is not considered impaired, and no further analysis is required. If the carrying value of each of the Company's reporting units exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates its long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, the Company estimates the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series B Redeemable Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Purchase Agreements (as described in Note 9) for the issuance of shares of Series B Redeemable Preferred Stock were accounted for as forward sales contracts at fair value in accordance with ASC Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Series B Redeemable Preferred Stock was classified as mezzanine equity and recorded at fair value upon issuance, net of issuance costs, due to its redemption features that are outside of the Company’s control. Mezzanine equity is presented separately on the consolidated balance sheets between liabilities and shareholders’ equity because it shares characteristics of both. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the year ended December 31, 2022, the Company recognized a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million loss on the forward sales of Series B Preferred Stock and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million loss on the Bridge Loans due to the increase in the price of the Company's common stock from January 23, 2022 (the date of the Purchase Agreements and the Bridge Loan agreements) to the Private Placement Closing Date. See Note 9 for additional information.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring and Related Charges</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Costs for involuntary separation programs are recorded when management has approved the plan for separation, the employees are identified and made aware of the benefits they are entitled to, it is unlikely that the plan will change significantly, and if applicable, any required governmental notification is made. Costs associated with benefits that are contingent on the employee continuing to provide service are recognized over the required service period. Costs associated with leased facilities (net of sublease income, if applicable) that the Company has vacated as part of a restructuring plan are also included.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Transaction-related Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expensed certain costs incurred related to the merger agreement with SomaLogic, described further in Note 16, including legal, advisory, accounting and other transaction-related costs. The expenses in the prior period relate to the private placement whereby the Company issued and sold an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of convertible preferred stock in connection with the conversion of the bridge loans, which closed on April 4, 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Grant Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the NIH Contract have been principally recorded as capital expenditures and to offset applicable operating costs. The non-operating income recognized from the grant proceeds received in excess of the amounts spent for capital expenditures and operating expenses is reflected on the consolidated statement of operations as surplus funding from the NIH contract.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NIH Contract met the definition of grants related to assets as the primary purpose for the payments was to fund the purchase and construction of capital assets to scale up production capacity. The Company elected to record the grants received as deferred income in accordance with International Accounting Standards (IAS) 20.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred grant income related to production capacity expansion is being amortized for the related assets as a reduction of depreciation expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Term Loan, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term loan is recorded at its carrying value, which includes the outstanding principal amount and the cumulative accreted final payment, less unamortized debt issuance costs. Amortization of the debt issuance costs and accretion of the final payment are reflected in interest expense. The final payment is being accreted to the carrying value of the term loan through the expected maturity of July 1, 2025 using the effective interest method. Debt issuance costs were recorded as an offset to the carrying value of the loan and are amortized over the expected term also using the effective interest method.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Notes, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records the 2014 Notes and 2019 Notes (as described in Note 6) at their carrying values, which includes their principal amounts plus accrued and unpaid interest. Offering-related costs, including underwriting costs, on the 2014 Notes and 2019 Notes were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treasury Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the cost method to account for the repurchases of its common stock in accordance with ASC 505-30, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-Treasury Stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The direct costs associated with settled share repurchases, including trading commissions, are reported as treasury stock in the shareholders’ equity (deficit) section of the Company's consolidated balance sheets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's financial instruments consist primarily of cash and cash equivalents, restricted cash, short-term investments, accounts receivable, accounts payable, term loan and convertible notes. The Company's cash equivalents, restricted cash, accounts receivable and accounts payable generally have short maturity or payment periods. Accordingly, their carrying values approximated their fair values at December 31, 2023 and 2022. The Company's short-term investments consist of U.S. treasury securities that are classified as available-for-sale and reported at fair value on the Company's consolidated balance sheets. The convertible notes and term loan are presented at their net carrying values.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a basis for computing fair value, the Company follows a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level I: observable inputs such as quoted prices in active markets;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level III: unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's cash equivalents, which include money market funds are classified as Level I because they are valued using quoted market prices. The Company's short-term investments, which include U.S. treasuries, are classified as Level II because they are valued using non-binding market consensus prices that were corroborated with observable market data, quoted market prices for similar instruments, or pricing models.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's convertible notes are not regularly traded, and it is difficult to estimate a reliable and accurate market price for these securities. The estimated fair values of these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the Company's term loan also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's term loan was estimated using a discounted cash flows approach and current market interest rate data for similar loans. The carrying value of the Company's lines of term loan approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes research and development expenses in the period incurred. Research and development (R&amp;D) expenses generally consist of personnel costs, independent contractor costs, prototype and materials expenses, allocated facilities and information technology expenses, and related overhead expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advertising Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expenses advertising costs as incurred. The Company incurred advertising costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation costs for all stock-based awards, including stock options, Restricted Share Units (RSUs), Performance Share Units (PSUs) and stock purchased under the Company's Employee Share Purchase Plan (ESPP), based on the grant date fair value of the award. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service periods for non-performance-based awards. For RSUs, fair value is measured based on the closing fair market value of the Company's common stock on the date of grant. For PSUs with a market condition, the Company uses a Monte Carlo simulation pricing model to incorporate the market condition effects at the grant date. The Monte Carlo pricing model requires inputs which are subjective and generally requires judgment. For PSUs with performance conditions, stock-based compensation expense is recognized over the requisite service period when the achievement of each individual performance goal becomes probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of options and stock purchases under ESPP on the grant date is estimated using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions, including expected term, volatility, risk-free interest rate and the fair value of the Company's common stock. These assumptions generally require judgment. The Company determines the expected volatility based on the Company's historical stock price volatility generally commensurate with the estimated expected term of the stock awards. The expected term of an award is based on historical forfeiture experience, exercise activity, and the terms and conditions of the stock awards. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each grant’s expected term. The Company accounts for forfeitures as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans and estimates. Should the actual amounts differ from the Company's estimates, the amount of the valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to the Company's tax provision in a period in which such estimates are changed, which in turn would affect net income or loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. Any interest and penalties related to uncertain tax positions are reflected in the income tax provision.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's CEO, who is its Chief Operating Decision Maker (CODM), measures segment performance using gross profit which is determined by subtracting cost of product and service revenues from segment revenues. Depreciation and amortization expense is included in each segment’s gross profit.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on the Company's short-term investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. RSUs, PSUs, stock options to purchase the Company's common stock, ESPP shares pending issuance, Series B Preferred Stock and convertible notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs, PSUs, stock options and ESPP shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,740</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,752</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series B Preferred Stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,164</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,164</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,966</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,966</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2014 Notes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110,880</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,892</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,741,374</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. Refer to Note 6 for additional information on the 2019 Notes.</span></div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,709,703</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares that were repurchased during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> have also been excluded from the Company's earnings per share and diluted earnings per share calculations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Changes and Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adoption of New Accounting Guidance</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting standards are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires disclosure of more detailed information about a reportable segment’s expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASU 2023-09, Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts in the consolidated financial statements have been reclassified from their original presentation to conform to current year presentation.</span></p></div> <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of the Company's wholly owned subsidiaries. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, Italy, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves, the carrying value of goodwill and other long-lived assets, and the potential outcome of uncertain tax positions that have been recognized in the Company's financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company's consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities of non-U.S. subsidiaries that use their local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. Income and expense accounts are translated at monthly average exchange rates during the year. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity (deficit).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue primarily from the sale of its products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. The Company also generates revenue from product development agreements, license and royalty agreements, and grants. Revenue is reported net of any sales, use and value-added taxes the Company collects from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue based on the amount of consideration it expects to receive in exchange for the goods and services it transfers to the customer. The Company's commercial arrangements typically include multiple distinct products and services, and the Company allocates revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Service and Other Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a672786e-a172-48cb-9ca9-7d4b067c4876;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company believes this time-elapsed approach is appropriate for service contracts because the Company provides services on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments made in advance of service are reported on the Company's consolidated balance sheet as deferred revenue.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as the grant agreement is not with a customer. As there is no authoritative U.S. GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC Topic 958, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Not-for-Profit Entities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Judgments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applying the revenue recognition practices discussed above often requires significant judgment. Significant judgment is required when interpreting commercial terms in sales agreements and determining when control of goods and services passes to the customer. Judgment is also required when identifying performance obligations, estimating SSP and allocating purchase consideration in agreements that include multiple performance obligations. Any material changes created by errors in judgment could have a material effect on the Company's operating results and overall financial condition.</span></p> P30D P60D P3Y <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid financial instruments with maturities at the time of purchase of three months or less to be cash equivalents. Cash and cash equivalents balance at December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> represent cash on deposit with banks and money market funds.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investments are comprised of U.S treasury securities that mature within one year. The Company classifies its short-term investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets. Any unrealized gains and losses from short-term investments are reported as a component of other comprehensive income (loss) within the consolidated statements of comprehensive loss and as a separate component of stockholders’ equity (deficit). The Company evaluates its short-term investments to assess whether investments with unrealized loss positions are other-than-temporarily impaired. An investment is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">considered </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to be other-than-temporarily impaired if the impairment is related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of their cost basis. No investment has been assessed as other than temporarily impaired. Realized gains and losses are calculated on the specific identification method and are recorded as interest income (loss). There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains and losses from sales of short-term investments during any of the periods presented.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excludes accrued interest from the fair value and amortized cost basis of its short-term investments.</span></p> 0 0 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trade accounts receivable are recorded at net invoice value. The Company reviews its exposure to accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The Company evaluates such allowances on a regular basis and adjust them as needed.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Business and Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, short-term investments, and accounts receivable. The Company's cash, cash equivalents, and short-term investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of risk. Under the Company's investment policy, the Company invests exclusively in securities issued by the U.S. government or U.S. government agencies, or in government money-market funds. The goals of the Company's investment policy, in order of priority, are to: preserve capital, meet liquidity needs, and optimize returns. For these reasons, management believes that the Company is not exposed to significant credit risk.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generally does not require collateral to support credit sales. To reduce credit risk, the Company performs credit evaluations of its customers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's products include components that are currently procured from a single source or a limited number of sources. The Company believes that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, the Company attempts to maintain an adequate supply of critical limited-source components.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories are stated at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company regularly reviews inventory for excess and obsolete products and components. Significant judgment is required in determining provisions for slow-moving, excess, and obsolete inventories which are recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, product expiration, discontinuance of product lines, and quality issues.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Accumulated depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The estimated useful lives of the Company's property and equipment are generally as follows: computer equipment and software, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_19f8079b-4c08-44e0-aad5-5c7e979235d0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; laboratory and manufacturing equipment, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3da92a74-6815-434d-91af-6f8ebc86d6a3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; and office furniture and fixtures, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p> P4Y P7Y P5Y <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. Lease terms are determined at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For its long-term operating leases, the Company recognizes a lease liability and a right-of-use asset (ROU) on its consolidated balance sheets. ROU assets represent the Company's right-to-use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The lease liability is determined at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a term similar to the lease arrangement. Significant judgment is required in determining the incremental</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collateralized borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. Lease expense is recognized on a straight-line basis over the lease term. Sublease income from an operating lease is recognized on a straight-line basis over the sublease term. The Company does not have any finance leases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify, the Company will not recognize ROU assets or lease liabilities for leases with an initial lease term of one year or less. The Company also elected not to separate lease and nonlease components for the Company's building leases. The nonlease components are generally variable in nature and are expected to represent most of the Company's variable lease costs. Variable costs are expensed as incurred. The Company has taken a portfolio approach for its vehicle leases by country.</span></p> <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has completed acquisitions of businesses in the past and may acquire additional businesses or technologies in the future. The results of businesses acquired in a business combination are included in the Company's consolidated financial statements from the date of acquisition. The Company allocates the purchase price, which is the sum of the consideration provided in a business combination, to the identifiable assets and liabilities of the acquired business at their acquisition date fair values. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and estimates of future revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The Company's intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Judgment is needed to assess the factors that could indicate an impairment of intangible assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that the Company will be required to recognize an impairment charge include, but are not limited to, declines in the Company's stock price or market capitalization, economic downturns and other macroeconomic events, declines in the Company's market share or revenues, or significant litigation. Any impairment charges could have a material adverse effect on the Company's operating results and net asset value in the period in which the Company recognizes the impairment charge.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In evaluating goodwill and intangible assets with indefinite lives for indications of impairment, the Company first conducts an assessment of qualitative factors to determine whether it is more likely than not that the fair value of each of the Company's reporting units is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of each of its reporting units is less than its carrying amount, the Company compares the fair value of each of its reporting units to its carrying value. If the fair value of each of the Company's reporting units exceeds its carrying value, goodwill is not considered impaired, and no further analysis is required. If the carrying value of each of the Company's reporting units exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill.</span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates its long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, the Company estimates the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series B Redeemable Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Purchase Agreements (as described in Note 9) for the issuance of shares of Series B Redeemable Preferred Stock were accounted for as forward sales contracts at fair value in accordance with ASC Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Series B Redeemable Preferred Stock was classified as mezzanine equity and recorded at fair value upon issuance, net of issuance costs, due to its redemption features that are outside of the Company’s control. Mezzanine equity is presented separately on the consolidated balance sheets between liabilities and shareholders’ equity because it shares characteristics of both. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the year ended December 31, 2022, the Company recognized a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million loss on the forward sales of Series B Preferred Stock and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million loss on the Bridge Loans due to the increase in the price of the Company's common stock from January 23, 2022 (the date of the Purchase Agreements and the Bridge Loan agreements) to the Private Placement Closing Date. See Note 9 for additional information.</span></p> 60100000 -13700000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring and Related Charges</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Costs for involuntary separation programs are recorded when management has approved the plan for separation, the employees are identified and made aware of the benefits they are entitled to, it is unlikely that the plan will change significantly, and if applicable, any required governmental notification is made. Costs associated with benefits that are contingent on the employee continuing to provide service are recognized over the required service period. Costs associated with leased facilities (net of sublease income, if applicable) that the Company has vacated as part of a restructuring plan are also included.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Transaction-related Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expensed certain costs incurred related to the merger agreement with SomaLogic, described further in Note 16, including legal, advisory, accounting and other transaction-related costs. The expenses in the prior period relate to the private placement whereby the Company issued and sold an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of convertible preferred stock in connection with the conversion of the bridge loans, which closed on April 4, 2022.</span></p> 225000000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Grant Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the NIH Contract have been principally recorded as capital expenditures and to offset applicable operating costs. The non-operating income recognized from the grant proceeds received in excess of the amounts spent for capital expenditures and operating expenses is reflected on the consolidated statement of operations as surplus funding from the NIH contract.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NIH Contract met the definition of grants related to assets as the primary purpose for the payments was to fund the purchase and construction of capital assets to scale up production capacity. The Company elected to record the grants received as deferred income in accordance with International Accounting Standards (IAS) 20.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred grant income related to production capacity expansion is being amortized for the related assets as a reduction of depreciation expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Term Loan, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term loan is recorded at its carrying value, which includes the outstanding principal amount and the cumulative accreted final payment, less unamortized debt issuance costs. Amortization of the debt issuance costs and accretion of the final payment are reflected in interest expense. The final payment is being accreted to the carrying value of the term loan through the expected maturity of July 1, 2025 using the effective interest method. Debt issuance costs were recorded as an offset to the carrying value of the loan and are amortized over the expected term also using the effective interest method.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Notes, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records the 2014 Notes and 2019 Notes (as described in Note 6) at their carrying values, which includes their principal amounts plus accrued and unpaid interest. Offering-related costs, including underwriting costs, on the 2014 Notes and 2019 Notes were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treasury Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the cost method to account for the repurchases of its common stock in accordance with ASC 505-30, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-Treasury Stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The direct costs associated with settled share repurchases, including trading commissions, are reported as treasury stock in the shareholders’ equity (deficit) section of the Company's consolidated balance sheets.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's financial instruments consist primarily of cash and cash equivalents, restricted cash, short-term investments, accounts receivable, accounts payable, term loan and convertible notes. The Company's cash equivalents, restricted cash, accounts receivable and accounts payable generally have short maturity or payment periods. Accordingly, their carrying values approximated their fair values at December 31, 2023 and 2022. The Company's short-term investments consist of U.S. treasury securities that are classified as available-for-sale and reported at fair value on the Company's consolidated balance sheets. The convertible notes and term loan are presented at their net carrying values.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a basis for computing fair value, the Company follows a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level I: observable inputs such as quoted prices in active markets;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level III: unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's cash equivalents, which include money market funds are classified as Level I because they are valued using quoted market prices. The Company's short-term investments, which include U.S. treasuries, are classified as Level II because they are valued using non-binding market consensus prices that were corroborated with observable market data, quoted market prices for similar instruments, or pricing models.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's convertible notes are not regularly traded, and it is difficult to estimate a reliable and accurate market price for these securities. The estimated fair values of these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the Company's term loan also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's term loan was estimated using a discounted cash flows approach and current market interest rate data for similar loans. The carrying value of the Company's lines of term loan approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes research and development expenses in the period incurred. Research and development (R&amp;D) expenses generally consist of personnel costs, independent contractor costs, prototype and materials expenses, allocated facilities and information technology expenses, and related overhead expenses.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advertising Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expenses advertising costs as incurred. The Company incurred advertising costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p> 2000000 3900000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation costs for all stock-based awards, including stock options, Restricted Share Units (RSUs), Performance Share Units (PSUs) and stock purchased under the Company's Employee Share Purchase Plan (ESPP), based on the grant date fair value of the award. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service periods for non-performance-based awards. For RSUs, fair value is measured based on the closing fair market value of the Company's common stock on the date of grant. For PSUs with a market condition, the Company uses a Monte Carlo simulation pricing model to incorporate the market condition effects at the grant date. The Monte Carlo pricing model requires inputs which are subjective and generally requires judgment. For PSUs with performance conditions, stock-based compensation expense is recognized over the requisite service period when the achievement of each individual performance goal becomes probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of options and stock purchases under ESPP on the grant date is estimated using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions, including expected term, volatility, risk-free interest rate and the fair value of the Company's common stock. These assumptions generally require judgment. The Company determines the expected volatility based on the Company's historical stock price volatility generally commensurate with the estimated expected term of the stock awards. The expected term of an award is based on historical forfeiture experience, exercise activity, and the terms and conditions of the stock awards. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each grant’s expected term. The Company accounts for forfeitures as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans and estimates. Should the actual amounts differ from the Company's estimates, the amount of the valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to the Company's tax provision in a period in which such estimates are changed, which in turn would affect net income or loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. Any interest and penalties related to uncertain tax positions are reflected in the income tax provision.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's CEO, who is its Chief Operating Decision Maker (CODM), measures segment performance using gross profit which is determined by subtracting cost of product and service revenues from segment revenues. Depreciation and amortization expense is included in each segment’s gross profit.</span></p> 2 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on the Company's short-term investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of comprehensive loss.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. RSUs, PSUs, stock options to purchase the Company's common stock, ESPP shares pending issuance, Series B Preferred Stock and convertible notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs, PSUs, stock options and ESPP shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,740</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,752</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series B Preferred Stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,164</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,164</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,966</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,966</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2014 Notes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110,880</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,892</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,741,374</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. Refer to Note 6 for additional information on the 2019 Notes.</span></div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,709,703</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares that were repurchased during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> have also been excluded from the Company's earnings per share and diluted earnings per share calculations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs, PSUs, stock options and ESPP shares</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,740</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,752</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series B Preferred Stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,164</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,164</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,966</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,966</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2014 Notes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110,880</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,892</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,741,374</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. Refer to Note 6 for additional information on the 2019 Notes.</span></div></div> 16740000 15752000 75164000 75164000 18966000 18966000 10000 10000 110880000 109892000 4741374 2709703 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Changes and Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adoption of New Accounting Guidance</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting standards are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires disclosure of more detailed information about a reportable segment’s expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASU 2023-09, Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts in the consolidated financial statements have been reclassified from their original presentation to conform to current year presentation.</span></p> <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Revenue and Geographic Area</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disaggregation of Revenue by Product Type and Geographic Area</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the Company's revenue for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively, based on product type and the geographic location of customers’ facilities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Instruments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,459</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,664</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consumables</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,739</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,790</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total product revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,198</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,454</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,980</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,712</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Product and service revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,178</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,166</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,162</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,782</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,340</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,948</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Americas</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,196</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,982</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Europe, Middle East and Africa (EMEA)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,201</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,136</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Asia-Pacific</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,943</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,830</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,340</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,948</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Most of the Company's principal operations, other than manufacturing, are located at its corporate headquarters in the United States. Revenue from customers in the United States represented $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">44.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, of total revenues for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, of total revenues for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022. Refer to Note 13 for additional information on revenue by reporting segment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from customers in China represented $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, of total revenues for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total revenues for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022. With the exception of China in 2023 and 2022, no foreign country or jurisdiction had revenue in excess of 10% of the Company's total revenue during the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One genomics customer accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's total revenue for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of outstanding net trade receivables at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. No other customer represented more than 10% of the Company's total revenue for the fiscal years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Revenue from the Company's five largest customers represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total revenue for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total revenue the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-lived Assets by Geographical Area</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had long-lived assets consisting of property and equipment, net of accumulated depreciation, and operating lease ROU assets, net of accumulated amortization, in the following geographic areas for each year presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United States</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,646</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,785</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Singapore</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,097</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,178</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canada</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,394</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other Asia-Pacific</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">889</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">875</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">EMEA</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">987</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">303</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,850</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,535</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfulfilled Performance Obligations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated balance sheets as of December 31, 2023 and 2022 included total deferred revenue of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the opening deferred revenue balance was recognized as revenue and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of net additional advance payments, primarily for instrument service contracts, were received from customers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 in the following periods (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expected Revenue </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_92b638ef-c7a2-457d-a189-0e8513fb86e1;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,253</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_0f516329-398a-4809-aed9-29eaab55121d;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,634</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_9fc75aae-76f7-4ded-845b-9d0bc16ac4e9;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,061</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_2001acf1-19d1-450f-9f70-4d2d8081df9c;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,112</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,060</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins.</span></div></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also has unsatisfied performance obligations for service contracts with an expected term of one year or less not included in the amounts above.</span></p> <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the Company's revenue for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively, based on product type and the geographic location of customers’ facilities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Instruments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,459</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,664</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consumables</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,739</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,790</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total product revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,198</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,454</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,980</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,712</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Product and service revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,178</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,166</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,162</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,782</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,340</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,948</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Americas</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,196</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,982</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Europe, Middle East and Africa (EMEA)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,201</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,136</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Asia-Pacific</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,943</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,830</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,340</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,948</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 37459000 25664000 41739000 46790000 79198000 72454000 25980000 23712000 105178000 96166000 1162000 1782000 106340000 97948000 46196000 43982000 36201000 33136000 23943000 20830000 106340000 97948000 44100000 0.42 41000000 0.42 15800000 0.15 0.11 0.10 0.11 0.14 0.16 0.24 0.19 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had long-lived assets consisting of property and equipment, net of accumulated depreciation, and operating lease ROU assets, net of accumulated amortization, in the following geographic areas for each year presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United States</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,646</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,785</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Singapore</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,097</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,178</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canada</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,394</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other Asia-Pacific</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">889</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">875</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">EMEA</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">987</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">303</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,850</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,535</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 29646000 31785000 17097000 21178000 6231000 5394000 889000 875000 987000 303000 54850000 59535000 15100000 14600000 10600000 11100000 <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 in the following periods (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expected Revenue </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_92b638ef-c7a2-457d-a189-0e8513fb86e1;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,253</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_0f516329-398a-4809-aed9-29eaab55121d;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,634</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_9fc75aae-76f7-4ded-845b-9d0bc16ac4e9;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,061</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_2001acf1-19d1-450f-9f70-4d2d8081df9c;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,112</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,060</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins.</span></div></div> 13253000 6634000 3061000 1112000 24060000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Goodwill and Intangible Assets, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2022, the Company discontinued the sale of products that utilized the developed technology acquired from InstruNor and recorded a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million impairment charge to write-off the unamortized portion of the related intangible asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company assessed goodwill for impairment when it performed its annual testing at the end of the fourth quarter of 2023. A qualitative approach was employed which included assessing significant events and circumstances such as the Company's current results,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assumptions </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regarding future performance, strategic initiatives and overall macroeconomic factors to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of each of the Company's reporting units is less than their carrying value. The Company determined there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The changes in the carrying value of goodwill by segment are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Proteomics</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Genomics</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,752</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,499</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,251</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,798</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,519</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,317</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets with finite lives include developed technology, patents and licenses. In the consolidated balance sheets, developed technology is reported separately while patents and licenses are reported in other non-current assets. Intangible assets, net, were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.37%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:11.202%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="13" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Amount</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization<br/>and<br/>Impairment</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Amortization<br/>Period</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Developed technology</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,354</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,954</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents and licenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,250</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,243</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.37%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:11.202%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="13" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Amount</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Amortization<br/>Period</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Developed technology</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,194</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,594</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,600</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents and licenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,247</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,669</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">578</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total amortization expense of the Company's intangible assets was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million impairment charge for the InstruNor developed technology intangible asset was recorded in research and development expense in 2022 and it is reflected in accumulated amortization in the above table.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the net carrying value of intangible assets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company expects annual amortization expense to be as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Developed<br/>Technology<br/>Amortization<br/>Expense</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Patents and<br/>Licenses<br/>Amortization<br/>Expense</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,407</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,407</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 3500000 0 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The changes in the carrying value of goodwill by segment are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Proteomics</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Genomics</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,752</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,499</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,251</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,798</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,519</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,317</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 85752000 20499000 106251000 46000 20000 66000 85798000 20519000 106317000 <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets with finite lives include developed technology, patents and licenses. In the consolidated balance sheets, developed technology is reported separately while patents and licenses are reported in other non-current assets. Intangible assets, net, were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.37%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:11.202%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="13" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Amount</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization<br/>and<br/>Impairment</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Amortization<br/>Period</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Developed technology</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,354</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,954</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents and licenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,250</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,243</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.37%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:11.202%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="13" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Amount</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Amortization<br/>Period</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Developed technology</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,194</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,594</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,600</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents and licenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,247</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,669</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">578</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 117354000 115954000 1400000 P10Y 11250000 11243000 7000 P7Y 117194000 104594000 12600000 P10Y 11247000 10669000 578000 P7Y 11800000 12200000 3500000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the net carrying value of intangible assets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company expects annual amortization expense to be as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> <td style="width:1.399%;"></td> <td style="width:1%;"></td> <td style="width:10.776%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Developed<br/>Technology<br/>Amortization<br/>Expense</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Patents and<br/>Licenses<br/>Amortization<br/>Expense</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,407</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,407</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 1400000 7000 1407000 1400000 7000 1407000 <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Balance Sheet Details</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><div style="font-size:10pt;font-family:Times New Roman;"><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,704</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,309</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">795</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,015</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,499</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,324</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in other non-current assets on the consolidated balance sheets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories, net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,539</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,866</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">282</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">945</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,753</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,245</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total inventory, gross</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,574</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,056</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for excess and obsolete inventory</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,041</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,583</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total inventories, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,533</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,473</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory and manufacturing equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,563</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,329</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,785</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,234</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment and software</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,232</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,793</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office furniture and fixtures</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,762</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,713</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, gross</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,342</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,069</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,489</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,029</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction-in-progress</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,334</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,612</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,187</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,652</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Compensation and Related Benefits</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation and related benefits, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued incentive compensation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,337</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,170</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued vacation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,795</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll taxes and other</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">994</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,174</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued restructuring</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">825</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,014</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related benefits</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,867</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,153</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 14 for additional information on restructuring.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accrued liabilities, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued commissions</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">800</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">318</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued legal expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">964</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued taxes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,230</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,443</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uninvoiced receipts</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,516</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,078</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued warranties</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,593</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">678</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer advances</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">447</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">577</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued restructuring</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,097</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">913</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,152</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,175</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Grant Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the Company executed a contract with the National Institutes of Health (NIH) under NIH’s Rapid Acceleration of Diagnostics program to support the expansion of the Company’s production capacity for its COVID-19 test products. Under the now-completed contract, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of funding from the NIH and used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on capital expenditures for their Singapore manufacturing facility. The amortization of the deferred income, which is offset against depreciation, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Cumulative amounts amortized and offsetting against depreciation expense for these assets placed in service were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and the carrying values of these assets were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, as of these same dates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current portion of deferred grant income on the Company’s consolidated balance sheets represents amounts expected to be offset against depreciation expense over the next twelve months. The non-current portion of deferred grant income includes amounts expected to be offset against depreciation expense in later periods.</span></p> <div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,704</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,309</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">795</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,015</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,499</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,324</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,704</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,309</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">795</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,015</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,499</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,324</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 51704000 81309000 795000 1015000 52499000 82324000 800000 1000000 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,539</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,866</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">282</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">945</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,753</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,245</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total inventory, gross</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,574</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,056</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for excess and obsolete inventory</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,041</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,583</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total inventories, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,533</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,473</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 15539000 16866000 282000 945000 11753000 15245000 27574000 33056000 7041000 11583000 20533000 21473000 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory and manufacturing equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,563</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,329</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,785</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,234</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment and software</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,232</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,793</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office furniture and fixtures</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,762</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,713</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, gross</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,342</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,069</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,489</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,029</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction-in-progress</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,334</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,612</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,187</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,652</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 35563000 33329000 13785000 12234000 6232000 5793000 1762000 1713000 57342000 53069000 35489000 29029000 2334000 1612000 24187000 25652000 3400000 2800000 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation and related benefits, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued incentive compensation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,337</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,170</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued vacation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,795</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll taxes and other</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">994</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,174</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued restructuring</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">825</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,014</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related benefits</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,867</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,153</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 7337000 1170000 2711000 2795000 994000 1174000 825000 4014000 11867000 9153000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accrued liabilities, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued commissions</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">800</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">318</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued legal expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">964</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued taxes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,230</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,443</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uninvoiced receipts</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,516</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,078</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued warranties</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,593</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">678</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer advances</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">447</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">577</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued restructuring</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,097</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">913</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,152</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,175</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 1010000 800000 295000 318000 964000 349000 1230000 1443000 1516000 1078000 2593000 678000 447000 577000 0 19000 1097000 913000 9152000 6175000 34000000 22200000 3600000 3500000 7800000 4200000 14400000 18000000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Debt</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying value of debt consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.367%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:14.777000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:14.777000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible notes:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2014 Notes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">569</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">568</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Notes, non-current</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,047</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Notes, current</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,530</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total convertible notes, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,099</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,615</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan, non-current</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,414</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,194</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan, current</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,083</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,513</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,892</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Notes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2014, the Company closed an underwritten public offering of 2014 Senior Convertible Notes (2014 Notes), which will mature on February 1, 2034, unless earlier converted, redeemed or repurchased in accordance with the terms of the 2014 Notes. Holders may require the Company to repurchase all or a portion of their 2014 Notes on each of February 6, 2024 and February 6, 2029, at a repurchase price in cash equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount of the 2014 Notes plus accrued and unpaid interest. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 6, 2024, one holder of the 2014 Notes exercised their repurchase right, and the Company repurchased an immaterial amount of principal and accrued interest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2019, the Company issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of 2019 Senior Convertible Notes (2019 Notes). Net proceeds from the 2019 Notes issuance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deductions for commissions and other debt issuance costs, were used to retire all but $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the aggregate principal value of the 2014 Notes then outstanding. The 2019 Notes bear interest at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per annum, payable semiannually on June 1 and December 1 of each year. The 2019 Notes will mature on December 1, 2024, unless</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">earlier </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">repurchased or converted pursuant to their terms. The 2019 Notes will be convertible at the option of the holder at any point prior to the close of business on the second scheduled trading day preceding the maturity date. The initial conversion rate of the 2019 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">344.8276</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company’s common stock per $</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1afd2ff2-f829-4985-a496-2157b4b656e1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,000</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share). The conversion rate is subject to adjustment upon the occurrence of certain specified events. Those certain specified events include voluntary conversion of the 2019 Notes prior to the Company’s exercise of the Issuer’s Conversion Option (as defined therein) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2019 Notes. The conversion rate will not be adjusted for any accrued and unpaid interest. The 2019 Notes are convertible at the Company’s option in whole but not in part into shares of the Company’s common stock upon certain conditions if the volume-weighted average price of the Company’s common stock has equaled or exceeded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the conversion price then in effect for a specified number of days.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Offering-related costs related to both notes were capitalized as debt issuance costs and are recorded as an offset to the carrying value of the 2019 Notes.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revolving Credit Facility</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 2, 2018, the Company entered into a revolving credit facility with Silicon Valley Bank (as amended, the Revolving Credit Facility) in an aggregate principal amount of up to the lesser of (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or (ii) the sum of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of eligible receivables and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of eligible inventory, in each case, subject to certain limitations (Borrowing Base), provided that the amount of eligible inventory that may be counted towards the Borrowing Base shall be subject to a cap as set forth in the Revolving Credit Facility. The Revolving Credit Facility was collateralized by substantially all the Company’s property, other than intellectual property and contained certain financial covenants. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> borrowings under the Revolving Credit Facility and it expired on August 2, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Term Loan Facility, net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 2, 2021, the Company amended its Revolving Credit Facility to, amongst other things, provide for a new $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million term loan facility (the Term Loan Facility). As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Term Loan Facility was fully drawn with an outstanding principal balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a carrying value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The interest rate on the Term Loan Facility is the greater of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum or a floating per annum rate equal to the prime rate plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. Interest on any outstanding term loan advances is due and payable monthly. In addition to the monthly interest payments, a final payment equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the original principal amount of each advance is due the earlier of the maturity date or the date the advance is repaid. Principal balances are required to be repaid in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> equal installments which began on August 1, 2023. The stated maturity of the Term Loan Facility is July 1, 2025. However, if the principal amount of the Company’s convertible debt exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of June 1, 2024 or if the maturity date of the 2019 Notes has not been extended beyond January 1, 2026 by June 1, 2024, then the maturity date of the Term Loan Facility will be June 1, 2024. As there were no contractual requirement to repay the loan as of the balance sheet date, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Term Loan Facility's carrying value is classified as non-current, consistent with its terms, on the Company’s balance sheet as of December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 26, 2023, the Company entered into an amendment to the Term Loan Facility agreement which removed certain collateral covenants related to the Revolving Credit Facility due to its expiration on August 2, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum payments under the Term Loan Facility including the end of term fee payment as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.58%;"></td> <td style="width:1.88%;"></td> <td style="width:1%;"></td> <td style="width:18.54%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,917</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,917</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">End of term fee and debt issuance costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">497</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Term Loan Facility</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,414</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bridge Loans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 23, 2022, the Company entered into separate loan agreements (collectively, the Bridge Loan Agreements) with various investors for a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million term loan (collectively, the Bridge Loans). The Bridge Loans were fully drawn on January 24, 2022, and automatically converted into Series B Preferred Stock upon the subsequent closing of the Private Placement (as defined below) on April 4, 2022 (the Private Placement Closing Date).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applying the guidance in ASC 825 Financial Instruments, the Company elected to record the Bridge Loans at their fair value using a probability‐weighted expected return method for the valuation analysis of the Bridge Loans. This resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">change</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fair value of the Bridge Loans from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at inception to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of the Private Placement Closing Date, including the portion attributable to accrued interest, which is reflected as a non-operating unrealized loss on the Bridge Loans in the accompanying consolidated statements of operations for the year ended December 31, 2022. See Note 9 for further detail.</span></p> <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying value of debt consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.367%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:14.777000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:14.777000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible notes:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2014 Notes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">569</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">568</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Notes, non-current</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,047</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Notes, current</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,530</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total convertible notes, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,099</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,615</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan, non-current</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,414</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,194</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan, current</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,083</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,513</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,892</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 569000 568000 0 54047000 54530000 0 55099000 54615000 3414000 8194000 5000000 2083000 63513000 64892000 1 55000000 52700000 1100000 0.0525 344.8276 2.9 1.30 15000000 0.85 0.50 0 10000000 7900000 8400000 0.04 0.0075 0.065 24 600000 3400000 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum payments under the Term Loan Facility including the end of term fee payment as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.58%;"></td> <td style="width:1.88%;"></td> <td style="width:1%;"></td> <td style="width:18.54%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,917</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,917</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">End of term fee and debt issuance costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">497</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Term Loan Facility</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,414</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 5000000 2917000 7917000 497000 8414000 25000000 13700000 25000000 38700000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has operating leases for buildings, equipment and vehicles. Existing leases have remaining terms ranging from less than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Some leases contain options to extend the lease, usually for up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, along with termination options. The Company’s facility lease has an expiration date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 30, 2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contains an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">along with</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> termination options</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company is utilizing one floor (19</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> floor) for its corporate operations with all expense for this floor included within selling, general and administrative expense on the Company’s consolidated statement of operations for the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the Company’s restructuring plan discussed further in Note 14, in August 2022, the Company entered into an agreement to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of its corporate headquarters space (18</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> floor) in South San Francisco, California for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">months were remaining on the sublease. The Company expects to recognize $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of sublease income over the lease term that commenced in October 2022. At December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million sublease income is expected to be recognized over the remaining lease term. In addition, on February 28, 2023, the Company signed a second agreement to sublease an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of its corporate headquarters (21</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">st </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">floor) for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months, which commenced on December 1, 2023. The Company expects to recognize additional sublease income of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the lease term. At December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million sublease income is expected to be recognized over the remaining lease term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rent expense, net of sublease income, is reported within restructuring and related charges for the year ended December 31, 2023, in the consolidated statements of operations. The Company is currently in the process of fully vacating and potentially subleasing an additional floor (20</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">floor).</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about the Company's operating leases is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.257%;"></td> <td style="width:1.281%;"></td> <td style="width:1%;"></td> <td style="width:15.591000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.281%;"></td> <td style="width:1%;"></td> <td style="width:15.591000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term (in years)</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.9</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate per annum</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.992%;"></td> <td style="width:1.72%;"></td> <td style="width:1%;"></td> <td style="width:15.783000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.72%;"></td> <td style="width:1%;"></td> <td style="width:15.783000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost (including variable costs)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,159</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,917</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable costs (including non-lease components)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,164</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,930</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,679</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of<br/>   operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,931</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,540</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments and sublease income as of December 31, 2023 under commenced non-cancelable operating leases are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.03%;"></td> <td style="width:1.44%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.44%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.44%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Minimum Lease<br/>Payments for<br/>Operating Leases</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sublease Income</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Minimum Lease Payments for Operating Leases</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,086</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,877</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,209</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,135</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,952</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,183</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,821</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,381</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,440</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,395</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,430</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,965</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,355</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,480</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,875</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,225</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,058</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,167</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future minimum payments (receipts)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,017</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,178</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,839</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Imputed interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,320</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,697</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,323</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,374</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the normal course of business, the Company enters into various contractual and legally binding purchase commitments. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company's open commitments totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Capital expenditure commitments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were immaterial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into several license and patent agreements. Under these agreements, the Company pays annual license maintenance fees, non-refundable license issuance fees, and royalties as a percentage of net sales for the sale or sublicense of products using the licensed technology. Future payments related to these license agreements have not been included in the open commitments above, as the period of time over which the future license payments will be required to be made, and the amount of such payments, are indeterminable. The Company does not expect the license payments to be material in any particular year.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company has entered into indemnification provisions under certain of its agreements in the ordinary course of business, typically with business partners, customers and suppliers. Pursuant to these agreements, the Company may indemnify, hold harmless and agree to reimburse the indemnified parties on a case-by-case basis for losses suffered or incurred by the indemnified parties in connection with any patent or other intellectual property infringement claim by any third party with respect to the Company’s products. The term of these indemnification provisions is generally perpetual from the time of the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is typically not limited to a specific amount. In addition, the Company has entered into indemnification agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 28, 2023, a purported stockholder filed a complaint against the Company and the members of the Company’s Board in the United States District Court for the Northern District of California. The complaint has since been voluntarily dismissed. On December 12, 2023 two separate shareholder complaints were filed in the District of Delaware, The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. The Company is reviewing the complaints and has not yet formally responded to them. On December 13, 2023,</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed transaction, which was denied by the Court on January 4, 2024. The non-injunctive claims, including breach of fiduciary duty, are still being litigated. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs’ claim is successful, this type of litigation may result in significant costs and divert management’s attention and resources, which could adversely affect the operation of the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Between October 24, 2023 and January 3, 2024, SomaLogic received 16 letters from purported shareholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional lawsuits against the Company and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, the Company will not necessarily announce such additional filings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the normal course of business, the Company is from time to time involved in legal proceedings or potential legal proceedings, including matters involving employment, intellectual property, or others. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of any currently pending matters would not have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></p> P1Y P6Y P5Y 2030-04-30 contains an option to extend the lease true P5Y along with termination options true 0.25 P39M P24M 4800000 2900000 0.25 P77M 9100000 9000000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about the Company's operating leases is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.257%;"></td> <td style="width:1.281%;"></td> <td style="width:1%;"></td> <td style="width:15.591000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.281%;"></td> <td style="width:1%;"></td> <td style="width:15.591000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term (in years)</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.9</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate per annum</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.992%;"></td> <td style="width:1.72%;"></td> <td style="width:1%;"></td> <td style="width:15.783000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.72%;"></td> <td style="width:1%;"></td> <td style="width:15.783000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost (including variable costs)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,159</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,917</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable costs (including non-lease components)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,164</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,930</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,679</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of<br/>   operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,931</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,540</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> P5Y10M24D P6Y9M18D 0.118 0.118 11159000 10917000 3164000 2930000 2679000 189000 7931000 7540000 <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments and sublease income as of December 31, 2023 under commenced non-cancelable operating leases are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.03%;"></td> <td style="width:1.44%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.44%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.44%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Minimum Lease<br/>Payments for<br/>Operating Leases</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sublease Income</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Minimum Lease Payments for Operating Leases</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,086</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,877</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,209</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,135</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,952</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,183</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,821</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,381</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,440</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,395</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,430</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,965</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,355</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,480</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,875</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,225</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,058</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,167</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future minimum payments (receipts)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,017</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,178</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,839</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Imputed interest</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,320</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,697</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,323</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,374</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> </table> 8086000 2877000 5209000 8135000 2952000 5183000 7821000 1381000 6440000 7395000 1430000 5965000 7355000 1480000 5875000 10225000 2058000 8167000 49017000 12178000 36839000 14320000 34697000 4323000 30374000 9700000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Fair Value of Financial Instruments</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements At Reporting Date Using</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets For Identical Assets (Level 1)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Cash and cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,576</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements At Reporting Date Using</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets For Identical Assets (Level 1)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Cash and cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,369</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,369</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no transfers within the hierarchy and no changes in the valuation techniques used during the year ended December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes available-for-sale-securities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;"></td> <td style="width:1.08%;"></td> <td style="width:9.96%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity (in years)</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Cash and cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 or less</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,169</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,169</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,554</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,576</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;"></td> <td style="width:1.08%;"></td> <td style="width:9.96%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity (in years)</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Cash and cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 or less</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,977</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">502</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,977</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">502</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,871</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">502</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,369</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the available-for-sale securities held have been in an unrealized loss position for greater than 12 months. The Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t intend to sell these investments and it is not likely that the Company will be required to sell these investments before recovery of their amortized cost basis. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowance for credit losses was recorded.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2014 Notes and 2019 Notes (collectively, the Convertible Notes) are not regularly traded. The estimated fair values for these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the 2019 Notes was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">58.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">48.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. The carrying value of the 2014 Notes approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of the Term Loan Facility also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's Term Loan Facility was estimated using a discounted cash flow model and current market interest rate data for similar loans. The carrying value of the Company's lines of Term Loan Facility approximates fair value as interest rates applied to the underlying debt are adjusted quarterly to market interest rates.</span></p> <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements At Reporting Date Using</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets For Identical Assets (Level 1)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Cash and cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,576</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements At Reporting Date Using</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets For Identical Assets (Level 1)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Cash and cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,369</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,369</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 35385000 35385000 0 0 35385000 35385000 0 0 63191000 0 63191000 0 63191000 0 63191000 0 98576000 35385000 63191000 0 53894000 53894000 0 0 53894000 53894000 0 0 84475000 84475000 0 0 84475000 84475000 0 0 138369000 138369000 0 0 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes available-for-sale-securities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;"></td> <td style="width:1.08%;"></td> <td style="width:9.96%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity (in years)</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Cash and cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,385</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 or less</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,169</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,169</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,191</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,554</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,576</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;"></td> <td style="width:1.08%;"></td> <td style="width:9.96%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.08%;"></td> <td style="width:1%;"></td> <td style="width:7.960000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity (in years)</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Cash and cash equivalents:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short-term investments:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 or less</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,977</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">502</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,977</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">502</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,871</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">502</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,369</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 35385000 0 0 35385000 35385000 0 0 35385000 63169000 22000 0 63191000 63169000 22000 0 63191000 98554000 22000 0 98576000 53894000 0 0 53894000 53894000 0 0 53894000 84977000 0 502000 84475000 84977000 0 502000 84475000 138871000 0 502000 138369000 0 0 0 58200000 48400000 <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Mezzanine Equity</span><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series B Redeemable Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 23, 2022, the Company entered into separate Series B Convertible Preferred Stock Purchase Agreements (collectively, the Purchase Agreements) with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, Casdin), and Viking Global Opportunities Illiquid Investments Sub Master LP and Viking Global Opportunities Drawdown LP (together, Viking, and together with Casdin, the Lenders), whereby the Company issued and sold an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of convertible preferred stock, consisting of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">112,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company’s Series B-1 Convertible Preferred Stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the Series B-1 Preferred Stock), at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share; and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">112,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company’s Series B-2 Convertible Preferred Stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the Series B-2 Preferred Stock, and together with the Series B-1 Preferred Stock, the Series B Preferred Stock or the Series B Redeemable Preferred Stock) at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (together with the issuance of shares of Series B Preferred Stock in connection with the conversion of the Bridge Loans, the Private Placement). On the Private Placement Closing Date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of Series B Preferred Stock were issued in accordance with the Purchase Agreements and the Bridge Loans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">converted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30,559</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series B Preferred Stock, for a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">255,559</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series B Preferred Stock. The Company recorded the Series B Preferred Stock as mezzanine equity at its fair value upon issuance, net of any issuance costs, on the consolidated balance sheets as it has features, such as change of control and liquidation preference, which are outside of the Company’s control.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Purchase Agreements were accounted for as forward sales contracts at fair value in accordance with the authoritative accounting guidance as the Series B Preferred Stock included certain contingent redemption features that created an obligation for the Company to repurchase its shares. The fair value of the payable portion of the forward sales contracts was determined using a Monte Carlo Simulation, which relies on significant assumptions regarding the estimated yield and term of the Series B Preferred Stock.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the carrying value of the Series B Preferred Stock as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from Purchase Agreements</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from Bridge Loans</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of Forward Purchase Agreements</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,081</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in the fair value of Bridge Loans</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,719</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less equity issuance costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,547</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Series B Redeemable Preferred Stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">311,253</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Series B Preferred Stock ranks senior to the Company's common stock with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The holders of Series B Preferred Stock are entitled to participate in all dividends declared on the Company's common stock on an as-converted basis.</span></p> 225000000 112500 0.001 1000 112500 0.001 1000 225000 30559 255559 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the carrying value of the Series B Preferred Stock as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from Purchase Agreements</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from Bridge Loans</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of Forward Purchase Agreements</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,081</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in the fair value of Bridge Loans</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,719</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less equity issuance costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,547</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Series B Redeemable Preferred Stock</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">311,253</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 225000000 225000000 25000000 25000000 60081000 60081000 13719000 13719000 12547000 12547000 311253000 311253000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Shareholders' Deficit</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Repurchase Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 23, 2022, the Company’s board of directors authorized the repurchase of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company’s common stock in the open market or in negotiated transactions through December 31, 2023. The Company repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,709,703</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the program at a cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, excluding commission fees, for an average of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. Repurchases under the program were able to be suspended or discontinued at any time at the Company’s discretion, and on October 4, 2023, the Company terminated the program in connection with the announcement of the merger agreement with SomaLogic.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Shares Reserved</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.431%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.162%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.162%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.242%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Securities To Be Issued Upon Exercise Of Options</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Securities To Be Issued Upon Release Of Restricted Stock</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number Of Remaining Securities Available For Future Issuance</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022 Inducement Equity Incentive Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,595</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,277</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">208</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2011 Equity Incentive Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,640</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,964</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,656</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2017 Inducement Award Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2017 Employee Stock Purchase Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,581</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,294</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,243</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,445</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 20000000 2709703 5400000 1.98 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.431%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.162%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.162%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.242%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Securities To Be Issued Upon Exercise Of Options</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Securities To Be Issued Upon Release Of Restricted Stock</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number Of Remaining Securities Available For Future Issuance</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022 Inducement Equity Incentive Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,595</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,277</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">208</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2011 Equity Incentive Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,640</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,964</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,656</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2017 Inducement Award Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2017 Employee Stock Purchase Plan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,581</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,294</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,243</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,445</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 7595000 1277000 208000 1640000 5964000 4656000 59000 2000 0 0 0 1581000 9294000 7243000 6445000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Stock-based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Compensation Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2011 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2011, the Company's board of directors adopted the 2011 Equity Incentive Plan (2011 Plan) under which incentive stock options, non-statutory stock options, RSUs, stock appreciation rights, PSUs, and performance shares may be granted to its employees, directors, and consultants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Inducement Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, the Company's board of directors adopted the 2022 Inducement Plan and reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of common stock for the issuance of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares and PSUs. In accordance with Nasdaq listing rules, equity awards issued under the 2022 Inducement Plan are restricted to individuals who are not already employees or directors of the Company. The terms and conditions of the 2022 Inducement Plan are substantially similar to those of the 2011 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's board of directors sets the terms, conditions, and restrictions related to the grant of stock options, RSUs and performance-based awards under its stock-based plans, as well as employee participation in the 2017 Employee Stock Purchase Plan (ESPP). The Company's board of directors determines the number of awards to grant and also sets vesting criteria. In general, RSUs vest on a quarterly basis over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the first anniversary of the grant date and ratably each quarter over the remaining 12 quarters, or ratably over 16 quarters, subject to the employees’ continued employment. The Company may grant RSUs with different vesting terms from time to time. Stock options granted under the Company's 2022 Inducement Plan and 2011 Plan have a term of no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and an exercise price of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the underlying common stock on the date of grant. Generally, options vest at a rate of either </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the first anniversary of the option grant date and ratably each month over the remaining period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months, or ratably each month over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months. The Company may grant options with different vesting terms from time to time. For performance-based share awards, the Company's board of directors sets the performance objectives and other vesting provisions in determining the number of shares or value of performance units and performance shares that will be paid out. Such payout will be a function of the extent to which performance objectives or other vesting provisions have been achieved.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.36%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.88%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Units<br/> (in thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant Date Fair Value per Unit</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,120</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.58</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSU granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,728</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.32</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSU released</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,970</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.68</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSU forfeited</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">945</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.17</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,933</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.46</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the unrecognized compensation costs related to outstanding unvested RSUs under the Company’s equity incentive plans were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects to recognize those costs over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:8.942%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of <br/>Options (in thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price<br/>per Option</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Remaining Contractual Life (in years)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> (in thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,882</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.43</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,609</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.57</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.84</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options cancelled</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,153</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.84</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,294</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.62</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">439</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,497</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.98</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested awards at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,797</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.40</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">361</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aggregate intrinsic value as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was calculated as the difference between the closing price per share of the Company’s common stock on the last trading day of December, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the exercise price of the options, multiplied by the number of in-the-money options.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022 was immaterial. The total intrinsic value of options vested during the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the unrecognized compensation costs related to outstanding unvested options under the Company’s equity incentive plans were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects to recognize those costs over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average assumptions used to estimate the fair value of options granted were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.882%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.882%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average expected volatility</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average expected term</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average risk-free interest rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average fair value per share</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.49</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.21</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—The expected term of options granted represents the period of time that the options are expected to be outstanding and is derived by analyzing historical exercise behavior.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—The estimated volatility was based on the historical volatility of the common stock of the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—The risk-free interest rate is the implied yield in effect at the time of the option grant based on U.S. Treasury securities with contract maturities similar to the expected term of the Company’s stock options.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance-based Awards</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company previously granted PSUs to certain executive officers and senior-level employees with the number of PSUs ultimately earned under these awards being calculated by comparing the Total Shareholder Return (TSR) of the Company’s common stock over the applicable </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period against the TSR of a defined group of peer companies. The Company’s relative performance against its peer group determined the payout, which could range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the base awards. As these awards required continuous service in order to vest and these officers and senior level employees are no longer with the Company, they were canceled as of June 30, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company granted performance-based restricted stock units to certain executive officers that will vest in the first quarter of 2024 based upon the achievement of specified revenue and EBITDA targets for the twelve months ended December 31, 2023, and the executive’s continued employment with the Company. Stock-based compensation expense is being recognized over the requisite service period, as it is deemed probable the Company will satisfy the performance measures.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity under the performance-based awards was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.36%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.88%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Units <br/>(in thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant Date Fair Value per Unit</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.81</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PSU granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">309</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.42</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PSU released</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.60</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance adjustment for 2020 awards</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.19</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">309</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.42</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is reported in the Company's consolidated statement of operations as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of product revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">811</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">592</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,671</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,481</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,641</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,807</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,123</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,880</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 9500000 P4Y 0.25 P10Y 1 0.25 P36M P48M <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.36%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.88%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Units<br/> (in thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant Date Fair Value per Unit</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,120</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.58</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSU granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,728</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.32</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSU released</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,970</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.68</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSU forfeited</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">945</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.17</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,933</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.46</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 7120000 2.58 3728000 2.32 2970000 2.68 945000 2.17 6933000 2.46 13900000 P2Y6M <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:8.942%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of <br/>Options (in thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price<br/>per Option</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Remaining Contractual Life (in years)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> (in thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,882</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.43</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,609</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.57</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.84</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options cancelled</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,153</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.84</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,294</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.62</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">439</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,497</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.98</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested awards at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,797</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.40</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">361</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aggregate intrinsic value as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was calculated as the difference between the closing price per share of the Company’s common stock on the last trading day of December, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the exercise price of the options, multiplied by the number of in-the-money options.</span></p> 7882000 4.43 P7Y10M24D 0 2609000 2.57 44000 1.84 1153000 6.84 9294000 3.62 P8Y6M 439000 3497000 3.98 P8Y2M12D 78000 5797000 3.4 P8Y8M12D 361000 2.21 100000 0 12400000 P2Y3M18D <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average assumptions used to estimate the fair value of options granted were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.882%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.882%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average expected volatility</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average expected term</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average risk-free interest rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average fair value per share</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.49</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.21</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 0.971 0.918 P4Y8M12D P4Y3M18D 0.039 0.026 0 0 1.49 2.21 P3Y 0 2 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity under the performance-based awards was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.36%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.88%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Units <br/>(in thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant Date Fair Value per Unit</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.81</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PSU granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">309</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.42</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PSU released</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.60</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance adjustment for 2020 awards</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.19</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">309</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.42</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 453000 4.81 309000 2.42 52000 9.6 -401000 4.19 309000 2.42 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is reported in the Company's consolidated statement of operations as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of product revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">811</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">592</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,671</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,481</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,641</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,807</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,123</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,880</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 811000 592000 1671000 2481000 10641000 11807000 13123000 14880000 <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company' </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss before income taxes consists of the following (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,587</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">174,041</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">International</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,617</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,887</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,204</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,928</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company's benefit (expense) from income taxes are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">373</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">405</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current tax expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">570</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">492</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,322</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred benefit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,322</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total benefit (expense) from income taxes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,830</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reconciliation of income taxes at the statutory rate to the benefit (expense) from income taxes recorded in the statements of operations is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.360000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.34%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax benefit at federal statutory rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax expense, net of federal benefit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign tax expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NOL carryforwards expiring unutilized</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.9</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal R&amp;D credit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible interest/premium</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible loss on Forward Sale of Preferred Stock and<br/>   Bridge Loans</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D tax credits expiring unutilized</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transaction costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive stock-based compensation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Return to provision</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforward</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,242</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,182</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reserves and accruals</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,152</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,943</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">564</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">563</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,962</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,840</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,463</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,456</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,064</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,782</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,663</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross deferred tax assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,308</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,711</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance on deferred tax assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,124</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107,893</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets, net of valuation allowance</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,184</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,818</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets and intangibles</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,913</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,836</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,729</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,890</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,642</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liability</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">706</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">824</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability per balance sheet</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">841</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,055</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less deferred tax assets included in other long-term assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liability</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">706</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">824</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company completed its Section 382 Study through December 31, 2022 and determined that an ownership change occurred on April 4, 2022 due to the issuance of preferred equity. As a result of this ownership change, a portion of net operating loss (NOL) carryforwards and all R&amp;D credits will expire unutilized. Further limitations are also expected as a result of the merger with SomaLogic that occurred on January 5, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company establishes a valuation allowance for deferred tax assets if the Company determines it is more likely than not the related tax benefit will not be realized. The Company relies on several factors when assessing the realizability of deferred tax assets, including historical financial results, the Company's ability to recover net operating loss carry-forwards, the projected future operating results, and the Company's ability to use tax planning strategies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The valuation allowances of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">124.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">107.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively, primarily relate to temporary tax differences, net operating losses and research and development credits generated in the current and prior years. The Company believes it is more likely than not that U.S. federal and state, Canada and Netherlands deferred tax assets relating to temporary differences, net operating losses and research and development credits are not realizable. As such, full valuation allowances have been applied against the deferred tax assets relating to jurisdictions of the U.S. federal and state, Canada and Netherlands.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation Allowance</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2021</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,087</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charges to earnings</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charges to other accounts</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,194</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107,893</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charges to earnings</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charges to other accounts</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,124</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had net operating loss carryforwards for U.S. federal income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">363.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and U.S. federal research and development tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin expiring in 2042. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">had net operating loss carryforwards for state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">220.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which will expire through 2043, and California research and development tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which do not expire. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we had foreign net loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which will begin to expire in 2041, and foreign tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in 2037.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate changes in the balance of the Company's gross unrecognized tax benefits during </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, and 2022 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2021</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,515</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases in balances related to tax positions during a prior<br/>   period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases in balances related to tax positions taken during<br/>   current period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases in balances related to tax positions taken during prior<br/>   period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,697</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,972</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases in balances related to tax positions during a prior<br/>   period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases in balances related to tax positions taken during<br/>   current period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,939</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized tax benefits that, if recognized, would reduce the Company's effective tax rate. The Company does not anticipate that existing unrecognized tax benefits will significantly increase or decrease within the next 12 months.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued interest and penalties related to unrecognized tax benefits was included in the income tax provision. The amount was immaterial as of December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files income tax returns in the United States, its various states, and in certain foreign jurisdictions. As a consequence of having operating loss carryforwards, all tax years are open to federal and state examination in the United States. Tax years from 2012 are open to examination in various foreign countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss before income taxes consists of the following (in thousands):</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,587</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">174,041</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">International</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,617</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,887</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,204</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,928</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> </table> -40587000 -174041000 -33617000 -18887000 -74204000 -192928000 <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company's benefit (expense) from income taxes are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">373</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">405</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current tax expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">570</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">492</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,322</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred benefit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,322</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total benefit (expense) from income taxes</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,830</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 0 0 197000 87000 373000 405000 570000 492000 0 0 0 0 -118000 -3322000 -118000 -3322000 452000 -2830000 <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reconciliation of income taxes at the statutory rate to the benefit (expense) from income taxes recorded in the statements of operations is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.360000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.34%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax benefit at federal statutory rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax expense, net of federal benefit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign tax expense</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NOL carryforwards expiring unutilized</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.9</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal R&amp;D credit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible interest/premium</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible loss on Forward Sale of Preferred Stock and<br/>   Bridge Loans</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D tax credits expiring unutilized</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transaction costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive stock-based compensation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Return to provision</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 0.21 0.21 0.013 0.008 -0.081 -0.008 0.055 0.228 -0.219 0.171 -0.002 -0.002 0 0.009 0 0.003 0 0.08 0 0.052 -0.015 0 0.026 0.008 0.025 0 0.02 0.022 -0.004 0.015 <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforward</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,242</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,182</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reserves and accruals</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,152</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,943</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">564</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">563</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,962</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,840</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,463</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,456</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,064</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,782</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,663</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross deferred tax assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,308</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,711</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance on deferred tax assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,124</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107,893</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets, net of valuation allowance</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,184</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,818</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets and intangibles</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,913</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,836</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,729</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,890</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,642</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liability</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">706</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">824</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability per balance sheet</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">841</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,055</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less deferred tax assets included in other long-term assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liability</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">706</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">824</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> </table> 96242000 85182000 3152000 3943000 564000 563000 5962000 3840000 15463000 14456000 1143000 2064000 7782000 8663000 130308000 118711000 124124000 107893000 6184000 10818000 54000 3913000 6836000 7729000 6890000 11642000 706000 824000 841000 1055000 135000 231000 706000 824000 124100000 107900000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation Allowance</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2021</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,087</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charges to earnings</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charges to other accounts</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,194</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107,893</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charges to earnings</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charges to other accounts</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,124</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 141087000 0 -33194000 107893000 0 16231000 124124000 363500000 500000 220400000 14000000 36600000 6900000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate changes in the balance of the Company's gross unrecognized tax benefits during </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, and 2022 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2021</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,515</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases in balances related to tax positions during a prior<br/>   period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases in balances related to tax positions taken during<br/>   current period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases in balances related to tax positions taken during prior<br/>   period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,697</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,972</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases in balances related to tax positions during a prior<br/>   period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases in balances related to tax positions taken during<br/>   current period</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,939</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 8515000 154000 0 1697000 6972000 105000 138000 6939000 0 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Segment Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2023, the CODM began using gross profit to measure the operating performance of the segments. The Company determines each segment’s gross profit by subtracting cost of product and service revenues from segment revenues.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not prepare or report segmented balance sheet information as the CODM does not use the information to assess segment operating performance. The segments adhere to the same accounting policies as the Company as a whole.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's business segment information was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proteomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,883</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,502</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,457</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,446</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,340</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,948</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross profit:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proteomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,239</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,041</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,211</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross profit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,450</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,051</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Depreciation &amp; amortization:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proteomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,072</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,223</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">601</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">230</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total depreciation &amp; amortization</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,673</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,453</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 2 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's business segment information was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proteomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,883</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,502</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,457</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,446</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,340</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,948</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross profit:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proteomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,239</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,041</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,211</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross profit</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,450</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,051</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Depreciation &amp; amortization:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proteomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,072</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,223</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">601</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">230</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total depreciation &amp; amortization</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,673</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,453</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 63883000 52502000 42457000 45446000 106340000 97948000 26239000 20041000 24211000 17010000 50450000 37051000 12072000 12223000 601000 230000 12673000 12453000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Restructuring and Related Charges</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning with the appointment of the Company’s new management team in April 2022 and as further announced in August 2022, the Company has implemented a restructuring plan, including a reduction in force, to improve operational efficiency, achieve cost savings and align the Company’s workforce to the future needs of the business. In addition to the reduction in force, the Company is reducing leased office space, optimizing its manufacturing footprint and streamlining support functions. The Company is developing a more disciplined cost management culture throughout its organization by investing in training and advanced information systems.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records restructuring and related charges as incurred. These items are classified within restructuring and related charges in the consolidated statements of operations for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and primarily include severance costs as well as facility costs (net of sublease income) for leased space in South San Francisco that the Company has vacated as part of the restructuring plan. The Company recognized restructuring and related charges of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to relieve the majority of the existing liability for restructuring charges primarily related to employee severance in 2024. Ongoing restructuring charges will continue to be incurred for facility related costs through the termination of the facility leases. These estimates are subject to a number of assumptions, and actual results may differ.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the change in the Company’s restructuring and other related liabilities for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Severance<br/>and other<br/>employee-<br/>related<br/>benefits</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Facility <br/>Costs</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(2)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring and related charges</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,849</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,885</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">998</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,732</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash payments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,835</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,885</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">979</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,699</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,014</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,033</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring and related charges</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,379</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,160</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">537</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,076</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash payments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,568</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,160</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">556</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,284</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">825</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">825</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring liabilities are recorded in accrued compensation and related benefits on the consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the consolidated balance sheets.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s restructuring and related charges by segment and corporate were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proteomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,363</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">714</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,273</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,352</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,096</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total restructuring and related charges</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,076</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,732</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div> 7100000 9700000 <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the change in the Company’s restructuring and other related liabilities for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Severance<br/>and other<br/>employee-<br/>related<br/>benefits</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Facility <br/>Costs</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(2)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring and related charges</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,849</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,885</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">998</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,732</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash payments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,835</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,885</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">979</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,699</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,014</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,033</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring and related charges</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,379</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,160</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">537</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,076</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash payments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,568</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,160</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">556</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,284</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">825</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">825</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring liabilities are recorded in accrued compensation and related benefits on the consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the consolidated balance sheets.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s restructuring and related charges by segment and corporate were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proteomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,010</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,363</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genomics</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">714</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,273</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,352</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,096</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total restructuring and related charges</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,076</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,732</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table> 0 0 0 0 5849000 2885000 998000 9732000 1835000 2885000 979000 5699000 4014000 0 19000 4033000 2379000 4160000 537000 7076000 5568000 4160000 556000 10284000 825000 0 0 825000 1010000 1363000 714000 1273000 5352000 7096000 7076000 9732000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. 401(k) Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company sponsors a 401(k) savings plan for its employees in the United States that stipulates that eligible employees may elect to contribute to the plan, subject to certain limitations, up to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of eligible compensation or the maximum amount allowed by the U.S. Internal Revenue Service. In 2019 and onward, the employee match formula was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> annually. Employer matching contributions to the 401(k) plan were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p> 0.90 1 3000 500000 600000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Subsequent Event</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SomaLogic Merger</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 5, 2024, the Company completed the previously announced Merger pursuant to the Agreement and Plan of Merger, dated as of October 4, 2023 (the “Merger Agreement”), by and among the Company, SomaLogic, and Martis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub). Pursuant to the Merger Agreement, Merger Sub merged with and into SomaLogic, with SomaLogic surviving as a wholly owned subsidiary of Standard BioTools. At the consummation of the Merger, each issued and outstanding share of common stock of SomaLogic, was converted into the right to receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock of Standard BioTools, and cash in lieu of fractional shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Merger, SomaLogic’s common stockholders owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, and the Company’s common stockholders owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, of the outstanding shares of common stock of the combined company on a fully diluted basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of the effective time of the Merger, the Company assumed each SomaLogic stock incentive plan, outstanding option to purchase shares of SomaLogic common stock and outstanding restricted stock units convertible into shares of SomaLogic common stock, whether vested or unvested. In addition, as of the Effective Time, each SomaLogic warrant was treated in accordance with its terms.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the limited time between the Merger date and the filing of this Annual Report, it is not practicable for the Company to disclose the preliminary allocation of the purchase price to assets acquired and liabilities assumed.</span></p> 0.0111 0.57 0.43 Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins.